node_1|node_2|edge|chunk_id|count
Cardiovascular disease (CVD)|leading cause of mortality|in women in the United States|3dc851440134402d87573a15088a4351|4
women|men|comparison between men and women|51dc59c88fb141e1a0ad643fd6109a21|4
women|coronary artery disease (CAD)|having less obstructive but more diffuse coronary artery disease (CAD)|51dc59c88fb141e1a0ad643fd6109a21|4
women|1-year mortality rate after acute myocardial infarction|higher 1-year mortality rate after acute myocardial infarction|51dc59c88fb141e1a0ad643fd6109a21|4
women|black women|having the highest CAD death rates|51dc59c88fb141e1a0ad643fd6109a21|4
women|physicians|less aware of and less proficient in identifying CVD in women|51dc59c88fb141e1a0ad643fd6109a21|4
prevention and management of CVD in women|women|related to prevention and management of CVD in women|51dc59c88fb141e1a0ad643fd6109a21|4
CVD prevention|guidelines for women|were published in 2004 and later updated in 2007 and 2011|5e5c6f31324f4f8ea805b0964a33cf41|4
CVD prevention|general CVD risk factors|are similar in men and women|5e5c6f31324f4f8ea805b0964a33cf41|4
CVD prevention|exceptions unique to women|were detailed in these guidelines|5e5c6f31324f4f8ea805b0964a33cf41|4
CVD|risk factors for CVD|topic being discussed|08615e84dd1245e2b5c0037f8325f1c0|4
Non-Modifiable|Age|one of the non-modifiable risk factors|08615e84dd1245e2b5c0037f8325f1c0|4
Age|developing CVD|relationship between age and developing CVD|08615e84dd1245e2b5c0037f8325f1c0|4
Cardioprotective effect|estrogen for premenopausal women|cardioprotective effect of estrogen on premenopausal women|08615e84dd1245e2b5c0037f8325f1c0|4
Age|CAD in women|age as a risk factor for CAD in women|08615e84dd1245e2b5c0037f8325f1c0|4
After the age of 55|risk for CAD increases similarly in both men and women|relationship between increasing age and risk for CAD|08615e84dd1245e2b5c0037f8325f1c0|4
Modifiable|Smoking|one of the modifiable risk factors|08615e84dd1245e2b5c0037f8325f1c0|4
American Heart Association|according to|source for information on smoking as a risk factor|08615e84dd1245e2b5c0037f8325f1c0|4
CAD|women smokers|Greater risk of CAD in women smokers|bee9f43fb9a2448195d98d5d70438e54|4
women smokers|men smokers|Percentage of women smokers lower than men smokers|bee9f43fb9a2448195d98d5d70438e54|4
CAD|male smokers|Greater risk of CAD in male smokers|bee9f43fb9a2448195d98d5d70438e54|4
reduction in smoking|decline in|Reduction in smoking accounted for a decline in|bee9f43fb9a2448195d98d5d70438e54|4
CAD|Smoking|avoided by not smoking and avoiding environmental tobacco smoke|18addc8ee4224a739ad8c198b180916e|4
CAD|smoking cessation counseling|is advised for preventing CAD in women|18addc8ee4224a739ad8c198b180916e|4
smoking cessation counseling|pharmacotherapy options|are considered in conjunction with a formal smoking cessation program|18addc8ee4224a739ad8c198b180916e|4
smoking cessation counseling|encounter|should be advised at each encounter|18addc8ee4224a739ad8c198b180916e|4
Cardiovascular diseases|leading cause of morbidity and mortality|among women worldwide|d0041b09870440d890f6a8f7c4fd9482|4
pathophysiological basis|cardiovascular health among men and women|is not identical|d0041b09870440d890f6a8f7c4fd9482|4
variable cardiovascular responses|to stimulus|presentation of cardiovascular disease symptoms|d0041b09870440d890f6a8f7c4fd9482|4
Enrollment of women|Clinical trials|minimal enrollment in|ab41aca9e95b4c00a51ac0ed9416aba0|4
Lack of gender-specific analysis|Clinical trial data|caused by minimal enrollment|ab41aca9e95b4c00a51ac0ed9416aba0|4
absence of concrete risk factor assessment|women|in the context|41d55617165841138adf447ee9bc4560|4
scientific progress in the past decade|identified a spectrum of risk factors for cardiovascular diseases specific to women|related in one sentence|41d55617165841138adf447ee9bc4560|4
risk factors|may include menopause, hypertensive disease of pregnancy, and depression|in the context|41d55617165841138adf447ee9bc4560|4
additional risk in women|traditional risk factors|related in one sentence|41d55617165841138adf447ee9bc4560|4
current state of knowledge and awareness|about these risk factors is suboptimal at this time|in the context|41d55617165841138adf447ee9bc4560|4
risk factors|treatment of cardiovascular diseases|suboptimal at this time|049f37c70ac942f8b0ab05f93580571e|4
appropriate risk stratification|women compared to men|limited in women|98766d3c26264911a6e069fe8f407de8|4
Obesity|National Health and Nutrition Examination Survey (NHANES)|Obesity according to the 2013 NHANES|625ca13741b848cc90a19689e2c681ab|4
Obesity|U.S. adults aged ≥ 20 years|Among U.S. adults aged ≥ 20 years, Obesity|625ca13741b848cc90a19689e2c681ab|4
Obesity|37.7% were obese|37.7% of adults were obese|625ca13741b848cc90a19689e2c681ab|4
Obesity|metabolic syndrome|Obesity is thought to be related to metabolic syndrome|625ca13741b848cc90a19689e2c681ab|4
CAD|postmenopausal women|Impact of obesity on development of CAD in postmenopausal women|625ca13741b848cc90a19689e2c681ab|4
CAD|redistribution of fat around the abdominal area|Greater impact of obesity on CAD due to redistribution of fat|625ca13741b848cc90a19689e2c681ab|4
CAD|guidelines on CVD|The guidelines on CVD related to CAD|625ca13741b848cc90a19689e2c681ab|4
CVD prevention|weight maintenance|should be maintained or lost through appropriate physical activity, caloric intake, and formal behavior programs|7250a6b878334bcd8eac0e2c70aef3ff|4
CVD prevention|goal body mass index (BMI)|of < 25 kg/m^2 in women or waist size < 35 inches|7250a6b878334bcd8eac0e2c70aef3ff|4
CVD prevention|recommended exercise time for women and men|is at least 150 minutes/week of moderate exercise or 75 minutes/week of vigorous exercise|7250a6b878334bcd8eac0e2c70aef3ff|4
Endogenous estrogens|Hypertension|maintain|7250a6b878334bcd8eac0e2c70aef3ff|4
Hypertension|Endogenous estrogens|maintain vasodilation and contribute to blood pressure control|50e6eca99ff4403098ecebd3bd2d1d8b|4
Hypertension|Age|risk increases more in elderly women than in elderly men|50e6eca99ff4403098ecebd3bd2d1d8b|4
Hypertension|Race|significantly higher prevalence of hypertension independent of other factors|50e6eca99ff4403098ecebd3bd2d1d8b|4
antihypertensive agents|sex-specific analysis|not report|6d56e062ce564a058b7af6530f2bf2a1|4
BP target|individuals aged 60 years and older without diabetes or chronic kidney disease|recommended for|6d56e062ce564a058b7af6530f2bf2a1|4
TC ≥ 200 mg/dL|TC ≥ 240 mg/dL|are related to each other in the context|09939f43c40f4b10b3166292bc835a2b|4
Women ≥ 20 years|United States|are related to each other in the context|09939f43c40f4b10b3166292bc835a2b|4
LDL-C ≥ 130 mg/dL|Women ≥ 20 years|are related to each other in the context|09939f43c40f4b10b3166292bc835a2b|4
HDL-C < 40 mg/dL|Women ≥ 20 years|are related to each other in the context|09939f43c40f4b10b3166292bc835a2b|4
Elevated LDL-C, triglycerides, and non-HDL-C|Low HDL-C|have all been associated with an increased risk for CVD in women as in men|09939f43c40f4b10b3166292bc835a2b|4
Centers for Disease Control and Prevention|Recently reported|are related to each other in the context|09939f43c40f4b10b3166292bc835a2b|4
women|men|less likely to be prescribed statin therapy than|ec11983812da4f25aee69a242b76742f|4
CVD risk|statin therapy|individuals with established CVD, LDL-C ≥  190 mg/dL, diabetes, or an established 10-year CVD risk ≥  7.5% based on the pooled|ec11983812da4f25aee69a242b76742f|4
American College of Cardiology|AHA|recommend statin therapy|ec11983812da4f25aee69a242b76742f|4
cohort risk equation|10-year and lifetime atherosclerotic cardiovascular disease event risk|calculates|1e994013517947bfb0bb1e633601e1c2|4
statin therapy|physician-patient discussion|based on|1e994013517947bfb0bb1e633601e1c2|4
statin therapy|5% to 7.5% 10-year ASCVD risk|recommended for|1e994013517947bfb0bb1e633601e1c2|4
statin therapy|other factors|those with|1e994013517947bfb0bb1e633601e1c2|4
elevated calcium score|family history of premature ASCVD|association|ea764edf9ba04830bcbfe00312ee69ba|4
elevated high-sensitivity C-reactive protein (hs-CRP)|abnormal ankle-brachial index (ABI)|association|ea764edf9ba04830bcbfe00312ee69ba|4
Diabetes Mellitus|hemoglobin A1c|parameter|ea764edf9ba04830bcbfe00312ee69ba|4
gender-based differences|anatomical features|relationship|ea764edf9ba04830bcbfe00312ee69ba|4
vessel sizes|women|difference|ea764edf9ba04830bcbfe00312ee69ba|4
vessel sizes|men|comparison|ea764edf9ba04830bcbfe00312ee69ba|4
left ventricular size|men|smaller in women|efe35ad0a87d446082438b0bd2c66338|4
systolic function|women|greater than men|efe35ad0a87d446082438b0bd2c66338|4
diastolic compliance|women|less in women than men|efe35ad0a87d446082438b0bd2c66338|4
hormonal differences|estrogen|predominantly influential in women|efe35ad0a87d446082438b0bd2c66338|4
hormonal differences|testosterone|predominantly influential in men|efe35ad0a87d446082438b0bd2c66338|4
cardiovascular function differences|women|reduced sympathetic and higher parasympathetic activity than men|efe35ad0a87d446082438b0bd2c66338|4
cardiovascular function differences|men|higher sympathetic activity than women|efe35ad0a87d446082438b0bd2c66338|4
stroke volume|women|10% lower than men|efe35ad0a87d446082438b0bd2c66338|4
Cardiovascular adaptions|Women have an increased pulse rate with increased cardiac output versus men, who have higher blood pressure in response to high stress.|the context refers to the cardiovascular adaptations found between women and men.|883cc3ee06d24d0ba000e34f900a5388|4
Cardiovascular adaptions|Electrocardiographic findings Women have a longer corrected QT interval than men. Women have a shorter PR interval than men.|the context refers to the cardiovascular adaptations found in women compared to men through electrocardiographic findings.|883cc3ee06d24d0ba000e34f900a5388|4
Differences|Table 1. Differences in clinical parameters and manifestations in women compared to men.|the context refers to the differences shown in Table 1.|883cc3ee06d24d0ba000e34f900a5388|4
heart disease-related causes|mortality due to heart disease-related causes in adults with DM|Relation in one sentence|8ff37df50f114dd0b96e430682b5f322|4
adverse CV outcomes|(HbA1c)|Relation in one sentence|8ff37df50f114dd0b96e430682b5f322|4
mortality due to heart disease-related causes in adults with DM|two to four times higher than in those without DM|Relation in one sentence|8ff37df50f114dd0b96e430682b5f322|4
CVD mortality|significant gender difference in type 1 DM|Relation in one sentence|8ff37df50f114dd0b96e430682b5f322|4
type 1 DM|affects women and men equally|Relation in one sentence|8ff37df50f114dd0b96e430682b5f322|4
women with type I DM|37% increased|Relation in one sentence|8ff37df50f114dd0b96e430682b5f322|4
risk of all-cause mortality|twice the excess risk of fatal and nonfatal vascular events|compared to men with type I DM|893dce9a26084c39825556d85497f7dc|4
women with DM|appropriate glycemic control|less likely to have|893dce9a26084c39825556d85497f7dc|4
women with DM|aggressive treatment for many modifiable CAD risk factors|receive less compared to diabetic|893dce9a26084c39825556d85497f7dc|4
ASCVD benefit|intensive versus standard glycemic control|Clinical trial interventions have failed to demonstrate ASCVD benefit with intensive versus standard glycemic control|262b9aac3dcd44e4aa636a967fb5a51c|4
SGLT-2 inhibitors|CVD benefit|Recent trials with newer agents such as SGLT-2 inhibitors have started to show some benefit with respect to CVD|262b9aac3dcd44e4aa636a967fb5a51c|4
HbA1c of < 7%|Applicable guidelines|The current applicable guidelines recommend an HbA1c of < 7%, if achieved without causing significant hypoglycemia, for ASCVD risk reduction|262b9aac3dcd44e4aa636a967fb5a51c|4
Hypertensive Disorders of Pregnancy|NONTRADITIONAL RISK FACTORS|The NONTRADITIONAL RISK FACTORS include Hypertensive Disorders of Pregnancy|262b9aac3dcd44e4aa636a967fb5a51c|4
Hypertensive Disorders of Pregnancy|Pregnancy|cause and effect|a17a3007cd05467ca67752d3798e212f|4
Hypertensive Disorders of Pregnancy|cardiometabolic stressor|related to|a17a3007cd05467ca67752d3798e212f|4
Hypertensive Disorders of Pregnancy|vascular and metabolic abnormalities|unmask underlying|a17a3007cd05467ca67752d3798e212f|4
Hypertension|Pregnancies|affects approximately 10% of|a17a3007cd05467ca67752d3798e212f|4
Hypertension|leading causes of maternal and fetal morbidity and mortality|cause for|a17a3007cd05467ca67752d3798e212f|4
Gestational hypertensive disorders|Diabetes|linked to increased risk of developing hypertension as well as cardiovascular disease later in life|a17a3007cd05467ca67752d3798e212f|4
Hypertension|cardiovascular disease (CVD)|increased risk for|a17a3007cd05467ca67752d3798e212f|4
gestational hypertension disorders|preeclampsia|hypothesis of endothelial dysfunction, oxidative stress, inflammatory response, and increased expression of procoagulants|169e02a6481645109909bb0faa0cad22|4
preeclampsia|CVD|share similar risk factors including obesity, insulin resistance, renal disease|169e02a6481645109909bb0faa0cad22|4
ischemic heart disease|CVD in women|has an increased relative risk for incidence of ischemic heart disease and may be independently associated with CVD in women|34735db0077f4388b79a1eaafbd32097|4
preeclampsia|CVD|recognized as a risk factor for CVD|34735db0077f4388b79a1eaafbd32097|4
AHA|American College of Obstetrics and Gynecology|both organizations are involved in recognizing and assessing related health issues|34735db0077f4388b79a1eaafbd32097|4
yearly assessment|blood pressure, lipids, fasting blood glucose, body mass index|annual evaluation of the mentioned factors following a medical condition or risk factor|34735db0077f4388b79a1eaafbd32097|4
history of recurrent preeclampsia|preeclampsia with preterm birth|relationship between the two concepts, in one sentence|b7fac3ebcdb2414fbe8fd5729808b5bf|4
women with a history of hypertensive disorders during pregnancy|lifestyle modifications|relationship between the two concepts, in one sentence|b7fac3ebcdb2414fbe8fd5729808b5bf|4
history of recurrent preeclampsia or preeclampsia with preterm birth|more aggressive screening|relationship between the two concepts, in one sentence|b7fac3ebcdb2414fbe8fd5729808b5bf|4
Gestational Diabetes|Gestational diabetes mellitus (GDM)|relationship between the two concepts, in one sentence|b7fac3ebcdb2414fbe8fd5729808b5bf|4
normal glucose metabolism|after third trimester of pregnancy|relationship between the two concepts, in one sentence|b7fac3ebcdb2414fbe8fd5729808b5bf|4
pregnancy|glucose metabolism|Returns to normal|a02f6713ba2141ce8bcb194de0c54795|4
GDM|diabetes mellitus|Patients with history have elevated risk|a02f6713ba2141ce8bcb194de0c54795|4
screening and lifestyle modification|more aggressive consideration|Recommended for patients with a history of GDM|a02f6713ba2141ce8bcb194de0c54795|4
Systemic autoimmune disorders|CVD|Associated with|a02f6713ba2141ce8bcb194de0c54795|4
women|men|Tend to affect more often|a02f6713ba2141ce8bcb194de0c54795|4
rheumatoid arthritis|patients with rheumatoid arthritis|Reported to have a|a02f6713ba2141ce8bcb194de0c54795|4
higher risk of myocardial infarction (MI)|systemic lupus erythematosus|Increased the risk of MI between 9- and 50-fold over the general population|117fd34163584b759f3c2285b38348fb|4
higher risk of stroke|systemic lupus erythematosus|Increased the risk of stroke by 50%|117fd34163584b759f3c2285b38348fb|4
inflammatory diseases|microvasculature|Affect the microvasculature|117fd34163584b759f3c2285b38348fb|4
plaque instability|inflammatory diseases|Result in plaque instability|117fd34163584b759f3c2285b38348fb|4
acute CV events|inflammatory diseases|Increase the risk of acute CV events|117fd34163584b759f3c2285b38348fb|4
depression|acute CV events|Postulated that depression affects microvasculature and can result in plaque instability, increasing the risk of acute CV events|117fd34163584b759f3c2285b38348fb|4
Depression|antecedent to heart disease|Described as an antecedent|dedb68e59a554c14893c4a3e0d053b9c|4
NHANES I study|women with depression had a higher relative risk of CAD incidence compared to women without depression|study result|dedb68e59a554c14893c4a3e0d053b9c|4
depression|CV risk factors such as smoking and physical inactivity|associated with|dedb68e59a554c14893c4a3e0d053b9c|4
women|experience depression at approximately twice the rate of men|statistic|dedb68e59a554c14893c4a3e0d053b9c|4
depressed women|higher risk for CVD|studies have suggested|dedb68e59a554c14893c4a3e0d053b9c|4
depression|non-depressed women|differentiation in context|d1d2debda1dd4a8d858975e2a2d03384|4
chest pain|depression and anxiety disorders|association in presenting features|d1d2debda1dd4a8d858975e2a2d03384|4
tachycardia|depression and anxiety disorders|association in presenting features|d1d2debda1dd4a8d858975e2a2d03384|4
clinically appropriate cardiac evaluation|women with such symptoms|need for in context|d1d2debda1dd4a8d858975e2a2d03384|4
treatment of depression|improve cardiac outcomes|uncertainty in context|d1d2debda1dd4a8d858975e2a2d03384|4
Radiation therapy|Breast cancer|treatment for|b4cf928ab1b842d4924569c161962ec8|4
Radiation therapy|Cardiac mortality|associated with increased risk of|b4cf928ab1b842d4924569c161962ec8|4
Radiation therapy|Cardiac morbidity|associated with increased risk of|b4cf928ab1b842d4924569c161962ec8|4
Cigarette smoking|Counselling for cessation|Counselling for cessation is a method to help people quit cigarette smoking|b67b726c793645c5a738a5a4ade44ccc|4
Cigarette smoking|Nicotine replacement|Nicotine replacement can be used as an aid to help people quit cigarette smoking|b67b726c793645c5a738a5a4ade44ccc|4
Cigarette smoking|Pharmacotherapy|Pharmacotherapy is a treatment method that can be applied in conjunction with cessation efforts for cigarette smoking|b67b726c793645c5a738a5a4ade44ccc|4
Lifestyle intervention|Physical activity|Physical activity is one component of a lifestyle intervention.|b67b726c793645c5a738a5a4ade44ccc|4
Physical activity|Moderate exercise|Moderate exercise is one form of physical activity recommended in a lifestyle intervention.|b67b726c793645c5a738a5a4ade44ccc|4
Physical activity|Vigorous exercise|Vigorous exercise is another form of physical activity recommended in a lifestyle intervention.|b67b726c793645c5a738a5a4ade44ccc|4
Physical activity|Muscle strengthening activities|Muscle strengthening activities are an additional component of physical activity in a lifestyle intervention.|b67b726c793645c5a738a5a4ade44ccc|4
Cardiac rehabilitation|Recent acute coronary syndrome|Recommended for women with|9f12fde513e8453b840b639a0f8a132e|4
Cardiac rehabilitation|Revascularization|Recommended for women with|9f12fde513e8453b840b639a0f8a132e|4
Cardiac rehabilitation|CVA|Recommended for women with|9f12fde513e8453b840b639a0f8a132e|4
Cardiac rehabilitation|PAD|Recommended for women with|9f12fde513e8453b840b639a0f8a132e|4
BMI|< 25 kg/m|Recommended to maintain by exercise and appropriate diet|9f12fde513e8453b840b639a0f8a132e|4
Waist size|< 35 inches|Recommended to maintain by exercise and appropriate diet|9f12fde513e8453b840b639a0f8a132e|4
CLINICAL RISK FACTORS TARGETS AND USES IN RISK ASSESSMENT|Blood pressure < 140/90 mm Hg|Recommended|9f12fde513e8453b840b639a0f8a132e|4
High Blood pressure|Consider therapy from one of the indicated classes of antihypertensive drugs|If higher,|9f12fde513e8453b840b639a0f8a132e|4
LDL-C|70-189 mg/dL|at baseline|426fe5b8c62e4adfa880f23ac1d76acc|4
between 70-189 mg/dL|without clinical ASCVD|in ages 40-75 years|426fe5b8c62e4adfa880f23ac1d76acc|4
ASCVD risk score|≥ 7.5%|consider statins for|426fe5b8c62e4adfa880f23ac1d76acc|4
statins|high-intensity statin therapy|warrant due to higher risk|426fe5b8c62e4adfa880f23ac1d76acc|4
ASCVD risk factors|10-year ASCVD risk ≥ 7.5%|indicate higher risk and warrant high-intensity statin therapy ± ezetimibe (or colesevelam)|426fe5b8c62e4adfa880f23ac1d76acc|4
CKD|albuminuria|retinopathy, evidence of subclinical atherosclerosis, elevated lipoprotein(a), or elevated hs-CRP|426fe5b8c62e4adfa880f23ac1d76acc|4
evidence of subclinical atherosclerosis|elevated hs-CRP|indicate higher risk and warrant high-intensity statin therapy ± ezetimibe (or colesevelam)|426fe5b8c62e4adfa880f23ac1d76acc|4
elevated lipoprotein(a)|elevated hs-CRP|indicate higher risk and warrant high-intensity statin therapy ± ezetimibe (or colesevelam)|426fe5b8c62e4adfa880f23ac1d76acc|4
ezetimibe|colesevelam|high-intensity statin therapy|426fe5b8c62e4adfa880f23ac1d76acc|4
Hs-CRP > 3.0 mg/dL|high relative risk|high Hs-CRP level indicates higher relative risk|84b29136123a4ab7945487466274fed7|4
CAC scoring|disease severity|CAC scoring is used to determine the severity of identifiable disease|84b29136123a4ab7945487466274fed7|4
CIMT|routine ASCVD risk assessment|CIMT is not recommended for routine ASCVD risk assessment|84b29136123a4ab7945487466274fed7|4
aspirin|recommended therapy|Aspirin is recommended therapy|84b29136123a4ab7945487466274fed7|4
USPTF|women aged 50-59 years|USPTF recommends aspirin for women aged 50-59 years|84b29136123a4ab7945487466274fed7|4
10% or greater 10-year CVD risk|women aged 50-59 years|Women with 10% or greater 10-year CVD risk benefit from aspirin therapy|84b29136123a4ab7945487466274fed7|4
expert opinion|2013 ACC/AHA Guidelines|Recommendations are based on expert opinion in 2013 ACC/AHA Guidelines|84b29136123a4ab7945487466274fed7|4
cardiovascular diseases|women|interventions for prevention|71f802463a8b426cb8950c2c757b3eb2|4
cerebrovascular accident|current guidelines|assessment and interventions based on|71f802463a8b426cb8950c2c757b3eb2|4
includes stroke or transient ischemic attack|PAD: peripheral arterial disease|are both risk factors|915f6a6608df4ce491fd8a42b4df25be|4
BMI: body mass index|ASCVD: atherosclerotic cardiovascular disease|affects the risk of|915f6a6608df4ce491fd8a42b4df25be|4
CKD: chronic kidney disease|hs-CRP: high-sensitivity C-reactive protein|is associated with|915f6a6608df4ce491fd8a42b4df25be|4
LDL-C: low-density lipoprotein cholesterol|HDL-C: high-density lipoprotein cholesterol|are types of cholesterol|915f6a6608df4ce491fd8a42b4df25be|4
CAC: coronary artery calcium|CIMT : carotid intima–media thickness|are used to assess atherosclerosis risk|915f6a6608df4ce491fd8a42b4df25be|4
Radiation injury|Constrictive pericarditis|cause|2540a9b5e8d34359a912af7a25dab75d|4
Radiation injury|Myocardial fibrosis|cause|2540a9b5e8d34359a912af7a25dab75d|4
Radiation injury|Valvular and coronary artery lesions|cause|2540a9b5e8d34359a912af7a25dab75d|4
Increased risk of cardiovascular mortality|Dose volume of exposure to the heart|proportional to|2540a9b5e8d34359a912af7a25dab75d|4
postoperative radiation therapy|cardiac mortality|positively correlated|9154f7699e0a4c20b85fa7f11e0234aa|4
high-dose volumes|increased mortality|caused by|9154f7699e0a4c20b85fa7f11e0234aa|4
cardiac radiation dose-volume|ischemic heart disease|related to|9154f7699e0a4c20b85fa7f11e0234aa|4
preexisting cardiac risk factors|radiotherapy|greater absolute increase in risk from|9154f7699e0a4c20b85fa7f11e0234aa|4
radiotherapy regimens for breast cancer|women with breast cancer who have undergone therapy|treatment|a4a65d907e4646419bcb1b7c68454e6a|4
radiation|consideration in women with breast cancer|impact|a4a65d907e4646419bcb1b7c68454e6a|4
estrogen|estrogen receptors expressed both in vascular endothelial and smooth muscle cells|role|a4a65d907e4646419bcb1b7c68454e6a|4
estrogen|improves the arterial wall response to injury|benefit|a4a65d907e4646419bcb1b7c68454e6a|4
estrogen|promotes re-endothelialization|function|a4a65d907e4646419bcb1b7c68454e6a|4
smooth muscle cell proliferation|matrix deposition following vascular injury|inhibits|afb6c087fe084b3792a8e7ad9a0729ec|4
Estrogen|coronary artery spasm|prevents through vasodilation mediated by|afb6c087fe084b3792a8e7ad9a0729ec|4
Estrogen|nitric oxide (NO)|increases the production of|afb6c087fe084b3792a8e7ad9a0729ec|4
Estrogen|NO genes|induction of|afb6c087fe084b3792a8e7ad9a0729ec|4
Estrogen|endothelium and smooth muscle cells|impact on|afb6c087fe084b3792a8e7ad9a0729ec|4
Estrogen|cardiomyocytes|affects|afb6c087fe084b3792a8e7ad9a0729ec|4
Estrogen|cardiomyocyte apoptosis|prevents|afb6c087fe084b3792a8e7ad9a0729ec|4
cardiomyocyte hypertrophic response|estrogen|inhibits|1fc4b650dcd44c2ba11d9a797295fadc|4
conflicting data|hypertrophic response|on|1fc4b650dcd44c2ba11d9a797295fadc|4
postmenopausal women|cardioprotective effects of estrogen|lose|1fc4b650dcd44c2ba11d9a797295fadc|4
elevated risk for CVD|postmenopausal women|have an|1fc4b650dcd44c2ba11d9a797295fadc|4
ACC and AHA|menopause as a risk factor|recognize|1fc4b650dcd44c2ba11d9a797295fadc|4
HRT|evidence for promoting|controversial|1fc4b650dcd44c2ba11d9a797295fadc|4
Women’s Health Initiative (WHI) study|estrogen-progestin replacement|had no cardioprotective|1fc4b650dcd44c2ba11d9a797295fadc|4
Harm|HRT|effect and may have produced|3ffb058f21f8413aa8c78b8eb068d1d4|4
Secondary prevention cohort|HERS trials|Similar results in a|3ffb058f21f8413aa8c78b8eb068d1d4|4
HRT|Primary or secondary prevention of CVD|not recommended for|3ffb058f21f8413aa8c78b8eb068d1d4|4
Usage of HRT|WHI findings|As a result, has decreased|3ffb058f21f8413aa8c78b8eb068d1d4|4
Treatment decisions|Perimenopausal women in their 40s and 50s with distressing vasomotor symptoms|These findings have also affected|3ffb058f21f8413aa8c78b8eb068d1d4|4
USPSTF|recommendations|applies to|8979e4452961443fb0b63d6ef5f5ddb4|4
women under age 50|HRT for treatment of menopausal symptoms|do not apply to|8979e4452961443fb0b63d6ef5f5ddb4|4
risks and benefits|patient|should be considered and discussed with|8979e4452961443fb0b63d6ef5f5ddb4|4
pooled cohort risk equation|10-year CVD risk|used to assess|f73beb47e03f4396a3ff3070f71dbc3f|4
United States|current recommendation|for use in|f73beb47e03f4396a3ff3070f71dbc3f|4
future|nontraditional risk factors and markers|should be considered with|f73beb47e03f4396a3ff3070f71dbc3f|4
depression|radiation exposure|among other nontraditional risk factors|f73beb47e03f4396a3ff3070f71dbc3f|4
treatment thresholds|men and women|similar in men and women will need to be further explored|b32cedb5287a4ffe96c8e9858d094b38|4
2011 effectiveness-based guidelines|women|recommended different CVD prevention and treatment strategies specific to women compared to men|b32cedb5287a4ffe96c8e9858d094b38|4
2013 ACC/AHA lipid guidelines|men and women|have similar recommendations for men and women|b32cedb5287a4ffe96c8e9858d094b38|4
CAROTID INTIMA-MEDIA THICKNESS|risk markers|Ten-year risk assessments still have room for improvement; thus|b32cedb5287a4ffe96c8e9858d094b38|4
genetic biomarkers|serum biomarkers|both have been extensively studied in risk stratification|627de5693c7548b1913cf62b3681c913|4
imaging|carotid ultrasound and coronary computed tomography (CT)|have been extensively studied in risk stratification|627de5693c7548b1913cf62b3681c913|4
risk stratification|genetic biomarkers, serum biomarkers, imaging such as carotid ultrasound and coronary computed tomography (CT)|are used in|627de5693c7548b1913cf62b3681c913|4
carotid intima-media thickness (CIMT)/plaque information on a carotid ultrasound|risk prediction for CVD|improves|627de5693c7548b1913cf62b3681c913|4
2010 ACCF/AHA Guideline|endorsed assessment of carotid intima-media thickness (CIMT)/plaque information on a carotid ultrasound|for Assessment of Cardiovascular Risk in Asymptomatic Adults|627de5693c7548b1913cf62b3681c913|4
CT-based coronary calcium score (CAC)|threshold for initiating statin therapy|recommended by the ACC/AHA 2013 lipid guidelines|fb7b868ae52a4383985de90f6d6319fa|4
brachial index|treatment decisions|help to assist|2855388d1c9b4b4fa2aff871f2af7974|4
brachial index|uncertainty|after quantitative risk assessment|2855388d1c9b4b4fa2aff871f2af7974|4
therapies for primary prevention of CVD|statins in prevention|to treat|2855388d1c9b4b4fa2aff871f2af7974|4
JUPITER trial|individuals with a C-reactive protein > 2 mg/dL|included|2855388d1c9b4b4fa2aff871f2af7974|4
JUPITER trial|LDL-C < 130 mg/dL|also included|2855388d1c9b4b4fa2aff871f2af7974|4
REVIEW METHODIST DEBAKEY CARDIOVASC J|13 (4) 2017|is part of|5162569a2f3640d8a55cdeab31b1e77f|4
JOURNAL.HOUSTONMETHODIST.ORG|REVIEW METHODIST DEBAKEY CARDIOVASC J|hosting the journal|5162569a2f3640d8a55cdeab31b1e77f|4
HOPE-3 trial|intermediate-risk subjects without known CVD|focuses on|5162569a2f3640d8a55cdeab31b1e77f|4
statins help in the primary prevention of CVD|HOPE-3 trial|results from|5162569a2f3640d8a55cdeab31b1e77f|4
benefit occurs in both men and women|statins help in the primary prevention of CVD|explains|5162569a2f3640d8a55cdeab31b1e77f|4
CVD|prevention|The primary and secondary prevention of CVD is valuable in both men and women.|6b9f3622e10044c2a7c5ecaeba55658a|4
statin safety data|pregnancy|There is a lack of statin safety data in pregnancy.|6b9f3622e10044c2a7c5ecaeba55658a|4
women of childbearing age|counseling|These women need to be thoroughly counseled on contraceptive use.|6b9f3622e10044c2a7c5ecaeba55658a|4
contraceptive use|avoid pregnancy|Contraceptive use is needed to avoid pregnancy while on statin therapy.|6b9f3622e10044c2a7c5ecaeba55658a|4
statin therapy|secondary prevention of CVD|The use of statin therapy is for the secondary prevention of CVD.|6b9f3622e10044c2a7c5ecaeba55658a|4
aspirin|prevention|established|8dc9a0d8f6b04711857b86a08f40ed7e|4
aspirin|data supporting aspirin use|supporting|8dc9a0d8f6b04711857b86a08f40ed7e|4
aspirin|men|mainly reported in men before 2005|8dc9a0d8f6b04711857b86a08f40ed7e|4
aspirin|women|studied in women after 2005|8dc9a0d8f6b04711857b86a08f40ed7e|4
aspirin|low-dose aspirin|100 mg alternate-day dosing|8dc9a0d8f6b04711857b86a08f40ed7e|4
dose aspirin|risk of stroke|reduced without reducing MI|330a5811db1b4be08e1cca7911f0ac77|4
age|determinant|most important|330a5811db1b4be08e1cca7911f0ac77|4
low-dose aspirin|risk of major cardiovascular events|significantly reduced|330a5811db1b4be08e1cca7911f0ac77|4
women > 65 years old|group benefited|particularly for this group|330a5811db1b4be08e1cca7911f0ac77|4
aspirin therapy|higher bleeding risk|those assigned to aspirin therapy had|330a5811db1b4be08e1cca7911f0ac77|4
risk and benefits|weighed|the risk and benefits of aspirin therapy should be weighed|330a5811db1b4be08e1cca7911f0ac77|4
patient|has risk factors for bleeding|particularly if a patient has risk factors for bleeding|330a5811db1b4be08e1cca7911f0ac77|4
low-dose aspirin|type 2 DM|used in patients with type 2 DM|bcff9d8a552c4d848b2be3e90f27c8bd|4
low-dose aspirin|primary prevention of CVD|evaluated for long-term safety and efficacy in preventing CVD|bcff9d8a552c4d848b2be3e90f27c8bd|4
low-dose aspirin|CV outcomes|did not improve CV outcomes|bcff9d8a552c4d848b2be3e90f27c8bd|4
low-dose aspirin|gastrointestinal bleeding|increased the risk of gastrointestinal bleeding|bcff9d8a552c4d848b2be3e90f27c8bd|4
statin use|individuals|statin use among these individuals|bcff9d8a552c4d848b2be3e90f27c8bd|4
statin use|lower LDL-C|reduced previously known aspirin benefit|bcff9d8a552c4d848b2be3e90f27c8bd|4
U.S. Preventive Services Task Force|recommended the use of low-dose aspirin|for primary prevention in both women and men aged 50 to 59 years who have a 10% or greater 10-year CVD risk without an increased risk of bleeding|e2618b56407040aa8095a6dedc69e09c|4
low-dose aspirin|for primary prevention in both women and men aged 50 to 59 years who have a 10% or greater 10-year CVD risk without an increased risk of bleeding|Grade B recommendation|e2618b56407040aa8095a6dedc69e09c|4
primary prevention|in both women and men aged 50 to 59 years who have a 10% or greater 10-year CVD risk without an increased risk of bleeding|U.S. Preventive Services Task Force recommendation|e2618b56407040aa8095a6dedc69e09c|4
Women|Cardiovascular clinical trials|underrepresentation in therapeutic strategies|d081fb635e0448c9821c98ca52362eb4|4
Single-sex studies|Female participation|increased substantially|d081fb635e0448c9821c98ca52362eb4|4
Mixed-gender trials|Women|less than a third of participants|d081fb635e0448c9821c98ca52362eb4|4
Postulated reasons|Low female participation|in research enrollment|d081fb635e0448c9821c98ca52362eb4|4
enrollment|underestimated cardiac risk in women and atypical cardiac disease presentation|include|d65307a97848481a8c05e438f5689003|4
underestimated cardiac risk in women and atypical cardiac disease presentation|reduced referrals to cardiology practices|result|d65307a97848481a8c05e438f5689003|4
reduced referrals to cardiology practices|recruitment for CV clinical trials is performed|where|d65307a97848481a8c05e438f5689003|4
women manifest CVD later in life, and an age-gender bias may be present during the study enrollment process|enrollment|mentioned|d65307a97848481a8c05e438f5689003|4
other possible barriers to the recruitment of women|enrollment|Other|d65307a97848481a8c05e438f5689003|4
fear and distrust|research enterprise|caused by|2fec5246267142d2b011a86e3fbc5aa6|4
lack of knowledge|participation in research|due to|2fec5246267142d2b011a86e3fbc5aa6|4
lack of transportation|study participation|inhibits|2fec5246267142d2b011a86e3fbc5aa6|4
interference with work or family responsibilities|study participation|causes|2fec5246267142d2b011a86e3fbc5aa6|4
subject burden|study participation|results in|2fec5246267142d2b011a86e3fbc5aa6|4
financial costs|study participation|imposes|2fec5246267142d2b011a86e3fbc5aa6|4
preventive therapies for CVD|reducing mortality|achieves|2fec5246267142d2b011a86e3fbc5aa6|4
preventive therapies for CVD|preserving cardiovascular health in women|goal of|2fec5246267142d2b011a86e3fbc5aa6|4
CVD|leading cause of death|CVD is the leading cause of death|ed6b76e881a244a4a50c7b25d2ca2d97|4
CVD|United States|CVD is the leading cause of death in the United States|ed6b76e881a244a4a50c7b25d2ca2d97|4
scientific community|robust progress|The scientific community has made robust progress|ed6b76e881a244a4a50c7b25d2ca2d97|4
CVD|pathophysiology of CVD in women|The scientific community has made progress recognizing the clear differences in pathophysiology of CVD in women|ed6b76e881a244a4a50c7b25d2ca2d97|4
treatment approaches|women and men|Currently, there are no differences in treatment approaches between women and men.|ed6b76e881a244a4a50c7b25d2ca2d97|4
era of personalized medicine|move into an era|This hopefully will change as we move into an era of personalized medicine.|ed6b76e881a244a4a50c7b25d2ca2d97|4
personalized medicine|female patients|treated less aggressively|5b67d004d784412e90c78a54d4e3ad77|4
female patients|coronary interventions|fewer performed for similar presentations compared to men|5b67d004d784412e90c78a54d4e3ad77|4
overall risk|postmenopausal women and men|similarity of overall risk in postmenopausal women and men|5b67d004d784412e90c78a54d4e3ad77|4
comprehensive understanding|hormonal and genomic basis|pathophysiologic differences of CVD|5b67d004d784412e90c78a54d4e3ad77|4
comprehensive understanding|gender-specific care|key to providing gender-specific care|5b67d004d784412e90c78a54d4e3ad77|4
gender-specific care|research participation by women|Encouraging more research participation by women will help clarify gender-based risk factors and aid in discovery of beneficial treatments.|d3584d854134469093ce6946646ea293|4
conflict of interest disclosure|gender-specific care|Conflict of Interest Disclosure: |d3584d854134469093ce6946646ea293|4
Conflict of Interest Disclosure|Dr. Nambi|is the subject for this disclosure|9706e03e974e4a1e825dc0ce05f1830e|4
Dr. Nambi|Merck|receives research funding from|9706e03e974e4a1e825dc0ce05f1830e|4
Dr. Nambi|Baylor College of Medicine|works with through Baylor College of Medicine for research funding|9706e03e974e4a1e825dc0ce05f1830e|4
Dr. Nambi|Sanofi-Regeneron|served on a regional advisory board for Sanofi-Regeneron|9706e03e974e4a1e825dc0ce05f1830e|4
Dr. Nambi|Siemens Healthcare Diagnostics|received an honorarium from Siemens Healthcare Diagnostics|9706e03e974e4a1e825dc0ce05f1830e|4
Dr. Nambi|Baylor College of Medicine|is associated with Baylor College of Medicine|9706e03e974e4a1e825dc0ce05f1830e|4
Dr. Nambi|Roche|holds a provisional patent filed by Baylor College of Medicine and Roche|9706e03e974e4a1e825dc0ce05f1830e|4
cardiovascular disease|risk factors|affect|e707a27ce512451d9c2fc373074fbf3c|4
women and CVD|postmenopausal CVD|association|e707a27ce512451d9c2fc373074fbf3c|4
Myocardial ischemia in women|Lessons from the NHLBI WISE study|is discussed in|b5894ae7effc45b6a05605539a218b4e|4
National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE)|Study conducted by the same organization|is a part of|b5894ae7effc45b6a05605539a218b4e|4
Abnormal coronary vasomotion|Prognostic indicator for cardiovascular events in women|is discussed in the same publication as|b5894ae7effc45b6a05605539a218b4e|4
myocardial infarction|women without angiographically obstructive coronary artery disease|cause|5284a3e0b6234ba89fb019b3f66aeda0|4
Circulation|Reynolds HR, Srichai MB, Iqbal SN, et al.|publication|5284a3e0b6234ba89fb019b3f66aeda0|4
Effectiveness-based guidelines|Prevention of cardiovascular disease in women|are for|a5898b926e51484ca609be0d7e2a9e39|4
2011 update|Effectiveness-based guidelines|for|a5898b926e51484ca609be0d7e2a9e39|4
American Heart Association|Effectiveness-based guidelines|from the|a5898b926e51484ca609be0d7e2a9e39|4
American Heart Association|Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Hypertension, Council on Lifestyle and Cardiometabolic Health, and Council on Quality of Care and Outcomes Research|is involved in|d614bd24e6204ab7b08b4354b7fc9dd4|4
McSweeney JC, Rosenfeld AG, Abel WM, et al.|American Heart Association Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Hypertension, Council on Lifestyle and Cardiometabolic Health, and Council on Quality of Care and Outcomes Research|are authors or members|d614bd24e6204ab7b08b4354b7fc9dd4|4
Circulation|2016 Mar|is the publication date|d614bd24e6204ab7b08b4354b7fc9dd4|4
American Heart Association|Circulation|organization and journal|b8d086d58c964fe29f2137b3f2d03654|4
Circulation|2016 Mar 29|publication date|b8d086d58c964fe29f2137b3f2d03654|4
Circulation|133(13)|issue number and volume|b8d086d58c964fe29f2137b3f2d03654|4
Circulation|1302-31|page range|b8d086d58c964fe29f2137b3f2d03654|4
Hu FB|Trends in the incidence of coronary heart disease|study by Hu FB about trends|b4190ca2ad734b9680a9b3c6bcc244ca|4
Stampfer MJ|Trends in the incidence of coronary heart disease|study by Stampfer MJ about trends|b4190ca2ad734b9680a9b3c6bcc244ca|4
Manson JE|Cardiovascular Disease in Women: Clinical Perspectives|study by Manson JE on cardiovascular disease|b4190ca2ad734b9680a9b3c6bcc244ca|4
Garcia M|Cardiovascular Disease in Women: Clinical Perspectives|study by Garcia M on cardiovascular disease|b4190ca2ad734b9680a9b3c6bcc244ca|4
Merz CN|Cardiovascular Disease in Women: Clinical Perspectives|study by Merz CN on cardiovascular disease|b4190ca2ad734b9680a9b3c6bcc244ca|4
Buring JE|Cardiovascular Disease in Women: Clinical Perspectives|study by Buring JE on cardiovascular disease|b4190ca2ad734b9680a9b3c6bcc244ca|4
N Engl J Med|Trends in the incidence of coronary heart disease|published in N Engl J Med|b4190ca2ad734b9680a9b3c6bcc244ca|4
Circ Res|Cardiovascular Disease in Women: Clinical Perspectives|published in Circ Res|b4190ca2ad734b9680a9b3c6bcc244ca|4
Eighth Joint National Committee|JNC 8|is also referred to as|cf8dc8ea671f4e469d02bb64d48b5f11|4
panel members appointed|the Eighth Joint National Committee|are from|cf8dc8ea671f4e469d02bb64d48b5f11|4
Evidence-based guideline|James PA, Oparil S, Carter BL, et al.|is by|cf8dc8ea671f4e469d02bb64d48b5f11|4
Management of high blood pressure in adults|the Eighth Joint National Committee|guide is for|cf8dc8ea671f4e469d02bb64d48b5f11|4
James PA, Oparil S, Carter BL, et al.|JAMA|is published in|cf8dc8ea671f4e469d02bb64d48b5f11|4
JAMA|February 5;311(5):507-20.|specific issue and page of|cf8dc8ea671f4e469d02bb64d48b5f11|4
Goff DC Jr|American College of Cardiology|authored a document for|319fe67103614c0fa083d9f261b6e06a|4
Goff DC Jr|American Heart Association|co-authored a guideline with|319fe67103614c0fa083d9f261b6e06a|4
J Am Coll Cardiol|Guidelines|published a document on|319fe67103614c0fa083d9f261b6e06a|4
2013 ACC/AHA guideline on the assessment of cardiovascular risk|cardiovascular risk|focused on|319fe67103614c0fa083d9f261b6e06a|4
J Am Coll Cardiol|American College of Cardiology/American Heart Association Task Force on Practice Guidelines|published a document by|319fe67103614c0fa083d9f261b6e06a|4
Saeed A|Cardiovascular Risk|discusses the importance of|319fe67103614c0fa083d9f261b6e06a|4
Saeed A|Type 2 Diabetes|focuses on|319fe67103614c0fa083d9f261b6e06a|4
Curr Cardiol Rep|Assessing Cardiovascular Risk and Testing in Type 2 Diabetes|published a document on|319fe67103614c0fa083d9f261b6e06a|4
Diabetes|Cardiovascular disease|Framingham study|4fd0824a16ce4864b568811b2cbe043a|4
Women|Men|type 1 diabetes|4fd0824a16ce4864b568811b2cbe043a|4
All-cause mortality|Vascular events|women versus men with type 1 diabetes|4fd0824a16ce4864b568811b2cbe043a|4
Pregnancy|Risk for Cardiometabolic Disease|Reveals Evolving|387610c622d7403f8f8db4750717d9e0|4
Pregnancy|Cardiovascular sequelae of preeclampsia/eclampsia|Causes|387610c622d7403f8f8db4750717d9e0|4
Pre-eclampsia|cardiovascular disease and cancer|systematic review and meta-analysis|a39490d353f34c5da0f37541f76ff5e8|4
Gestational diabetes mellitus|Cardiovascular disease|increases the risk of|eb6d8f5937a74de8acafba747046fa75|4
systemic inflammation|cardiovascular risk factors|predict rapid progression of atherosclerosis|08ae2169b431481dacd28fe36873e135|4
inflammatory markers|serum lipids|risk of cardiovascular events in patients with rheumatoid arthritis|08ae2169b431481dacd28fe36873e135|4
Depression|Heart disease|antecedent to|9dab25a1621142d0a7878c27caf18cec|4
National Health and Nutrition Examination Survey|Study|part of|9dab25a1621142d0a7878c27caf18cec|4
Men and women|Depression and heart disease|among|9dab25a1621142d0a7878c27caf18cec|4
NHANES I study|Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML|authors of|9dab25a1621142d0a7878c27caf18cec|4
radiation-induced heart disease|Pathology of radiation-induced heart disease|is a study of|42b8eb43a54e45ea94457911fdb72134|4
27 cases|study of 27 cases|focuses on|42b8eb43a54e45ea94457911fdb72134|4
Estradiol|Reendothelialization|accelerates|4e6045b4550242a3bcaf07f15e5f463f|4
Estradiol|Estrogen receptor-alpha|binds to|4e6045b4550242a3bcaf07f15e5f463f|4
Estradiol|Estrogen receptor-beta|does not bind to|4e6045b4550242a3bcaf07f15e5f463f|4
Carotid artery|Reendothelialization|in|4e6045b4550242a3bcaf07f15e5f463f|4
Estrogen|Cardiomyocyte apoptosis|prevents|e08a1238d5d3451687449efebf9838c0|4
Estrogen|Reactive oxygen species|inhibition of|e08a1238d5d3451687449efebf9838c0|4
Estrogen|p38 kinase isoforms|differential regulation of|e08a1238d5d3451687449efebf9838c0|4
Estrogen|Cardiomyocyte hypertrophy|attenuates|e08a1238d5d3451687449efebf9838c0|4
Estrogen receptor-dependent pathway|Calcineurin degradation|increases|e08a1238d5d3451687449efebf9838c0|4
Estrogens|cardiac hypertrophy|mediate|ac1f8cfd25a24620a2df739854e0674a|4
Endocrinology|2012 Sep;153(9);4480-90|publication|ac1f8cfd25a24620a2df739854e0674a|4
Estrogens|stimulus-dependent manner|mediate in|ac1f8cfd25a24620a2df739854e0674a|4
Menopause|Treatment of Symptoms|subject|ac1f8cfd25a24620a2df739854e0674a|4
Endocrine Society Clinical Practice Guideline|2015 Nov;100(11);3975-4011|publication|ac1f8cfd25a24620a2df739854e0674a|4
Clinical Care|Getting Back on Track|improvement|ac1f8cfd25a24620a2df739854e0674a|4
U.S. Preventive Services Task Force|Moyer V A|Author of the paper on Menopausal hormone therapy|d3bb1f34000343dd83a8290d8e3ed0a0|4
Ann Intern Med.|34. Moyer V A; U.S. Preventive Services Task Force|Publication of the paper on Menopausal hormone therapy|d3bb1f34000343dd83a8290d8e3ed0a0|4
JUPITER Study Group|Ridker PM, Danielson E, Fonseca FA, et al.|Authors of the paper on Rosuvastatin to prevent vascular events|d3bb1f34000343dd83a8290d8e3ed0a0|4
N Engl J Med.|35. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group|Publication of the paper on Rosuvastatin to prevent vascular events|d3bb1f34000343dd83a8290d8e3ed0a0|4
low-dose aspirin|cardiovascular disease|treatment for|cd37c5e26924460696415a1979a91586|4
low-dose aspirin|primary prevention|in the context of|cd37c5e26924460696415a1979a91586|4
low-dose aspirin|cardiovascular events|prevention of|cd37c5e26924460696415a1979a91586|4
low-dose aspirin|randomized controlled trial|tested in|cd37c5e26924460696415a1979a91586|4
low-dose aspirin|patients with type 2 diabetes mellitus|for primary prevention of cardiovascular events in|cd37c5e26924460696415a1979a91586|4
Status of women in cardiovascular clinical trials|Arterioscler Thromb V asc Biol.|is published in|48d1370ec5ef46058ef2f89541cb316b|4
Kim ESH|Status of women in cardiovascular clinical trials|author of|48d1370ec5ef46058ef2f89541cb316b|4
Menon V|Status of women in cardiovascular clinical trials|author of|48d1370ec5ef46058ef2f89541cb316b|4
Lee PY|Representation of elderly persons and women in published randomized trials of acute coronary syndromes|author of|48d1370ec5ef46058ef2f89541cb316b|4
Alexander KP|Representation of elderly persons and women in published randomized trials of acute coronary syndromes|author of|48d1370ec5ef46058ef2f89541cb316b|4
Hammill BG|Representation of elderly persons and women in published randomized trials of acute coronary syndromes|author of|48d1370ec5ef46058ef2f89541cb316b|4
Pasquali SK|Representation of elderly persons and women in published randomized trials of acute coronary syndromes|author of|48d1370ec5ef46058ef2f89541cb316b|4
Peterson ED|Representation of elderly persons and women in published randomized trials of acute coronary syndromes|author of|48d1370ec5ef46058ef2f89541cb316b|4
JAMA.|Representation of elderly persons and women in published randomized trials of acute coronary syndromes|is published in|48d1370ec5ef46058ef2f89541cb316b|4
Mediterranean Diet|Components|The Mediterranean Diet consists of its components.|361d96d56cae459cab98ece5ecf87147|4
Mediterranean Diet|Cardiovascular Disease|The Mediterranean diet is studied for its effects on cardiovascular disease.|361d96d56cae459cab98ece5ecf87147|4
Authors|Institution|The authors are affiliated with Mayo School of Graduate Medical Education.|361d96d56cae459cab98ece5ecf87147|4
Mediterranean diet|cardiovascular health|the best studied diet for|0442cce1568c405c81ac3fbc7d938c9a|4
Mediterranean diet|fish, monounsaturated fats from olive oil, fruits, vegetables, whole grains, legumes/nuts, moderate alcohol consumption|consists of|0442cce1568c405c81ac3fbc7d938c9a|4
Mediterranean diet|reduce the burden, or prevent the development, of cardiovascular disease, breast cancer, depression, colorectal|has been shown to|0442cce1568c405c81ac3fbc7d938c9a|4
cancer|diabetes|related health issues|1b107fac8e3a4cd28b6056d9017a1e9f|4
obesity|asthma|related health issues|1b107fac8e3a4cd28b6056d9017a1e9f|4
erectile dysfunction|cognitive decline|related health issues|1b107fac8e3a4cd28b6056d9017a1e9f|4
waist-to-hip ratio|lipids|surrogates of cardiovascular disease|1b107fac8e3a4cd28b6056d9017a1e9f|4
markers of inflammation|primary cardiovascular disease outcomes|surrogates of cardiovascular disease|1b107fac8e3a4cd28b6056d9017a1e9f|4
death|events|primary cardiovascular disease outcomes|1b107fac8e3a4cd28b6056d9017a1e9f|4
blockers|ACE-inhibitors|mentioned in the same sentence as a comparison|8094b290b19847f2a3451b756fc3ffea|4
Mediterranean diet|cardiovascular disease benefit|mentioned in the same sentence as a possible source of benefit|8094b290b19847f2a3451b756fc3ffea|4
individual constituents|aggregate|mentioned in the same sentence as a method to determine diet's effect|8094b290b19847f2a3451b756fc3ffea|4
concrete cardiovascular disease endpoints|randomized trials or observational studies|mentioned in the same sentence as something yet to be validated|8094b290b19847f2a3451b756fc3ffea|4
cardiovascular disease morbidity or mortality|Mediterranean diet|potential for the Mediterranean diet to act as a key player in cardiovascular disease prevention|c669e30c1c8d475ab34802ce1481e9a3|4
cardio-protection|certain aspects of the diet which are particularly beneficial for|certain aspects of the diet which are particularly beneficial for cardio-protection|c669e30c1c8d475ab34802ce1481e9a3|4
Elsevier Inc|Publisher|is|73724c3efe634b9aa5c1243da654a167|4
All rights reserved|copyright|indicates|73724c3efe634b9aa5c1243da654a167|4
manuscript|copyediting|will undergo|f348ae552e2c4878a2e3012a3676a969|4
manuscript|typesetting|will undergo|f348ae552e2c4878a2e3012a3676a969|4
manuscript|proof review|will undergo|f348ae552e2c4878a2e3012a3676a969|4
production process|errors discovered|may be|f348ae552e2c4878a2e3012a3676a969|4
errors discovered|content affected|could affect|f348ae552e2c4878a2e3012a3676a969|4
legal disclaimers|apply to the journal|pertain|f348ae552e2c4878a2e3012a3676a969|4
authors|conflicts|have no conflicts|725284eaa94c4157a0e77c52fa7d2a3e|4
author|contribution|has contributed substantially|725284eaa94c4157a0e77c52fa7d2a3e|4
author|materials and data access|access to all materials and data|725284eaa94c4157a0e77c52fa7d2a3e|4
author manuscript|publication|available in PMC 2016 March 01|725284eaa94c4157a0e77c52fa7d2a3e|4
Am J Med.|author manuscript|published in final edited form as:|725284eaa94c4157a0e77c52fa7d2a3e|4
Am J Med.|year month date|2015 March ; 128(3): 229–238|725284eaa94c4157a0e77c52fa7d2a3e|4
author manuscript|doi|doi:10.1016/j.amjmed.2014.10.014|725284eaa94c4157a0e77c52fa7d2a3e|4
Mediterranean Diet|Cardiovascular Disease|relationship between proper diet and cardiovascular disease|d50a91e50fc748c1a93610e7353ec4b5|4
cardiovascular disease burden|lifestyle choices|account for up to 40% of premature cardiovascular disease deaths|14382570400b442dabcd428aa9198665|4
Mediterranean diet|reduce cardiovascular morbidity and mortality|consistently been shown to in meta-analyses, cohort studies, and randomized control trials|14382570400b442dabcd428aa9198665|4
Mediterranean diet|cardiovascular disease burden|reductions in|95f5f41893a94b9c987081055684d9e8|4
RCTs|improvements|match to|95f5f41893a94b9c987081055684d9e8|4
highly proven and advertised interventions|reductions in cardiovascular disease burden|demonstrated by|95f5f41893a94b9c987081055684d9e8|4
physical activity|measures such as smoking cessation|approach to|95f5f41893a94b9c987081055684d9e8|4
smoking cessation|measures such as physical activity|approached by|95f5f41893a94b9c987081055684d9e8|4
professional society guidelines|historical and narrative review|examines|95f5f41893a94b9c987081055684d9e8|4
Seven Countries Study|concept|dating back to the inception of such a concept|c38ef7802467427b856ece25bf775ae1|4
Seven Countries Study|Mediterranean diet|examining the role of the Mediterranean diet|c38ef7802467427b856ece25bf775ae1|4
Mediterranean Diet|cardiovascular disease|critically examine the role in ameliorating|c38ef7802467427b856ece25bf775ae1|4
developed world|farmers of Crete|consuming large amounts of fat yet had|c38ef7802467427b856ece25bf775ae1|4
lowest cardiovascular mortality rate|diet|The diet is associated with the lowest cardiovascular mortality rate.|b78c6126e7b64004a58e4703d42c9916|4
specific food items|single out|The diet does not single out specific food items.|b78c6126e7b64004a58e4703d42c9916|4
plant foods|abundance of|An abundance of plant foods is emphasized in the diet.|b78c6126e7b64004a58e4703d42c9916|4
olive oil|principal source of fat|Olive oil is the principal source of fat in the diet.|b78c6126e7b64004a58e4703d42c9916|4
limited dairy products|consumption|Limited dairy products are consumed.|b78c6126e7b64004a58e4703d42c9916|4
moderate amounts of fish, poultry, and wine|consumption|Moderate amounts of fish, poultry, and wine are consumed.|b78c6126e7b64004a58e4703d42c9916|4
red meat|low amounts|Low amounts of red meat are consumed.|b78c6126e7b64004a58e4703d42c9916|4
fresh fruit daily|consumption|Fresh fruit is consumed daily.|b78c6126e7b64004a58e4703d42c9916|4
American Heart Association (AHA) and European Society of Cardiology (ESC)|recommendations for dietary caloric distribution|The diet follows the current American Heart Association and European Society of Cardiology recommendations for dietary caloric distribution.|b78c6126e7b64004a58e4703d42c9916|4
dietary caloric distribution|Mediterranean diet|Principle in the data favoring the Mediterranean diet|0c426ae3d2754bb69f7086d252b9c848|4
Lyon Heart Study|cardiovascular disease events and death|established it as a staple in secondary prevention|0c426ae3d2754bb69f7086d252b9c848|4
PREDIMED|low Mediterranean diet|completed an RCT comparing|0c426ae3d2754bb69f7086d252b9c848|4
fat diet|Mediterranean diet|supplemented with either olive oil or nuts|c9f3b4d8b1d4407fa8006d9636b5998e|4
Mediterranean diet|Metiterranean diet arms of the trial|in fact, halted early after a significant reduction in cardiovascular disease events|c9f3b4d8b1d4407fa8006d9636b5998e|4
Mediterranean diet|preventative cardiovascular medicine|at the forefront of|4a3248c6947e4632a41ced716554aded|4
More Widmer et al.|prevention|researchers on|4a3248c6947e4632a41ced716554aded|4
Page 2|Am J Med|in|4a3248c6947e4632a41ced716554aded|4
PMC 2016 March 01|available in|date of availability|4a3248c6947e4632a41ced716554aded|4
Author manuscript|NIH-PA Author Manuscript|are|4a3248c6947e4632a41ced716554aded|4
copious, yet congruent, observational and RCT data|Mediterranean diet|exists with one RCT evaluating surrogate markers of cardiovascular disease prevention|132f93bb656c4333ac359eed01982319|4
Further RCT evidence|supports the use of a Mediterranean diet|to reduce genetic predisposition for risk factors|132f93bb656c4333ac359eed01982319|4
risk factors|not cardiovascular disease morbidity or mortality and their complications|in a high-risk population (9)|132f93bb656c4333ac359eed01982319|4
Mediterranean diet|patients on the Mediterranean diet|A sub-study of PREDIMED|268121036fca4d59960395b7ded8cabb|4
Mediterranean diet|fewer monocytes, inflammatory markers|had fewer monocytes, inflammatory markers and beneficial modulation of gene expression involved in LDL-oxidation|268121036fca4d59960395b7ded8cabb|4
Mediterranean diet|metabolic syndrome (12), diabetes (11)|showed beneficial effects regarding the metabolic syndrome and diabetes compared to low-fat diets|268121036fca4d59960395b7ded8cabb|4
Mediterranean diet|low-fat diets enriched with nuts or olive oil (12)|especially when enriched with either nuts or olive oil|268121036fca4d59960395b7ded8cabb|4
Observational and ecological studies|Seven-Countries Study|Study reference|6c00620d481e4245964d74ff966a8ff7|4
Mediterranean diet|cardio-protection|Benefit provided by the diet|6c00620d481e4245964d74ff966a8ff7|4
Mediterranean diet|surrogate markers for cardiovascular disease|Associated with|6c00620d481e4245964d74ff966a8ff7|4
Mediterranean diet|overall morbidity and mortality|Effect on|6c00620d481e4245964d74ff966a8ff7|4
Large meta-analysis|50,000 patients|Sample size|6c00620d481e4245964d74ff966a8ff7|4
Mediterranean diet|metabolic syndrome|Reduced risk of|6c00620d481e4245964d74ff966a8ff7|4
Mediterranean diet|risk factors such as metabolic syndrome|Protects against|6c00620d481e4245964d74ff966a8ff7|4
waist circumference|Mediterranean diet|comparable to other interventions|1497b0d078654f0c9cd7583d8a93f08d|4
lipids|Mediterranean diet|provided a more robust reduction in cardiovascular disease risk factors|1497b0d078654f0c9cd7583d8a93f08d|4
glucose|Mediterranean diet|provided a more robust reduction in cardiovascular disease risk factors|1497b0d078654f0c9cd7583d8a93f08d|4
blood pressure|Mediterranean diet|provided a more robust reduction in cardiovascular disease risk factors|1497b0d078654f0c9cd7583d8a93f08d|4
anti-hypertensives|Mediterranean diet|comparable to other interventions|1497b0d078654f0c9cd7583d8a93f08d|4
aspirin|Mediterranean diet|comparable to other interventions|1497b0d078654f0c9cd7583d8a93f08d|4
statins|Mediterranean diet|comparable to other interventions|1497b0d078654f0c9cd7583d8a93f08d|4
physical activity|Mediterranean diet|comparable to other interventions|1497b0d078654f0c9cd7583d8a93f08d|4
cardiovascular disease morbidity|estimates|are based on|067bd162797f4bd2a8880f2276363496|4
cardiovascular disease morbidity|reduction|is the primary goal of Mediterranean diet|067bd162797f4bd2a8880f2276363496|4
cardiovascular disease mortality|estimates|are based on|067bd162797f4bd2a8880f2276363496|4
cardiovascular disease mortality|reduction|is the primary goal of Mediterranean diet|067bd162797f4bd2a8880f2276363496|4
vast heterogeneity|studies|exists in|067bd162797f4bd2a8880f2276363496|4
varieties|studies|include|067bd162797f4bd2a8880f2276363496|4
subjects|styles|are factors in studies|067bd162797f4bd2a8880f2276363496|4
primary/secondary end points|studies|are based on|067bd162797f4bd2a8880f2276363496|4
Mediterranean diet|cardiovascular disease morbidity and mortality reduction|is effective for|067bd162797f4bd2a8880f2276363496|4
Mediterranean diet|robust data|supports|067bd162797f4bd2a8880f2276363496|4
primary prevention RCT|Mediterranean diet|demonstrates overwhelming benefit for|067bd162797f4bd2a8880f2276363496|4
Overwhelming benefit|RCT|The context mentions that there is an overwhelming benefit of RCT.|153d69f539954b989cfef911c7d7e251|4
Mediterranean diet|Foods|The context talks about examining the foods which comprise the Mediterranean diet.|153d69f539954b989cfef911c7d7e251|4
Observational versus RCT data|Individual components|The context discusses reviewing observational versus RCT data of the individual components of the diet.|153d69f539954b989cfef911c7d7e251|4
Cardiovascular disease morbidity and mortality|Reduction|The context mentions that these foods may offer a reduction in cardiovascular disease morbidity and mortality.|153d69f539954b989cfef911c7d7e251|4
Omega-3 Polyunsaturated Fats|Fish|The text describes marine omega-3 fatty acids found in fish.|153d69f539954b989cfef911c7d7e251|4
Polyunsaturated fatty acids|Marine omega-3 fatty acids|The context mentions that marine omega-3 fatty acids are polyunsaturated fatty acids.|153d69f539954b989cfef911c7d7e251|4
Widely studied|Omega-3 fatty acids|The text states that marine omega-3 fatty acids are widely studied.|153d69f539954b989cfef911c7d7e251|4
Mediterranean diet|fish|recommendation|18385538e2704b97b3b36a52424fe6d9|4
AHA/ACC|fish|consume twice per week|18385538e2704b97b3b36a52424fe6d9|4
European guidelines|isocaloric consumption of fish|endorse for primary and secondary cardiovascular disease and possibly dysrhythmia protection|18385538e2704b97b3b36a52424fe6d9|4
meta-analyses|cardiovascular disease morbidity and mortality benefit|potential with increased fish intake|18385538e2704b97b3b36a52424fe6d9|4
increased fish intake|mainly secondary prevention|with cardiovascular disease morbidity and mortality benefit|18385538e2704b97b3b36a52424fe6d9|4
systematic review of RCTs|marine omega-3|shown that|2bb413042d224296a3ebac1e4e1bdfee|4
marine omega-3|Widmer et al.|confirmed by|2bb413042d224296a3ebac1e4e1bdfee|4
Authors|Am J Med|Page 3|2bb413042d224296a3ebac1e4e1bdfee|4
Diet and reinfarction trial|RCTs|principal sources|35a61bd4d867438ca66e4a0a228938c1|4
DART|principal sources|for these data|35a61bd4d867438ca66e4a0a228938c1|4
GISSI-Prevention|principal sources|for these data|35a61bd4d867438ca66e4a0a228938c1|4
Japan EPA Lipid Intervention Study JELIS studies|principal sources|for these data|35a61bd4d867438ca66e4a0a228938c1|4
Recent meta-analyses of observational studies|support|the intake of higher amounts of fish|35a61bd4d867438ca66e4a0a228938c1|4
Higher amounts of fish|intake|in high-risk populations|35a61bd4d867438ca66e4a0a228938c1|4
High-risk populations|higher amounts of fish intake|recommended|35a61bd4d867438ca66e4a0a228938c1|4
primary prevention data|favorable|is|ac042f72e0e44e94be8f137c7ea3eb46|4
patients|balance|between|ac042f72e0e44e94be8f137c7ea3eb46|4
fish intake|favorable|so long as|ac042f72e0e44e94be8f137c7ea3eb46|4
fish intake|mercury toxicity|minimize the risk of|ac042f72e0e44e94be8f137c7ea3eb46|4
heterogeneity|fish intake versus fish oil supplementation|in these larger meta-analyses|ac042f72e0e44e94be8f137c7ea3eb46|4
RCTs|examining|fish oil supplementation in patients already on maximal medical therapy|ac042f72e0e44e94be8f137c7ea3eb46|4
reduced effect|on cardiovascular disease outcomes|has shown|ac042f72e0e44e94be8f137c7ea3eb46|4
well-controlled confounders in fish oil supplementation RCTs|source of discrepancies|between these studies and larger, positive observational trials|640c17066435411aac57fd8bbe9111bf|4
largest cohort trials examining fish intake and cardiovascular disease|Physician’s Health Study published in 1995|utilized prospective cohort data to argue against an association between fish consumption and cardiovascular disease benefit|640c17066435411aac57fd8bbe9111bf|4
increased fish consumption|reduced cardiovascular disease mortality|no association|0c9f800b64464f3a911f76b9d82c3a97|4
observational studies|selection bias and recall bias|must be taken into consideration when evaluating these data|0c9f800b64464f3a911f76b9d82c3a97|4
cardiovascular benefits|fish|in moderate to high-risk cardiovascular disease patients.|56014157b01a4a7eb51449227d1a2c69|4
mechanisms|beneficial effects of fish|underlying the cardiovascular disease|56014157b01a4a7eb51449227d1a2c69|4
reduced blood pressure|beneficial effects of fish|through 38, 39, 40|56014157b01a4a7eb51449227d1a2c69|4
reduced inflammation, oxidation, and coagulation|beneficial effects of fish|presumably through 41, 42|56014157b01a4a7eb51449227d1a2c69|4
moderate fish intake|diets|seem to confer cardiovascular disease benefits|56014157b01a4a7eb51449227d1a2c69|4
independent|benefits of fish|of their|56014157b01a4a7eb51449227d1a2c69|4
Mediterranean diet|heart-healthy diet|should comprise a key culinary component for|3d7fe4e3e88842fd8c47159f247ecd1a|4
Unsaturated Fats|Olive Oil|such as one of its sources|3d7fe4e3e88842fd8c47159f247ecd1a|4
Mediterranean diet|remainder of the Mediterranean diet|in conjunction with|3d7fe4e3e88842fd8c47159f247ecd1a|4
AHA/ACC|guidelines|endorse substituting mono- and polyunsaturated fats in place of saturated and trans-fatty acids|b7ea023df6b24880a11f12daafac3a88|4
ESC guidelines|AHA/ACC|endorse substituting mono- and polyunsaturated fats in place of saturated and trans-fatty acids|b7ea023df6b24880a11f12daafac3a88|4
olive oil consumption|cardiovascular disease prevention|research on impact has expanded over the last decades|b7ea023df6b24880a11f12daafac3a88|4
hard cardiovascular disease endpoints|RCTs|currently lacking from the data in the form of RCTs|b7ea023df6b24880a11f12daafac3a88|4
minor polar compounds|antioxidant properties|have|3d1a214ecffe4b9cb411969f375313b4|4
minor polar compounds|phenols|include|3d1a214ecffe4b9cb411969f375313b4|4
extra virgin olive oils|appreciable amounts|contain|3d1a214ecffe4b9cb411969f375313b4|4
cardio-protective effects of olive oil|presence of phenolic compounds|attributed to|3d1a214ecffe4b9cb411969f375313b4|4
olive oil's phenolic compounds|water-soluble fraction|obtained from|3d1a214ecffe4b9cb411969f375313b4|4
Widmer et al.|Am J Med|published in|3d1a214ecffe4b9cb411969f375313b4|4
Author|Manuscript|Author creates or edits a manuscript|0ec89c493fbf4d4e9842c16e9105b939|4
NIH-PA Author Manuscript|Document|NIH-PA Author Manuscript is a type of document|0ec89c493fbf4d4e9842c16e9105b939|4
hydroxytyrosol|antioxidants|A low-molecular weight molecule and potent antioxidant|be502f3b91e64665a25119a0a1f8f53c|4
oleuropein|potent antioxidants|Another related concept, also a potent antioxidant|be502f3b91e64665a25119a0a1f8f53c|4
potential of olive oil|mildly dyslipidemic patients|effect on|4be3e2add6294630beb7767afcd30900|4
seven week treatment period|levels of thromboxane B2|timeframe for change in|4be3e2add6294630beb7767afcd30900|4
seven week treatment period|total antioxidant capacity of plasma|timeframe for change in|4be3e2add6294630beb7767afcd30900|4
administration of olive oil|change in overall serum lipid profiles|causal relationship to|4be3e2add6294630beb7767afcd30900|4
EUROLIVE study|randomized, crossover controlled trial|type of|4be3e2add6294630beb7767afcd30900|4
Mediterranean Diet|olive oil|rich with|5337ddd538d248499c43a20eeb1e254c|4
research centers|patients|performed at six research centers across five European studies|5337ddd538d248499c43a20eeb1e254c|4
phenolic content|olive oil|with low, medium or high|5337ddd538d248499c43a20eeb1e254c|4
linear decrease in markers of oxidative stress|increasing phenolic content|with|5337ddd538d248499c43a20eeb1e254c|4
3 weeks|patients received olive oil|for three weeks with intervening two week washout periods|5337ddd538d248499c43a20eeb1e254c|4
endothelial function|systemic inflammation|improve endothelial function and reduce systemic inflammation|7e39e74624db4fe191721f202c258ebd|4
endothelial progenitor cell numbers|marker of increased endothelial repair|the authors report as a marker of increased endothelial repair (49)|7e39e74624db4fe191721f202c258ebd|4
butter- and walnut-rich meals|olive oil-rich meal|consumption of an olive oil-rich meal does not induce the postprandial activation of NF-kB pathway in monocytes (50)|7e39e74624db4fe191721f202c258ebd|4
postprandial activation of NF-kB pathway|monocytes|in contrast to butter- and walnut-rich meals|7e39e74624db4fe191721f202c258ebd|4
inflammatory effect|olive oil supplementation|has a beneficial effect on endothelial function|22ba883f26b44322a34d6d679ad659b5|4
endothelial function|low-moderate risk patients|increased in|22ba883f26b44322a34d6d679ad659b5|4
monounsaturated fatty acid intake|lipid levels|increases|22ba883f26b44322a34d6d679ad659b5|4
HDL|lipid levels|part of|22ba883f26b44322a34d6d679ad659b5|4
cardiovascular disease|surrogate markers|related to|22ba883f26b44322a34d6d679ad659b5|4
monounsaturated fats|cardiovascular disease mortality|inverse correlation|39aff62be8b34a8ca80bf5213eabebae|4
large meta-analysis|inverse correlation between blood pressure and monounsaturated fats intake|suggests|39aff62be8b34a8ca80bf5213eabebae|4
Mediterranean diet|olive oil|supplemented with|39aff62be8b34a8ca80bf5213eabebae|4
Mediterranean diet supplemented with olive oil|cardiovascular disease surrogate and morbidity benefit|proffers|39aff62be8b34a8ca80bf5213eabebae|4
olive oil|primary benefit in trials|teasing apart is difficult to do|39aff62be8b34a8ca80bf5213eabebae|4
supplementation|primary outcomes|showed similar results|c3cf4b71c508498c865c1848dfa53964|4
Fruits and Vegetables|improving cardiovascular health|encourages daily intake of multiple servings of both fruits and vegetables|c3cf4b71c508498c865c1848dfa53964|4
Mediterranean diet|aimed at improving cardiovascular health|including the Mediterranean|c3cf4b71c508498c865c1848dfa53964|4
cardiovascular disease risk reduction|ESC strongly endorses|the dietary use of fruits and vegetables|c3cf4b71c508498c865c1848dfa53964|4
AHA|re-affirmed stance|has twice re-affirmed a similar stance|c3cf4b71c508498c865c1848dfa53964|4
phytochemicals|cardiovascular disease|the prevention of cardiovascular disease by the intake of a variety of phytochemicals|5cdc7e2eeb9240139162caaf877b324f|4
observational studies|preventing cardiovascular disease|recommendations are based upon a broad base of observational studies for preventing cardiovascular disease|5cdc7e2eeb9240139162caaf877b324f|4
fruits and vegetables|cardiovascular disease prevention|large quantities of phytochemicals in fruits and vegetables recommended for prevention of cardiovascular disease|5cdc7e2eeb9240139162caaf877b324f|4
Widmer et al.|Am J Med|author manuscript published in the Am J Med by Widmer et al.|5cdc7e2eeb9240139162caaf877b324f|4
NIH-PA Author Manuscript|Author|is by|1034a9f574e64c3c9521112492250357|4
reduction in cardiovascular disease surrogates|increased consumption of fruits and vegetables|shows a relationship|2f0b976667424961a97bccf113b803d2|4
study|2003|showed a 3.0 mmHg drop in systolic blood pressure among women who consumed a higher amount of fruits, vegetables, or vitamin C with no difference in men (55)|2f0b976667424961a97bccf113b803d2|4
fruit and vegetables|vitamin C|consumption|2f0b976667424961a97bccf113b803d2|4
vegetable consumption|blood pressure|inversely associated|99e366de61944a079142c9bfc5e7d0a3|4
Mediterranean population|high vegetable-fat intake|associated with|99e366de61944a079142c9bfc5e7d0a3|4
fruit and vegetable intake|lower body mass index|linked with|99e366de61944a079142c9bfc5e7d0a3|4
cross-sectional study|increased fruit and vegetable intake|associated with|99e366de61944a079142c9bfc5e7d0a3|4
prospective Chicago Western Electric Study|red meat intake|slight benefit on blood pressure compared to|99e366de61944a079142c9bfc5e7d0a3|4
red meat consumption|blood pressure elevation|increased red meat consumption produces net blood pressure elevation in middle-aged men compared to increased fruit and vegetable intake.|247d2713d6b64fcfb9a8851a2294fee9|4
fruit and vegetable intake|cardiovascular disease|increased fruit and vegetable intake is associated with a reduced relative risk in cardiovascular disease compared to red meat consumption.|247d2713d6b64fcfb9a8851a2294fee9|4
vegetables serving|relative risk reduction|each serving of vegetables is associated with a 4% relative risk reduction in cardiovascular disease.|247d2713d6b64fcfb9a8851a2294fee9|4
fruit daily increase|relative risk reduction|each daily increase in servings of fruit is associated with a 7% relative risk reduction in cardiovascular disease.|247d2713d6b64fcfb9a8851a2294fee9|4
heterogeneity|publication bias|affected by|5d2e3219ee91424f93baeefedd25aabd|4
large meta-analysis|over 200,000 patients|involving|5d2e3219ee91424f93baeefedd25aabd|4
reduction in cardiovascular disease events|three to five servings of fruits and vegetables daily|resulting from|5d2e3219ee91424f93baeefedd25aabd|4
primary endpoint|17% reduction|being|5d2e3219ee91424f93baeefedd25aabd|4
data reaffirmed two years later|(60, 61)|from|5d2e3219ee91424f93baeefedd25aabd|4
population-based evidence|Evaluating Pimobendan In Cardiomegaly (EPIC)-Heart study|provided by|5d2e3219ee91424f93baeefedd25aabd|4
fruits and vegetables|lower risk|showed, after an eight-year follow up of 313,074 patients without overt atherosclerosis, a 22% lower risk|55ef922cf2bd4ad3824b4cb78d65f11b|4
fruits and vegetables|portions|consuming eight portions of fruits and vegetables a day as compared to three portions or less|55ef922cf2bd4ad3824b4cb78d65f11b|4
patients without overt atherosclerosis|follow up|an eight-year follow up of 313,074 patients without overt atherosclerosis|55ef922cf2bd4ad3824b4cb78d65f11b|4
fruits and vegetables|fatal ischemic heart disease|a 22% lower risk of fatal ischemic heart disease in those consuming eight portions of fruits and vegetables a day as compared to three portions or less|55ef922cf2bd4ad3824b4cb78d65f11b|4
RCT data|not convincing|RCT data is not as convincing|55ef922cf2bd4ad3824b4cb78d65f11b|4
cardiovascular disease benefits|fruits and vegetables|utilizing cardiovascular disease surrogates as endpoints|55ef922cf2bd4ad3824b4cb78d65f11b|4
2001 RCT|increased fruits and vegetables|showed that increased fruits and vegetables|bd99ed69191e4d9d85cfa140ed88582d|4
no significant change|lipid or blood pressure profiles|in lipid or blood pressure profiles|bd99ed69191e4d9d85cfa140ed88582d|4
strong trend|both|existed for both|bd99ed69191e4d9d85cfa140ed88582d|4
subsequent RCT|statistically significant effect|showed a statistically significant effect of fruit and vegetable consumption on both plasma antioxidant concentrations and blood pressure|bd99ed69191e4d9d85cfa140ed88582d|4
potential benefit|fruits and vegetables|could lie in reduced total caloric|bd99ed69191e4d9d85cfa140ed88582d|4
antioxidant properties|fruit and vegetables|evidence establishes the antioxidant properties of fruit and vegetables|598ec24e90bf40a9b8ed2ce7e26e7a7f|4
health benefits|increased flavonol intake|establishes the health benefits of increased flavonol intake|598ec24e90bf40a9b8ed2ce7e26e7a7f|4
alternative mechanisms|proposed (67)|alternative mechanisms have been proposed|598ec24e90bf40a9b8ed2ce7e26e7a7f|4
effects of nitric oxide species|concomitant weight loss|could include the effects of nitric oxide or concomitant weight loss associated with diets high in fruits and vegetables|598ec24e90bf40a9b8ed2ce7e26e7a7f|4
RCT, outcomes-based data|wide array|a wide array of RCT, outcomes-based data does|598ec24e90bf40a9b8ed2ce7e26e7a7f|4
fruits and vegetables|cardiovascular disease prevention|used for|1af414a434a345a6bd90ef78bd2170ee|4
Mediterranean diet|cardiovascular disease benefit|provide the most|1af414a434a345a6bd90ef78bd2170ee|4
Author|Manuscript|is written by|76088bd637744b0fbbab97d14f7cb08b|4
Whole Grain Foods High in Fiber|Morbidity and Mortality|beneficial effect on|2cc28a0086c94e66ade42b52e54ed1b4|4
AHA Guidelines|Diets high in fiber|indicate that|2cc28a0086c94e66ade42b52e54ed1b4|4
Total Dietary Fiber Intake|25-30 g per day from whole foods|recommend a|2cc28a0086c94e66ade42b52e54ed1b4|4
whole grains consumption|dietary fiber intake|promotes cardiovascular disease health|ec66e41d4c5c47c08edb0dab7fe27bbf|4
cardiovascular disease health|blood pressure, cholesterol, markers of inflammation|surrogate markers|ec66e41d4c5c47c08edb0dab7fe27bbf|4
RCTs|hard cardiovascular disease endpoints|mixed data|ec66e41d4c5c47c08edb0dab7fe27bbf|4
BMI|waist circumference|both were mentioned as factors being compared in the group randomized to hypocaloric whole grains.|7d0b9410adfe4e23bb43961cf9617977|4
hypocaloric whole grains|hypocaloric refined grains|both are mentioned as part of a comparison in the given context.|7d0b9410adfe4e23bb43961cf9617977|4
whole grains +/− whole|refined carbohydrates|they were compared in a RCT (randomized controlled trial).|7d0b9410adfe4e23bb43961cf9617977|4
overweight individuals|control, intermediate whole grain, high whole grain diets|randomized to|84c7b564424a4971afd3cd6a692685b5|4
control, intermediate whole grain, high whole grain diets|normal carbohydrate intake|in substitution for their|84c7b564424a4971afd3cd6a692685b5|4
overweight individuals|cardiovascular disease surrogate markers|no significant differences in observed after four months|84c7b564424a4971afd3cd6a692685b5|4
whole grains|cardiovascular disease|reduce|3855e44a0a974f57b915917293ecdb3a|4
series of prospective cohort studies|21% reduction in cardiovascular disease events and mortality|showed a collective benefit in|3855e44a0a974f57b915917293ecdb3a|4
Iowa Women's Study|Nurses Health Study|Both are referenced as sources for the study of disease morbidity with increased intake of whole grain sources.|73491b808ec042e88785a23ecedb0fef|4
whole grains|improved all cause and cardiovascular disease mortality|Consumption of whole grains is associated with improved all cause and cardiovascular disease mortality in women with type 2 diabetes.|73491b808ec042e88785a23ecedb0fef|4
mechanisms|benefit of whole grains on cardiovascular disease|Mechanisms are provided for the benefit of whole grains on cardiovascular disease.|73491b808ec042e88785a23ecedb0fef|4
whole-body benefits|increased fiber from whole grains|The whole-body benefits of increased fiber from whole grains are related to the study.|73491b808ec042e88785a23ecedb0fef|4
reduced inflammation|reactive oxidation|related in the context of observational studies|3dcfd9ac7a0a40219f351a6812545c46|4
lipid profiles|blood pressure|mentioned together in same sentence in context|3dcfd9ac7a0a40219f351a6812545c46|4
benefits extend to improved glucose metabolism|reduction in weight|related in the context of observational studies|3dcfd9ac7a0a40219f351a6812545c46|4
high-fiber whole grain diets|absorption of fats, simple carbohydrates, or toxins|alternative for the benefit of increased fiber intake|3dcfd9ac7a0a40219f351a6812545c46|4
large cohort studies and meta-|benefit of increased fiber intake|confirmed by large cohort studies and meta-|3dcfd9ac7a0a40219f351a6812545c46|4
recommendation promoting whole grains|RCT data regarding a reduction in cardiovascular disease morbidity or mortality|relationship between the two concepts, node_1 and node_2 in one sentence|0b3eeac4ea874bcfa84715bc05cbbd08|4
increased whole grain intake|cardiovascular disease prevention|relationship between the two concepts, node_1 and node_2 in one sentence|0b3eeac4ea874bcfa84715bc05cbbd08|4
whole grains|remainder of the Mediterranean diet|relationship between the two concepts, node_1 and node_2 in one sentence|0b3eeac4ea874bcfa84715bc05cbbd08|4
NIH-PA Author Manuscript|Manuscript|is a type of|09cad9f7e23049ba8af836d3706b7e2c|4
NIH-PA Author Manuscript|NIH-PA|is an instance of|09cad9f7e23049ba8af836d3706b7e2c|4
nuts and legumes|positive effect|Predominantly, the data regarding the beneficial effect of moderate nut consumption is positive|25b5429d25b340c09f3fdeec605dbd99|4
moderate nut consumption|cardiovascular disease morbidity and mortality impact|Nuts, but most early observational data point to a reduction in cardiovascular disease risk with isocaloric nut consumption|25b5429d25b340c09f3fdeec605dbd99|4
beneficial effect|isocaloric nut consumption|similar convincing evidence cannot support the same for legumes|25b5429d25b340c09f3fdeec605dbd99|4
early observational data|cardiovascular disease risk reduction|Nuts, but most early observational data point to a reduction in cardiovascular disease risk with isocaloric nut consumption|25b5429d25b340c09f3fdeec605dbd99|4
nut consumption|preventative risk reduction on heart disease|offer|02986d8493a840a481cbe4593d05ad61|4
walnuts, peanuts, almonds|replacing|for a serving of carbohydrates or saturated fats|02986d8493a840a481cbe4593d05ad61|4
blood lipids|reduced|with the risk for cardiovascular disease by 30% and 45%, respectively|02986d8493a840a481cbe4593d05ad61|4
cholesterol|walnut consumption|increased walnut consumption leads to reduced cholesterol|a91e834dc2aa41f5ad807f8843ee3ff5|4
inflammatory and oxidants mediators|walnut consumption|increased walnut consumption reduces inflammation and oxidant mediators|a91e834dc2aa41f5ad807f8843ee3ff5|4
no evidence|reductions in other risk factors or cardiovascular disease mortality|no significant impact observed on other risk factors or CV disease mortality with increased walnut consumption|a91e834dc2aa41f5ad807f8843ee3ff5|4
meta-analysis|nuts|study suggests benefits of nuts on weight loss|a91e834dc2aa41f5ad807f8843ee3ff5|4
meta-analysis of four observational studies|large studies|a large scale study was a meta-analysis of four observational studies|a91e834dc2aa41f5ad807f8843ee3ff5|4
Study|Physician’s Health Study|both are types of studies|bdfa17612c094902bdacd71112308671|4
Cardiovascular disease|Nut consumption|inverse relationship between nut consumption and cardiovascular disease|bdfa17612c094902bdacd71112308671|4
Primary endpoint|Cardiovascular disease|primary endpoint is related to cardiovascular disease|bdfa17612c094902bdacd71112308671|4
Servings per week|Nut consumption|number of servings per week is related to nut consumption|bdfa17612c094902bdacd71112308671|4
Primary cardiovascular disease|Incidence|primary cardiovascular disease incidence is discussed|bdfa17612c094902bdacd71112308671|4
RCT data|Underpowered studies|RCT data relates to underpowered studies|bdfa17612c094902bdacd71112308671|4
Studies|Large|large relates to studies|bdfa17612c094902bdacd71112308671|4
Mediterranean diet|cardiovascular disease prevention benefits|supplemented with nuts offers evidence|92584f58a7674c0eb42e7b1c9ca1c163|4
nuts|benefits|that could be studied|92584f58a7674c0eb42e7b1c9ca1c163|4
remainder of the Mediterranean diet|ascribing the benefit solely to nuts|so ascribing the benefit solely to|92584f58a7674c0eb42e7b1c9ca1c163|4
numerous cohort studies|quite a few|in conjunction with the remainder of the Mediterranean diet, so ascribing the benefit solely to nuts would be an overstatement of the data.|92584f58a7674c0eb42e7b1c9ca1c163|4
smaller RCTs|benefit in terms of lipid profiles|smaller RCTs have shown a benefit in terms of lipid profiles|62fe3e95dd1a4bb68cb0e800f5b05de7|4
reducing ROS|improving vascular function|smaller RCTs have shown a benefit in terms of lipid profiles, reducing ROS, improving vascular function|62fe3e95dd1a4bb68cb0e800f5b05de7|4
reducing blood pressure|improving cardiovascular morbidity and mortality|smaller RCTs have shown a benefit in terms of lipid profiles, reducing ROS, improving vascular function, reducing blood pressure, and improving cardiovascular morbidity and mortality|62fe3e95dd1a4bb68cb0e800f5b05de7|4
increased nut consumption|cardiovascular disease prevention|smaller RCTs have shown a benefit in terms of lipid profiles, reducing ROS, improving vascular function, reducing blood pressure, and improving cardiovascular morbidity and mortality. Furthermore, such convincing evidence regarding increased nut consumption on cardiovascular disease prevention would likely lend it to being a food which can be consumed in isolation, without the added benefit offered by the Mediterranean diet although|62fe3e95dd1a4bb68cb0e800f5b05de7|4
Mediterranean diet|consumed in isolation|smaller RCTs have shown a benefit in terms of lipid profiles, reducing ROS, improving vascular function, reducing blood pressure, and improving cardiovascular morbidity and mortality. Furthermore, such convincing evidence regarding increased nut consumption on cardiovascular disease prevention would likely lend it to being a food which can be consumed in isolation, without the added benefit offered by the Mediterranean diet although|62fe3e95dd1a4bb68cb0e800f5b05de7|4
Mediterranean diet|greater cardiovascular disease benefit|When added to the Mediterranean diet, it can offer greater cardiovascular disease benefit|2b4d95fc0e144475be99181b9c2f9219|4
Legumes|considered seeds of plants that contain roots|They are typically considered the seeds of plants that contain roots|2b4d95fc0e144475be99181b9c2f9219|4
Legumes|Nitrogen-fixing bacteria on their roots|These seeds utilize nitrogen-fixing bacteria on their roots|2b4d95fc0e144475be99181b9c2f9219|4
Legumes|Wide variety of sources and types difficult to study|A wide variety of sources and types of legumes are difficult to carefully study|2b4d95fc0e144475be99181b9c2f9219|4
Legumes|low-glycemic|These seeds are considered low-glycemic|2b4d95fc0e144475be99181b9c2f9219|4
Legumes|useful dietary source of protein and fiber|They are a useful dietary source of protein and fiber|2b4d95fc0e144475be99181b9c2f9219|4
legume and soy intake|preventing cardiovascular disease|Initial observational studies showed legume and soy intake to be beneficial toward preventing cardiovascular disease|50e80b3dd48c4457b6b439c2ff76794d|4
NHANES data|cardiovascular disease|showed an 11% reduction in cardiovascular disease in women who consumed legumes four or more times weekly over those who consumed legumes one, or fewer, times weekly|50e80b3dd48c4457b6b439c2ff76794d|4
legume and soy intake|beneficial effect on health|Initial observational studies showed legume and soy intake to be beneficial toward preventing cardiovascular disease|50e80b3dd48c4457b6b439c2ff76794d|4
data from Japan|similar observational data|Similar observational data has been reported out of Japan|50e80b3dd48c4457b6b439c2ff76794d|4
data from China|similar observational data|Similar observational data has been reported out of China|50e80b3dd48c4457b6b439c2ff76794d|4
NIH-PA Author Manuscript|Author Manuscript|is a type of|59e4ffaf1caf414b9077346f842c6230|4
RCT data|hard cardiovascular disease endpoints|rarely addresses|75292b19faf447e2a63e004fc326a439|4
grouped data|benefits|only shows marginal|75292b19faf447e2a63e004fc326a439|4
small RCTs in low-moderate risk patients|little to no change|show|75292b19faf447e2a63e004fc326a439|4
lipid levels|90-92|no change in|75292b19faf447e2a63e004fc326a439|4
meta-analysis|5% reduction in LDL levels|in patients who were randomized to high legume intake|75292b19faf447e2a63e004fc326a439|4
randomization|high legume intake|noted to have an|75292b19faf447e2a63e004fc326a439|4
effect on hard cardiovascular disease endpoints|RCTs|have shown a benefit|9d7804957096454f9cbaee5fbd31d652|4
blood pressure|patients with moderate hypertension ( 94)|in patients|9d7804957096454f9cbaee5fbd31d652|4
no benefit of soy|on NO bioavailability or BP in moderately hypertensive, post-menopausal women ( 95)|in moderately hypertensive, post-menopausal women|9d7804957096454f9cbaee5fbd31d652|4
meta-analyses|have been less convincing regarding cardiovascular|subsequent meta-analyses|9d7804957096454f9cbaee5fbd31d652|4
surrogate endpoints|studies|examining the effect|52b14b7662be452d9f2e5f078327a17d|4
anti-inflammatory and vaso-protective benefit|soy|providing potential for studies|52b14b7662be452d9f2e5f078327a17d|4
endothelial function|soy supplementation|examining the effect on|52b14b7662be452d9f2e5f078327a17d|4
benefit of soy|endothelial function|demonstrated in a meta-analysis of RCTs|52b14b7662be452d9f2e5f078327a17d|4
age-related results|baseline endothelial function|adjusted for|52b14b7662be452d9f2e5f078327a17d|4
RCTs studies|normotensive patients|studies showed no benefit on|b63ab1c985194df6a78d1b6e8a171349|4
earlier meta-analysis|RCTs studies|mirrored the findings of|b63ab1c985194df6a78d1b6e8a171349|4
abundance of observational data|little direct evidence|despite an abundance of|b63ab1c985194df6a78d1b6e8a171349|4
legume intake|direct cardiovascular disease benefit|we find little direct evidence that|b63ab1c985194df6a78d1b6e8a171349|4
nuts|legume intake|usually grouped together with|b63ab1c985194df6a78d1b6e8a171349|4
legume intake|Mediterranean diet|part of|cc04583bebea49ea97cb08d9874c5485|4
CVD protection|legume intake|positive impact on|cc04583bebea49ea97cb08d9874c5485|4
Mediterranean diet|cardiovascular disease|prevent|cc04583bebea49ea97cb08d9874c5485|4
Mediterranean diet|chronic diseases|prevents|cc04583bebea49ea97cb08d9874c5485|4
best-studied diet|Mediterranean Diet|is|cc04583bebea49ea97cb08d9874c5485|4
healthy eating|Mediterranean Diet|template of|cc04583bebea49ea97cb08d9874c5485|4
Mediterranean diet|cardiovascular disease risk reduction|reduces by mechanisms including|995f859e339b48cc9a55198d4560eab9|4
Mediterranean diet|NO bioavailability and antioxidant|providing|995f859e339b48cc9a55198d4560eab9|4
Mediterranean diet|secondary cardiovascular disease prevention benefit|has proven|e318729ed90b408bb21a0efb1b6ee125|4
Mediterranean diet|improvements in surrogate markers for cardiovascular disease|evidenced by observational, RTC, and even meta-analyses|e318729ed90b408bb21a0efb1b6ee125|4
constituents of the Mediterranean diet|fish and nuts|established|e318729ed90b408bb21a0efb1b6ee125|4
constituents of the Mediterranean diet|cardiovascular morbidity/mortality benefits|which can possibly be noted in|e318729ed90b408bb21a0efb1b6ee125|4
Mediterranean diet|Improvement in cardiovascular disease prevention|Observational and RCT data documented the relationship|84e8dcdd6d04468fb55772ec61a77981|4
Constituents of Mediterranean diet|Should be consumed in moderation|For a balanced diet and avoid caloric excess|84e8dcdd6d04468fb55772ec61a77981|4
Mediterranean diet|Preventive measures depend strongly upon length of time|As per Widmer et al. Page 9 Am J Med.|84e8dcdd6d04468fb55772ec61a77981|4
Author|Manuscript|Writes|9b9311516a81484284bed444a41a6d82|4
NIH-PA|Author Manuscript|Related to|9b9311516a81484284bed444a41a6d82|4
life-long commitment|episodic|opposed|52811eef53034f98b7b9b0fee1f2c9db|4
duration|intensity|relationship|52811eef53034f98b7b9b0fee1f2c9db|4
difficult to sustain|high intensities|reason for relationship|52811eef53034f98b7b9b0fee1f2c9db|4
dietary pattern|individual constituents|more important than|52811eef53034f98b7b9b0fee1f2c9db|4
detrimental effects|changing one or following a few dietary constituents|exclude relationship|52811eef53034f98b7b9b0fee1f2c9db|4
best culinary interventions|specific foods|do not involve|63877eb387e748828bc19a012a497810|4
best culinary interventions|collection of healthy nutrients|may relate to|63877eb387e748828bc19a012a497810|4
healthy nutrients|Mediterranean diet|comparable to|63877eb387e748828bc19a012a497810|4
Gertrud Siegenthaler Foundation|University of Zurich|support|20723fee2a444313b6d1794c7dd229bd|4
Swiss foundation for medical-biological scholarships (SSMBS; SNSF No PASMP3_132551)|University of Zurich|scholarship provider|20723fee2a444313b6d1794c7dd229bd|4
Lloyd-Jones D|References|author of|20723fee2a444313b6d1794c7dd229bd|4
Heart Disease|Stroke|both are health issues discussed in the context|308e7bc4123c4a01b338cfdf482ca7da|4
American Heart Association|Statistics Committee|the American Heart Association has a Statistics Committee|308e7bc4123c4a01b338cfdf482ca7da|4
Stroke|Stroke Statistics Subcommittee|the Stroke Statistics Subcommittee is a part of the larger Stroke division|308e7bc4123c4a01b338cfdf482ca7da|4
Circulation|Publication|Circulation is mentioned as a journal where the report was published|308e7bc4123c4a01b338cfdf482ca7da|4
2010; 121:e1–e170|[PubMed: 20048228]|reference|11aedb7c7b194e47abeecf6160cb4e33|4
2007; 357(12):1221–8|[PubMed: 17881753]|reference|11aedb7c7b194e47abeecf6160cb4e33|4
Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease|Harvard University Press; Cambridge, MA: 1980|publication|11aedb7c7b194e47abeecf6160cb4e33|4
dietary fatty acids|J Am Diet Assoc. 2007; 107:1599–611.|article reference|004a9e5167034e46aee17223b80c1bda|4
American Heart Association Nutrition Committee|Diet and lifestyle recommendations revision 2006|created by|004a9e5167034e46aee17223b80c1bda|4
Nutrition Committee|Circulation|published in|91a39900840a4e0fa59e5d4fe69ec08b|4
Circulation|PubMed: 16785338|cited in|91a39900840a4e0fa59e5d4fe69ec08b|4
Mediterranean diet|traditional risk factors|related to|91a39900840a4e0fa59e5d4fe69ec08b|4
Lyon Diet Heart Study|myocardial infarction|study on|91a39900840a4e0fa59e5d4fe69ec08b|4
Circulation|PubMed: 9989963|cited in|91a39900840a4e0fa59e5d4fe69ec08b|4
Mediterranean Diet|Cardiovascular Disease|Primary Prevention|0dd9c758d6674161ad6c3e6804be5f13|4
NEJM|Publication|Published in|0dd9c758d6674161ad6c3e6804be5f13|4
de Lorgeril M|Researcher|Researchers involved|0dd9c758d6674161ad6c3e6804be5f13|4
Mediterranean diet|pro-atherogenic genes|Effect of Mediterranean diet on the expression of pro-atherogenic genes|2363b6c6fd3c46028b4b9dee2d11c6fc|4
population at high cardiovascular risk|Mediterranean diet|in a population at high cardiovascular risk|2363b6c6fd3c46028b4b9dee2d11c6fc|4
Mediterranean-style diet|Effects|cause and effect|00e2a65f6c904315945b3bf017b84888|4
Mediterranean-style diet|Widmer et al.|referenced in the study|00e2a65f6c904315945b3bf017b84888|4
Mediterranean-style diet|Page 10|appears on page 10|00e2a65f6c904315945b3bf017b84888|4
cardiovascular risk factors|randomized trial|a randomized trial on cardiovascular risk factors|73b3138f887e4ff3a6794cb0cf503fe5|4
cardiovascular risk factors|Ann Intern Med|published in Ann Intern Med|73b3138f887e4ff3a6794cb0cf503fe5|4
cardiovascular risk factors|PubMed: 16818923|cited PubMed: 16818923|73b3138f887e4ff3a6794cb0cf503fe5|4
A concept from extracted ontology|Salas-Salvadó J, Bulló M, Babio N, Martínez-González MÁ, Ibarrola-Jurado N, Basora J, Estruch R, Covas MI, Corella D, Arós F, Ruiz-Gutiérrez V, Ros E, PREDIMED Study Investigators|authors of the study|73b3138f887e4ff3a6794cb0cf503fe5|4
A concept from extracted ontology|PREDIMED-Reus nutrition intervention randomized trial|study conducted in PREDIMED-Reus nutrition intervention randomized trial|73b3138f887e4ff3a6794cb0cf503fe5|4
A concept from extracted ontology|Diabetes Care|published in Diabetes Care|73b3138f887e4ff3a6794cb0cf503fe5|4
A concept from extracted ontology|[PubMed: 20929998]|cited PubMed: 20929998|73b3138f887e4ff3a6794cb0cf503fe5|4
Mediterranean diet supplemented with nuts|metabolic syndrome|effect of a Mediterranean diet on metabolic syndrome|6931b7840482414e8f267c62af2f5d4d|4
PREDIMED randomized trial|one-year results|status of the PREDIMED randomized trial|6931b7840482414e8f267c62af2f5d4d|4
19221219|PubMed|refers to|585faf415a4b4455b7935243d4581545|4
1986|year|occurs in the date range of|585faf415a4b4455b7935243d4581545|4
7|countries|in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Keys A|first author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Menotti A|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Karvonen MJ|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Aravanis C|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Blackburn H|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Buzina R|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Djordjevic BS|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Dontas AS|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Fidanza F|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Keys MH|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Am J Epidemiol|publication of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
3776973|PubMed|refers to|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Keys A|first author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Menotti A|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Karvonen MJ|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Aravanis C|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Blackburn H|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Buzina R|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Djordjevic BS|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Dontas AS|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Fidanza F|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
A concept from extracted ontology|Keys MH|co-author of The diet and 15-year death rate in the seven countries study|585faf415a4b4455b7935243d4581545|4
534,906 individuals|J Am Coll Cardiol|cited in the same context|2e3d8277b5d7432dafa7440da47520af|4
Nordmann A|Suter-Zimmermann K|co-authors of a study|2e3d8277b5d7432dafa7440da47520af|4
Harris WS|American Heart Association|affiliated with an organization|2e3d8277b5d7432dafa7440da47520af|4
consumption|fish oil|consumption of fish oil|6ef3c22c7e2743f89577c41091dda75e|4
fish oil|omega-3 fatty acids|contained in fish oil|6ef3c22c7e2743f89577c41091dda75e|4
omega-3 fatty acids|cardiovascular disease|associated with omega-3 fatty acids and cardiovascular disease|6ef3c22c7e2743f89577c41091dda75e|4
European Society of Cardiology|Committee for Practice Guidelines|is a part of|c8c0d968a5064e6dad68abfa71f60500|4
Fourth Joint Task Force|European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice|constituted by|c8c0d968a5064e6dad68abfa71f60500|4
Heart J|28(19):2375–414|is a reference to an article|88e7b344dc2845d7a27bd3e133278c9b|4
PubMed: 17726041|Heart J|provides a citation for the article|88e7b344dc2845d7a27bd3e133278c9b|4
2007|Heart J|denotes the year of publication|88e7b344dc2845d7a27bd3e133278c9b|4
Bucher H|Hengstler P|are authors of a different study|88e7b344dc2845d7a27bd3e133278c9b|4
Schindler C|Meier G|are authors of another study|88e7b344dc2845d7a27bd3e133278c9b|4
N-3 polyunsaturated fatty acids in coronary heart disease|a meta-analysis of randomized controlled trials|is the topic of the study|88e7b344dc2845d7a27bd3e133278c9b|4
Am J Med. 2002; 112(4):298–304|PubMed: 11893369|provides a citation for the study|88e7b344dc2845d7a27bd3e133278c9b|4
Carroll D|Roth MT|are authors of a different study|88e7b344dc2845d7a27bd3e133278c9b|4
Evidence for the cardioprotective effects of omega-3 Fatty acids|Ann Pharmacother. 2002; 36(12):1950–6|is the topic of the study|88e7b344dc2845d7a27bd3e133278c9b|4
PubMed: 12452760|Ann Pharmacother. 2002; 36(12):1950–6|provides a citation for the study|88e7b344dc2845d7a27bd3e133278c9b|4
omega-3 fatty acid|sudden cardiac death prevention|Effects of omega-3 fatty acid for sudden cardiac death prevention|70d94a95cf374eb0b9311a3e44e2e896|4
cardiovascular disease|patients with|Effects of omega-3 fatty acid for sudden cardiac death prevention in patients with cardiovascular disease|70d94a95cf374eb0b9311a3e44e2e896|4
cardioprotective strategies|ω-3 fatty acids|strategies include ω-3 fatty acids|fd6f2523932c49ff997f2edcd73e0b40|4
Thromb Haemost.|2010; 104(4):664–80|article published in Thromb Haemost.|fd6f2523932c49ff997f2edcd73e0b40|4
PubMed: 20806105|Thromb Haemost. 2010; 104(4):664–80|article citation with PubMed ID|fd6f2523932c49ff997f2edcd73e0b40|4
Filion K, El Khoury F, Bielinski M, Schiller I, Dendukuri N, Brophy JM| Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2010; 10(24)|researchers and their publication|fd6f2523932c49ff997f2edcd73e0b40|4
Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, Worthington HV|cardioprotective strategies and ω-3 fatty acids in perspective|researchers and their research topic|fd6f2523932c49ff997f2edcd73e0b40|4
omega 3 fats|mortality|risks and benefits|0d6f8a93e44448d4a58d6ab9c53609f9|4
omega 3 fats|cardiovascular disease|risks and benefits|0d6f8a93e44448d4a58d6ab9c53609f9|4
omega 3 fats|cancer|risks and benefits|0d6f8a93e44448d4a58d6ab9c53609f9|4
Fish consumption|Coronary heart disease mortality|relationship between the two concepts in one sentence|7c79cf42266c41ab83493549ad8678f5|4
Omega-3 fatty acids|Cardiovascular benefits|relationship between the two concepts in one sentence|7c79cf42266c41ab83493549ad8678f5|4
Fish intake|Meta-analysis of observational studies|relationship between the two concepts in one sentence|7c79cf42266c41ab83493549ad8678f5|4
coronary heart disease|Am J Cardiol|Published in|a9bc794180e6476488544b26b344a139|4
coronary heart disease|Yzebe D, Lievre M|Authored a paper on|a9bc794180e6476488544b26b344a139|4
coronary heart disease|Fish oils in the care of coronary heart disease patients|Related to|a9bc794180e6476488544b26b344a139|4
coronary heart disease|PubMed: 15110203|Cited in|a9bc794180e6476488544b26b344a139|4
Fish oils in the care of coronary heart disease patients|Yzebe D, Lievre M|Authored by|a9bc794180e6476488544b26b344a139|4
coronary heart disease|Arch Intern Med|Published in|a9bc794180e6476488544b26b344a139|4
coronary heart disease|Mente A, de Koning L, Shannon HS, Anand SS|Authored a systematic review on|a9bc794180e6476488544b26b344a139|4
dietary factors|coronary heart disease|Related to|a9bc794180e6476488544b26b344a139|4
PubMed: 15364995|Mente A, de Koning L, Shannon HS, Anand SS|Cited in|a9bc794180e6476488544b26b344a139|4
PubMed: 19364995|PubMed: 12571649|Citations in the same context|4112953ed5384d2bacab2b4e077e4483|4
Burr M, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, Zotos PC, Haboubi NA, Elwood PC|Angina|Relation between author's name and a concept in their study|4112953ed5384d2bacab2b4e077e4483|4
Dietary advice to men with angina|Controlled trial|Type of experiment conducted|4112953ed5384d2bacab2b4e077e4483|4
GISSI-Prevenzione Trial|Lancet|the results of the GISSI-Prevenzione Trial were published in the Lancet journal|666d8cd294aa4668866d708dffded095|4
Yokoyama M|Origasa H|Yokoyama and Origasa are co-authors of a study|666d8cd294aa4668866d708dffded095|4
Endpoint analysis|Lancet|Publication related to Endpoint analysis|deea402198894f05958114dde46ace53|4
2007; 369:1090–8|Lancet|Volume and page number of the article in Lancet|deea402198894f05958114dde46ace53|4
PubMed: 17398308|Endpoint analysis|Citation for further information on Endpoint analysis|deea402198894f05958114dde46ace53|4
Burr M, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM|Effects of changes in fat, fish and fibre intakes on death and reinfarction: diet and reinfarction trial (DART). Lancet. 1989; 2(8666):757–61.|Authors and publication related to a specific study|deea402198894f05958114dde46ace53|4
PubMed: 2571009|Endpoint analysis|Citation for further information on Endpoint analysis|deea402198894f05958114dde46ace53|4
Fish consumption|Coronary heart disease mortality|meta-analysis of cohort studies|4fa2f3edcd7146ae94c7bcade956beb4|4
Cohort studies|Fish consumption and coronary heart disease mortality|systematic review of prospective cohort studies|4fa2f3edcd7146ae94c7bcade956beb4|4
Cardiovascular Disease|Fish Consumption|study|4fa2f3edcd7146ae94c7bcade956beb4|4
Physicians’ Health Study|Prospective Study|is a type of|c1322d3da33247ada5e8fc7a1034048b|4
American Journal of Epidemiology|1995; 142(2): 166–75.|is published in|c1322d3da33247ada5e8fc7a1034048b|4
PubMed: 7598116|Physicians’ Health Study|is associated with|c1322d3da33247ada5e8fc7a1034048b|4
Ascherio A|Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC.|co-authors of Dietary intake of marine n-3 fatty acids|c1322d3da33247ada5e8fc7a1034048b|4
Dietary intake of marine n-3 fatty acids|risk of coronary disease among men.|is studied for|c1322d3da33247ada5e8fc7a1034048b|4
N Engl J Med|332(15): 977–82.|is published in|c1322d3da33247ada5e8fc7a1034048b|4
PubMed: 7885425|Physicians’ Health Study|is associated with|c1322d3da33247ada5e8fc7a1034048b|4
Balk E, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J.|Effects of omega-3 fatty acids|are researchers|c1322d3da33247ada5e8fc7a1034048b|4
omega-3 fatty acids| marine n-3 fatty acids, fish intake, and the risk of coronary disease among men.|is a type of|c1322d3da33247ada5e8fc7a1034048b|4
Systematic Review|Atherosclerosis|is a research article in|63a8b1e3867341c897c9c5c23843e502|4
Cardiovascular Disease Risk|Serum Markers|are the focus of the study|63a8b1e3867341c897c9c5c23843e502|4
Fish Oil Supplementation|Blood Pressure Reduction|is investigated in a meta-analysis|63a8b1e3867341c897c9c5c23843e502|4
trials|Circulation|publication in|dad5f3fde54f4202a3dad093be48adf2|4
Circulation|1993; 88(2):523–33|volume and issue|dad5f3fde54f4202a3dad093be48adf2|4
Publication: 8339414] |PubMed|citation reference|dad5f3fde54f4202a3dad093be48adf2|4
Calder P.|n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond). 2004; 107(1):1–11. [PubMed: 15132735]|author|dad5f3fde54f4202a3dad093be48adf2|4
n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored|Clin Sci (Lond). 2004; 107(1):1–11. [PubMed: 15132735]|article title|dad5f3fde54f4202a3dad093be48adf2|4
Clinical and mechanistic perspectives|Atherosclerosis. 2008; 197:12–24. [PubMed: 18160071]|article title|dad5f3fde54f4202a3dad093be48adf2|4
Omega-3 fatty acids and coronary heart disease risk|Atherosclerosis. 2008; 197:12–24. [PubMed: 18160071]|article title|dad5f3fde54f4202a3dad093be48adf2|4
Harris W, Miller M, Tighe AP, Davidson MH, Schaefer EJ|Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives. Atherosclerosis. 2008; 197:12–24. [PubMed: 18160071]|authors|dad5f3fde54f4202a3dad093be48adf2|4
Publication: 15132735] |PubMed|citation reference|dad5f3fde54f4202a3dad093be48adf2|4
PubMed|18160071|citation|bed79d9321bb43bb9685b0f4544a7143|4
Howard B|Van Horn L|co-author|bed79d9321bb43bb9685b0f4544a7143|4
Van Horn L|Hsia J|co-author|bed79d9321bb43bb9685b0f4544a7143|4
Snetselaar LG|Stevens VJ|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Tinker LF|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Trevisan M|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Vitolins MZ|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Anderson GL|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Assaf AR|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Bassford T|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Beresford SA|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Black HR|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Brunner RL|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Brzyski RG|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Caan B|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Chlebowski RT|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Gass M|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Granek I|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Greenland P|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Hays J|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Heber D|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Heiss G|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Hendrix SL|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Hubbell FA|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Johnson KC|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Snetselaar LG|Kotchen JM|co-authors in the same sentence|538314f417114a7ab2c98ed98fa776e4|4
Diet and lifestyle recommendations revision|American Heart Association Nutrition Committee|part of|64d68d2f93204f5d99438660f71b73c3|4
Diet and lifestyle recommendations revision 2006|a scientific statement from the American Heart Association|is a version or edition|64d68d2f93204f5d99438660f71b73c3|4
a scientific statement from the American Heart Association|Nutrition Committee|by|64d68d2f93204f5d99438660f71b73c3|4
Diet and lifestyle recommendations revision 2006|Circulation. 2009; 114:82–96|appeared in|64d68d2f93204f5d99438660f71b73c3|4
M, Wylie-Rosett J|American Heart Association Nutrition Committee|member of|64d68d2f93204f5d99438660f71b73c3|4
Diet and lifestyle recommendations revision 2006|Circulation. 2009; 114:82–96|referenced by|64d68d2f93204f5d99438660f71b73c3|4
B Fuhrman, M Aviram|Flavonoids protect LDL from oxidation and attenuate atherosclerosis|researchers of|64d68d2f93204f5d99438660f71b73c3|4
Covas MI|polyphenols in olive oil|author of a study on the effect of polyphenols in olive oil|b8783ef810a140d683a0719d88a8a732|4
Nyyssonen K|heart disease risk factors|co-author studying heart disease risk factors with polyphenols in olive oil|b8783ef810a140d683a0719d88a8a732|4
Poulsen HE|randomized trial|contributor to a randomized trial on the effect of polyphenols in olive oil|b8783ef810a140d683a0719d88a8a732|4
Ann Intern Med|journal publication|published article in Ann Intern Med journal|b8783ef810a140d683a0719d88a8a732|4
47|year|reference to the year 2006|b8783ef810a140d683a0719d88a8a732|4
Visioli F|Virgin Olive Oil Study (VOLOS)|author of VOLOS study on vasoprotective potential of extra virgin olive oil|b8783ef810a140d683a0719d88a8a732|4
Caruso D|Virgin Olive Oil Study (VOLOS)|author of VOLOS study on vasoprotective potential of extra virgin olive oil|b8783ef810a140d683a0719d88a8a732|4
Grande S|Virgin Olive Oil Study (VOLOS)|author of VOLOS study on vasoprotective potential of extra virgin olive oil|b8783ef810a140d683a0719d88a8a732|4
Extra Virgin Olive Oil|vasoprotective potential|studied the vasoprotective potential in VOLOS study|b8783ef810a140d683a0719d88a8a732|4
mildly dyslipidemic patients|Virgin Olive Oil Study (VOLOS)|subjects of the VOLOS study on vasoprotective potential|b8783ef810a140d683a0719d88a8a732|4
Eur J Nutr|journal publication|published article in Eur J Nutr journal|b8783ef810a140d683a0719d88a8a732|4
Marin C|study on mildly dyslipidemic patients|researcher studying mildly dyslipidemic patients|b8783ef810a140d683a0719d88a8a732|4
Ramirez R|study on mildly dyslipidemic patients|co-researcher studying mildly dyslipidemic patients|b8783ef810a140d683a0719d88a8a732|4
Delgado-Lista J|study on mildly dyslipidemic patients|co-researcher studying mildly dyslipidemic patients|b8783ef810a140d683a0719d88a8a732|4
Yubero-Serrano EM|study on mildly dyslipidemic patients|co-researcher studying mildly dyslipidemic patients|b8783ef810a140d683a0719d88a8a732|4
Perez-Martinez P|study on mildly dyslipidemic patients|co-researcher studying mildly dyslipidemic patients|b8783ef810a140d683a0719d88a8a732|4
Carracedo J|study on mildly dyslipidemic patients|co-researcher studying mildly dyslipidemic patients|b8783ef810a140d683a0719d88a8a732|4
Mediterranean diet|endothelial damage|reduces|8f29cb6ebf4b4677ab2da16cb5caaf8d|4
Mediterranean diet|regenerative capacity of endothelium|improves|8f29cb6ebf4b4677ab2da16cb5caaf8d|4
Butter and walnuts|olive oil|but not|8f29cb6ebf4b4677ab2da16cb5caaf8d|4
Mensink R|Katan MB|co-author on a publication|178c0853c67f4b45b739f97c68ef550f|4
52. Mensink R, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials.|Arterioscler Thromb|publication in this journal|178c0853c67f4b45b739f97c68ef550f|4
53. Shah M, Adams-Huet B, Garg A. Effect of high-carbohydrate or high-cis-monounsaturated fat diets on blood pressure: a meta-analysis of intervention trials.|Am J Clin Nutr|publication in this journal|178c0853c67f4b45b739f97c68ef550f|4
54. Howard B, Kritchevsky D. Phytochemicals and cardiovascular disease.|A statement for healthcare|topics discussed in this statement|178c0853c67f4b45b739f97c68ef550f|4
American Heart Association|professionals|work for|9d202345913348b4b442d1aeeec0a696|4
Circulation|American Heart Association|published by|9d202345913348b4b442d1aeeec0a696|4
1997; 95(11):2591–3|Circulation|volume and issue|9d202345913348b4b442d1aeeec0a696|4
PubMed: 9184593|Circulation|cited in|9d202345913348b4b442d1aeeec0a696|4
Beitz R|professionals|authors|9d202345913348b4b442d1aeeec0a696|4
Menisk GBM|Beitz R|co-author|9d202345913348b4b442d1aeeec0a696|4
Fischer B|Beitz R|co-author|9d202345913348b4b442d1aeeec0a696|4
Blood pressure and vitamin C and fruit and vegetable intake|Annals of Nutr & Metabolism|article title|9d202345913348b4b442d1aeeec0a696|4
2003; 47:214–20|Annals of Nutr & Metabolism|volume and issue|9d202345913348b4b442d1aeeec0a696|4
Alonso A|professionals|authors|9d202345913348b4b442d1aeeec0a696|4
de la Fuente C|Alonso A|co-author|9d202345913348b4b442d1aeeec0a696|4
Martín-Arnau AM|Alonso A|co-author|9d202345913348b4b442d1aeeec0a696|4
de Irala J|Alonso A|co-author|9d202345913348b4b442d1aeeec0a696|4
Martínez JA|Alonso A|co-author|9d202345913348b4b442d1aeeec0a696|4
Martínez-González MA|Alonso A|co-author|9d202345913348b4b442d1aeeec0a696|4
Fruit and vegetable consumption is inversely associated with blood pressure in a Mediterranean|study title|article title|9d202345913348b4b442d1aeeec0a696|4
population with a high vegetable-fat intake|Seguimiento Universidad de Navarra (SUN) Study|is associated with|4404a78d856b493db76dd5fc6773a7db|4
Brit J Nutr|2004; 92:311–319|cites as reference|4404a78d856b493db76dd5fc6773a7db|4
PubMed|15333163|cites as reference|4404a78d856b493db76dd5fc6773a7db|4
Food Review|2002; 25:28–32|cites as reference|4404a78d856b493db76dd5fc6773a7db|4
Lin B, Morrison RM|Higher fruit consumption linked with lower body mass index|authors of the study|4404a78d856b493db76dd5fc6773a7db|4
Miura K, Greenland P, Stamler J, Liu K, Daviglus ML, Nakagawa H|Relation of vegetable, fruit, and meat intake to 7-year blood pressure change in middle-aged men: the Chicago Western|authors of the study|4404a78d856b493db76dd5fc6773a7db|4
Electric Study|Am J Epidemiol.|Cited in same context|19760a3b475449499f110bac6b60866f|4
Dauchet L, Amouyel P, Hercberg S, Dallongeville J.|Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies|Title of research article|19760a3b475449499f110bac6b60866f|4
J Nutr.|Dauchet L, Amouyel P, Hercberg S, Dallongeville J.|Publication details of research article|19760a3b475449499f110bac6b60866f|4
Am J Med|Widmer et al.|Cited in same context|19760a3b475449499f110bac6b60866f|4
Page 13|Widmer et al.|Page number in context|19760a3b475449499f110bac6b60866f|4
Author manuscript|Am J Med|Publication type|19760a3b475449499f110bac6b60866f|4
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript|Author manuscript|Cited in same context|19760a3b475449499f110bac6b60866f|4
Increased consumption of fruit and vegetables|reduced risk of coronary heart disease|is related to|98a4d2519ff940eea7a834e0bcea6933|4
Fruits, vegetables|coronary heart disease|are related to|98a4d2519ff940eea7a834e0bcea6933|4
Heart Study Collaborators|Fruit and vegetable intake|study conducted by|e310f2d894134e50a0ae97c2d537c8e5|4
Fruit and vegetable intake|mortality from ischaemic heart disease|factor related to|e310f2d894134e50a0ae97c2d537c8e5|4
European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart study|Fruit and vegetable intake|research data from|e310f2d894134e50a0ae97c2d537c8e5|4
EPIC-Heart study|Heart Study Collaborators|study conducted by|e310f2d894134e50a0ae97c2d537c8e5|4
Eur Heart J.|Publication source|published in|e310f2d894134e50a0ae97c2d537c8e5|4
32(10):1235–43|Publication details|found on page numbers|e310f2d894134e50a0ae97c2d537c8e5|4
PubMed: 21245490|Publication reference|cited as|e310f2d894134e50a0ae97c2d537c8e5|4
Broekmans W, Klopping-Ketelaars WAA, Kluft C, van den Berg H, Kok FJ, van Poppel G|Authors|authors of the study|e310f2d894134e50a0ae97c2d537c8e5|4
Fruit and vegetables|cardiovascular risk profile|related to|e310f2d894134e50a0ae97c2d537c8e5|4
Eur J Clin Nutr.|Publication source|published in|e310f2d894134e50a0ae97c2d537c8e5|4
55(8):636–42|Publication details|found on page numbers|e310f2d894134e50a0ae97c2d537c8e5|4
PubMed: 11477461|Publication reference|cited as|e310f2d894134e50a0ae97c2d537c8e5|4
Nutr. 2001; 55(8):636–42|[PubMed: 11477461]|citation|626139f2754f4cecb72534a18f3d8c97|4
John J, Ziebland S, Yudkin P, Roe LS, Neil HAW, Oxford Fruit and Vegetable Study Group|Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomized controlled trial|authorship|626139f2754f4cecb72534a18f3d8c97|4
Lancet. 2002; 359(9322):1969–74|[PubMed: 12076551]|citation|626139f2754f4cecb72534a18f3d8c97|4
Knekt P, Ritz J, Pereira MA, O’Reilly EJ, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL|Publication|authorship|626139f2754f4cecb72534a18f3d8c97|4
Antioxidant vitamins|coronary heart disease risk|cause and effect|1785e426660549138555dc8a53e86760|4
Hallmans G|Ascherio A|co-authorship|1785e426660549138555dc8a53e86760|4
Antioxidant vitamins|9 cohorts|study on|1785e426660549138555dc8a53e86760|4
Huxley R|Neil HA|co-authorship|1785e426660549138555dc8a53e86760|4
dietary flavonol intake|coronary heart disease mortality|cause and effect|1785e426660549138555dc8a53e86760|4
polyphenols|cardiovascular health in humans|The biological relevance of direct antioxidant effects|1a950b88fc244f68aaabb77ecdbb9407|4
fiber|coronary heart disease|A statement for healthcare professionals|1a950b88fc244f68aaabb77ecdbb9407|4
Nutrition Committee|American Heart Association|is from|f6c25dc5e542406cbff23c5da9eb7cdb|4
Circulation|American Heart Association|published by|f6c25dc5e542406cbff23c5da9eb7cdb|4
A concept from extracted ontology|Publication Year|is from the year 1997|f6c25dc5e542406cbff23c5da9eb7cdb|4
increased consumption of whole-grain foods|blood pressure|Effect on|bb80285a4daf44659432f669daa3440e|4
increased consumption of whole-grain foods|cardiovascular risk markers|Effect on|bb80285a4daf44659432f669daa3440e|4
healthy middle-aged persons|randomized controlled trial|Subject of|bb80285a4daf44659432f669daa3440e|4
WHOLEheart|Markers of cardiovascular risk|Study on|bb80285a4daf44659432f669daa3440e|4
WHOLEheart|increased whole-grain intake|Effect of|bb80285a4daf44659432f669daa3440e|4
study|randomised, controlled dietary intervention|is a type of|2193c31ae9434fb0931053d0b477cb00|4
Br J Nutr|2010; 104(1):125–34|is the reference of the study|2193c31ae9434fb0931053d0b477cb00|4
PubMed: 20307353|Br J Nutr. 2010; 104(1):125–34|is the publication code of the study|2193c31ae9434fb0931053d0b477cb00|4
Mellen P, Walsh TF, Herrington DM|Whole grain intake and cardiovascular disease: a meta-analysis|is related to a different study|2193c31ae9434fb0931053d0b477cb00|4
Nutr Metab Cardiovasc Dis|2008; 18(4):283–90|is the reference of the study|2193c31ae9434fb0931053d0b477cb00|4
PubMed: 17449231|Nutr Metab Cardiovasc Dis. 2008; 18(4):283–90|is the publication code of the study|2193c31ae9434fb0931053d0b477cb00|4
Liu S, Stampfer MJ, Hu FB, Giovannucci E, Rimm E, Manson JE, Hennekens CH, Willett WC|Whole-grain consumption and risk of coronary heart disease: results from the Nurses’ Health|is related to a different study|2193c31ae9434fb0931053d0b477cb00|4
Nurses' Health Study|Whole-grain consumption and risk of coronary heart disease: results from the Nurses’ Health|is a reference to the study|2193c31ae9434fb0931053d0b477cb00|4
Study|Am J Clin Nutr.|is part of|3de1c649ee9e4f2983e260c71778266e|4
PubMed|10479204|refers to|3de1c649ee9e4f2983e260c71778266e|4
Jacobs DJ, Meyer KA, Kushi LH, Folsom AR|Whole-grain intake may reduce the risk of ischemic heart disease death in postmenopausal women: the Iowa Women’s Health Study. Am J Clin Nutr. 1998; 68(2):248–57.|authors of|3de1c649ee9e4f2983e260c71778266e|4
Widmer et al|Page 14|refers to|3de1c649ee9e4f2983e260c71778266e|4
Am J Med.|Author manuscript; available in PMC 2016 March 01|is the source of|3de1c649ee9e4f2983e260c71778266e|4
whole-grain|cereal fiber, bran, and germ intake|Whole-grain is a type of food which contains cereal fiber, bran, and germ|39bddfe0eea04fe0b9a0f4ff79a7717b|4
whole-grain|risks of all-cause and cardiovascular disease-specific mortality among women with type 2 diabetes mellitus|The intake of whole-grain may affect the risks of all-cause and cardiovascular disease-specific mortality among women with type 2 diabetes mellitus|39bddfe0eea04fe0b9a0f4ff79a7717b|4
dietary fiber|health benefits|Dietary fiber has health benefits as mentioned in the context|39bddfe0eea04fe0b9a0f4ff79a7717b|4
whole grain foods|heart disease risk|cause and effect relationship|7f84c0744ed44bf18dad9302a824860a|4
wholemeal breads|proportion of whole or cracked grain|relationship between ingredients|7f84c0744ed44bf18dad9302a824860a|4
glycaemic response|effect on glycemic control|cause and effect relationship|7f84c0744ed44bf18dad9302a824860a|4
Antioxidant activity|Grains|study about antioxidant activity of grains|d46e49e10581402a8f7185e710e9cf7a|4
Coronary heart disease|Dietary fat types|a review on types of dietary fat and risk of coronary heart disease|d46e49e10581402a8f7185e710e9cf7a|4
Nut consumption|Risk of coronary heart disease|a review on epidemiologic evidence about nut consumption and risk of coronary heart disease|d46e49e10581402a8f7185e710e9cf7a|4
Walnut consumption|Cardiovascular risk factors|Effects of walnut consumption on blood lipids and other cardiovascular risk factors|fa9a82f8c22349e7b0406b447340b72f|4
Meta-analysis|Systematic review|84. Banel D, Hu FB conducted a systematic review and meta-analysis|fa9a82f8c22349e7b0406b447340b72f|4
Changes in diet and lifestyle|Long-term weight gain|Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB studied changes in diet and lifestyle and their impact on long-term weight gain|fa9a82f8c22349e7b0406b447340b72f|4
Hyperlipidemia|Diet and exercise|Kelly R discussed the management of hyperlipidemia through diet and exercise|fa9a82f8c22349e7b0406b447340b72f|4
Legume consumption|Risk of coronary heart disease|related to each other|c989db6af22644da9c10420b737c4771|4
NHANES I Epidemiologic Follow-up Study|Legume consumption and risk of coronary heart disease in US men and women|study|c989db6af22644da9c10420b737c4771|4
Arch Intern Med.|Publication|Published in|c989db6af22644da9c10420b737c4771|4
PubMed: 20433126|Source of information|Found in|c989db6af22644da9c10420b737c4771|4
Soy food consumption|lower risk of coronary heart disease|associated with|0e0d8cdcb33742898f0ee1c24926ad7f|4
Soy isoflavones|plasma lipids|improve|0e0d8cdcb33742898f0ee1c24926ad7f|4
Soy isoflavones|normocholesterolemic and mildly hypercholesterolemic postmenopausal women|in|0e0d8cdcb33742898f0ee1c24926ad7f|4
intact soy protein|isoflavones|rich in|1081beaee3b14b2c9efb588e6416be23|4
ethanol-extracted soy protein|isoflavones|poor in|1081beaee3b14b2c9efb588e6416be23|4
HDL|intact soy protein|increase|1081beaee3b14b2c9efb588e6416be23|4
transforming growth factor beta(1)|intact soy protein|do not influence|1081beaee3b14b2c9efb588e6416be23|4
hemostatic risk factors for coronary heart disease|intact soy protein|do not influence|1081beaee3b14b2c9efb588e6416be23|4
high-isoflavone soyfoods|low-isoflavone soyfoods|effects on blood lipids, oxidized LDL, homocysteine, and blood pressure|ac980bb87245401bb63830cfe9518405|4
Affected individuals|Men and women|hyperlipidemic|ac980bb87245401bb63830cfe9518405|4
soybean protein|blood pressure|Effect of soybean protein on blood pressure|bee8b92369744021b49286195ff9cf4d|4
soy isoflavone supplementation|nitric oxide metabolism|Effect of soy isoflavone supplementation on nitric oxide metabolism|786b305a60f0446082b293054574ce09|4
soy isoflavone supplementation|blood pressure in menopausal women|Effect of soy isoflavone supplementation on blood pressure in menopausal women|786b305a60f0446082b293054574ce09|4
oral isoflavone supplementation|vascular endothelial function|Effect of oral isoflavone supplementation on vascular endothelial function|786b305a60f0446082b293054574ce09|4
oral isoflavone supplementation|postmenopausal women|Effect of oral isoflavone supplementation on postmenopausal women|786b305a60f0446082b293054574ce09|4
meta-analysis|randomized controlled trials|methodology|f7537f4f60a348e198eaaaf0c45d2e10|4
soy isoflavones|blood pressure|effect on|f7537f4f60a348e198eaaaf0c45d2e10|4
systematic review|randomized placebo-controlled trials|J. Hypertens. study|652061bbf446462cbb5728a6dd12283b|4
Adult humans|meta-analysis of randomized placebo-controlled trials|J. Hypertens. study|652061bbf446462cbb5728a6dd12283b|4
Food synergy|nutrition|Am J Clin Nutr. paper|652061bbf446462cbb5728a6dd12283b|4
Women|men|J Am Coll Cardiol 2012 study|652061bbf446462cbb5728a6dd12283b|4
Statins|Cardiovascular disease|Statins are used in primary prevention of cardiovascular disease.|2c8f883f317a46c88b41cf1c4abb0d27|4
Exercise|Mortality outcomes|Comparative effectiveness study of exercise and drug interventions on mortality outcomes.|2c8f883f317a46c88b41cf1c4abb0d27|4
Smoking cessation|Coronary heart disease| Smoking cessation for the secondary prevention of coronary heart disease.|2c8f883f317a46c88b41cf1c4abb0d27|4
Cochrane Database Syst Rev|2004; 1:CD003041|refers to a publication in the context|d396581f663b45e0b3ab526afdc7764f|4
disease|Cochrane Database Syst Rev|study about a disease is mentioned in Cochrane Database Syst Rev|d396581f663b45e0b3ab526afdc7764f|4
Cochrane Database Syst Rev|McAlister F, Marzona I, Dagenais GR, Teo KK, Yusuf S, Jung H, Turnbull F, Neal B, Chalmers J, MacMahon S, Lowering BP, Gerstein H, Marre M, Fox K, Simoons M, Nissen S, Heerspink HL, Brenner B, De Zeeuw D, Pfeffer M, Kober L, Diener HC, Sacco R, Renin Angiotension System Modulator Meta-Analysis Investigators|authors are associated with the Cochrane Database Syst Rev|d396581f663b45e0b3ab526afdc7764f|4
angiotensin receptor blockers|beneficial in normotensive atherosclerotic patients|relationship|7e374010bacd4fc988afdf4008c0b587|4
collaborative meta-analysis of randomized trials|Eur Heart J. 2012; 33(4):505–14|reference|7e374010bacd4fc988afdf4008c0b587|4
PubMed: 22041554|Eur Heart J. 2012; 33(4):505–14|reference|7e374010bacd4fc988afdf4008c0b587|4
Ronksley P, Brien SE, Turner BJ, Mukamal KJ, Ghali WA|association of alcohol consumption with selected cardiovascular disease outcomes|systematic review and meta-analysis|7e374010bacd4fc988afdf4008c0b587|4
BMJ. 2011; 342:d671|[PubMed: 21343207]|reference|7e374010bacd4fc988afdf4008c0b587|4
Mediterranean diet|health|accruing evidence on benefits of adherence|e27efc1192084b42a8f64f59590bf61a|4
adherence|benefits|on health: an updated systematic review and meta-analysis|e27efc1192084b42a8f64f59590bf61a|4
Aspirin|Primary and secondary prevention of vascular disease|used for|39e50f00af044f95ba0ecfe1c99fff78|4
Collaborative meta-analysis|Individual participant data from randomized trials|performed on|39e50f00af044f95ba0ecfe1c99fff78|4
PubMed: 19482214|Atenolol vs nonatenolol β-blockers for the treatment of hypertension|is about|58a9e274c1224fc683015f14e8b34071|4
Can J Cardiol. 2014; 30(5 Supple):S47–S53.|Atenolol vs nonatenolol β-blockers for the treatment of hypertension|refers to|58a9e274c1224fc683015f14e8b34071|4
PubMed: 24750981|Kuyper L, Khan NA. Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis.|is about|58a9e274c1224fc683015f14e8b34071|4
L|Kuyper L, Khan NA. Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis.|author|58a9e274c1224fc683015f14e8b34071|4
R|Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, Durrington PN, Ness AR, Capps NE, Davey Smith G, Riemersma RA, Ebrahim SB. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev.|author|58a9e274c1224fc683015f14e8b34071|4
2004|Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, Durrington PN, Ness AR, Capps NE, Davey Smith G, Riemersma RA, Ebrahim SB. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev.|year|58a9e274c1224fc683015f14e8b34071|4
PubMed|15495044|is associated with|d68e96b9983f48b8b8d8564f9082bede|4
Widmer et al.|Am J Med|is associated with|d68e96b9983f48b8b8d8564f9082bede|4
Mediterranean Diet|beneficial for both primary and secondary prevention of cardiovascular disease|has been proven by randomized controlled trials, observational studies, and meta-analyses|ddcea39c149e4f76a5b7590d37fbc177|4
Mediterranean Diet|no specific component|No specific component of the Mediterranean diet has been shown to be as beneficial as the whole.|ddcea39c149e4f76a5b7590d37fbc177|4
Mediterranean diet|contribution of the constituents|required to understand|14a51247e9ac4742a1d53087dec3c7d1|4
Estimates of risk ratio reduction|recent meta-analyses of trials examining medication adherence vs. placebo|Examined in the same sentence|5b157e2d46e74a368e9746b164619afb|4
Estimates of risk ratio reduction|lifestyle interventions vs. control|Mentioned together in the context|5b157e2d46e74a368e9746b164619afb|4
niacin|recent meta-analyses including recent negative data|Excluded from estimates due to lack of recent studies|5b157e2d46e74a368e9746b164619afb|4
relative risks|logarithmic conversions and standard errors|Reported in the same context|5b157e2d46e74a368e9746b164619afb|4
lifestyle modifications|Mediterranean diet|Examples of lifestyle interventions mentioned|5b157e2d46e74a368e9746b164619afb|4
diet as a whole (106)|fruits and vegetables (59, 61, 62)|relationship between the two concepts in one sentence|d616b9313bc0495aae3c366fbd901a3d|4
smoking cessation (103)|improved physical activity (102)|relationship between the two concepts in one sentence|d616b9313bc0495aae3c366fbd901a3d|4
omega-3 fatty acids (110)|fruits and vegetables (59, 61, 62)|relationship between the two concepts in one sentence|d616b9313bc0495aae3c366fbd901a3d|4
statins (100, 101)|diet as a whole (106)|relationship between the two concepts in one sentence|d616b9313bc0495aae3c366fbd901a3d|4
renin-angiotensin system blockade (104)|standard medical therapies|relationship between the two concepts in one sentence|d616b9313bc0495aae3c366fbd901a3d|4
Fibrates (107)|statins (100, 101)|relationship between the two concepts in one sentence|d616b9313bc0495aae3c366fbd901a3d|4
aspirin (108)|standard medical therapies|relationship between the two concepts in one sentence|d616b9313bc0495aae3c366fbd901a3d|4
beta-blockers (109)|standard medical therapies|relationship between the two concepts in one sentence|d616b9313bc0495aae3c366fbd901a3d|4
NIH-PA|Author Manuscript|is a|e52c28505c42478ead33b882ef77da73|4
Protective effect|Cardiovascular disease|Underlying protective mechanisms for|a667664671a34b9c9ca011f9e37c06c5|4
Advantages|Food groups|Deriving the greatest benefit for patients|a667664671a34b9c9ca011f9e37c06c5|4
Ingredient|Single mechanism|Can't account for all advantages|a667664671a34b9c9ca011f9e37c06c5|4
Balanced variety|Calorically sensible|Deriving the greatest benefit for patients|a667664671a34b9c9ca011f9e37c06c5|4
Widmer et al.|Page 19|Reference in Am J Med|a667664671a34b9c9ca011f9e37c06c5|4
Population-based Data|RCT|type of study|1d152d27f29b47c99a4a615bd33cd91d|4
Data|CVD|data related to condition|1d152d27f29b47c99a4a615bd33cd91d|4
Effect|Proposed Mechanisms|explanation of the effect|1d152d27f29b47c99a4a615bd33cd91d|4
Mediterranean Diet|Improved lipids, reduces ROS, endothelial function, platelet function|result of the diet|1d152d27f29b47c99a4a615bd33cd91d|4
Unsaturated Fats|Improved lipids, reduces ROS, endothelial function, platelet function|effect of unsaturated fats|1d152d27f29b47c99a4a615bd33cd91d|4
Fish|Improves lipid profiles and BP|effect of fish consumption|1d152d27f29b47c99a4a615bd33cd91d|4
Fruits/Vegetables|Improves lipid profiles and BP; reduces ROS|effect of fruits/vegetables consumption|1d152d27f29b47c99a4a615bd33cd91d|4
Whole Grains|Improved glucose metabolism, reduced inflammation, ROS, lipid profiles, and blood pressure|whole grains are associated with|892bf2139ab44a8ea662e0938c0d81c2|4
Eggs|NC Controversial data without mechanistic evidence|eggs have controversial data related to|892bf2139ab44a8ea662e0938c0d81c2|4
Garlic|Improves lipid profiles|garlic is associated with|892bf2139ab44a8ea662e0938c0d81c2|4
Alcohol|Improves lipid profiles, BP, (+/−) ROS, and endothelial function|alcohol is associated with|892bf2139ab44a8ea662e0938c0d81c2|4
Nuts|ROS and lipid profiles; improves BP and endothelial function|nuts are associated with|892bf2139ab44a8ea662e0938c0d81c2|4
HIV|cardiovascular disease|are related medical conditions|bf261f0dec5a490e9f44b280a8493225|4
Kaku So-Armah, PhD|Boston University School of Medicine, Boston, MA, USA|is affiliated with|bf261f0dec5a490e9f44b280a8493225|4
Laura A Benjamin, PhD|UCL Queen Square Institute of Neurology, University College London, London, UK|is affiliated with|bf261f0dec5a490e9f44b280a8493225|4
Institute of Infection and Global Health, University of Liverpool, Liverpool, UK|Gerald S Bloomfield, MD|is affiliated with|bf261f0dec5a490e9f44b280a8493225|4
Duke Global Health Institute, Duke University, Durham, North Carolina, NC, USA|Gerald S Bloomfield, MD|is affiliated with|bf261f0dec5a490e9f44b280a8493225|4
Northwestern University Feinberg School of Medicine, Chicago, IL, USA|Matthew J Feinstein, MD|is affiliated with|bf261f0dec5a490e9f44b280a8493225|4
Prof Priscilla Hsue, MD|University of California, San Francisco, CA, USA|professor affiliation with university|30d3bcbe2a914bdb98f292dfa3fa9943|4
Benson Njuguna, BPharm|Moi Teaching and Referral Hospital, Eldoret, Kenya|professional at hospital|30d3bcbe2a914bdb98f292dfa3fa9943|4
Matthew S Freiberg Prof, MD|Vanderbilt University Medical Center, Nashville VA Medical Center, VA Tennessee Valley Healthcare System, Nashville, TN, USA|professor affiliation with multiple institutions|30d3bcbe2a914bdb98f292dfa3fa9943|4
37.9 million people living with HIV worldwide|HIV-related cardiovascular disease|estimated to have HIV, and may experience mechanisms of cardiovascular disease|b102bd4506a147e2848a9fae53005a91|4
Sub-Saharan Africa|younger population|geographical location where a younger population is found|b102bd4506a147e2848a9fae53005a91|4
Sub-Saharan Africa|higher prevalence of elevated blood pressure|located in the area with higher prevalence of elevated blood pressure|b102bd4506a147e2848a9fae53005a91|4
Sub-Saharan Africa|lower smoking rates|geographical location where lower smoking rates are found|b102bd4506a147e2848a9fae53005a91|4
Sub-Saharan Africa|lower prevalence of elevated cholesterol|located in the area with lower prevalence of elevated cholesterol|b102bd4506a147e2848a9fae53005a91|4
Western Europe|older population|geographical location where an older population is found|b102bd4506a147e2848a9fae53005a91|4
Western Europe|higher prevalence of elevated blood pressure|located in the area with higher prevalence of elevated blood pressure|b102bd4506a147e2848a9fae53005a91|4
Western Europe|higher smoking rates|geographical location where higher smoking rates are found|b102bd4506a147e2848a9fae53005a91|4
Western Europe|higher prevalence of elevated cholesterol|located in the area with higher prevalence of elevated cholesterol|b102bd4506a147e2848a9fae53005a91|4
cardiovascular disease|profile|differs|fa0d5da48f7748dc928e7d292e046fb7|4
low-income countries|high-income countries|variations between|fa0d5da48f7748dc928e7d292e046fb7|4
Research in|implementation of|and|fa0d5da48f7748dc928e7d292e046fb7|4
research|advocacy|and|fa0d5da48f7748dc928e7d292e046fb7|4
data acquisition|data analysis and interpretation|participated in|fa0d5da48f7748dc928e7d292e046fb7|4
data acquisition, analysis, and interpretation|All authors|participated in|fa0d5da48f7748dc928e7d292e046fb7|4
manuscript|final approval|reviewed the|2bb366f53f3c4085ac6e1c1577e5a598|4
honoraria|Gilead Sciences and Merck|reports honoraria from|2bb366f53f3c4085ac6e1c1577e5a598|4
honoraria|outside the submitted work|PH reports honoraria from|2bb366f53f3c4085ac6e1c1577e5a598|4
grants|Global Health Catalyst (Africa Non-Communicable Diseases Open Lab)|reports grants from|2bb366f53f3c4085ac6e1c1577e5a598|4
grants|outside the submitted work|Global Health Catalyst (Africa Non-Communicable Diseases Open Lab) reports grants from|2bb366f53f3c4085ac6e1c1577e5a598|4
World Population Maps|ined.fr/en/everything_about_population/graphs-maps/world-maps-interactiv|see|44fb960a9b264aeab2f4827dffa59a75|4
WHO Map Gallery|http://gamapserver.who.int/mapLibrary/app/searchResults.aspx|see|44fb960a9b264aeab2f4827dffa59a75|4
See Online|for appendix|see|44fb960a9b264aeab2f4827dffa59a75|4
HHS Public Access|Author manuscript|Affiliations.|44fb960a9b264aeab2f4827dffa59a75|4
Author manuscript|Lancet HIV|Published in final edited form as:|44fb960a9b264aeab2f4827dffa59a75|4
Lancet HIV|e279–e293. doi:10.1016/S2352-3018(20)30036-9.|Published in final edited form as:|44fb960a9b264aeab2f4827dffa59a75|4
risk reduction of cardiovascular disease|global context of HIV|account for differences|4c2f98f7ce794570896839fab549dd53|4
traditional cardiovascular disease risk factors|HIV|differences in the distribution|4c2f98f7ce794570896839fab549dd53|4
traditional cardiovascular disease risk factors|hypertension|eg, hypertension|4c2f98f7ce794570896839fab549dd53|4
traditional cardiovascular disease risk factors|smoking|eg, smoking|4c2f98f7ce794570896839fab549dd53|4
non-traditional cardiovascular disease risk factors|access to antiretroviral therapy|consider non-traditional cardiovascular disease risk factors|4c2f98f7ce794570896839fab549dd53|4
non-traditional cardiovascular disease risk factors|more benign cardiovascular disease side effect profiles|with more benign cardiovascular disease side effect profiles|4c2f98f7ce794570896839fab549dd53|4
non-traditional cardiovascular disease risk factors|indoor air pollution|eg, indoor air pollution|4c2f98f7ce794570896839fab549dd53|4
relevant risk reduction approaches for cardiovascular disease|HIV-|encourage the inclusion of relevant risk reduction approaches for cardiovascular disease|4c2f98f7ce794570896839fab549dd53|4
implementation science|integrated HIV and cardiovascular disease care models|to scale up and expand|7e6e9683283d4ba5894713e7dc82c02d|4
sub-Saharan Africa|integrated HIV and cardiovascular disease care models|have shown promise in|7e6e9683283d4ba5894713e7dc82c02d|4
HIV and cardiovascular disease epidemiology|women|include|7e6e9683283d4ba5894713e7dc82c02d|4
tobacco cessation|people living with HIV|for|7e6e9683283d4ba5894713e7dc82c02d|4
disease|risk factors|driving cardiovascular disease|4c20058aab6040fcb838992e157b57e8|4
cardiovascular disease|access to life-preserving combination antiretroviral therapy (ART)|people with HIV are living longer and could have increased risk for diseases of ageing|4c20058aab6040fcb838992e157b57e8|4
AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort|median age|people with HIV on ART will increase from 43∙9|4c20058aab6040fcb838992e157b57e8|4
years|2030|time frame for the increase in diagnosed cardiovascular disease among people with HIV|8ecc31a8533a4e4c9413b3b094d81387|4
78%|people with HIV|percentage of people with HIV who will have been diagnosed with cardiovascular disease by 2030|8ecc31a8533a4e4c9413b3b094d81387|4
increase in relative risk|myocardial infarction among people with HIV|comparison of relative risk between people with and without HIV|8ecc31a8533a4e4c9413b3b094d81387|4
viral suppression|increased relative risk|condition persists even among those with viral suppression|8ecc31a8533a4e4c9413b3b094d81387|4
type 1 and type 2 acute myocardial infarction events|increased relative risk|applies to both type 1 and type 2 acute myocardial infarction events|8ecc31a8533a4e4c9413b3b094d81387|4
more pronounced in women|increased relative risk|potentially more pronounced in women than in men|8ecc31a8533a4e4c9413b3b094d81387|4
coronary heart disease|acute myocardial infarction|cause and effect|e084a2d036544a7784e245a485446bc7|4
risk factors for coronary heart disease|absolute rates of acute myocardial infarction|effect on|e084a2d036544a7784e245a485446bc7|4
HIV|people with HIV|affected group|e084a2d036544a7784e245a485446bc7|4
good cardiac health|relative risk of acute myocardial infarction|effect on|e084a2d036544a7784e245a485446bc7|4
ischaemic stroke|strokes in people with HIV|accounts for|e084a2d036544a7784e245a485446bc7|4
haemorrhagic stroke|rest of strokes in people with HIV|accounted for by|e084a2d036544a7784e245a485446bc7|4
heart failure|HIV|causation|5971e16434a34120aac253c2bfbfc3ed|4
heart failure|ART|association|5971e16434a34120aac253c2bfbfc3ed|4
overt AIDS cardiomyopathy|HIV|causation|5971e16434a34120aac253c2bfbfc3ed|4
preserved ejection fraction|heart failure|type of|5971e16434a34120aac253c2bfbfc3ed|4
ischaemic post-myocardial infarction|heart failure|type of|5971e16434a34120aac253c2bfbfc3ed|4
reduced ejection fraction|heart failure|type of|5971e16434a34120aac253c2bfbfc3ed|4
HIV-associated risk|excess in HIV|greater for|5971e16434a34120aac253c2bfbfc3ed|4
failure|So-Armah et al.|authored|3708213ebe23468596b0f82b0e0ca948|4
failure|Lancet HIV|published in|3708213ebe23468596b0f82b0e0ca948|4
Peripheral artery disease|HIV|Understudied among people|0fa4e59714c84d1eaee7e3eed9f29515|4
Peripheral artery disease|Atherosclerosis|Presentations of atherosclerosis|0fa4e59714c84d1eaee7e3eed9f29515|4
Studies on HIV and Peripheral artery disease|Inconsistent results|Report inconsistent results|0fa4e59714c84d1eaee7e3eed9f29515|4
HIV infection|peripheral artery disease|risk factor|448af327be2a4ac09cd0805ded10d880|4
General population|prevalence estimates|relationship|448af327be2a4ac09cd0805ded10d880|4
People aged 40–49 years|3.9% prevalence|percentage|448af327be2a4ac09cd0805ded10d880|4
Veterans Aging Cohort Study|over 90,000 participants|sample size|448af327be2a4ac09cd0805ded10d880|4
USA|study location|geographical relation|448af327be2a4ac09cd0805ded10d880|4
cardiovascular disease|Tanzania|one cohort from Tanzania, all other from western Europe or North America|0d56e9f83dd84266bb23e04ec4f1ca64|4
distribution|geographical location|varies by geographical location|0d56e9f83dd84266bb23e04ec4f1ca64|4
Sub-Saharan Africa|HIV prevalence|greatest prevalence of HIV in Sub-Saharan Africa|0d56e9f83dd84266bb23e04ec4f1ca64|4
younger population|Sub-Saharan Africa|younger population in Sub-Saharan Africa|0d56e9f83dd84266bb23e04ec4f1ca64|4
elevated blood pressure prevalence|Sub-Saharan Africa|higher elevated blood pressure prevalence in Sub-Saharan Africa|0d56e9f83dd84266bb23e04ec4f1ca64|4
tobacco smoking rates|lower tobacco smoking rates|lower tobacco smoking rates|0d56e9f83dd84266bb23e04ec4f1ca64|4
prevalence of elevated|lower prevalence of elevated|lower prevalence of elevated in Sub-Saharan Africa|0d56e9f83dd84266bb23e04ec4f1ca64|4
cardiac and pulmonary health|HIV|effect on cardiac and pulmonary health|fc71f24df00f4c0aa6f52da5df6f42f3|4
high-income settings|unique exposures|relevance in high-income settings|fc71f24df00f4c0aa6f52da5df6f42f3|4
HIV virus|CD4+ T-cell depletion|depletion caused by the HIV virus|a62d4c235ff24c9c998111590e0c6715|4
HIV virus|increased intestinal permeability|caused by the HIV virus|a62d4c235ff24c9c998111590e0c6715|4
HIV virus|microbial translocation|resulting from increased intestinal permeability caused by HIV|a62d4c235ff24c9c998111590e0c6715|4
HIV virus|altered cholesterol metabolism|affected by the HIV virus|a62d4c235ff24c9c998111590e0c6715|4
chronic inflammation|biomarkers|measurement of biomarkers for chronic inflammation|a62d4c235ff24c9c998111590e0c6715|4
monocyte activation|biomarkers|monocyte activation is a biomarker|a62d4c235ff24c9c998111590e0c6715|4
altered coagulation|biomarkers|altered coagulation is a biomarker|a62d4c235ff24c9c998111590e0c6715|4
atherogenesis|inflammatory process|atherogenesis is an inflammatory process|a62d4c235ff24c9c998111590e0c6715|4
people living with HIV|biomarkers of chronic inflammation|elevated biomarkers of chronic inflammation in people living with HIV|a62d4c235ff24c9c998111590e0c6715|4
myocardial infarction|sex-based differences|differences in response to acute HIV infection|4ce3c60f6b4d455094dfb2cbecc0dedf|4
sex-based differences|greater inclusion of women and sex-stratified analyses|higher rates of myocardial infarction among women|4ce3c60f6b4d455094dfb2cbecc0dedf|4
CD4+ T-cell depletion|people with HIV|is associated with higher rates and risk of|5755ec4125464872b7ea059f08a29372|4
CD4+ T-cell depletion|incident acute myocardial infarction|is associated with higher rates and risk of|5755ec4125464872b7ea059f08a29372|4
CD4+ T-cell depletion|heart failure|is associated with higher rates and risk of|5755ec4125464872b7ea059f08a29372|4
CD4+ T-cell depletion|peripheral artery disease|is associated with higher rates and risk of|5755ec4125464872b7ea059f08a29372|4
CD4+ T-cell depletion|ischaemic stroke|is associated with higher rates and risk of|5755ec4125464872b7ea059f08a29372|4
inflammatory response|cardiovascular disease|might lead to|f592a6dda40d47af913cff2e638c845e|4
infectious myocarditis|cardiovascular disease|part of|f592a6dda40d47af913cff2e638c845e|4
HIV|cardiomyopathy|cause via direct infection|f592a6dda40d47af913cff2e638c845e|4
depletion of CD4+|CD4+ So-Armah et al.|caused by|f592a6dda40d47af913cff2e638c845e|4
Lancet HIV|So-Armah et al. Page 3|published in|f592a6dda40d47af913cff2e638c845e|4
T cells|HIV infection|cause and effect|bb15aa8b642546b282b063073e554eea|4
T cells in the gut mucosa|damages the lining of the gut|resulting from|bb15aa8b642546b282b063073e554eea|4
gut permeability|microbial translocation products|cause and effect|bb15aa8b642546b282b063073e554eea|4
microbial translocation process|portal circulation|transmission medium|bb15aa8b642546b282b063073e554eea|4
chronic immune activation|inflammation|resulting from|bb15aa8b642546b282b063073e554eea|4
HIV|other viral infections|like other|bb15aa8b642546b282b063073e554eea|4
cholesterol metabolism|atherogenic lipid and cholesterol profiles|resulting in|2f404005e0cb48089b81243a1acc6dff|4
HIV|blood–brain barrier|alters through infected monocytes|2f404005e0cb48089b81243a1acc6dff|4
infected monocytes|peripheral circulation|routinely surveil the brain from|2f404005e0cb48089b81243a1acc6dff|4
HIV-infected cells|inflammatory microenvironment|accentuates|2f404005e0cb48089b81243a1acc6dff|4
endothelial dysfunction|vessel wall remodelling|are both mechanisms that mediate adverse cardiovascular effects|38a37a555e3e4bad88112d6eec9bfad2|4
periphery|brain|their roles in the mechanism may be different|38a37a555e3e4bad88112d6eec9bfad2|4
ART-related mechanisms|cardiovascular disease risk|the effects of ART can influence both|38a37a555e3e4bad88112d6eec9bfad2|4
life-preserving effects|reducing HIV viraemia|ART's benefits are weighed against these factors|38a37a555e3e4bad88112d6eec9bfad2|4
Older ART regimens|Low-income settings|used in|30430ef074084bdc979fe533129ba8d6|4
Older ART regimens|Side-effect profiles|had|30430ef074084bdc979fe533129ba8d6|4
Side-effect profiles|Cardiovascular health|detrimental to|30430ef074084bdc979fe533129ba8d6|4
Older ART regimens|Altered glucose and lipid metabolism|caused|30430ef074084bdc979fe533129ba8d6|4
Older ART regimens|Mitochondrial toxicity|caused|30430ef074084bdc979fe533129ba8d6|4
Mitochondrial toxicity|Cardiac myopathy|resulting in|30430ef074084bdc979fe533129ba8d6|4
Older ART regimens|Impaired left ventricular function|caused|30430ef074084bdc979fe533129ba8d6|4
Other regimens|Less detrimental effects on cardiovascular health|might have|30430ef074084bdc979fe533129ba8d6|4
Whether these cardiotoxic-ART effects differ by sex|Unclear|Whether|30430ef074084bdc979fe533129ba8d6|4
weight gain|ART side-effects|are associated|b6797d27f5694e6f9ec6cffb1d5b6c7f|4
weight gain|HIV viral suppression|is related to|b6797d27f5694e6f9ec6cffb1d5b6c7f|4
weight gain|catabolic state|in part reflects|b6797d27f5694e6f9ec6cffb1d5b6c7f|4
fluctuating trends in weight gain|low-income and high-income settings|are found in|b6797d27f5694e6f9ec6cffb1d5b6c7f|4
weight gain|incident diabetes|is associated with|b6797d27f5694e6f9ec6cffb1d5b6c7f|4
weight gain|cardiovascular disease risk factor|is a risk factor for|b6797d27f5694e6f9ec6cffb1d5b6c7f|4
People ageing with HIV|chronic comorbidities|have multiple chronic comorbidities|63174ed5579a42449a7ba1dc73ef1275|4
People ageing with HIV|multidrug regimens|requiring multidrug regimens|63174ed5579a42449a7ba1dc73ef1275|4
People ageing with HIV|polypharmacy|resulting in polypharmacy|63174ed5579a42449a7ba1dc73ef1275|4
HIV infection|prolonged QT intervals|associated with HIV infection|63174ed5579a42449a7ba1dc73ef1275|4
Prolonged QT intervals|increased risk of sudden cardiac death|are associated with increased risk|63174ed5579a42449a7ba1dc73ef1275|4
People with HIV|4-times increased risk|have a 4-times increased risk|63174ed5579a42449a7ba1dc73ef1275|4
sudden cardiac death|people without HIV|comparison|3be9670cd94e4bae87cf17787e653be7|4
Non-HIV specific mechanisms|increased risk of cardiovascular disease|contribution to|3be9670cd94e4bae87cf17787e653be7|4
Non-HIV specific mechanisms|traditional and non-traditional cardiovascular disease risk factors|include|3be9670cd94e4bae87cf17787e653be7|4
traditional risk factors|smoking|part of|3be9670cd94e4bae87cf17787e653be7|4
traditional risk factors|diabetes|part of|3be9670cd94e4bae87cf17787e653be7|4
traditional risk factors|dyslipidaemia|part of|3be9670cd94e4bae87cf17787e653be7|4
traditional risk factors|hypertension|part of|3be9670cd94e4bae87cf17787e653be7|4
traditional risk factors|biological sex|part of|3be9670cd94e4bae87cf17787e653be7|4
exposure|risk factors|are related in the context of a study|e58f0d7fe8c8449c888a0b14d7636065|4
women with HIV|higher odds|are related as women with HIV might have higher odds of developing metabolic syndrome than men|e58f0d7fe8c8449c888a0b14d7636065|4
metabolic syndrome|developing|are related in the context of a study|e58f0d7fe8c8449c888a0b14d7636065|4
men|higher odds|are related as women with HIV might have higher odds of developing metabolic syndrome than men|e58f0d7fe8c8449c888a0b14d7636065|4
relative|So-Armah et al.|are related in the context of a study|e58f0d7fe8c8449c888a0b14d7636065|4
risk of acute myocardial infarction|people with HIV|compared with people without HIV|4c6a98f394bf4490aa1ca022b4cd842a|4
absolute rates of acute myocardial infarction|HIV status|still 2-times higher|4c6a98f394bf4490aa1ca022b4cd842a|4
exposure to risk factors|cardiovascular disease risk|leads to an exponential increase in|4c6a98f394bf4490aa1ca022b4cd842a|4
combination of risk factors and HIV infection|subclinical atherosclerosis|have been variably associated with|4c6a98f394bf4490aa1ca022b4cd842a|4
calcification|vascular alterations|part of|0eed991199184ea3b202ccfad39e96dc|4
variability|geographical distribution|related to|0eed991199184ea3b202ccfad39e96dc|4
traditional cardiovascular disease risk factors|subclinical cardiovascular disease|related to|0eed991199184ea3b202ccfad39e96dc|4
HIV-related cardiovascular disease|risk reduction globally|need for studies in|0eed991199184ea3b202ccfad39e96dc|4
Non-traditional cardiovascular disease risk factors|HIV|are also accentuated in|0eed991199184ea3b202ccfad39e96dc|4
Unhealthy alcohol consumption|Depression|co-infection|01d416a02d324109a4c1e1cad57efc8f|4
Unhealthy alcohol consumption|Hepatitis C|cause and effect relationship|01d416a02d324109a4c1e1cad57efc8f|4
Unhealthy alcohol consumption|Cytomegalovirus co-infection|possibly causing co-infection|01d416a02d324109a4c1e1cad57efc8f|4
Unhealthy alcohol consumption|Microbial translocation|causing microbial translocation|01d416a02d324109a4c1e1cad57efc8f|4
Unhealthy alcohol consumption|Kupffer cells|driving chronic inflammation|01d416a02d324109a4c1e1cad57efc8f|4
Liver fibrosis|Increased heart failure risk|associated with increased risk|01d416a02d324109a4c1e1cad57efc8f|4
Unhealthy alcohol consumption|ART non-adherence|associated with ART non-adherence|01d416a02d324109a4c1e1cad57efc8f|4
Unhealthy alcohol consumption|Increased HIV risk|increasing HIV risk|01d416a02d324109a4c1e1cad57efc8f|4
viral replication|cardiovascular disease risk|increase|598ad8703fae47e3bb0638c6b0eb3539|4
Major depressive disorder|people with HIV|affects between 5% and 10% of|598ad8703fae47e3bb0638c6b0eb3539|4
Depression|heart failure among people with HIV|risk factor|598ad8703fae47e3bb0638c6b0eb3539|4
Hepatitis C|common co-infections among people with HIV|are common co-infections|27fad468e3244a5fadd07b98dfdcdd4f|4
Hepatitis C|incident cardiovascular disease events|has been linked to incident cardiovascular disease events in many, but not all, studies|27fad468e3244a5fadd07b98dfdcdd4f|4
Underlying mechanisms|chronic inflammation, endothelial dysfunction, exacerbating microbial translocation through hepatic damage|are thought to be related|27fad468e3244a5fadd07b98dfdcdd4f|4
Cytomegalovirus|risk factor for cardiovascular disease|role as a risk factor for cardiovascular disease is less clear|27fad468e3244a5fadd07b98dfdcdd4f|4
Observational studies|Cytomegalovirus antibody status|link to incident cardiovascular disease|8fb02935616a404c986749398f972915|4
Cytomegalovirus antibody status|Incident cardiovascular disease|in general population|8fb02935616a404c986749398f972915|4
No studies|People with HIV|exist for people with HIV|8fb02935616a404c986749398f972915|4
Some evidence|Cytomegalovirus status|links to immunosenescence|8fb02935616a404c986749398f972915|4
Immunosenescence|Cardiovascular disease risk|might predispose to|8fb02935616a404c986749398f972915|4
Disparities in cardiovascular care|People with HIV|are less likely to receive aspirin|8fb02935616a404c986749398f972915|4
HMG-CoA|Primary cardiovascular disease prevention|no studies found for people with HIV|8fb02935616a404c986749398f972915|4
reductase inhibitor therapy|diabetes|is used for treating|9a4f9e2062494b5e96dd767a2172e688|4
reductase inhibitor therapy|cardiovascular disease|is used for treating|9a4f9e2062494b5e96dd767a2172e688|4
reductase inhibitor therapy|dyslipidaemia|is used for treating|9a4f9e2062494b5e96dd767a2172e688|4
invasive procedures|myocardial infarction|are for|9a4f9e2062494b5e96dd767a2172e688|4
HIV status|disparities|in cardiovascular disease|9a4f9e2062494b5e96dd767a2172e688|4
substance use disorders|worsen|disparities by HIV status|9a4f9e2062494b5e96dd767a2172e688|4
female sex|contribute to|disparities by HIV status|9a4f9e2062494b5e96dd767a2172e688|4
racial and ethnic minorities|experience disparities|by HIV status|9a4f9e2062494b5e96dd767a2172e688|4
insufficient cardiovascular disease risk stratification tools|guidelines tailored for So-Armah et al.|are needed|616128c33a4048cf9872e123165b8534|4
So-Armah et al.|Lancet HIV|is a research article published by|616128c33a4048cf9872e123165b8534|4
author manuscript|PMC 2022 August 03|available in|616128c33a4048cf9872e123165b8534|4
HIV|Cardiovascular disease risk calculators|derived from HIV uninfected populations in high-income countries|7215ff5a18924dc2b88967296e616a55|4
HIV|HIV-specific risk estimation model|exists, derived from a largely white European population and relies on data from before the modern ART era|7215ff5a18924dc2b88967296e616a55|4
Cardiovascular disease risk prediction for people living with HIV in sub-Sahara Africa|HIV-specific risk estimation model|faces another challenge|7215ff5a18924dc2b88967296e616a55|4
epidemiology|traditional cardiovascular disease risk factors|unique from that in high-income countries|9295016401264e31a2c0ca7c867a62bf|4
results of studies|REPRIEVE, SEARCH, and EVERLAST48|studies including REPRIEVE, SEARCH, and EVERLAST48|9295016401264e31a2c0ca7c867a62bf|4
important incidence and risk factor data|cardiovascular disease risk prediction for people with HIV|provide important incidence and risk factor data to inform cardiovascular disease risk prediction|9295016401264e31a2c0ca7c867a62bf|4
guidance|The American Heart Association (AHA)|recently provided guidance62 on applying the|9295016401264e31a2c0ca7c867a62bf|4
atherosclerotic cardiovascular disease risk calculator|people living with HIV|in people living with HIV|49ccb2cb0f534405a9bb0b786a7596bb|4
HIV-related cardiovascular disease risk-enhancing factors|clinicians|for patients with HIV-related cardiovascular disease risk-enhancing factors, clinicians might adjust the calculated risk estimate upward|49ccb2cb0f534405a9bb0b786a7596bb|4
calculated risk estimate|HIV-related factors|by basing on that most risk calculators tend to underestimate cardiovascular disease risk in this group, HIV-related factors are taken into account|49ccb2cb0f534405a9bb0b786a7596bb|4
low nadir|specific HIV-related factors|eg, low nadir and|49ccb2cb0f534405a9bb0b786a7596bb|4
current CD4 count|cardiovascular disease risk elevation|are associated with|b60ea705f6f04b9d83ff66e19dde9714|4
Traditional|atherosclerotic cardiovascular disease risk factors|should be considered|b60ea705f6f04b9d83ff66e19dde9714|4
Traditional|non-traditional atherosclerotic cardiovascular disease risk factors|in one or two sentences|b60ea705f6f04b9d83ff66e19dde9714|4
Intervention|lifestyle optimisation regardless of risk|involves a combination of|b60ea705f6f04b9d83ff66e19dde9714|4
Intervention|pharmacotherapy with rosuvastatin, atorvastatin, pravastatin, or pitavastatin|for people at sufficiently high risk|b60ea705f6f04b9d83ff66e19dde9714|4
AHA scientific statement on HIV|risk adjustment approach|is also incorporated|b60ea705f6f04b9d83ff66e19dde9714|4
European Society for Cardiology guidelines|people with HIV at high risk for cardiovascular disease|suggest treating LDL-cholesterol to a goal of less than 70 mg/dL|411d40ecf6ec4559b7ab679ef7afd980|4
European Society for Cardiology guidelines|low-income and middle-income countries|suggest treating LDL-cholesterol to a goal of less than 70 mg/dL|411d40ecf6ec4559b7ab679ef7afd980|4
people with HIV at high risk for cardiovascular disease|South Africa|people living with HIV are considered to be at low risk for atherosclerotic cardiovascular disease|411d40ecf6ec4559b7ab679ef7afd980|4
general population|HIV|guidelines are suggested for people living with|c422b23802984bcebba82296b022c407|4
South African guidelines|management of ischaemic stroke and transient|for the 2010 management of|c422b23802984bcebba82296b022c407|4
2010 South African guidelines|HIV infection|were not specific about|c422b23802984bcebba82296b022c407|4
AHA guidance|cardiovascular risk scores|extrapolating to existing for stroke risk prediction in low-income and middle-income countries is|c422b23802984bcebba82296b022c407|4
reasonable|previously discussed limitations|relationship between the two concepts, reasonable and previously discussed limitations in one sentence|bedb4c4564fd4bea8cbf919b74de1af0|4
intracranial|large to medium sized ischaemic strokes|relationship between the two concepts, intracranial and large to medium sized ischaemic strokes in one sentence|bedb4c4564fd4bea8cbf919b74de1af0|4
non-traditional vascular risk factors|ischaemic strokes|relationship between the two concepts, non-traditional vascular risk factors and ischaemic strokes in one sentence|bedb4c4564fd4bea8cbf919b74de1af0|4
cardiovascular disease|stroke epidemiology|relationship between the two concepts, cardiovascular disease and stroke epidemiology in one sentence|bedb4c4564fd4bea8cbf919b74de1af0|4
International Classification of Diseases and Related Health Problems -11|oversight to be rectified|relationship between the two concepts, International Classification of Diseases and Related Health Problems -11 and oversight to be rectified in one sentence|bedb4c4564fd4bea8cbf919b74de1af0|4
emphasis on stroke|high-income settings|in same sentence|f0d3fff6e82244cc87878770fb8e02bb|4
AHA|cause of stroke|in same sentence|f0d3fff6e82244cc87878770fb8e02bb|4
HIV infection|stage of HIV infection|in same sentence|f0d3fff6e82244cc87878770fb8e02bb|4
opportunistic infection|HIV-associated vasculitis|in same sentence|f0d3fff6e82244cc87878770fb8e02bb|4
atherosclerosis|stable So-Armah et al. Page 6 Lancet HIV|in same context, different sentences|f0d3fff6e82244cc87878770fb8e02bb|4
undefined (non-vasculitic, non-atherosclerotic) vasculopathy|stable So-Armah et al. Page 6 Lancet HIV|in same context, different sentences|f0d3fff6e82244cc87878770fb8e02bb|4
disease|HIV|is less advanced in high-income countries, but still present with opportunistic infections when ART fails or late presentation of HIV|15d350591bc04d3f97c28878d74aac80|4
ART.35,62,77|HIV|is taken by those on|15d350591bc04d3f97c28878d74aac80|4
cerebrospinal fluid HIV escape syndrome|inflammatory vasculopathy|can occur in the context of|15d350591bc04d3f97c28878d74aac80|4
stable disease|cerebrospinal fluid HIV escape syndrome|among those with|15d350591bc04d3f97c28878d74aac80|4
ART.79|HIV|those on ART are affected by|15d350591bc04d3f97c28878d74aac80|4
primary and secondary prevention|cardiovascular disease in high-risk groups|main therapies for|3934c68486d549888fb0f79d6610be79|4
other targeted therapies|after a stroke|might be required|3934c68486d549888fb0f79d6610be79|4
guidelines|for HIV-related heart failure prevention and treatment|no guidelines exist for|3934c68486d549888fb0f79d6610be79|4
clinical trial data|observational data on heart failure|are being discussed together in the context|7835d291bc734297b0b649e8655d5941|4
AHA scientific statement|heart failure examination and therapy|suggests that they should be similar for HIV positive people|7835d291bc734297b0b649e8655d5941|4
uncertainty about the mechanisms of heart failure in HIV|similarity in treatment recommendation|is the reason behind this suggestion|7835d291bc734297b0b649e8655d5941|4
Diuretics, renally-excreted β blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor|medications used in heart failure treatment|are mentioned as part of the treatment recommendation|7835d291bc734297b0b649e8655d5941|4
blockers (ARBs)|losartan and irbesartan|do not have with the exception of|cd328c8e761f4545b8c5ceea27974e55|4
providers|heart failure medication|should be aware of|cd328c8e761f4545b8c5ceea27974e55|4
ART|ritonavir and cobicistat|that can inhibit|cd328c8e761f4545b8c5ceea27974e55|4
clinical indications|general population|applicable to|4859b282e0884a8981a29b827e01e277|4
experts|guidelines|recommend following|4859b282e0884a8981a29b827e01e277|4
peripheral artery disease|sudden cardiac death|provided by|4859b282e0884a8981a29b827e01e277|4
American College of Cardiology|AHA|and|4859b282e0884a8981a29b827e01e277|4
European Society for Vascular Surgery|European Society of Cardiology|with|4859b282e0884a8981a29b827e01e277|4
Peripheral artery disease|Additional testing (eg, ankle-brachial index)|is suggestive of|82588cc74cbb4bdf86c83a256e827e21|4
Revascularisation|Assessment of left ventricular ejection fraction|can be considered as|82588cc74cbb4bdf86c83a256e827e21|4
Consideration of electrophysiology and an implantable cardiac defibrillator|Reducing the risk of sudden cardiac death|is a preventative strategy for|82588cc74cbb4bdf86c83a256e827e21|4
Cardiovascular disease risk reduction in HIV|Sub-Saharan Africa and low-income and middle-income countries|in|82588cc74cbb4bdf86c83a256e827e21|4
country-level HIV programmes|traditionally focused health systems|helped transition|ac3e2a56d962479f97f7b69a1e5625a2|4
acute, episodic care|chronic care programmes|developed some of the first chronic care programmes|ac3e2a56d962479f97f7b69a1e5625a2|4
effort to reduce coronary heart disease risk|low-income and middle-income countries|deployed and evaluated in national HIV programmes|ac3e2a56d962479f97f7b69a1e5625a2|4
much of the effort|reduce coronary heart disease risk in low-income and middle-income countries|has been deployed and evaluated in these national HIV programmes|ac3e2a56d962479f97f7b69a1e5625a2|4
approaches to cardiovascular disease risk reduction|people with HIV|Most approaches|ac3e2a56d962479f97f7b69a1e5625a2|4
HIV management|coronary heart disease risk screening|are related as HIV management deals with the initial steps of addressing coronary heart disease risk|f2a73160a3eb47c492ff8bec8d51b011|4
HIV management|referral and risk factor management|are related as HIV management also covers referral and managing risk factors|f2a73160a3eb47c492ff8bec8d51b011|4
Active HIV replication|coronary heart disease risk|are related as active HIV replication is an important driver of coronary heart disease risk|f2a73160a3eb47c492ff8bec8d51b011|4
Strengths and weaknesses|screening programmes at the community-level|are related as strengths and weaknesses describe the characteristics of these programmes|f2a73160a3eb47c492ff8bec8d51b011|4
Strengths and weaknesses|clinic-level screening programmes|are related as strengths and weaknesses also apply to clinic-level programmes|f2a73160a3eb47c492ff8bec8d51b011|4
population health approaches|exploring|exploration of|8e79d67d017941e5b412f79df6f62c15|4
key|So-Armah et al.|authorship by|8e79d67d017941e5b412f79df6f62c15|4
So-Armah et al.|Page 7|reference to page number|8e79d67d017941e5b412f79df6f62c15|4
So-Armah et al.|Lancet HIV|article title|8e79d67d017941e5b412f79df6f62c15|4
So-Armah et al.|Author manuscript|manuscript authorship by|8e79d67d017941e5b412f79df6f62c15|4
So-Armah et al.|PMC 2022 August 03|available in publication date|8e79d67d017941e5b412f79df6f62c15|4
efficiency|testing new deployments of existing resources|in sub-Saharan Africa|e510129dda6a4d4db4e36f9f1050561e|4
illustrative examples|Malawi and Uganda|in sub-Saharan Africa|e510129dda6a4d4db4e36f9f1050561e|4
population-based integrated HIV screening|non-communicable disease screening|in Uganda|e510129dda6a4d4db4e36f9f1050561e|4
HIV and hypertension|integrated care|people with|e510129dda6a4d4db4e36f9f1050561e|4
successful linkage to care|45%|of people with HIV and hypertension were referred to receive integrated care.|e510129dda6a4d4db4e36f9f1050561e|4
prevalence|people living with HIV|screened for hypertension|7e6f537536454289b84c9123a4c50792|4
hypertension|prevalence|revealing an 11%|7e6f537536454289b84c9123a4c50792|4
hypertension|treatment, or lifestyle modification advice|subsequently, 85% of people with HIV and hypertension received|7e6f537536454289b84c9123a4c50792|4
blood pressure control rates|people with HIV who had|at 6 months of|7e6f537536454289b84c9123a4c50792|4
mild hypertension|30% in people with HIV who had moderate hypertension|is related to|ac91ea8634a24ba8b8d63726edadadd2|4
risk reduction strategies|stroke in people with HIV|apply to|ac91ea8634a24ba8b8d63726edadadd2|4
antiplatelet therapy|secondary preventive agent|is added as|ac91ea8634a24ba8b8d63726edadadd2|4
individuals with haemorrhagic stroke|brain imaging|can help to risk-stratify these patients|ac91ea8634a24ba8b8d63726edadadd2|4
effective prevention and treatment of heart failure in people with HIV|low-income and middle-income countries|are scarce in|ac91ea8634a24ba8b8d63726edadadd2|4
ACE inhibitors|ARBs|are mentioned together in the context|a3cb4cf2955a46e6a1149c6b9c9a8c15|4
ARBs|β blockers|are mentioned together in the context|a3cb4cf2955a46e6a1149c6b9c9a8c15|4
ACE inhibitors, ARBs, β blockers, or mineralocorticoid antagonists|diuretics|are compared regarding their prescription rate|a3cb4cf2955a46e6a1149c6b9c9a8c15|4
device and mechanical therapies for heart failure|people with HIV|are mentioned together in the context of insufficient data|a3cb4cf2955a46e6a1149c6b9c9a8c15|4
risk reduction approaches for coronary heart disease|peripheral artery disease|are compared as applicable|a3cb4cf2955a46e6a1149c6b9c9a8c15|4
2009 South African study|patients with advanced peripheral artery disease and poor|are mentioned together in the context|a3cb4cf2955a46e6a1149c6b9c9a8c15|4
HIV control|CD4+ T-cell count|used CD4+ T-cell count to guide vascular intervention decisions|dc013d71eae94828b442163ae14911f9|4
Lower CD4 counts|Conservative surgical approaches|led to more conservative surgical approaches|dc013d71eae94828b442163ae14911f9|4
Standard surgical techniques|Patients with AIDS|broad spectrum antibiotics and fluconazole were used instead of cefazolin prophylaxis|dc013d71eae94828b442163ae14911f9|4
Smoking rates|Important intervention point|in this study were high (79%) and are an important intervention point|dc013d71eae94828b442163ae14911f9|4
Little availability|CD4+ T-cell count|for CD4+ T-cell count|dc013d71eae94828b442163ae14911f9|4
cardiac arrhythmias|low-income countries in sub-Saharan Africa|services exist to diagnose and treat|57ef4853dfe9428abe0f0c70cd43ee87|4
sudden cardiac death|low-income countries in sub-Saharan Africa|prevention is limited in these settings|57ef4853dfe9428abe0f0c70cd43ee87|4
high-income countries|coronary heart disease and stroke prevention|might not be adequately addressed|57ef4853dfe9428abe0f0c70cd43ee87|4
people with HIV|current primary care|prevention is not adequately addressed|57ef4853dfe9428abe0f0c70cd43ee87|4
people with HIV|cardiovascular disease|discussed only 19% with their providers|57ef4853dfe9428abe0f0c70cd43ee87|4
hypertension|family history of cardiovascular disease|discussed together in one sentence|215329f9fce84f2d9e0db61080ee2511|4
hypercholesterolaemia|smoking|discussed together in one sentence|215329f9fce84f2d9e0db61080ee2511|4
Studies|USA95 and sub-Saharan Africa96|are conducted in|4bf22457b7234605842b4d52c8893945|4
coronary heart disease risk factors|access to care for people with HIV|are affected by|4bf22457b7234605842b4d52c8893945|4
people without HIV|people with HIV|have different control of coronary heart disease risk factors than|4bf22457b7234605842b4d52c8893945|4
So-Armah et al.|Page 8 Lancet HIV|citation on|4bf22457b7234605842b4d52c8893945|4
benefit|lower thresholds for lipid, blood pressure, or glucose control|unknown relationship|62242f15ab6f47249d986655b7547c20|4
stroke patients with HIV|high-income countries|managed in stroke units|62242f15ab6f47249d986655b7547c20|4
rapid patient assessment|offer life-saving and disability-saving therapy|required for HIV diagnosis|62242f15ab6f47249d986655b7547c20|4
high-quality studies|guidance on the safety and effectiveness|no guidance available due to lack of research|62242f15ab6f47249d986655b7547c20|4
HIV life expectancy|promising outcomes of therapies|cause for improvement|a0b37fec040e44d2ae88070956712e1d|4
people with HIV|health centres|lack experience and expertise in treatment|a0b37fec040e44d2ae88070956712e1d|4
HIV|contraindication to heart|clinicians' consideration|a0b37fec040e44d2ae88070956712e1d|4
heart failure with preserved ejection fraction|HIV| Strategies to prevent or treat heart failure with preserved ejection fraction in HIV remain undefined.|e6f7bf0896944609b6177cc118015d5b|4
peripheral artery disease|unsuppressed HIV viraemia|The risk of peripheral artery disease is highest among those with unsuppressed HIV viraemia|e6f7bf0896944609b6177cc118015d5b|4
peripheral artery disease|low CD4 T-cell counts|The risk of peripheral artery disease is highest among those with low CD4 T-cell counts|e6f7bf0896944609b6177cc118015d5b|4
HIV management|reducing risk|HIV management is an important factor in reducing risk.|e6f7bf0896944609b6177cc118015d5b|4
traditional risk factors|peripheral artery disease|Traditional risk factors such as smoking and diabetes are also strongly associated with peripheral artery disease.|e6f7bf0896944609b6177cc118015d5b|4
Peripheral artery disease|Approaches to reducing sudden cardiac death|associated with|52983fccfa064158bd3d7f9fb30b4af1|4
General population|Data|All data on approaches to reducing sudden cardiac death are from the|52983fccfa064158bd3d7f9fb30b4af1|4
Individuals who have ischaemic heart disease|Electrophysiological evaluation|recommended in some clinical scenarios|52983fccfa064158bd3d7f9fb30b4af1|4
Individuals with particular infiltrative conditions|Implantable cardiac defibrillator|consideration of an implantable cardiac defibrillator are recommended in some clinical scenarios|52983fccfa064158bd3d7f9fb30b4af1|4
sarcoidosis|implantable cardiac defibrillator|considering for an implantable cardiac defibrillator based on clinical history, structural heart disease, or cardiac MRI findings|d7d77e64c2b345bb90108389c3a265c7|4
HIV-infected individuals|different defibrillator thresholds|whether they will benefit from different defibrillator thresholds requires further research|d7d77e64c2b345bb90108389c3a265c7|4
current approaches|reducing cardiovascular disease risk and their effectiveness|these approaches need to be evaluated|d7d77e64c2b345bb90108389c3a265c7|4
Sub-Saharan Africa|low-income and middle-income countries|referring to the geographical locations|d7d77e64c2b345bb90108389c3a265c7|4
coronary heart disease risk factors|people with HIV|are found in|c489cf2a0b054c8698978a3791ebb0a0|4
hypertension|prevalence|in low-income and middle-income countries|c489cf2a0b054c8698978a3791ebb0a0|4
elevated LDL cholesterol|prevalence|in low-income and middle-income countries|c489cf2a0b054c8698978a3791ebb0a0|4
hypertriglyceridaemia|prevalence|in low-income and middle-income countries|c489cf2a0b054c8698978a3791ebb0a0|4
low LDL cholesterol|prevalence|in low-income and middle-income countries|c489cf2a0b054c8698978a3791ebb0a0|4
overweight|prevalence|in low-income and middle-income countries|c489cf2a0b054c8698978a3791ebb0a0|4
obesity|prevalence|in low-income and middle-income countries|c489cf2a0b054c8698978a3791ebb0a0|4
undiagnosed hypertension cases|screening programmes|identify|c489cf2a0b054c8698978a3791ebb0a0|4
elevated cholesterol cases|screening programmes|identify|c489cf2a0b054c8698978a3791ebb0a0|4
coronary heart disease-related clinical endpoints|low-income and middle-income countries|needed in these countries|970c9dad297a4ea0ae4cfaca4b186ee9|4
models for integrating HIV care|coronary heart disease risk reduction|include facility-based and community-based integrated care|970c9dad297a4ea0ae4cfaca4b186ee9|4
feasibility of models|existing HIV-care delivery|promising preliminary findings on their effect|970c9dad297a4ea0ae4cfaca4b186ee9|4
outcomes in general|coronary heart disease risk reduction|are unavailable|c442596e36284570abd40b6228233365|4
So-Armah et al.|Lancet HIV|Page 9|c442596e36284570abd40b6228233365|4
reducing stroke burden|people with HIV|not the current focus of attention in many low-income and middle-income countries|ad426ed5a80945689174bc8b0d0b31d2|4
progress|reduce stroke burden in general population|needed to reduce stroke burden in the general population|ad426ed5a80945689174bc8b0d0b31d2|4
stroke preventive strategies|people with HIV|might improve the disproportionate increase of stroke incidence in HIV endemic regions|f8f9e005b83a401591ea511b04b5b521|4
hypertensive heart disease|cases of heart failure|account for approximately two-thirds|f8f9e005b83a401591ea511b04b5b521|4
rheumatic heart disease|cases of heart failure|account for approximately two-thirds|f8f9e005b83a401591ea511b04b5b521|4
cardiomyopathy|cases of heart failure|account for approximately two-thirds|f8f9e005b83a401591ea511b04b5b521|4
Hospitalised patients|Ischaemic heart disease|less common in hospitalised patients|bc905f90e76c4b9fb67d7a28c31dc58e|4
Hypertension|Heart failure|recognised risk factor for heart failure|bc905f90e76c4b9fb67d7a28c31dc58e|4
Prevalence of hypertension|Low-income and middle-income countries|increased by 8% between 2000 and 2010|bc905f90e76c4b9fb67d7a28c31dc58e|4
People with HIV|Heart failure outcomes|worse in low-income and middle-income countries|bc905f90e76c4b9fb67d7a28c31dc58e|4
General population|Outcomes of people with HIV|compare to general population|bc905f90e76c4b9fb67d7a28c31dc58e|4
Heart Failure (THESUS-HF)|62% greater risk|conferred a 62% greater risk of all-cause mortality at 180 days after a heart failure admission|bc14953a455c44e284a47f0915ece3fb|4
HIV infection|peripheral artery disease|Little is known about the burden of peripheral artery disease over time among people with HIV in low-income and middle-income countries.|bc14953a455c44e284a47f0915ece3fb|4
Peripheral Artery Disease (PAD)|People with HIV|Presentation for peripheral artery disease among people with HIV in places such as South Africa might be delayed.|bc14953a455c44e284a47f0915ece3fb|4
untreated HIV patients|vascular unit|admitted to|61617873c30f4420a64c07a2933eaef8|4
advanced stage vascular disease|Fontaine stage III or IV|corresponding to|61617873c30f4420a64c07a2933eaef8|4
high primary limb amputation rate|32%|resulting in|61617873c30f4420a64c07a2933eaef8|4
study from Nigeria|higher peripheral artery disease prevalence|suggested|61617873c30f4420a64c07a2933eaef8|4
people with HIV|virologically-suppressed people with HIV|compared with|61617873c30f4420a64c07a2933eaef8|4
people without HIV|similar prevalence|in|61617873c30f4420a64c07a2933eaef8|4
studies|sudden cardiac death|reported|9c45cffa028e44ca8e6b3ca9988b5d44|4
study in Cameroon|9·4% rate of sudden cardiac death|reported|9c45cffa028e44ca8e6b3ca9988b5d44|4
Cameroon|study|location|9c45cffa028e44ca8e6b3ca9988b5d44|4
9·4% rate of sudden cardiac death|31·3% per 100 000 person-years|crude incident rate|9c45cffa028e44ca8e6b3ca9988b5d44|4
reducing ischaemic heart disease|establishing sudden cardiac death risk|affecting|9c45cffa028e44ca8e6b3ca9988b5d44|4
high-income countries|few data|regarding temporal trends of clinical coronary heart disease incidence|9c45cffa028e44ca8e6b3ca9988b5d44|4
people with HIV|coronary heart disease risk factor burden|among people with HIV|278dadc014f849b3a8819add4e84ddb5|4
study in Europe|followed up 8762 people with HIV since 2000|A study in Europe112 followed up|278dadc014f849b3a8819add4e84ddb5|4
European study|showed that coronary heart disease risk factor burden is high|the study showed|278dadc014f849b3a8819add4e84ddb5|4
modification of risk factors such as hypertension|appears to be improving over time|that modification of risk factors appears to be improving|278dadc014f849b3a8819add4e84ddb5|4
identifying the role of coronary heart disease risk-factor management|in temporal changes in cardiovascular disease mortality for people with HIV|Identifying the role of coronary heart disease risk-factor management|278dadc014f849b3a8819add4e84ddb5|4
difficult given concomitant changes|changes in cardiovascular disease mortality for people with HIV|given concomitant changes in|278dadc014f849b3a8819add4e84ddb5|4
coronary heart disease|absolute and relative risks|affects|d8d784296bbc4f81a29cb3dfc33e86ab|4
cardiovascular disease mortality|people with HIV|for|d8d784296bbc4f81a29cb3dfc33e86ab|4
HIV treatment uptake|absolute rates of cardiovascular disease mortality|primary reason for decline in|d8d784296bbc4f81a29cb3dfc33e86ab|4
CD4 cell count|improved HIV treatment uptake and related continuous improvement|because of which|d8d784296bbc4f81a29cb3dfc33e86ab|4
Author|Manuscript|created by|e5ff81059892427f996353dfd97aa134|4
ageing population|increasing disease to mortality|because of|e165243cb4b64026ba3934fc5abaa378|4
high-income countries|decreasing risks of AIDS-related deaths|in|e165243cb4b64026ba3934fc5abaa378|4
US-based longitudinal analysis|ART increasing uptake|showed that despite|e165243cb4b64026ba3934fc5abaa378|4
HIV-associated cardiovascular disease|epidemiology|HIV-associated cardiovascular disease tripled between 1990 and 2015.|98f75bf5545c44699bd70464abe82fbe|4
HIV-associated cardiovascular disease|ART era|shifted in the ART era|98f75bf5545c44699bd70464abe82fbe|4
high-income settings|HIV-associated heart failure|epidemiology of HIV-associated heart failure has most likely shifted|98f75bf5545c44699bd70464abe82fbe|4
severe left ventricular systolic dysfunction|uncontrolled HIV replication|in the setting of uncontrolled HIV replication and AIDS|98f75bf5545c44699bd70464abe82fbe|4
diastolic and systolic dysfunction|chronic, cumulative comorbidities|shifted from severe left ventricular systolic dysfunction to diastolic and systolic dysfunction in the setting|98f75bf5545c44699bd70464abe82fbe|4
heart failure risk factors|interact with|How heart failure risk factors interact with|98f75bf5545c44699bd70464abe82fbe|4
HIV-related cardiovascular disease|risk factors|to drive myocardial dysfunction and heart failure|e65012597e3443f3a3c4e439ae169448|4
HIV-associated heart failure|shortened survival|among people living with HIV or AIDS|e65012597e3443f3a3c4e439ae169448|4
HIV-associated heart failure|outcomes comparable|with people without HIV|e65012597e3443f3a3c4e439ae169448|4
Future studies|ascertain the effect of HIV control and risk factor control|on peripheral artery disease risk in HIV|e65012597e3443f3a3c4e439ae169448|4
underlying condition|sudden cardiac death|associated with|50b3f0536a6a4838b9cf46b21ceb6e14|4
general population|incidence of sudden cardiac death in the setting of ischaemic heart disease|in|50b3f0536a6a4838b9cf46b21ceb6e14|4
ischaemic heart disease|decreasing incidence of sudden cardiac death|in the setting of|50b3f0536a6a4838b9cf46b21ceb6e14|4
structural heart disease|including cardiomyopathy|associated with|50b3f0536a6a4838b9cf46b21ceb6e14|4
myocardial fibrosis|and left ventricular hypertrophy|are increasing|50b3f0536a6a4838b9cf46b21ceb6e14|4
scant data|on sudden cardiac death in HIV|make it challenging to assess|50b3f0536a6a4838b9cf46b21ceb6e14|4
approaches to reduce ischaemic heart|scarcity of data on sudden cardiac death in HIV|challenging to assess how|50b3f0536a6a4838b9cf46b21ceb6e14|4
disease|sudden cardiac death risk|affecting|bab14af38bcb411fa1fbb27701af7c8d|4
HIV|people with HIV|are affecting the disease in|bab14af38bcb411fa1fbb27701af7c8d|4
coronary heart disease risk factor screening|routine care for people with HIV|should be part of|bab14af38bcb411fa1fbb27701af7c8d|4
few resources|absence of cost-effective data on routine coronary heart disease risk factor screening|limited by|bab14af38bcb411fa1fbb27701af7c8d|4
routine screening|people with HIV older than 40 years|feasibility has been shown|f1b54829c2334bf285dfb8fb68e4c257|4
practical approach|barriers to scale up and expand|exist|f1b54829c2334bf285dfb8fb68e4c257|4
contextually appropriate innovations|people with HIV at high risk for coronary heart disease|such as targeted screening, task redistribution, and the use of point-of-care diagnostics would|f1b54829c2334bf285dfb8fb68e4c257|4
coronary heart disease|people with HIV|improving risk awareness|9594d6a3931747d7aa5850f9d4dc9546|4
surveillance efforts|risk awareness for coronary heart disease among treated people with HIV|augment|9594d6a3931747d7aa5850f9d4dc9546|4
early diagnosis|pharmacotherapy in most cases|attenuate the need for|9594d6a3931747d7aa5850f9d4dc9546|4
pathway to care|people with HIV who screen positive for|there should be|9594d6a3931747d7aa5850f9d4dc9546|4
coronary heart disease risk factors|low-income and middle-income countries|unique to or dominant in|a908a05bb36244f7817fba92b81ac477|4
access to essential medicines|coronary heart disease risk factors|for coronary heart disease risk factors|a908a05bb36244f7817fba92b81ac477|4
integrated care approach|So-Armah et al.|ie, as mentioned in|a908a05bb36244f7817fba92b81ac477|4
HIV care|coronary heart disease care|are provided in the same clinic visit|ce5ca16cc0bb48dc9822451f442448a8|4
feasible approach|improve linkage and retention in care|is for chronic disease management|ce5ca16cc0bb48dc9822451f442448a8|4
low-income and middle-income countries|uptake of this approach|remains slow|ce5ca16cc0bb48dc9822451f442448a8|4
policy interventions for people with HIV|exposure to coronary heart disease|can be decreased by timely interventions|ce5ca16cc0bb48dc9822451f442448a8|4
heart disease|risk factors|heart disease risk factors such as tobacco, high cholesterol diets, and excessive alcohol|ab29a2d4db4f4b539c5a943fb729eb8e|4
tobacco|high cholesterol diets|hear disease risk factors such as tobacco, high cholesterol diets, and excessive alcohol|ab29a2d4db4f4b539c5a943fb729eb8e|4
excessive alcohol|high cholesterol diets|heart disease risk factors such as tobacco, high cholesterol diets, and excessive alcohol|ab29a2d4db4f4b539c5a943fb729eb8e|4
cigarette smoking|dyslipidaemia|The prevalence of cigarette smoking, dyslipidaemia, and obesity are lower in many low-income and middle-income countries than high-income countries|ab29a2d4db4f4b539c5a943fb729eb8e|4
dyslipidaemia|obesity|The prevalence of cigarette smoking, dyslipidaemia, and obesity are lower in many low-income and middle-income countries than high-income countries|ab29a2d4db4f4b539c5a943fb729eb8e|4
low-income countries|middle-income countries|lower in many low-income and middle-income countries than high-income countries|ab29a2d4db4f4b539c5a943fb729eb8e|4
low-income countries|high-income countries|lower in many low-income and middle-income countries than high-income countries|ab29a2d4db4f4b539c5a943fb729eb8e|4
middle-income countries|high-income countries|lower in many low-income and middle-income countries than high-income countries|ab29a2d4db4f4b539c5a943fb729eb8e|4
urbanisation|rise of factors|these factors are on the rise because of urbanisation|ab29a2d4db4f4b539c5a943fb729eb8e|4
public education|tobacco-product taxation|effective and cost-effective methods|ab29a2d4db4f4b539c5a943fb729eb8e|4
public education|legislation to reduce availability of trans-fatty acids|effective and cost-effective methods|ab29a2d4db4f4b539c5a943fb729eb8e|4
primary prevention|coronary heart disease|for|8cc25f427e5841af8c3f11fc0a73a3fe|4
low-income and middle-income countries|coronary heart disease|in|8cc25f427e5841af8c3f11fc0a73a3fe|4
people with HIV|coronary heart disease|among|8cc25f427e5841af8c3f11fc0a73a3fe|4
low-income and middle-income countries|interventions|in|8cc25f427e5841af8c3f11fc0a73a3fe|4
interventions|scaling up and scaling out|for|8cc25f427e5841af8c3f11fc0a73a3fe|4
people with HIV|coronary heart disease prevention|in|8cc25f427e5841af8c3f11fc0a73a3fe|4
cardiovascular disease|discussed in this Review (figure 3)|are mentioned in the same sentence|11c86d8a8f3747d3b5ca6ace9495e719|4
large HIV-population cohorts|in sub-Saharan Africa and low-income and middle-income countries|are mentioned in the same sentence|11c86d8a8f3747d3b5ca6ace9495e719|4
sub-Saharan Africa|HIV-population cohorts are from there|are related by the geographical context|11c86d8a8f3747d3b5ca6ace9495e719|4
tailored risk scores for stroke prevention|using HIV-population cohorts|are mentioned in the same sentence and are related by their purpose|11c86d8a8f3747d3b5ca6ace9495e719|4
priority should be given to|developing stroke diagnostic and treatment pathways|are mentioned in the same sentence and are related by the context of importance|11c86d8a8f3747d3b5ca6ace9495e719|4
stroke diagnostic and treatment pathways|centred around stroke units where|are mentioned in the same sentence and are related by their composition|11c86d8a8f3747d3b5ca6ace9495e719|4
brain imaging|available|is available|82b4f02c499545f7a6a7b66ae42dc6aa|4
complex management and rehabilitation|provided|can be provided|82b4f02c499545f7a6a7b66ae42dc6aa|4
Government-operated stroke units|commonplace in sub-Saharan Africa|are not commonplace|82b4f02c499545f7a6a7b66ae42dc6aa|4
stroke units|clustered in South Africa, Nigeria, and Ghana|are currently clustered|82b4f02c499545f7a6a7b66ae42dc6aa|4
early admission to a stroke unit|saves lives and reduces disability|save lives and reduce disability|82b4f02c499545f7a6a7b66ae42dc6aa|4
financial constraints|more frequent factors encountered in sub-Saharan Africa|are more frequent factors encountered|82b4f02c499545f7a6a7b66ae42dc6aa|4
sociocultural factors|more frequent factors encountered in sub-Saharan Africa|are more frequent factors encountered|82b4f02c499545f7a6a7b66ae42dc6aa|4
denial of a stroke|more frequent factors encountered in sub-Saharan Africa|is a factor encountered|82b4f02c499545f7a6a7b66ae42dc6aa|4
Research to understand the disparity in heart failure outcomes for people with HIV|Screening of individuals at greatest risk for heart failure62|needs to occur|cdf8131485c944848b43e9dd40bc3aa9|4
Care delivery for heart failure|Task redistribution|could mimic from the HIV-care framework|cdf8131485c944848b43e9dd40bc3aa9|4
In Rwanda|Nurses have been successfully deployed|for decentralised|cdf8131485c944848b43e9dd40bc3aa9|4
heart failure diagnosis|care delivery since 2006|relation|3ad6a574239d4e72bc29e956622cccc9|4
echocardiography skills|diagnose common presentations of heart failure|application|3ad6a574239d4e72bc29e956622cccc9|4
tailored algorithms|manage heart failure|use|3ad6a574239d4e72bc29e956622cccc9|4
nurse-led programme|36% 5-year mortality rate|result|3ad6a574239d4e72bc29e956622cccc9|4
public education|signs and symptoms of peripheral artery disease|about|3ad6a574239d4e72bc29e956622cccc9|4
people with HIV|low-income and middle-income countries|targeted to|3ad6a574239d4e72bc29e956622cccc9|4
late disease presentation|incidence of avoidable amputations|occurrence|9cb1e82e75664e08a9e9395f09eb89fc|4
increased awareness|sudden death|needed for|9cb1e82e75664e08a9e9395f09eb89fc|4
development of tools|risk stratification|for|9cb1e82e75664e08a9e9395f09eb89fc|4
preventive strategy|symptom identification|as a|9cb1e82e75664e08a9e9395f09eb89fc|4
High-income countries|research on thrombotic risk reduction strategies for HIV|Optimal thrombotic risk reduction strategies are needed in regions where the comorbid burden of cardiovascular disease and HIV is greatest.|2e2404ebb9354bc688843a0168f92d1f|4
regions|comorbid burden of cardiovascular disease and HIV|The comorbid burden of cardiovascular disease and HIV is greatest in these regions.|2e2404ebb9354bc688843a0168f92d1f|4
HIV care|lifestyle modification|Lifestyle modification should be emphasized in HIV care.|2e2404ebb9354bc688843a0168f92d1f|4
smoking cessation and reduction|atherosclerotic cardiovascular disease risk|Smoking cessation and reduction helps reduce atherosclerotic cardiovascular disease risk.|2e2404ebb9354bc688843a0168f92d1f|4
healthy diet|excess weight gain|Maintaining a healthy diet is essential to avoid excess weight gain.|2e2404ebb9354bc688843a0168f92d1f|4
HIV primary care|lifestyle optimisation strategies|implementing these lifestyle optimisation strategies in HIV primary care|89edc68f66424a5aa87e5ce86d59b750|4
HIV-related cardiovascular|diabetes|appropriate management of cardiovascular disease risk factors, particularly diabetes|89edc68f66424a5aa87e5ce86d59b750|4
HIV-related cardiovascular|hypertension|appropriate management of cardiovascular disease risk factors, particularly hypertension|89edc68f66424a5aa87e5ce86d59b750|4
HIV-related cardiovascular|dyslipidaemia|appropriate management of cardiovascular disease risk factors, particularly dyslipidaemia|89edc68f66424a5aa87e5ce86d59b750|4
disease risk factors|atherosclerotic cardiovascular disease|cause-effect|fd8debf21eab4190aebdb1049595ddf8|4
anti-inflammatory strategies|atherosclerotic cardiovascular disease|counteracting effect|fd8debf21eab4190aebdb1049595ddf8|4
attention should be paid to|sex-based differences in response to HIV|reason for investigation|fd8debf21eab4190aebdb1049595ddf8|4
strategies to lower inflammation|HIV specific therapies|potential application|fd8debf21eab4190aebdb1049595ddf8|4
intestinal barrier dysfunction|cytomegalovirus|co-infection|d731d095c2a24990bc29fb2fd0ef1e48|4
cytomegalovirus|HIV cure|related to|d731d095c2a24990bc29fb2fd0ef1e48|4
ART initiation|cardiovascular disease|early initiation of ART and cardiovascular disease risk associated with newer ART regimens|d731d095c2a24990bc29fb2fd0ef1e48|4
WHO International Classification of Diseases|stroke|recognising stroke as a separate outcome|d731d095c2a24990bc29fb2fd0ef1e48|4
scores|clinical trials|are derived from clinical trials|608147fbfe5c4a679c7df930d57220fe|4
population effect metrics|clinical trials|are derived from clinical trials|608147fbfe5c4a679c7df930d57220fe|4
people with HIV|HIV|affected by HIV|608147fbfe5c4a679c7df930d57220fe|4
intracranial HIV-associated vasculopathy|HIV|is associated with HIV|608147fbfe5c4a679c7df930d57220fe|4
mechanistic studies|drug discoveries|are focused on guiding drug discoveries|608147fbfe5c4a679c7df930d57220fe|4
epidemiological data|heart failure in HIV|shows an increased occurrence of heart failure in HIV|608147fbfe5c4a679c7df930d57220fe|4
deep clinical phenotyping|heart failure presentations and triggers|aims to supplement the existing data with deeper understanding|608147fbfe5c4a679c7df930d57220fe|4
identification of targets|prevention and|will enable identification of targets for prevention and treatment|608147fbfe5c4a679c7df930d57220fe|4
interventions|heart failure|aimed at controlling the onset and progression of|65ac5d7ae65d4ff6ae9de9592d245d95|4
effective therapies|heart failure with preserved ejection fraction|for are still absent in the general population.|65ac5d7ae65d4ff6ae9de9592d245d95|4
investigating|immunopathogenesis|might inform broader understanding|65ac5d7ae65d4ff6ae9de9592d245d95|4
HIV-associated heart failure|immunological and inflammatory contributors|targeting of|65ac5d7ae65d4ff6ae9de9592d245d95|4
prevalence|peripheral artery disease|estimation in context|24130a4b70bc425e8c7c0d94cfbb499c|4
incidence|peripheral artery disease|estimation in context|24130a4b70bc425e8c7c0d94cfbb499c|4
severity|peripheral artery disease|estimation in context|24130a4b70bc425e8c7c0d94cfbb499c|4
HIV|people with HIV|context mentioning relationship|24130a4b70bc425e8c7c0d94cfbb499c|4
mechanistic studies|peripheral artery disease|evaluation for context|24130a4b70bc425e8c7c0d94cfbb499c|4
mediators|increased peripheral artery disease|context mentioning relationship|24130a4b70bc425e8c7c0d94cfbb499c|4
sudden cardiac death|people with HIV|evaluation context|24130a4b70bc425e8c7c0d94cfbb499c|4
HIV viral suppression|treatment modalities|context mentioning relationship|24130a4b70bc425e8c7c0d94cfbb499c|4
immune restoration|treatment modalities|context mentioning relationship|24130a4b70bc425e8c7c0d94cfbb499c|4
management|traditional risk factors|context mentioning relationship|24130a4b70bc425e8c7c0d94cfbb499c|4
atherosclerosis|peripheral artery disease|Smoking is a strong modifiable risk factor for peripheral artery disease.|c94828dc64c6447d917bd155c9a2a78c|4
efforts to reduce smoking|peripheral artery disease incidence and progression|Efforts to reduce smoking in people living with HIV are almost certain to reduce peripheral artery disease incidence and progression.|c94828dc64c6447d917bd155c9a2a78c|4
increased awareness|peripheral artery disease and sudden cardiac death|Additionally, increased awareness about peripheral artery disease and sudden cardiac death is needed.|c94828dc64c6447d917bd155c9a2a78c|4
routine ankle-brachial index screening|increase awareness|One approach to increase awareness that is worth investigating is routine ankle-brachial index screening.|c94828dc64c6447d917bd155c9a2a78c|4
Lancet HIV|Author manuscript|is available in PMC|241eef65ec5046598fc72d0f133088d3|4
HIV disease burden|populations included in published HIV-related cardiovascular disease research|relationship between the two concepts, exists in one sentence|30600b702aac44c19f38b69d1d5ed9c6|4
HIV infection|myocardial infarction, stroke, and heart failure|strong evidence linking HIV infection to these conditions in one sentence|30600b702aac44c19f38b69d1d5ed9c6|4
HIV infection|peripheral artery disease and sudden cardiac death|scarce data that also link HIV infection to these conditions in one sentence|30600b702aac44c19f38b69d1d5ed9c6|4
HIV|cardiovascular disease risk factors|the distribution of cardiovascular disease risk factors varies by geographical location|64dfd079b76949fc8c3ed07105885d35|4
geographical location|low-income and middle-income countries|varies in low-income and middle-income countries compared with high-income countries|64dfd079b76949fc8c3ed07105885d35|4
geographical location|HIV|HIV has different profiles of cardiovascular disease risk in different geographical locations|64dfd079b76949fc8c3ed07105885d35|4
low-income and middle-income countries|high-income countries|different profiles of cardiovascular disease risk in low-income and  middle-income countries compared with high-income countries|64dfd079b76949fc8c3ed07105885d35|4
cardiovascular disease risk factors|public and individual health approaches|calls for thoughtful balancing of public and individual health approaches to reduce cardiovascular disease risk globally among people with HIV|64dfd079b76949fc8c3ed07105885d35|4
evidence-informed strategies|expert health-care and patient|To reduce cardiovascular disease risk globally among people with HIV calls for evidence-informed strategies, expert health-care and patient|64dfd079b76949fc8c3ed07105885d35|4
opinions|HIV burden|areas with the highest HIV burden|ba70bb2f1169459db629ad41e6c477c6|4
supplementary material|Web version on PubMed Central|Refer to|ba70bb2f1169459db629ad41e6c477c6|4
References|Systematic review and meta-analysis|in HIV Med 2012; 13: 453–68|ba70bb2f1169459db629ad41e6c477c6|4
Global burden of atherosclerotic cardiovascular disease|HIV|Global burden of atherosclerotic cardiovascular disease in areas with the highest HIV burden|ba70bb2f1169459db629ad41e6c477c6|4
people living with HIV|Circulation|publication|cb4e5e86c2b640f3b5467cead5b01dfa|4
people living with HIV|PubMed: 29967196|references|cb4e5e86c2b640f3b5467cead5b01dfa|4
Circulation|138: 1100–12|volume and page|cb4e5e86c2b640f3b5467cead5b01dfa|4
people living with HIV|Smit M, Brinkman K, Geerlings S, et al.|authors of the next publication|cb4e5e86c2b640f3b5467cead5b01dfa|4
people living with HIV|Lancet Infect Dis 2015|related publication|cb4e5e86c2b640f3b5467cead5b01dfa|4
future challenges|clinical care of an ageing population infected with HIV|concept|cb4e5e86c2b640f3b5467cead5b01dfa|4
clinical care of an ageing population infected with HIV|a modelling study|description|cb4e5e86c2b640f3b5467cead5b01dfa|4
Smit M, Brinkman K, Geerlings S, et al.|Lancet Infect Dis 2015|authors and publication|cb4e5e86c2b640f3b5467cead5b01dfa|4
HIV infection|ischemic stroke|association|cb4e5e86c2b640f3b5467cead5b01dfa|4
HIV infection|incidence of ischemic stroke|cause|cb4e5e86c2b640f3b5467cead5b01dfa|4
HIV|antiretroviral treatment|associated with|9395b399d6824046abfd4e11abbf3073|4
hypertension|stroke|related to|9395b399d6824046abfd4e11abbf3073|4
Malawian adults|case-control study|subject of|9395b399d6824046abfd4e11abbf3073|4
Benjamin LA, Corbett EL, Connor MD, et al.|HIV , antiretroviral treatment, hypertension, and stroke|author of|9395b399d6824046abfd4e11abbf3073|4
Neurology 2016; 86: 324–33.|source publication|published in|9395b399d6824046abfd4e11abbf3073|4
Alonso A, Barnes AE, Guest JL, Shah A, Shao IY , Marconi V .|HIV infection and incidence of cardiovascular diseases|author of|9395b399d6824046abfd4e11abbf3073|4
J Am Heart Assoc 2019; 8: e012241.|source publication|published in|9395b399d6824046abfd4e11abbf3073|4
HIV-infected patients|myocardial infarction|Increased risk of myocardial infarction in HIV-infected patients relative to the general population|7f79f551812d4e04b739e4199edfec89|4
HIV infection|heart failure with reduced ejection fraction and preserved ejection fraction|Association between HIV infection and the risk of heart failure|7f79f551812d4e04b739e4199edfec89|4
therapy era|Veterans Aging Cohort Study|is conducted by|afd2d1db5f664f1eb36d0d97baba4f18|4
JAMA Cardiol 2017|therapy era|citation in|afd2d1db5f664f1eb36d0d97baba4f18|4
PubMed: 28384660|JAMA Cardiol 2017|refers to|afd2d1db5f664f1eb36d0d97baba4f18|4
Feinstein MJ, Steverson AB, Ning H, et al.|Adjudicated heart failure in HIV-infected and uninfected men and women|authored by|afd2d1db5f664f1eb36d0d97baba4f18|4
J Am Heart Assoc 2018|Feinstein MJ, Steverson AB, Ning H, et al.|citation in|afd2d1db5f664f1eb36d0d97baba4f18|4
PubMed: 30571387|J Am Heart Assoc 2018|refers to|afd2d1db5f664f1eb36d0d97baba4f18|4
Beckman JA, Duncan MS, Alcorn CW, et al.|Association of human immunodeficiency virus infection and risk of peripheral artery disease|authored by|afd2d1db5f664f1eb36d0d97baba4f18|4
Circulation 2018|Beckman JA, Duncan MS, Alcorn CW, et al.|citation in|afd2d1db5f664f1eb36d0d97baba4f18|4
PubMed: 29535090|Circulation 2018|refers to|afd2d1db5f664f1eb36d0d97baba4f18|4
cardiovascular diseases|HIV/AIDS patient cohort in Taiwan|Incidence of cardiovascular diseases in a nationwide HIV/AIDS patient cohort|4b608810b5274cf6ae545393c4691bbd|4
sudden cardiac death|patients living with heart failure and human immunodeficiency virus|The risk for sudden cardiac death among patients living with heart failure and human immunodeficiency virus|4b608810b5274cf6ae545393c4691bbd|4
HIV infection|acute myocardial infarction|is associated with|dcee105344a1486ba581d0c23f906f1b|4
human immunodeficiency virus-infected individuals|myocardial infarction|are at risk of developing|dcee105344a1486ba581d0c23f906f1b|4
human immunodeficiency virus infection|heart disease risks|is related to|dcee105344a1486ba581d0c23f906f1b|4
HIV infection|cardiovascular disease risk factor profile|and risk for acute myocardial infarction|1fe5c0ed511a4ee89b0ae36c2efb1558|4
HIV infection|stroke|in human immunodeficiency virus-infected|1fe5c0ed511a4ee89b0ae36c2efb1558|4
systematic review|J Stroke Cerebrovasc Dis|is published in|0f091e71e6e0458e807e389c5d4e08a0|4
individuals in sub-Saharan Africa (SSA)|systematic review|is the topic of the systematic review|0f091e71e6e0458e807e389c5d4e08a0|4
sub-Saharan Africa (SSA)|peripheral artery disease|related to individuals in sub-Saharan Africa (SSA)|0f091e71e6e0458e807e389c5d4e08a0|4
J Stroke Cerebrovasc Dis 2018|27: 1828–36|is the publication of|0f091e71e6e0458e807e389c5d4e08a0|4
A concept from extracted ontology|J Stroke Cerebrovasc Dis 2018|is a source of information|0f091e71e6e0458e807e389c5d4e08a0|4
Cedarbaum E, Ma Y , Scherzer R, et al.|Contributions of HIV , hepatitis C virus, and traditional vascular risk factors to peripheral artery disease in women|authored the paper|0f091e71e6e0458e807e389c5d4e08a0|4
A concept from extracted ontology|AIDS 2019; 33: 2025–33|is a source of information|0f091e71e6e0458e807e389c5d4e08a0|4
Cedarbaum E, Ma Y , Scherzer R, et al.|AIDS 2019; 33: 2025–33|authored the paper|0f091e71e6e0458e807e389c5d4e08a0|4
Kamdem F, Mapoure Y , Hamadou B, et al.|Prevalence and risk factors of peripheral artery disease|authored the paper|0f091e71e6e0458e807e389c5d4e08a0|4
Vasc Health Risk|black Africans with HIV infection|study on|453fa797a8ed47f69813a01e82dec2a1|4
Hospital-based study|Vasc Health Risk|is a type of|453fa797a8ed47f69813a01e82dec2a1|4
Cross-sectional|study|type of study|453fa797a8ed47f69813a01e82dec2a1|4
Black Africans with HIV infection|Population|is the population for the study|453fa797a8ed47f69813a01e82dec2a1|4
Cardiovascular risk|Subclinical marker|is a subclinical marker of|453fa797a8ed47f69813a01e82dec2a1|4
Ankle brachial index|Subclinical marker|is an example of|453fa797a8ed47f69813a01e82dec2a1|4
Rural African population|Study|is the study on|453fa797a8ed47f69813a01e82dec2a1|4
Distribution|Study|is the main focus of the study|453fa797a8ed47f69813a01e82dec2a1|4
HIV-associated cardiomyopathy|causes|Lumsden RH, Bloomfield GS. The causes of HIV-associated cardiomyopathy: a tale of two worlds.|721c39ca0f444047a4f91d5d285b1dcc|4
older adults with multiple co-morbidities in rural South Africa|Cardiometabolic risk|Gaziano TA, Abrahams-Gessel S, Gomez-Olive FX, et al. Cardiometabolic risk in a population of older adults with multiple co-morbidities in rural South Africa: the HAALSI (health and aging in Africa: longitudinal studies of INDEPTH communities) study.|721c39ca0f444047a4f91d5d285b1dcc|4
isolated right heart failure|women|in women from western Kenya|1cad1339b0fc4f088bf679d6e99876ae|4
HIV|noncommunicable cardiovascular and pulmonary diseases|in low- and middle-income countries in the ART era|1cad1339b0fc4f088bf679d6e99876ae|4
Markers of inflammation, coagulation, and renal function|HIV infection|are elevated in adults with|05ad60268a3b4b09be9fd9b7af40d9c3|4
Acquired immunodeficiency syndrome|Cardiac involvement|in the acquired immunodeficiency syndrome:|05ad60268a3b4b09be9fd9b7af40d9c3|4
Studio Cardiologico|pazienti affetti da AIDS|are related to each other in one sentence|df93d84874f54c86ad985201874e4518|4
AIDS Res Hum Retroviruses|Studio Cardiologico|are mentioned in the same citation|df93d84874f54c86ad985201874e4518|4
AIDS Investigators|pazienti affetti da AIDS|are related to each other in one sentence|df93d84874f54c86ad985201874e4518|4
CD4+ T cell depletion|HIV disease|are discussed together in the same context|df93d84874f54c86ad985201874e4518|4
gastrointestinal tract|CD4+ T cell depletion|are related to each other in one sentence|df93d84874f54c86ad985201874e4518|4
J Exp Med|Brenchley JM|are mentioned in the same citation|df93d84874f54c86ad985201874e4518|4
2004|CD4+ T cell depletion|are related to each other in one sentence|df93d84874f54c86ad985201874e4518|4
759|Brenchley JM|are related to each other in one sentence|df93d84874f54c86ad985201874e4518|4
Cardiol 1990; 66: 203–06|[PubMed: 2371952]|is cited in|2c115433022c41c09dd92d5cbe7cee39|4
Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection.|Nat Med 2006; 12: 1365–71|is published in|2c115433022c41c09dd92d5cbe7cee39|4
So-Armah et al. Page 15|Lancet HIV|is published in|2c115433022c41c09dd92d5cbe7cee39|4
Author manuscript; available in PMC 2022 August 03.|PMC 2022 August 03|is related to|2c115433022c41c09dd92d5cbe7cee39|4
HIV-infected brain|improve ischemic stroke outcome|Targeting|f2a1bc623b984999b1c9fd073b4e24bc|4
macrophages|eradication|barrier|f2a1bc623b984999b1c9fd073b4e24bc|4
associated vasculopathy|etiology of stroke|cause and effect|3ad40ede319c4f1b987d7a3bc6bffe2c|4
J Infect Dis|2017; 216: 545–53|publication details|3ad40ede319c4f1b987d7a3bc6bffe2c|4
PubMed|28931222|reference|3ad40ede319c4f1b987d7a3bc6bffe2c|4
El-Sadr WM|Lundgren J|coauthors|3ad40ede319c4f1b987d7a3bc6bffe2c|4
CD4+ count-guided interruption of antiretroviral treatment|N Engl J Med 2006; 355: 2283–96|publication details|3ad40ede319c4f1b987d7a3bc6bffe2c|4
PubMed|17135583|reference|3ad40ede319c4f1b987d7a3bc6bffe2c|4
Worm SW|Sabin C|coauthors|3ad40ede319c4f1b987d7a3bc6bffe2c|4
Weber R|data|researchers|3ad40ede319c4f1b987d7a3bc6bffe2c|4
study|adverse events|the study investigates adverse events|da36cde196c642bba37885746729c907|4
study|anti-HIV drugs|the study is on the adverse effects of anti-HIV drugs|da36cde196c642bba37885746729c907|4
ritonavir-boosted protease inhibitor|dolutegravir-based regimen|switching from ritonavir to dolutegravir for HIV maintenance|da36cde196c642bba37885746729c907|4
ritonavir-boosted protease inhibitor|high cardiovascular risk|the switch is due to patients with high cardiovascular risk|da36cde196c642bba37885746729c907|4
cardiovascular disease|protease|use of contemporary protease and cardiovascular disease|da36cde196c642bba37885746729c907|4
D:A:D international prospective multicohort study|Lancet HIV 2018|Published|c8dfdb73e0814183bdfd22f876555f6e|4
Solomon D|Cardiovascular disease in women living with HIV|Narrative review|c8dfdb73e0814183bdfd22f876555f6e|4
Maturitas 2018|58–70|Page range|c8dfdb73e0814183bdfd22f876555f6e|4
Bourgi K|Greater weight gain in treatment naïve persons starting dolutegravir-based antiretroviral therapy|Clin Infect Dis 2019|c8dfdb73e0814183bdfd22f876555f6e|4
ciz407|Publication|Citation|c8dfdb73e0814183bdfd22f876555f6e|4
HIV-infected veterans|antiretroviral therapy|initiating|0141da30c9e94147ab49f3b349ca953b|4
HIV-infected veterans|uninfected individuals|comparison|0141da30c9e94147ab49f3b349ca953b|4
Polypharmacy|aging HIV-infected population|risk of antiretroviral drug interactions|0141da30c9e94147ab49f3b349ca953b|4
HIV and AIDS|Drugs and cardiotoxicity|are related in the context of 44. Fantoni M, Autore C, Del Borgo C.|7ec4d968120442c187c6cfaef240c791|4
HIV infection|Atherosclerotic process|is mentioned together in the context of Sun D, Wu Y , Yuan Y , Wang Y , Liu W, Yang J.|7ec4d968120442c187c6cfaef240c791|4
Antiretroviral therapy|Atherosclerotic process|are related concepts in the context of Sun D, Wu Y , Yuan Y , Wang Y , Liu W, Yang J.|7ec4d968120442c187c6cfaef240c791|4
Protease inhibitor exposure|Atherosclerotic process|are related concepts in the context of Sun D, Wu Y , Yuan Y , Wang Y , Liu W, Yang J.|7ec4d968120442c187c6cfaef240c791|4
PubMed: 31796103|EVERLAST study|is a paper discussing the protocol for|07d4b78a64d74e6bbe189d110cac57c2|4
Sarfo FS, Nichols M, Gebregziabher M, et al.|Evaluation of vascular event risk while on long-term anti-retroviral suppressive therapy|is a list of authors for the study|07d4b78a64d74e6bbe189d110cac57c2|4
eNeurologicalSci 2019; 15: 100189|Publication Journal and Volume|is a publication information for the paper|07d4b78a64d74e6bbe189d110cac57c2|4
PubMed: 31011634|Nonterah EA, Boua PR, Klipstein-Grobusch K, et al.|is a paper discussing the findings|07d4b78a64d74e6bbe189d110cac57c2|4
Sub-Saharan Africa|Population and geographic location|is where the study is conducted|07d4b78a64d74e6bbe189d110cac57c2|4
HIV|Classical cardiovascular risk factors|are associated with carotid intima-media thickness in adults from Sub-Saharan Africa|07d4b78a64d74e6bbe189d110cac57c2|4
H3Africa AWI-Gen study|J Am Heart Assoc|is published in|24ccb2868e144c43a91833c60dc07f1c|4
So-Armah et al.|H3Africa AWI-Gen study|authored|24ccb2868e144c43a91833c60dc07f1c|4
Lancet HIV|Author manuscript|is published in|24ccb2868e144c43a91833c60dc07f1c|4
PMC|Author Manuscript|available at|24ccb2868e144c43a91833c60dc07f1c|4
FIB-4 stage of liver fibrosis|incident heart failure|predicts|f4091a11f3ff47b0b7d189a7cf838e6e|4
HIV-infected patients|uninfected patients|among|f4091a11f3ff47b0b7d189a7cf838e6e|4
alcohol consumption|antiretroviral therapy and survival|influence on|f4091a11f3ff47b0b7d189a7cf838e6e|4
depressive disorders|incident|association between|f4091a11f3ff47b0b7d189a7cf838e6e|4
acute myocardial infarction|human immunodeficiency virus–infected adults|affected in|c086aebbf0fd41939394b10c18db228f|4
veterans aging cohort study|JAMA Cardiol 2016|published in|c086aebbf0fd41939394b10c18db228f|4
White JR|human immunodeficiency virus infection|study by|c086aebbf0fd41939394b10c18db228f|4
chronic|myocardial infarction|risk of|c086aebbf0fd41939394b10c18db228f|4
hepatitis C virus infection|population-based cohort study|is a subject of|5a3c59fd37e54289a2fe66912459d721|4
hepatitis C virus infection|J Viral Hepat 2012|is published in|5a3c59fd37e54289a2fe66912459d721|4
hepatitis C virus infection|22404725|has this PubMed ID|5a3c59fd37e54289a2fe66912459d721|4
Wang H, Peng G, Bai J, et al.|cytomegalovirus infection|study is about|5a3c59fd37e54289a2fe66912459d721|4
cytomegalovirus infection|cardiovascular disease (ischaemic heart disease, stroke, and cardiovascular death)|is related to|5a3c59fd37e54289a2fe66912459d721|4
Wang H, Peng G, Bai J, et al.|meta-analysis of prospective studies up to 2016|conducting the research|5a3c59fd37e54289a2fe66912459d721|4
Wang H, Peng G, Bai J, et al.|J Am Heart Assoc 2017|published in|5a3c59fd37e54289a2fe66912459d721|4
Wang H, Peng G, Bai J, et al.|28684641|has this PubMed ID|5a3c59fd37e54289a2fe66912459d721|4
Lee SA, Sinclair E, Hatano H, et al.|impact of HIV on CD8+ T cell CD57 expression|study is about|5a3c59fd37e54289a2fe66912459d721|4
CMV and aging|PLoS One 2014; 9: e89444|mentioned in the same sentence|8e3803007c4c4f59a57bc1cf9831d7e6|4
aspirin for primary prevention of cardiovascular disease|HIV-infected patients|research topic discussed in the context|8e3803007c4c4f59a57bc1cf9831d7e6|4
underutilization of aspirin|cardiovascular disease|research topic discussed in the context|8e3803007c4c4f59a57bc1cf9831d7e6|4
HIV-infected patients|Burkholder GA, Tamhane AR, Salinas JL, et al.|authors of research paper|8e3803007c4c4f59a57bc1cf9831d7e6|4
aspirin for primary prevention of cardiovascular disease|Clin Infect Dis 2012; 55: 1550–57.|research published in|8e3803007c4c4f59a57bc1cf9831d7e6|4
PubMed: 22942209|Burkholder GA, Tamhane AR, Salinas JL, et al.|research citation|8e3803007c4c4f59a57bc1cf9831d7e6|4
aspirin for primary prevention of cardiovascular disease|HIV-infected patients|research topic discussed in the context|8e3803007c4c4f59a57bc1cf9831d7e6|4
in-hospital mortality from acute myocardial infarction|HIV sero-positive versus sero-negative individuals|research topic discussed in the context|8e3803007c4c4f59a57bc1cf9831d7e6|4
Am J Cardiol 2012;|Pearce D, Ani C, Espinosa-Silva Y , et al.|research published in|8e3803007c4c4f59a57bc1cf9831d7e6|4
PubMed: 22942209|Pearce D, Ani C, Espinosa-Silva Y , et al.|research citation|8e3803007c4c4f59a57bc1cf9831d7e6|4
Cardiovascular disease risk prediction|American College of Cardiology (ACC)/American Heart Association (AHA) atherosclerotic cardiovascular disease (ASCVD) risk score|is used for|55cb666f3bb649b3a03b8be84e15fa9d|4
Cardiovascular disease risk prediction|HIV-infected patients in sub-Saharan Africa|applied among|55cb666f3bb649b3a03b8be84e15fa9d|4
Cardiovascular disease risk prediction|PLoS One 2017; 12: e0172897|published in|55cb666f3bb649b3a03b8be84e15fa9d|4
The association|HIV|between|55cb666f3bb649b3a03b8be84e15fa9d|4
The association|atherosclerotic|and|55cb666f3bb649b3a03b8be84e15fa9d|4
cardiovascular disease|sub-Saharan Africa|location|3531c20bf67a4e64a8a5009bcf17fc54|4
systematic review|BMC Public Health|source|3531c20bf67a4e64a8a5009bcf17fc54|4
Prediction model of global risk|cardiovascular disease in HIV-positive persons|concept|3531c20bf67a4e64a8a5009bcf17fc54|4
data-collection on adverse effects of anti-HIV drugs|study|context|3531c20bf67a4e64a8a5009bcf17fc54|4
cardiovascular disease in HIV-positive persons|global risk prediction model|focus|3531c20bf67a4e64a8a5009bcf17fc54|4
European Journal of Preventive Cardiology|publication|reference|3531c20bf67a4e64a8a5009bcf17fc54|4
cardiovascular disease|people living with HIV|associated with|a75c15f1e1c94239bdaab70e7335c592|4
American Heart Association|Circulation|published in|a75c15f1e1c94239bdaab70e7335c592|4
Kenya national guidelines for cardiovascular diseases management|Ministry of Health|from|a75c15f1e1c94239bdaab70e7335c592|4
cardiovascular disease|African dyslipidaemia guideline consensus statement|related to|a75c15f1e1c94239bdaab70e7335c592|4
South African Heart Association (SA Heart)|Lipid and Atherosclerosis Society of Southern Africa (LASSA)|joint statement|be685c6bf8b34cb4ba733f0d03418eb8|4
Department of Health Republic of South Africa|National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults|issued by|be685c6bf8b34cb4ba733f0d03418eb8|4
Department of Health Republic of South Africa|South African Heart Association (SA Heart)|related entity|be685c6bf8b34cb4ba733f0d03418eb8|4
Department of Health Republic of South Africa|Lipid and Atherosclerosis Society of Southern Africa (LASSA)|related entity|be685c6bf8b34cb4ba733f0d03418eb8|4
British HIV Association|BHIV A guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals (2019 interim update). 2019|published by|59809bb1bd66461a9dbf6931bb250b12|4
https://www.bhiva.org/file/|BHIV A guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals (2019 interim update). 2019|is available at|59809bb1bd66461a9dbf6931bb250b12|4
DqZbRxfzlYtLg/Monitoring-Guidelines.pdf|Accessed|The PDF file DqZbRxfzlYtLg/Monitoring-Guidelines.pdf was accessed on Jan 24, 2020.|a1e561842cfe44ac8e66f0b91de301d1|4
Triant V A, Perez J, Regan S, et al.|Authors|Triant V A, Perez J, Regan S, et al. are authors of the mentioned article.|a1e561842cfe44ac8e66f0b91de301d1|4
Cardiovascular risk prediction functions|Underestimate risk in HIV infection|Cardiovascular risk prediction functions underestimate risk in HIV infection according to the article.|a1e561842cfe44ac8e66f0b91de301d1|4
HIV-1 RNA|virologically suppressive antiretroviral therapy|HIV-1 RNA is present in individuals on virologically suppressive antiretroviral therapy|fa79561f482b436e9b1a4b3caae0c702|4
CSF/plasma HIV-1 RNA|individuals on antiretroviral therapy|CSF/plasma HIV-1 RNA is detected in individuals on antiretroviral therapy|fa79561f482b436e9b1a4b3caae0c702|4
discordant CSF/plasma HIV-1 RNA|virologically suppressive antiretroviral therapy|discordant CSF/plasma HIV-1 RNA occurs in those on virologically suppressive antiretroviral therapy|fa79561f482b436e9b1a4b3caae0c702|4
CSF/plasma HIV-1 RNA discordance|individuals on antiretroviral therapy|CSF/plasma HIV-1 RNA discordance is found in individuals on antiretroviral therapy|fa79561f482b436e9b1a4b3caae0c702|4
antiretroviral therapy|AHA/ACC/HRS guideline|antiretroviral therapy is mentioned in the AHA/ACC/HRS guideline|fa79561f482b436e9b1a4b3caae0c702|4
management of patients with ventricular arrhythmias|prevention of sudden cardiac death|goal of the document|341ba57fd9d14b74b73f4702454b49d9|4
Circulation 2018|reference|document citation|341ba57fd9d14b74b73f4702454b49d9|4
Aboyans V, Ricco JB, Bartelink MEL, et al.|authors|creator of the document|341ba57fd9d14b74b73f4702454b49d9|4
2017 ESC Guidelines|document title|title of the document|341ba57fd9d14b74b73f4702454b49d9|4
diagnosis and treatment|peripheral arterial diseases|focus of the document|341ba57fd9d14b74b73f4702454b49d9|4
European Society for Vascular Surgery (ESVS)|collaborator|working with the society|341ba57fd9d14b74b73f4702454b49d9|4
atherosclerotic disease|extracranial carotid and vertebral|disease types addressed in document|341ba57fd9d14b74b73f4702454b49d9|4
European Stroke Organization|the task force for the diagnosis and treatment of peripheral arterial diseases|endorsed by|f98b78c87f3b4325952a8c6bdc926d2d|4
European Society of Cardiology (ESC)|the task force for the diagnosis and treatment of peripheral arterial diseases|of the European Society of Cardiology|f98b78c87f3b4325952a8c6bdc926d2d|4
European Society for Vascular Surgery (ESVS)|the task force for the diagnosis and treatment of peripheral arterial diseases|of the European Society for Vascular Surgery|f98b78c87f3b4325952a8c6bdc926d2d|4
Eur Heart J 2018|39: 763–816|cited in|f98b78c87f3b4325952a8c6bdc926d2d|4
PubMed|28886620|accessible through|f98b78c87f3b4325952a8c6bdc926d2d|4
Chamie G, Kwarisiima D, Clark TD, et al.|Leveraging rapid community-based HIV testing|authors and title of the research article|f98b78c87f3b4325952a8c6bdc926d2d|4
campaigns|non-communicable diseases|are in the same sentence|e2171d72813c487781be6fbaef1a29e5|4
rural Uganda|non-communicable diseases|are in the same sentence|e2171d72813c487781be6fbaef1a29e5|4
PloS One 2012; 7: e43400.|campaigns for non-communicable diseases|are related through citation|e2171d72813c487781be6fbaef1a29e5|4
PubMed: 22916256|PloS One 2012; 7: e43400.|are related through citation|e2171d72813c487781be6fbaef1a29e5|4
cardiovascular disease secondary prevention roadmap goals|entire care cascade in Western Kenya|are in the same sentence|e2171d72813c487781be6fbaef1a29e5|4
Glob Heart 2015; 10: 313–17.|Engaging the entire care cascade in Western Kenya|are related through citation|e2171d72813c487781be6fbaef1a29e5|4
Glob Heart 2015; 10: 313–17.|cardiovascular disease secondary prevention roadmap goals|are in the same sentence|e2171d72813c487781be6fbaef1a29e5|4
[PubMed: 26704963]|Glob Heart 2015; 10: 313–17.|are related through citation|e2171d72813c487781be6fbaef1a29e5|4
Vedanthan R, Kamano JH, Bloomfield GS, Manji I, Pastakia S, Kimaiyo SN|Engaging the entire care cascade in Western Kenya: a model to achieve the cardiovascular disease secondary prevention roadmap goals.|are authors|e2171d72813c487781be6fbaef1a29e5|4
Njuguna B, Vorkoper S, Patel P, et al.|Models of integration of HIV and non-communicable disease|are in the same sentence|e2171d72813c487781be6fbaef1a29e5|4
AIDS|sub-Saharan Africa|is a journal related to care in|aeb8850b137345bfabb7b3d086345b73|4
lessons learned|evidence gaps|are two different aspects discussed in|aeb8850b137345bfabb7b3d086345b73|4
AIDS 2018|S32-42|is the range of pages in the document that talks about|aeb8850b137345bfabb7b3d086345b73|4
So-Armah et al.|Page 18|are mentioned on page 18 of|aeb8850b137345bfabb7b3d086345b73|4
hypertension management|low-resource settings|integrating HIV and hypertension management in low-resource settings|47c5d5107a804bf988f001beeea89478|4
HIV|hypertension management|Integrating HIV and hypertension management in low-resource settings|47c5d5107a804bf988f001beeea89478|4
human immunodeficiency virus/acquired immunodeficiency syndrome epidemic|heart disease|de novo presentations of|cfa8013a6dae4999b468153ed1921ac6|4
Heart of Soweto Study cohort|human immunodeficiency virus/acquired immunodeficiency syndrome epidemic|to|cfa8013a6dae4999b468153ed1921ac6|4
heart failure|inflammatory and immune disorders|Preventing heart failure in inflammatory and immune disorders|1afe13984e43407fbc8eaa90bbbdcb6f|4
cardiac arrhythmia services|Africa in 2018|Status of cardiac arrhythmia services in Africa in 2018|1afe13984e43407fbc8eaa90bbbdcb6f|4
HIV provider-patient communication|cardiovascular risk|results from the AIDS Treatment for Life International Survey|c6fbd9df7d0448dbad3418885fd72fbe|4
statin prescribing practices|comprehensive care for HIV-infected patients|J Acquir Immune Defic Syndr 2017; 76: e26–29|c6fbd9df7d0448dbad3418885fd72fbe|4
statin utilization|race, ethnicity, HIV status|differences in statin utilization and lipid lowering|143eef25faee4c7db50b410c86a12855|4
human immunodeficiency virus|uninfected persons|real-world cohort of persons with human immunodeficiency virus and uninfected persons|143eef25faee4c7db50b410c86a12855|4
lipid lowering|race, ethnicity, HIV status|differences in statin utilization and lipid lowering|143eef25faee4c7db50b410c86a12855|4
nonlipid cardiovascular disease risk factor management|adherence to antiretroviral therapy|trends in nonlipid cardiovascular disease risk factor management|143eef25faee4c7db50b410c86a12855|4
Women’s interagency HIV study|adherence to antiretroviral therapy|association with adherence to antiretroviral therapy|143eef25faee4c7db50b410c86a12855|4
AIDS Patient Care STDS 2016|Publication|is a publication|bd0506c6e6104790be2f925c68848edd|4
PubMed|Database|used for referencing scientific literature|bd0506c6e6104790be2f925c68848edd|4
Feinstein MJ, Kim JH, Bibangambah P, et al.|Researchers|authors of a research study|bd0506c6e6104790be2f925c68848edd|4
Ideal cardiovascular health and carotid atherosclerosis in a mixed cohort of HIV-infected and uninfected Ugandans|Study title|title of the study|bd0506c6e6104790be2f925c68848edd|4
AbdelRazek MA, Gutierrez J, Mampre D, et al.|Researchers|authors of a research study|bd0506c6e6104790be2f925c68848edd|4
Intravenous thrombolysis for stroke and presumed stroke in human immunodeficiency virus-infected adults: a retrospective, multicenter US study|Study title|title of the study|bd0506c6e6104790be2f925c68848edd|4
Human immunodeficiency virus-infected adults|Patient group|group of patients studied|bd0506c6e6104790be2f925c68848edd|4
Stroke|49: 228-31|Publication details|f69e0ce10ccb4d8faf433eba51dc40fa|4
PubMed|29273597|Citation details|f69e0ce10ccb4d8faf433eba51dc40fa|4
Uriel N|Nahumi N|Co-authorship|f69e0ce10ccb4d8faf433eba51dc40fa|4
Colombo PC|et al.|Co-authorship|f69e0ce10ccb4d8faf433eba51dc40fa|4
J Heart Lung Transplant|2014; 33: 924–30|Publication details|f69e0ce10ccb4d8faf433eba51dc40fa|4
PubMed|24929646|Citation details|f69e0ce10ccb4d8faf433eba51dc40fa|4
Patel P|Rose CE|Co-authorship|f69e0ce10ccb4d8faf433eba51dc40fa|4
Collins PY|et al.|Co-authorship|f69e0ce10ccb4d8faf433eba51dc40fa|4
AIDS|32 (suppl 1): S5–20|Publication details|f69e0ce10ccb4d8faf433eba51dc40fa|4
PubMed|29952786|Citation details|f69e0ce10ccb4d8faf433eba51dc40fa|4
Scaling up chronic care systems|HIV programs|leveraging|88f8a99f07374be2bf89ea28c49fbc2f|4
HIV programs|noncommunicable disease services|supporting|88f8a99f07374be2bf89ea28c49fbc2f|4
Comprehensive primary care|rural Malawi|working toward in|88f8a99f07374be2bf89ea28c49fbc2f|4
Chronic care services|comprehensive primary care|integrated within|88f8a99f07374be2bf89ea28c49fbc2f|4
Feasibility of integrated, multilevel care|Cardiovascular diseases (CVD) and HIV|concepts related in one sentence|761179fa4fe749aaa447898ca18a71ee|4
Global, regional, and national burden of stroke|Systematic analysis for the Global Burden of Disease Study 2016|concepts related in one sentence|761179fa4fe749aaa447898ca18a71ee|4
Cardiac manifestations|HIV infection|are related to|aa93af9b4f7b456993652aa7f47bfd9f|4
Global disparities|Hypertension prevalence and control|of|aa93af9b4f7b456993652aa7f47bfd9f|4
Population-based studies|90 countries|from|aa93af9b4f7b456993652aa7f47bfd9f|4
Predictors and outcomes|Sub-Saharan Africa|are discussed in the context|82eda6ac362f4117aa67224ba4499522|4
THESUS-HF registry|Eur Heart J 2013|is the source of data for the study|82eda6ac362f4117aa67224ba4499522|4
Agu CE|Uchendu IK|are authors in a study on prevalence and associated risk factors|82eda6ac362f4117aa67224ba4499522|4
Peripheral artery disease|HIV-infected individuals|are the subject of interest in the study|82eda6ac362f4117aa67224ba4499522|4
Antiretroviral therapy|Kwara state, Nigeria|is being conducted in a specific location|82eda6ac362f4117aa67224ba4499522|4
HIV-1 infected individuals|myocardial infarction risk|increased risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France|531f90fc1b524bb5bb8922501d71889a|4
gender|myocardial infarction risk|impact of gender on myocardial infarction risk in HIV-1-infected individuals|531f90fc1b524bb5bb8922501d71889a|4
immune status|myocardial infarction risk|impact of immune status on myocardial infarction risk in HIV-1-infected individuals|531f90fc1b524bb5bb8922501d71889a|4
cardiovascular risk management|people living with HIV in Europe|The cardiovascular risk management is being discussed for people living with HIV in Europe.|c1d4606ee66240a59043c2a8b6eef1d4|4
HIV infected individuals|cardiovascular mortality|Patterns of cardiovascular mortality are found in HIV-infected individuals.|c1d4606ee66240a59043c2a8b6eef1d4|4
United States|adults|time period from 1999 to 2013|8fa8564cdfce495fa1c130ef259f2f0f|4
Am J Cardiol|2016; 117: 214–20|reference for data related to adults in the United States from 1999 to 2013|8fa8564cdfce495fa1c130ef259f2f0f|4
Ovbiagele B, Nath A|Increasing incidence of ischemic stroke in patients with HIV infection|authors and title of the study related to increasing incidence of ischemic stroke|8fa8564cdfce495fa1c130ef259f2f0f|4
Neurology 2011; 76: 444–50|[PubMed: 21248273]|reference for the study by Ovbiagele B and Nath A|8fa8564cdfce495fa1c130ef259f2f0f|4
Junttila MJ, Hookana E, Kaikkonen KS, Kortelainen ML, Myerburg RJ, Huikuri HV|Temporal trends in the clinical and pathological characteristics of victims of sudden cardiac death in the|authors and title of the study related to temporal trends in sudden cardiac death|8fa8564cdfce495fa1c130ef259f2f0f|4
absence of previously identified heart disease|Circ Arrhythm Electrophysiol 2016; 9: e003723|publication|7e5be98e1e3542f58a3608beb40da408|4
A study by Hookana E, Junttila MJ, Puurunen VP, et al.|Heart Rhythm 2011; 8: 1570–75|publication|7e5be98e1e3542f58a3608beb40da408|4
A study by Nugent R, Barnabas RV , Golovaty I, et al.|AIDS 2018; 32 (suppl 1): S83–92|publication|7e5be98e1e3542f58a3608beb40da408|4
cardiovascular disease risk factor screening|HIV services|integrating into|7e9b90d53d5e482b93264bd9fb842585|4
noncommunicable diseases|hiv-infected persons|management of|7e9b90d53d5e482b93264bd9fb842585|4
hypertension|diabetes mellitus|Both are diseases mentioned in the context of their burden on adult Malawians|b9c3913519ec4aac895f7b242ef670fc|4
hypertension|cardiovascular risk factors|Hypertension is one of the cardiovascular risk factors|b9c3913519ec4aac895f7b242ef670fc|4
hypertension|adult Malawians in HIV care|The burden of hypertension affects adult Malawians in HIV care|b9c3913519ec4aac895f7b242ef670fc|4
hypertension|integrated services|Hypertension has consequences for integrated services|b9c3913519ec4aac895f7b242ef670fc|4
HIV|Malawians in HIV care|The context discusses the issue of hypertension and diabetes among Malawians receiving HIV care|b9c3913519ec4aac895f7b242ef670fc|4
translation platform|Malawi Med J|is published in|dbbcb592117b49dda139c178a1ceecef|4
translation platform|So-Armah et al.|cites as a reference|dbbcb592117b49dda139c178a1ceecef|4
Lancet HIV|Author manuscript|is an author manuscript of|dbbcb592117b49dda139c178a1ceecef|4
Author Manuscript|Author Manuscript|refers to itself|dbbcb592117b49dda139c178a1ceecef|4
healthcare services|older South Africans|accessing healthcare services among older South Africans|3967864fae744c0991a50632c895592f|4
HIV and non-communicable diseases|older South Africans|with HIV and non-communicable diseases|3967864fae744c0991a50632c895592f|4
Integrated hypertension and HIV care cascades|HIV treatment program in eastern Uganda|in an HIV treatment program|3967864fae744c0991a50632c895592f|4
retrospective cohort study|J Acquir Immune Defic Syndr|is published in|b189b6a9da2841b4817aae12302d67db|4
J Acquir Immune Defic Syndr 2019|81: 552–61|refers to page numbers|b189b6a9da2841b4817aae12302d67db|4
PubMed: 31045649|retrospective cohort study|is related to through citation|b189b6a9da2841b4817aae12302d67db|4
Iwelunmor J, Ezechi O, Obiezu-Umeh C, et al.|Capabilities, opportunities and motivations for integrating evidence-based strategy for hypertension control into HIV clinics in southwest Nigeria|is a research paper|b189b6a9da2841b4817aae12302d67db|4
PLoS One 2019; 14: e0217703|Iwelunmor J, Ezechi O, Obiezu-Umeh C, et al.|refers to the page numbers|b189b6a9da2841b4817aae12302d67db|4
PubMed: 31170220|Shang C, Lee HM, Chaloupka FJ, Fong GT, Thompson M, O’Connor RJ.|is related to through citation|b189b6a9da2841b4817aae12302d67db|4
Association between|Shang C, Lee HM, Chaloupka FJ, Fong GT, Thompson M, O’Connor RJ.|is the topic of the research|b189b6a9da2841b4817aae12302d67db|4
International Tobacco Control Policy (ITC) Project|Tax structure|is a subject of research|2f463a75fb494ad0839af3ab80316642|4
Tax structure|Cigarette consumption|affects|2f463a75fb494ad0839af3ab80316642|4
HIV|Sub-Saharan Africa|located in|59386e9e99184db093590c61eea797bb|4
HIV|non-communicable disease services|services for HIV patients|59386e9e99184db093590c61eea797bb|4
Sub-Saharan Africa|systematic review|subject of systematic review|59386e9e99184db093590c61eea797bb|4
AIDS|32 (suppl 1): S93–S105|publication information|59386e9e99184db093590c61eea797bb|4
HIV and non-communicable disease services|Sub-Saharan Africa|services provided in Sub-Saharan Africa|59386e9e99184db093590c61eea797bb|4
AIDS 2018|32 (suppl 1): S93–S105|publication|59386e9e99184db093590c61eea797bb|4
PubMed: 29952795|AIDS 2018; 32 (suppl 1): S93–S105|citation|59386e9e99184db093590c61eea797bb|4
Burton A|South Africa: stroke units out of the blue|authorship|59386e9e99184db093590c61eea797bb|4
Lancet Neurol 2016|15: 359–60|publication information|59386e9e99184db093590c61eea797bb|4
PubMed: 26971657|Burton A South Africa: stroke units out of the blue|citation|59386e9e99184db093590c61eea797bb|4
Jenkins C, Ovbiagele B, Arulogun O, et al.|Knowledge, attitudes and practices related to stroke in Ghana and Nigeria: A SIREN call to action|authorship|59386e9e99184db093590c61eea797bb|4
PLoS One 2018|13: e0206548|publication information|59386e9e99184db093590c61eea797bb|4
PubMed: 30444884|Jenkins C, Ovbiagele B, Arulogun O, et al. Knowledge, attitudes and practices related to stroke in Ghana and Nigeria: A SIREN call to action|citation|59386e9e99184db093590c61eea797bb|4
stroke treatments|next generation|will come from|34a0b61dfed24ee4ba38d10e4202a46c|4
Howells DW|Donnan GA|co-author of the study|34a0b61dfed24ee4ba38d10e4202a46c|4
PLoS Med|2010|publication year and journal|34a0b61dfed24ee4ba38d10e4202a46c|4
20208999|PubMed|database reference|34a0b61dfed24ee4ba38d10e4202a46c|4
Howells DW|Donnan GA|co-author of the study|34a0b61dfed24ee4ba38d10e4202a46c|4
PLoS Med 2010|e1000224|article identifier|34a0b61dfed24ee4ba38d10e4202a46c|4
Baatiema L|de-Graft Aikins A|co-author of the study|34a0b61dfed24ee4ba38d10e4202a46c|4
Sav A|Mnatzaganian G|co-author of the study|34a0b61dfed24ee4ba38d10e4202a46c|4
Chan CKY|Somerset S|co-author of the study|34a0b61dfed24ee4ba38d10e4202a46c|4
BMJ Open 2017|e015385|article identifier|34a0b61dfed24ee4ba38d10e4202a46c|4
Noncommunicable disease clinic|District hospital level|Located at|cd0c57db08094e10966fcfdb5f2df305|4
Integrated noncommunicable disease clinic|Sub-Saharan Africa|Geographic location|cd0c57db08094e10966fcfdb5f2df305|4
JACC Heart Fail 2013|Research paper|Reference in context|cd0c57db08094e10966fcfdb5f2df305|4
Publication|PubMed: 24621875|Citation details|cd0c57db08094e10966fcfdb5f2df305|4
Heart failure outcomes|Nurse-driven clinics|Relation in study|cd0c57db08094e10966fcfdb5f2df305|4
Rural sub-Saharan Africa|Study location|Geographic context|cd0c57db08094e10966fcfdb5f2df305|4
J Am Coll Cardiol 2019|Research paper|Reference in context|cd0c57db08094e10966fcfdb5f2df305|4
Publication|PubMed: 30819366|Citation details|cd0c57db08094e10966fcfdb5f2df305|4
Warning symptoms|Survival|Association in study|cd0c57db08094e10966fcfdb5f2df305|4
sudden cardiac arrest|Ann Intern Med 2016; 164: 23–29|reference to a journal article on sudden cardiac arrest|aa0004bef58a41b2985bb9799b7d5b56|4
antiinflammatory therapy with canakinumab for atherosclerotic disease|N Engl J Med 2017; 377: 1119–31|reference to a journal article on antiinflammatory therapy with canakinumab for atherosclerotic disease|aa0004bef58a41b2985bb9799b7d5b56|4
So-Armah et al.|Lancet HIV|author's article in Lancet HIV|aa0004bef58a41b2985bb9799b7d5b56|4
Search strategy and selection criteria|PubMed searches|identified by|cda55c4f8c0d48568d52df29dec94304|4
References for this Review|PubMed searches|were identified by|cda55c4f8c0d48568d52df29dec94304|4
HIV or AIDS|types of cardiovascular disease|and|cda55c4f8c0d48568d52df29dec94304|4
Human immunodeficiency virus|acquired immunodeficiency syndrome|or|cda55c4f8c0d48568d52df29dec94304|4
cardiac death|atherosclerosis|caused by|855a487cb6c74648bffc5e0789dc034d|4
Africa|Kenya|located in|855a487cb6c74648bffc5e0789dc034d|4
Africa|Uganda|located in|855a487cb6c74648bffc5e0789dc034d|4
Africa|Malawi|located in|855a487cb6c74648bffc5e0789dc034d|4
Africa|Nigeria|located in|855a487cb6c74648bffc5e0789dc034d|4
Asia|Thailand|located in|855a487cb6c74648bffc5e0789dc034d|4
Asia|India|located in|855a487cb6c74648bffc5e0789dc034d|4
Asia|China|located in|855a487cb6c74648bffc5e0789dc034d|4
Asia|Russia|located in|855a487cb6c74648bffc5e0789dc034d|4
South America|low income country|consists of|855a487cb6c74648bffc5e0789dc034d|4
South America|middle income country|consists of|855a487cb6c74648bffc5e0789dc034d|4
low income country|LMIC|is a type of|855a487cb6c74648bffc5e0789dc034d|4
middle income country|LMIC|is a type of|855a487cb6c74648bffc5e0789dc034d|4
meta-analysis|manuscripts|reviewed|855a487cb6c74648bffc5e0789dc034d|4
manuscripts|last 5 years|published in|855a487cb6c74648bffc5e0789dc034d|4
manuscripts|incident clinical events|assessed|855a487cb6c74648bffc5e0789dc034d|4
manuscripts|meta-analyses|comprehensively summarising existing data|855a487cb6c74648bffc5e0789dc034d|4
published in|English|only papers|855a487cb6c74648bffc5e0789dc034d|4
Lancet HIV|Author manuscript|is related to|b33155f4096048ff95c5711cf6031457|4
Author manuscript|PMC 2022 August 03|is available on this date|b33155f4096048ff95c5711cf6031457|4
HIV|World maps|Prevalence distribution of HIV|7c549f6356744c8793ce5888a9f82a18|4
HIV|WHO regions|classified by WHO regions|7c549f6356744c8793ce5888a9f82a18|4
HIV|Global prevalence|Global prevalence of HIV on average|38b2b80baa9a41599618dd6835e06e22|4
Median age|2017|median age in 2017|38b2b80baa9a41599618dd6835e06e22|4
Raised blood pressure|Systolic blood pressure|systolic blood pressure ≥140 mm Hg|38b2b80baa9a41599618dd6835e06e22|4
Raised blood pressure|Diastolic blood pressure|diastolic blood pressure ≥90 mm Hg|38b2b80baa9a41599618dd6835e06e22|4
Prevalence of raised blood cholesterol|Ages over 25 years|ages over 25 years for prevalence of raised blood cholesterol|38b2b80baa9a41599618dd6835e06e22|4
Age-standardised estimate|Both sexes|age-standardised estimate for both sexes|38b2b80baa9a41599618dd6835e06e22|4
Prevalence of tobacco smoking|People aged 15 years and older|age-standardised estimate|dfc961ff50b74416b8f0655154e14c01|4
So-Armah et al.|Lancet HIV|author manuscript; available in PMC 2022 August 03.|dfc961ff50b74416b8f0655154e14c01|4
HIV-associated cardiovascular disease|So-Armah et al.|authored a study on|809f953bb5434c0aa047d92041721c95|4
Mechanisms of HIV-associated cardiovascular disease|Lancet HIV|published in|809f953bb5434c0aa047d92041721c95|4
Author manuscript|PMC 2022 August 03|available in|809f953bb5434c0aa047d92041721c95|4
Intervention points|HIV-associated cardiovascular disease risk|reducing|54a1eb5232764880b8a896dee55e9d57|4
HIV-associated cardiovascular disease risk|income status|stratified by|54a1eb5232764880b8a896dee55e9d57|4
ART|antiretroviral therapy|=|54a1eb5232764880b8a896dee55e9d57|4
So-Armah et al.|Page 26|from|54a1eb5232764880b8a896dee55e9d57|4
Lancet HIV|Author manuscript|in|54a1eb5232764880b8a896dee55e9d57|4
Author Manuscript|So-Armah et al.|written by|b84bf65b0bbe443c950634ea304a7a41|4
Author Manuscript|Page 27|located on|b84bf65b0bbe443c950634ea304a7a41|4
Author Manuscript|Table 1:|contains|b84bf65b0bbe443c950634ea304a7a41|4
Studies|association of HIV status and clinical cardiovascular disease|focuses on|b84bf65b0bbe443c950634ea304a7a41|4
Location|Number of participants|represents|b84bf65b0bbe443c950634ea304a7a41|4
Number of HIV cases|HIV status|represents|b84bf65b0bbe443c950634ea304a7a41|4
CVD events|clinical cardiovascular disease|represents|b84bf65b0bbe443c950634ea304a7a41|4
Mean age (SD)|Outcome Measure|is a measure of|b84bf65b0bbe443c950634ea304a7a41|4
Effect estimate (95% CI)|Measure of effect|is a method of|b84bf65b0bbe443c950634ea304a7a41|4
Stroke|Cerebral infarction|is a type of|b84bf65b0bbe443c950634ea304a7a41|4
Odds ratio 3·2 (1·1–8·9)|Effect estimate (95% CI)|value for|b84bf65b0bbe443c950634ea304a7a41|4
Qureshi et al.|Grady Memorial Hospital, USA|located at|b84bf65b0bbe443c950634ea304a7a41|4
Baltimore-Washington Cooperative|Cole et al.|written by|b84bf65b0bbe443c950634ea304a7a41|4
Ischaemic stroke|Young Stroke Study|USA386 6 386 36|a762a21986654bc1a36200fa7d937361|4
Odds ratio|Ischaemic stroke|13·70 (6·10–30·80)|a762a21986654bc1a36200fa7d937361|4
Hazard ratio|Ischaemic stroke|1·21 (1·01–1·46)|a762a21986654bc1a36200fa7d937361|4
Relative risk|All stroke|2·16 (1·39–3·31)|a762a21986654bc1a36200fa7d937361|4
Tanzania and urban Dar-es-Salaam|All stroke Odds ratio|Study location|d2103626cc424567b260993cb311c98c|4
Marcus et al (2014)|Kaiser Permanente Southern California and Northern California, USA|Other studies/research locations|d2103626cc424567b260993cb311c98c|4
Rasmussen et al (2015)|Danish HIV Cohort Study|Other studies/research locations|d2103626cc424567b260993cb311c98c|4
Veterans Aging Cohort Study|USA|location|ca8cde1b78a145b7a8d2a36f3fe76450|4
Sico et al (2015)|Ischaemic stroke|study and condition|ca8cde1b78a145b7a8d2a36f3fe76450|4
Veterans Aging Cohort Study|76 835 participants|number of participants|ca8cde1b78a145b7a8d2a36f3fe76450|4
Veterans Aging Cohort Study|Hazard ratio|study and statistic|ca8cde1b78a145b7a8d2a36f3fe76450|4
Sico et al (2015)|1·17|hazard ratio value|ca8cde1b78a145b7a8d2a36f3fe76450|4
Sico et al (2015)|910 49 participants|number of participants|ca8cde1b78a145b7a8d2a36f3fe76450|4
Alonso et al (2019)|Truven Health MarketScan|database|ca8cde1b78a145b7a8d2a36f3fe76450|4
Alonso et al (2019)|Commercial Claims and Encounter|database|ca8cde1b78a145b7a8d2a36f3fe76450|4
Alonso et al (2019)|Medicare Supplemental and Coordination of Benefits databases|database|ca8cde1b78a145b7a8d2a36f3fe76450|4
Alonso et al (2019)|USA|location|ca8cde1b78a145b7a8d2a36f3fe76450|4
Alonso et al (2019)|Stroke Hazard ratio 2·3|study and statistic|ca8cde1b78a145b7a8d2a36f3fe76450|4
Myocardial infarction|Triant et al (2009)|study by Triant et al found relation to Myocardial infarction|45f59c875ce647038ed8679af4bee3a9|4
Massachusetts General Hospital|Triant et al (2009)|Triant et al study conducted at Massachusetts General Hospital|45f59c875ce647038ed8679af4bee3a9|4
Brigham and Women’s Hospital|Triant et al (2009)|Triant et al study conducted at Brigham and Women’s Hospital|45f59c875ce647038ed8679af4bee3a9|4
Myocardial infarction|Lang et al (2010)|study by Lang et al found relation to Myocardial infarction|45f59c875ce647038ed8679af4bee3a9|4
French hospital database on HIV|Lang et al (2010)|study used French hospital database on HIV|45f59c875ce647038ed8679af4bee3a9|4
Myocardial infarction|Durand et al (2011)|study by Durand et al found relation to Myocardial infarction|45f59c875ce647038ed8679af4bee3a9|4
Régie de l’Assurance maladie du Québec, Canada|Durand et al (2011)|study used Régie de l’Assurance maladie du Québec, Canada|45f59c875ce647038ed8679af4bee3a9|4
infarction|Hazard ratio|is related to|fcfdafc6471042d08b1fe8b96a7be029|4
Hazard ratio|2·11|has value of|fcfdafc6471042d08b1fe8b96a7be029|4
2·11|(1·69–2·63)|with confidence interval|fcfdafc6471042d08b1fe8b96a7be029|4
So-Armah et al. Author Manuscript|Page 28|author's manuscript, page|adfecd708aee44e2837e75c9f9c3a17a|4
Location|Number of participants|location, number of participants|adfecd708aee44e2837e75c9f9c3a17a|4
Location|HIV cases|location, HIV cases|adfecd708aee44e2837e75c9f9c3a17a|4
Location|CVD events|location, CVD events|adfecd708aee44e2837e75c9f9c3a17a|4
Mean age (SD)|Outcome Measure of effect|mean age, outcome measure|adfecd708aee44e2837e75c9f9c3a17a|4
Effect estimate (95% CI)|Klein et al. (2015)|effect estimate, Klein et al.|adfecd708aee44e2837e75c9f9c3a17a|4
Era of study|So-Armah et al. Author Manuscript|era of study, So-Armah et al.|adfecd708aee44e2837e75c9f9c3a17a|4
Infarction incidence rate|Ratio 1.40|rate ratio from a study|badf21797ec4429a985889e883769be4|4
Althoff et al (2015) study|USA Veterans Aging Cohort Study|study name and location|badf21797ec4429a985889e883769be4|4
USA Veterans Aging Cohort Study|83,527 participants|number of participants in the study|badf21797ec4429a985889e883769be4|4
Althoff et al (2015) study|Infarction incidence rate 1.40|rate ratio from a study|badf21797ec4429a985889e883769be4|4
Mid-50s Acute myocardial infarction|Hazard ratio 1.76|rate ratio from a study|badf21797ec4429a985889e883769be4|4
Rasmussen et al (2015) study|Danish HIV cohort|study name and location|badf21797ec4429a985889e883769be4|4
Danish HIV cohort|58,970 participants|number of participants in the study|badf21797ec4429a985889e883769be4|4
Rasmussen et al (2015) study|Incidence rate ratio 2.02|rate ratio from a study|badf21797ec4429a985889e883769be4|4
Alonso et al (2019) study|Truven Health MarketScan Commercial Claims and Encounter databases|study name and database source|badf21797ec4429a985889e883769be4|4
Myocardial infarction|Heart failure|Both are health conditions|a3826e933ce74af596f961735e0dbfc5|4
Congestive heart failure|Hazard ratio 1·41 (1·29–1·54)|Ratio of hazard related to congestive heart failure|a3826e933ce74af596f961735e0dbfc5|4
Adjudicated heart failure|Hazard ratio 2·10 (1·38–3·21)|Ratio of hazard related to adjudicated heart failure|a3826e933ce74af596f961735e0dbfc5|4
failureHazard ratio|Alonso et al (2019)|reference to a source|9cfc32958b794203ad23af95e9809d07|4
Heart failure Hazard ratio|failureHazard ratio|same context, related topic|9cfc32958b794203ad23af95e9809d07|4
Peripheral artery disease|Alonso et al (2019)|reference to a source|9cfc32958b794203ad23af95e9809d07|4
Peripheral artery|Heart failure Hazard ratio|same context, related topic|9cfc32958b794203ad23af95e9809d07|4
Peripheral artery disease|USA79|Peripheral artery disease from USA79|e8f8c8e1fee94b1d9f6668cce93dd973|4
Hazard ratio|Peripheral artery disease|Hazard ratio in context of Peripheral artery disease|e8f8c8e1fee94b1d9f6668cce93dd973|4
Beckman et al (2019)|Veterans Aging Cohort Study|Study by Beckman et al (2019) on Veterans Aging Cohort Study|e8f8c8e1fee94b1d9f6668cce93dd973|4
Taiwan Centers for Disease Control|HIV Surveillance Database|Association between Taiwan Centers for Disease Control and HIV Surveillance Database|e8f8c8e1fee94b1d9f6668cce93dd973|4
Lai et al (2018)|Taiwan Centers for Disease Control|Study by Lai et al (2018) on Taiwan Centers for Disease Control|e8f8c8e1fee94b1d9f6668cce93dd973|4
Peripheral artery disease|Standardised Incidence rate|Standardised Incidence rate related to Peripheral artery disease|e8f8c8e1fee94b1d9f6668cce93dd973|4
Sudden cardiac death|Peripheral artery disease|Association between sudden cardiac death and peripheral artery disease|e8f8c8e1fee94b1d9f6668cce93dd973|4
Tseng et al (2012)|HIV specialty clinic in San|Study by Tseng et al (2012) on HIV specialty clinic in San|e8f8c8e1fee94b1d9f6668cce93dd973|4
Tseng et al (2012)|HIV specialty clinic|in San Francisco, California, USA|3880f18a939742179dc26af67246cdda|4
Tseng et al (2012)|30 Median|of 2860 patients had a median of 39 (IQR 33–45)|3880f18a939742179dc26af67246cdda|4
Tseng et al (2012)|Sudden cardiac death|Standardised mortality ratio is 4.46|3880f18a939742179dc26af67246cdda|4
Lai et al (2018)|Taiwan Centers for Disease Control|HIV Surveillance Database|3880f18a939742179dc26af67246cdda|4
Lai et al (2018)|General population|26,272 patients were studied|3880f18a939742179dc26af67246cdda|4
Lai et al (2018)|Sudden cardiac death|Standardised Incidence rate is 3.01 (2.39–3.73)|3880f18a939742179dc26af67246cdda|4
Author Manuscript|So-Armah et al.|reference|d17bd634bb34402fb423dc470a707245|4
Location|Number of participants|related to number of participants in a location|d17bd634bb34402fb423dc470a707245|4
HIV cases|Participants|participants were HIV cases|d17bd634bb34402fb423dc470a707245|4
CVD events|Mean age (SD)|related to mean age and standard deviation of CVD events|d17bd634bb34402fb423dc470a707245|4
Outcome Measure|Effect estimate (95% CI)|used in measuring the effect estimate with a 95% confidence interval|d17bd634bb34402fb423dc470a707245|4
Alvi et al (2019)|Bronx Lebanon Hospital Center|location of Alvi et al study|d17bd634bb34402fb423dc470a707245|4
Icahn School of Medicine at Mount Sinai, USA|Alvi et al (2019)|affiliation of Alvi et al (2019)|d17bd634bb34402fb423dc470a707245|4
Number of participants|HIV cases|number of participants are HIV cases|d17bd634bb34402fb423dc470a707245|4
CVD events|Mean age (SD)|mean age and standard deviation of CVD events|d17bd634bb34402fb423dc470a707245|4
Outcome Measure|Effect estimate (95% CI)|used in measuring the effect estimate with a 95% confidence interval|d17bd634bb34402fb423dc470a707245|4
Tseng et al (CROI 2019, unpublished)|HIV specialty clinic in San|location of Tseng et al study|d17bd634bb34402fb423dc470a707245|4
HIV specialty clinic|San Francisco, California, USA|Location|9b7e89a08ffd4ad7835eb34adde14514|4
Sudden cardiac death|Incidence rate ratio|Measurement|9b7e89a08ffd4ad7835eb34adde14514|4
Incidence rate ratio|1·86 (1·39–2·50)|Value|9b7e89a08ffd4ad7835eb34adde14514|4
Sudden cardiac death|Freiberg et al (CROI 2019, unpublished)|Association|9b7e89a08ffd4ad7835eb34adde14514|4
Veterans Aging Cohort Study|USA|Location|9b7e89a08ffd4ad7835eb34adde14514|4
Veterans Aging Cohort Study|144 336 43 407 3035 50 (11)|Size|9b7e89a08ffd4ad7835eb34adde14514|4
Veterans Aging Cohort Study|Sudden cardiac death|Study topic|9b7e89a08ffd4ad7835eb34adde14514|4
Hazard ratio|1·14 (1·04–1·25)|Value|9b7e89a08ffd4ad7835eb34adde14514|4
Cardiovascular disease types|Population-based HIV-negative groups|Comparison group|9b7e89a08ffd4ad7835eb34adde14514|4
meta-analysis|Shah and others|Shah and others performed a meta-analysis|d3272a85bddf42aaa13006c5a3870693|4
Shah and others|All other studies (appendix p 1)|Studies by Shah and others included all other studies as part of their meta-analysis.|d3272a85bddf42aaa13006c5a3870693|4
meta-analysis|CVD|The meta-analysis discussed cardiovascular disease (CVD).|d3272a85bddf42aaa13006c5a3870693|4
meta-analysis|CROI|The meta-analysis took place during the conference on retroviruses and opportunistic Infections (CROI)|d3272a85bddf42aaa13006c5a3870693|4
Lancet HIV|meta-analysis|The Lancet HIV published a manuscript about this meta-analysis.|d3272a85bddf42aaa13006c5a3870693|4
Cardiovascular disease prevention, prediction, and risk reduction|Guidelines on cardiovascular disease prevention, prediction, and risk reduction|These are guidelines that mention cardiovascular disease prevention, prediction, and risk reduction.|c306c7b61d1245aeac24c1441db4aea1|4
Cardiovascular disease risk prediction|Tobacco Hypertension Diabetes Dyslipidaemia Drug interactions|These are factors involved in cardiovascular disease risk prediction.|c306c7b61d1245aeac24c1441db4aea1|4
Kenya National Guidelines for cardiovascular disease management (2018)|No HIV-specific recommendation|No HIV-specific recommendations are mentioned in the Kenya National Guidelines for Cardiovascular Disease Management (2018).|c306c7b61d1245aeac24c1441db4aea1|4
As in general population with exceptions on interactions of|No HIV-specific recommendation|The text implies that the guidelines follow a similar pattern for the general population, with some exceptions regarding interactions.|c306c7b61d1245aeac24c1441db4aea1|4
antihypertensive drugs|ART|interactions of|413b5e0c726f48698ecc792a16ff423a|4
baseline|annually|for|413b5e0c726f48698ecc792a16ff423a|4
glucose|lipids|Assess|413b5e0c726f48698ecc792a16ff423a|4
abnormal|yes|if|413b5e0c726f48698ecc792a16ff423a|4
South African dyslipidaemia guideline (2018)|National Consolidated HIV Guidelines (2015)|and|413b5e0c726f48698ecc792a16ff423a|4
HIV-infected black South Africans|Framingham risk tables|may be used to aid decision-making|413b5e0c726f48698ecc792a16ff423a|4
no HIV-specific|risk score|for|413b5e0c726f48698ecc792a16ff423a|4
decision-making|No HIV-specific recommendation|is|27a152d7822648d9aa041bd2e6e0ef30|4
No HIV-specific recommendation|Full lipogram recommended|after ART initiation|27a152d7822648d9aa041bd2e6e0ef30|4
Full lipogram recommended|repeated at 3 months after starting protease inhibitor|periodically thereafter|27a152d7822648d9aa041bd2e6e0ef30|4
Malawi HIV Testing Services Guidelines (2016)|No HIV-specific recommendation|66Not addressed Recommends stopping smoking|27a152d7822648d9aa041bd2e6e0ef30|4
Assess blood pressure at ART initiation|blood pressure thresholds|identified|27a152d7822648d9aa041bd2e6e0ef30|4
Assess blood pressure at ART initiation|repeat annually|Assess blood pressure at ART initiation|27a152d7822648d9aa041bd2e6e0ef30|4
specific blood pressure thresholds|lifestyle changes or pharmacotherapy|management|2ace3c0383ff42fb9dc2afdfbc8ad55e|4
hypertension management|screening|recommends|2ace3c0383ff42fb9dc2afdfbc8ad55e|4
Infectious Diseases Society of America HIV Guidelines (2013)|HIV guidelines|references|2ace3c0383ff42fb9dc2afdfbc8ad55e|4
Framingham risk scores|coronary heart disease risk assessment recommended|assumed given reference to NCEP guidelines|2ace3c0383ff42fb9dc2afdfbc8ad55e|4
smoking cessation|regular patient education|part of|2ace3c0383ff42fb9dc2afdfbc8ad55e|4
patient education|Blood pressure check|annually in all patients|954c44196af74a8cbdc2c63968609e4f|4
Blood pressure check|NHANES|Consider NHANES|954c44196af74a8cbdc2c63968609e4f|4
Blood pressure check|HbA1c cutoff of 5·8%|annually in all patients|954c44196af74a8cbdc2c63968609e4f|4
HbA1c cutoff of 5·8%|check fasting plasma glucose|every 6–12 months|954c44196af74a8cbdc2c63968609e4f|4
check fasting plasma glucose|HbA1c cutoff of 5·8%|check fasting plasma glucose and HbA1c every 6–12 months|954c44196af74a8cbdc2c63968609e4f|4
fasting plasma glucose|HbA1c cutoff of 5·8%|check fasting plasma glucose and HbA1c every 6–12 months|954c44196af74a8cbdc2c63968609e4f|4
fasting plasma glucose|lipid profile|1–3 months after and before ART initiation|954c44196af74a8cbdc2c63968609e4f|4
HbA1c cutoff of 5·8%|NCEP guidelines|management per NCEP guidelines|954c44196af74a8cbdc2c63968609e4f|4
lipid profile|NCEP guidelines|management per NCEP guidelines|954c44196af74a8cbdc2c63968609e4f|4
fasting lipid profile|ART|lipid lowering drugs interacting with ART|954c44196af74a8cbdc2c63968609e4f|4
American Heart Association Statement|HIV and Cardiovascular Disease|American Heart Association Statement on HIV and Cardiovascular Disease|954c44196af74a8cbdc2c63968609e4f|4
HIV and Cardiovascular Disease|Statement 62|Proposes upward adjustment of risk assessment by 1·5–2-times using ACC, AHA|954c44196af74a8cbdc2c63968609e4f|4
Smoking cessation|online resources|mentioned in the same sentence|5be2c4be404d45a19c9d03d6a86331b4|4
No HIV-specific recommendation|Lifestyle optimisation|mentioned in the same paragraph|5be2c4be404d45a19c9d03d6a86331b4|4
start low, go slow strategy|pharmacotherapy|mentioned in the same sentence|5be2c4be404d45a19c9d03d6a86331b4|4
European AIDS Clinical Society Guidelines Version 9·1 (2018)|Framingham score every two|mentioned in the same sentence|5be2c4be404d45a19c9d03d6a86331b4|4
Framingham score|men (>40 years) and women (>50 years)|Every two years in|545ec01598f749c59620827d64eb960a|4
HIV-specific calculators|alternatives|Provides|545ec01598f749c59620827d64eb960a|4
extensive risk assessment algorithm|drug sequencing algorithm|Includes|545ec01598f749c59620827d64eb960a|4
diagnostic criteria, risk assessment algorithm, and management algorithm|Risk assessment algorithm Yes|Yes;|545ec01598f749c59620827d64eb960a|4
drugs|cholesterol lowering drugs|interacting with ART|e9f792491a6647dcb0cb19eb3f250e17|4
ART|lowering drugs|interacting with|e9f792491a6647dcb0cb19eb3f250e17|4
British HIV Association|guidelines (2019 interim update)|recommended by|e9f792491a6647dcb0cb19eb3f250e17|4
69QRISK2|patients aged >40 years|for annually if no vascular disease|e9f792491a6647dcb0cb19eb3f250e17|4
vascular disease|no vascular disease|documented in the last 2 years (90%)|e9f792491a6647dcb0cb19eb3f250e17|4
Auditable targets|patients with a smoking history|include documented in last 2 years (90%)|e9f792491a6647dcb0cb19eb3f250e17|4
Annual screens|those with cardiovascular disease|for those with increased risk (10-year risk >10%)|e9f792491a6647dcb0cb19eb3f250e17|4
cardiovascular disease|increased risk|annual screens for at 10-year risk >10%|e9f792491a6647dcb0cb19eb3f250e17|4
cardiovascular disease|increased risk|Annual screens for those with established cardiovascular disease and at increased risk (10-year risk >10%)|c7e9863af40c4ce6b214f052b5d8029a|4
80 mg atorvastatin|Recommend all medications to be reviewed|high-dose (80 mg) atorvastatin for Recommend all medications to be reviewed|c7e9863af40c4ce6b214f052b5d8029a|4
potential drug–drug interactions|documented at each clinic visit|Recommend all medications to be reviewed and documented at each clinic visit|c7e9863af40c4ce6b214f052b5d8029a|4
Cardiovascular disease risk prediction|Tobacco|Cardiovascular disease risk prediction is affected by the presence of tobacco.|68ccc7f729ac42198ac5e3fda66b20cd|4
Cardiovascular disease risk prediction|Hypertension|Cardiovascular disease risk prediction is influenced by hypertension.|68ccc7f729ac42198ac5e3fda66b20cd|4
Cardiovascular disease risk prediction|Diabetes|Cardiovascular disease risk prediction is impacted by the presence of diabetes.|68ccc7f729ac42198ac5e3fda66b20cd|4
Cardiovascular disease risk prediction|Dyslipidaemia|Cardiovascular disease risk prediction is affected by dyslipidaemia.|68ccc7f729ac42198ac5e3fda66b20cd|4
Cardiovascular disease risk prediction|Drug interactions|Cardiovascular disease risk prediction may be influenced by drug interactions.|68ccc7f729ac42198ac5e3fda66b20cd|4
Established cardiovascular disease|ART|Established cardiovascular disease is related to antiretroviral therapy (ART).|68ccc7f729ac42198ac5e3fda66b20cd|4
NCEP|HIV-care guidelines|NCEP refers to HIV-care guidelines.|68ccc7f729ac42198ac5e3fda66b20cd|4
NHANES|National Health and Nutrition Examination Survey|is|875e5b56625f409fb31c593df1ec9974|4
ACC|American College of Cardiology|is|875e5b56625f409fb31c593df1ec9974|4
AHA|American Heart Association|is|875e5b56625f409fb31c593df1ec9974|4
ASCV|atherosclerotic cardiovascular disease|is|875e5b56625f409fb31c593df1ec9974|4
QRISK2|Quality Cardiovascular Risk Score 2|is|875e5b56625f409fb31c593df1ec9974|4
Author Manuscript|So-Armah et al.|authorship|61c8344660df49bdb13316c58314cd72|4
Author Manuscript|Page 32|reference to page number in author manuscript|61c8344660df49bdb13316c58314cd72|4
Table 3|Time trends of myocardial infarction incidence among people with HIV in high-income countries|title of table|61c8344660df49bdb13316c58314cd72|4
Number of people|with HIV|population affected by HIV|61c8344660df49bdb13316c58314cd72|4
HIV positive|effect estimate|estimated effect on HIV positive individuals|61c8344660df49bdb13316c58314cd72|4
HIV negative|effect estimate|estimated effect on HIV negative individuals|61c8344660df49bdb13316c58314cd72|4
Relative effect estimate|estimate by HIV|relative comparison between HIV positive and HIV negative individuals|61c8344660df49bdb13316c58314cd72|4
95% CI|(95% CI)|confidence interval for the study results|61c8344660df49bdb13316c58314cd72|4
Kaiser Permanente Southern California|and Northern California health plans|healthcare provider organization involved in the study|61c8344660df49bdb13316c58314cd72|4
1996–2011†|time period of the study|year range of study duration|61c8344660df49bdb13316c58314cd72|4
24 768|Number of AMI events|total number of acronym events|61c8344660df49bdb13316c58314cd72|4
2803|HIV positive effect estimate|estimated HIV positive effect on AMI incidence|61c8344660df49bdb13316c58314cd72|4
165|HIV negative effect estimate|estimated HIV negative effect on AMI incidence|61c8344660df49bdb13316c58314cd72|4
1996–2011|24 768 2803 268 165 1·4|time period and numbers related to the data|e6db3bd55c1d4542a539830cd0af28ab|4
1996–1999|276 136 1·8|time period and statistics for this specific era|e6db3bd55c1d4542a539830cd0af28ab|4
2000–2003|324 162 1·7|time period and statistics for this specific era|e6db3bd55c1d4542a539830cd0af28ab|4
2004–2007|270 178 1·3|time period and statistics for this specific era|e6db3bd55c1d4542a539830cd0af28ab|4
2008–2009|245 167 1·3|time period and statistics for this specific era|e6db3bd55c1d4542a539830cd0af28ab|4
2010–2011|195 165 1·0|time period and statistics for this specific era|e6db3bd55c1d4542a539830cd0af28ab|4
French hospital database on HIV|110|statistics related to the French hospital database|e6db3bd55c1d4542a539830cd0af28ab|4
2000–2002 early cART era|era43 628 132 men 196 148·0 1·35|time period, statistics, and related information for this cART era|e6db3bd55c1d4542a539830cd0af28ab|4
2003–2005 intermediate cART era|era51 007 205 men 229·5 133·4 1·74|time period, statistics, and related information for this cART era|e6db3bd55c1d4542a539830cd0af28ab|4
2006–2009 late cART era 58 866 259 men 185·2 161·1 1·12|era58 007 205 men 229·5 133·4 1·74|time period, statistics, and related information for this cART era|e6db3bd55c1d4542a539830cd0af28ab|4
2000-2002 early cART era|2003-2005 intermediate cART era|time sequence|e6f07b66c39f472fa587976d68e4bac2|4
2003-2005 intermediate cART era|2006-2009 late cART era|time sequence|e6f07b66c39f472fa587976d68e4bac2|4
Cohort of HIV adults of the AIDS research network (Spain)|HIV|participation in study|e6f07b66c39f472fa587976d68e4bac2|4
2004-2009 10 760 18 (HIV)|279 (265, 293)|measure of effect incidence rate per 100 000 person-years|e6f07b66c39f472fa587976d68e4bac2|4
2004-2009 10 760 18 (HIV)|199 (188, 209)|measure of effect incidence rate per 100 000 person-years|e6f07b66c39f472fa587976d68e4bac2|4
2010-2015 10 760 34 (HIV)|222 (211, 233)|measure of effect incidence rate per 100 000 person-years|e6f07b66c39f472fa587976d68e4bac2|4
2010-2015 10 760 34 (HIV)|173 (163, 183)|measure of effect incidence rate per 100 000 person-years|e6f07b66c39f472fa587976d68e4bac2|4
Measure of effect was the incidence rate per 100 000 person-years|1.41 (1.26–1.55)|statistical comparison|e6f07b66c39f472fa587976d68e4bac2|4
Measure of effect was the incidence rate per 100 000 person-years|1.28 (1.15–1.43)|statistical comparison|e6f07b66c39f472fa587976d68e4bac2|4
AMI events|people with HIV|occurred among|bcc29d19d5b049a39e340530074f2449|4
standardised incidence rate|men|Measure of effect was the|bcc29d19d5b049a39e340530074f2449|4
acute myocardial infarction|general Spanish male population|vs|bcc29d19d5b049a39e340530074f2449|4
Send Orders for Reprints|reprints@benthamscience.ae|to send orders to this email address|b9bd5857d8514736aa3a99919018bd44|4
Reprints|Bentham Science Publishers|Publishing company for reprints|b9bd5857d8514736aa3a99919018bd44|4
Current Cardiology Reviews|2018, 14, 153-163|Journal reference and pages|b9bd5857d8514736aa3a99919018bd44|4
Review Article|Current Cardiology Reviews|type of article in the journal|b9bd5857d8514736aa3a99919018bd44|4
153 REVIEW ARTICLE|Current Cardiology Reviews 2018, 14, 153-163|specific article reference|b9bd5857d8514736aa3a99919018bd44|4
1573-403X/18 $58.00+.00|Current Cardiology Reviews 2018, 14, 153-163|article price|b9bd5857d8514736aa3a99919018bd44|4
Current Cardiology Reviews 2018, 14, 153-163|Bentham Science Publishers|Published by Bentham Science Publishers|b9bd5857d8514736aa3a99919018bd44|4
Managing Measurable Variable Cardiovascular Disease' Risk Factors|Title of the review article|title of the reviewed article|b9bd5857d8514736aa3a99919018bd44|4
Sonja Frančula-Zaninović1,* and Iskra A. Nola2|Authors of the article|authors of the reviewed article|b9bd5857d8514736aa3a99919018bd44|4
Health Care Center Zagreb, Laginjina 16, Zagreb, Croatia|Affiliation of Sonja Frančula-Zaninović|affiliation of the first author|b9bd5857d8514736aa3a99919018bd44|4
Andrija Stampar School of Public Health, School of Medicine, University of Zagreb, Zagreb, Croatia|Affiliation of Iskra A. Nola|affiliation of the second author|b9bd5857d8514736aa3a99919018bd44|4
Variable cardiovascular risk factors|Their management|in everyday practice|120a510e37304d94b2033370da59ecb8|4
Aim|Summary|main findings on variable cardiovascular risk factors and their management in everyday practice|120a510e37304d94b2033370da59ecb8|4
variable cardiovascular risk factors|prevention of cardiovascular disease development|causation|eec9c86a64234ea49f46b491f972dd32|4
informative papers|exact measures for each variable risk factor|contrast|eec9c86a64234ea49f46b491f972dd32|4
everyday practice of family practitioners and cardiologists|incorporate in|action|eec9c86a64234ea49f46b491f972dd32|4
cardiologists|community|multidisciplinary team|7b8cd877ea5d46f9ac91b091244b3931|4
governmental and non-governmental organizations|improving the lifestyle of individuals and the entire community|contribute to|7b8cd877ea5d46f9ac91b091244b3931|4
cardiovascular disease prevention|multidisciplinary team of experts|should include|7b8cd877ea5d46f9ac91b091244b3931|4
individual risk factors|recognizing individual risk factors|most important factors in cardiovascular disease management|7b8cd877ea5d46f9ac91b091244b3931|4
monitoring them|most important factors in cardiovascular disease management|and assisting|7b8cd877ea5d46f9ac91b091244b3931|4
risk factors|monitoring them|directly affect the defined risk factors of a patient|c3af059769eb4cecbe30700d018f64a7|4
guidelines for CV prevention|national, cultural and socioeconomic aspects|needed in accordance with|c3af059769eb4cecbe30700d018f64a7|4
Keywords: Mortality and morbidity|Cardiovascular Diseases (CVDs)|related to|c3af059769eb4cecbe30700d018f64a7|4
dyslipidemia|obesity|risk factors for Cardiovascular Diseases|c3af059769eb4cecbe30700d018f64a7|4
smoking|sedentary lifestyle|risk factors for Cardiovascular Diseases|c3af059769eb4cecbe30700d018f64a7|4
arterial hypertension|diabetes mellitus|risk factors for Cardiovascular Diseases|c3af059769eb4cecbe30700d018f64a7|4
Cardiovascular Diseases (CVD)|heart and circulatory system disorders|are|5636167f693144289a43090a80fe2bf9|4
Cardiovascular Diseases (CVD)|atherosclerosis|underlying cause of development is most often|5636167f693144289a43090a80fe2bf9|4
Cardiovascular Diseases (CVD)|chronic diseases|are|5636167f693144289a43090a80fe2bf9|4
Cardiovascular Diseases (CVD)|asymptomatic for a long time|usually only the advanced disease causes symptoms or the first symptom can be sudden death|5636167f693144289a43090a80fe2bf9|4
Cardiovascular Diseases (CVD)|premature mortality across|leading cause of for years|5636167f693144289a43090a80fe2bf9|4
CVD|premature mortality|leading cause|5858afe30c1d44558b8f8632fc6ad382|4
CVD|mortality rate|mild tendency to decrease|5858afe30c1d44558b8f8632fc6ad382|4
CVD|Europe|occurs in|5858afe30c1d44558b8f8632fc6ad382|4
CVD|DALYS|most important cause of|5858afe30c1d44558b8f8632fc6ad382|4
CVD|public health importance|great public health importance on this topic|5858afe30c1d44558b8f8632fc6ad382|4
CVD|€ 192 billion|approximately € 192 billion is the|5858afe30c1d44558b8f8632fc6ad382|4
cost of annual health care for CVD|CVD in the European Union|is|7d195a7264ce4966b18586d29bf4e72b|4
Health Care Center Zagreb|author|by|7d195a7264ce4966b18586d29bf4e72b|4
multiple factors|CVD|are caused by|7d195a7264ce4966b18586d29bf4e72b|4
age|factor|is invariable|7d195a7264ce4966b18586d29bf4e72b|4
gender|factor|is invariable|7d195a7264ce4966b18586d29bf4e72b|4
genetic heritage|factor|is invariable|7d195a7264ce4966b18586d29bf4e72b|4
smoking tobacco|variable factor|can be affected|7d195a7264ce4966b18586d29bf4e72b|4
physical inactivity|variable factor|can be affected|7d195a7264ce4966b18586d29bf4e72b|4
poor eating habits|variable factor|can be affected|7d195a7264ce4966b18586d29bf4e72b|4
physical inactivity|poor eating habits|both are mentioned as risk factors for cardiovascular disease (CVD) in the context|030fa1f4780d4478867ffb13a918851f|4
physical inactivity|elevated blood pressure|physical inactivity can lead to elevated blood pressure, as mentioned in the context|030fa1f4780d4478867ffb13a918851f|4
poor eating habits|type 2 diabetes|poor eating habits can cause type 2 diabetes, as mentioned in the context|030fa1f4780d4478867ffb13a918851f|4
physical inactivity|CVD treatment|physical inactivity is mentioned as one of the factors contributing to CVD treatment|030fa1f4780d4478867ffb13a918851f|4
Prevention of CVD|CVD incidence and their consequences|relationship between preventing and eliminating/reducing CVD incidence|705c84ed714d42fe91d0ad1ccbc27c79|4
Expert Committee for the Prevention of the CVD|WHO|established in 1982|705c84ed714d42fe91d0ad1ccbc27c79|4
Prevention strategy|3 components|strategy has 3 components|705c84ed714d42fe91d0ad1ccbc27c79|4
Population strategy|Lifestyle habits and environmental factors|affect these activities at the level of the entire population|7d57cd93bd6e4101a876d72f6789f4d8|4
Population strategy|Socioeconomic determinants|may cause CVD development|7d57cd93bd6e4101a876d72f6789f4d8|4
Secondary prevention|Prevention of the occurrence or reoccurrence and progression of disease|in|7d57cd93bd6e4101a876d72f6789f4d8|4
reoccurrence|disease in patients with already proven CVD|causative relationship between the disease and its reoccurrence|e76cf8b448f34c90936c535667807138|4
High-risk strategy|individuals|strategy directed at individuals|e76cf8b448f34c90936c535667807138|4
Population strategy|community|focused on the entire community|e76cf8b448f34c90936c535667807138|4
population strategy|Europe, state, region and local community|integral part of policies at different levels|e76cf8b448f34c90936c535667807138|4
Population approach|clinical approach|should be complementary|e76cf8b448f34c90936c535667807138|4
CVD|Europe|population strategy for reducing the incidence|0414eedd67e94c91b7adedc3f33436c9|4
political activities|lifestyle habits|focusing on determinants of illness through political activities|0414eedd67e94c91b7adedc3f33436c9|4
smokers|physical activity|reducing the number of smokers and increasing physical activity|0414eedd67e94c91b7adedc3f33436c9|4
healthy living habits|European Cardiology guidelines|promoting healthy living habits as per guidelines|0414eedd67e94c91b7adedc3f33436c9|4
European Cardiology Society (ESC)|CVD Prevention|latest guidelines|761528eb89e242078449b972d8a6e2ea|4
population approach|prevention|focus on the population approach to prevention|761528eb89e242078449b972d8a6e2ea|4
female population|prevention|younger individuals and ethnic minorities|761528eb89e242078449b972d8a6e2ea|4
CVD Prevention measures|everyday medical work|must be an integral part|761528eb89e242078449b972d8a6e2ea|4
CVD prevention|optimal results|important for everyday medical work|2f7b4fbadf2543889be4b51842e10dd0|4
CVD prevention|CVD prevention guidelines|provide the procedures|2f7b4fbadf2543889be4b51842e10dd0|4
CVD prevention guidelines|health policies|consider individual countries' health policies|2f7b4fbadf2543889be4b51842e10dd0|4
CVD prevention guidelines|incidence of CVD in individual countries|based on the incidence in those countries|2f7b4fbadf2543889be4b51842e10dd0|4
CVD prevention guidelines|unambiguous access to patients|to achieve unambiguous access to patients|2f7b4fbadf2543889be4b51842e10dd0|4
consistent approach|defined monitoring parameters|based on a consistent approach|2f7b4fbadf2543889be4b51842e10dd0|4
risk assessment|individual's risk assessment|used in one sentence|f293301f1d6e4c64821875fa7f150779|4
goal of clinical and population preventative strategies|Reduction of CVD morbidity and mortality|used in one sentence|f293301f1d6e4c64821875fa7f150779|4
multifactorial|CVD are multifactorial|used in same sentence|f293301f1d6e4c64821875fa7f150779|4
monitoring parameters|defined monitoring parameters|used in one sentence|f293301f1d6e4c64821875fa7f150779|4
algorithm|algorithm according to ESC|used in one sentence|f293301f1d6e4c64821875fa7f150779|4
algorithm|professionals|according to|46fae8445e514d91aa2bf025216033b5|4
professionals|ESC guide-lines|in their work on CVD prevention|46fae8445e514d91aa2bf025216033b5|4
first ESC pre-vention guidelines|1994|were published in|46fae8445e514d91aa2bf025216033b5|4
multiple risk factors|risk of CVD|multiplies|46fae8445e514d91aa2bf025216033b5|4
risk of myocardial in-farction|progressively increases|[13-17]|46fae8445e514d91aa2bf025216033b5|4
CVD risk estimate|optimal management|of|46fae8445e514d91aa2bf025216033b5|4
optimal management|prevention and treatment|management refers to the most importance in prevention and treatment|c7a08ab1e39a4a188d0766631c5b9093|4
Stratification of CVD risk|people who do not yet have manifest atherosclerotic disease but can develop CVD|stratification is important because there are people with potential CVD risk|c7a08ab1e39a4a188d0766631c5b9093|4
Total CVD risk|individual is likely to develop a fatal cardiovascular event for a certain period of time|total CVD risk refers to an individual's likelihood of developing a fatal cardiovascular event|c7a08ab1e39a4a188d0766631c5b9093|4
physician|quick decision on further treatment|physician should make a quick decision on further treatment based on total CVD risk|c7a08ab1e39a4a188d0766631c5b9093|4
increased risk for developing CVD|monitoring models|help diagnose and monitor|b3cf0e534ca943c48f73299917c9b457|4
Systemic Coronary Risk Estimation (SCORE) tables|Europe|used in today in the form of Systemic Coronary Risk Estimation (SCORE) tables|b3cf0e534ca943c48f73299917c9b457|4
people without known CVD|SCORE tables|used for|b3cf0e534ca943c48f73299917c9b457|4
high CVD risk|group of people with already manifest atherosclerotic vascular disease|should be treated|b3cf0e534ca943c48f73299917c9b457|4
SCORE table|Recommendations|Used for|81939924486a40b281f72d4a31469913|4
Apparently healthy adults|without signs of CVD, Diabetes Mellitus (DM), chronic kidney dis-ease, familial hypercholesterolemia|Priory for intensive counseling on risk factors|81939924486a40b281f72d4a31469913|4
Total ten-year risk of death|by sex, smoking, age, systolic blood pressure and total cholesterol|Evaluate for each individual|81939924486a40b281f72d4a31469913|4
Low risk individuals|evaluate for each individual the total ten-year risk of death by sex, smoking, age, systolic blood pressure and total cholesterol.|For|81939924486a40b281f72d4a31469913|4
total cholesterol|Low risk individuals|maintain such status|248ebd1942814c42b0696d08b86399cc|4
estimated risk >5%|those with an estimated risk >5%|dedicate particular attention to reduce it|248ebd1942814c42b0696d08b86399cc|4
cholesterol, smoking status and systolic pressure|The effect of these factors|can be estimated from the table|248ebd1942814c42b0696d08b86399cc|4
treatment strategy|The decision on treatment strategy depends on|the initial risk level|248ebd1942814c42b0696d08b86399cc|4
initial risk level|Categorization into different groups of total CVD risks|is agreed but is recommended for its|248ebd1942814c42b0696d08b86399cc|4
CVD risks|simplicity|agreed for|080325de3c7d40cd98e0ab3bf001ce8f|4
total CVD risk|higher|may be|080325de3c7d40cd98e0ab3bf001ce8f|4
individual|older age group|moves to|080325de3c7d40cd98e0ab3bf001ce8f|4
asymptomatic patients|atherosclerotic disease|with signs of|080325de3c7d40cd98e0ab3bf001ce8f|4
individuals|significant positive family history|of early cardiovascular deaths|080325de3c7d40cd98e0ab3bf001ce8f|4
individuals|low high density lipoproteins (HDL) cholesterol|with|080325de3c7d40cd98e0ab3bf001ce8f|4
individuals|high triglycerides|glucose|080325de3c7d40cd98e0ab3bf001ce8f|4
HDL cholesterol|high triglycerides|are mentioned in the same sentence as being risk factors|585a310b7f0c49789765eb26138b81c5|4
glucose intolerance|elevated CRP|are mentioned in the same sentence as being risk factors|585a310b7f0c49789765eb26138b81c5|4
elevated fibrogen|elevated homocysteine|are mentioned in the same sentence as being risk factors|585a310b7f0c49789765eb26138b81c5|4
elevated APOB|elevated lipoproteins|are mentioned in the same sentence as being risk factors|585a310b7f0c49789765eb26138b81c5|4
obese people|sedentary lifestyle|are mentioned in the same sentence as contributing to risk factors|585a310b7f0c49789765eb26138b81c5|4
CVD Measurable Risk Factors|Current Cardiology Reviews|is a publication of|331681abd0014a0288f1b2c98eb7dc32|4
Vol. 14, No. 3|CVD Measurable Risk Factors|is the volume and issue of the publication|331681abd0014a0288f1b2c98eb7dc32|4
2018|Vol. 14, No. 3|is the year of publication|331681abd0014a0288f1b2c98eb7dc32|4
155|Vol. 14, No. 3|is the page number|331681abd0014a0288f1b2c98eb7dc32|4
Fig. (1). SCORE chart:|CVD Measurable Risk Factors|contains a figure|331681abd0014a0288f1b2c98eb7dc32|4
10-year risk of fatal cardiovascular disease (CVD)|SCORE chart:|is the subject of the chart|331681abd0014a0288f1b2c98eb7dc32|4
high CVD risk|countries|are countries with high CVD risk|331681abd0014a0288f1b2c98eb7dc32|4
2016 European Guidelines on cardiovascular disease pre-vention in clinical practice|Source:|is the source of the SCORE chart|331681abd0014a0288f1b2c98eb7dc32|4
available at:|https://academic.oup.com/eurheartj/article/37/29/2315/1748952/2016-European-Guidelines-on-cardiovascular-disease|is the location to access the publication|331681abd0014a0288f1b2c98eb7dc32|4
efforts toward those who will be most likely to bene-fit|reassurance and avoidance of side ef-fects in lower-risk persons who will derive less benefit|different approaches based on risk|fe9db32e55b94bf7bb8a1602ac64cb0d|4
The second|CVD is the product of more than 1 risk factors|different aspects of cardiovascular disease|fe9db32e55b94bf7bb8a1602ac64cb0d|4
A combination of several factors result in much higher total risk|SCORE system help to es-timate total risk|estimating the total risk using a scoring system|fe9db32e55b94bf7bb8a1602ac64cb0d|4
young person|relative risk esti-mation|using relative risk estimation for young people|fe9db32e55b94bf7bb8a1602ac64cb0d|4
high relative risk|CVD|relationship between the two concepts, high relative risk in one or two sentences|b5f032b8a03046f98d21175cafb996f3|4
risk evaluation and management|primary prevention of CVD|relationship between the two concepts, risk evaluation and management in one or two sentences|b5f032b8a03046f98d21175cafb996f3|4
CVD risk factors|atherosclerosis|relationship between the two concepts, CVD risk factors in one or two sentences|b5f032b8a03046f98d21175cafb996f3|4
invariable risk factors|age and gender|relationship between the two concepts, invariable risk factors in one or two sentences|b5f032b8a03046f98d21175cafb996f3|4
age and gender|men over age 45 and women over 55 years|Variable risk factors are determined based on.|43453d2f8a514c80a33aa1ad87dde623|4
inherited-positive family history|menopause in women|Both factors contribute to determining variable risk factors.|43453d2f8a514c80a33aa1ad87dde623|4
smoking|inadequate physical activity|These are bad habits that can be influenced and changed.|43453d2f8a514c80a33aa1ad87dde623|4
elevated blood pressure|increased body weight (obesity)|Both contribute to the variable risk factors for CVD morbidity and mortality.|43453d2f8a514c80a33aa1ad87dde623|4
increased levels of fat in the blood (cholesterol, triglyceride)|DM|Both contribute to the variable risk factors for CVD morbidity and mortality.|43453d2f8a514c80a33aa1ad87dde623|4
Variable risk factors|CVD morbidity and mortality|Goal of managing variable risk factors is to reduce them.|43453d2f8a514c80a33aa1ad87dde623|4
CVD morbidity and mortality|re-duce|to reduce CVD morbidity and mortality.|748fc0ae4f9540b99b2387c5ec4e9efe|4
Clinical studies|Framingham, Multiple Risk Factor Intervention Trial (MRFIT) [21], Asia Pacific Cohort Studies Collaboration (APCSC) [22], INTERHEART [23]|have been conducted|748fc0ae4f9540b99b2387c5ec4e9efe|4
Multiple risk factors|multiply CVD risk|are associated with an increased risk of CVD|748fc0ae4f9540b99b2387c5ec4e9efe|4
Myocardial infarction|risk progressively increases|the risk of myocardial infarction increases as more risk factors are present|748fc0ae4f9540b99b2387c5ec4e9efe|4
CVD|multifac-torial diseases|are influenced by multiple factors|748fc0ae4f9540b99b2387c5ec4e9efe|4
Monitoring|several levels|should be conducted at various levels|748fc0ae4f9540b99b2387c5ec4e9efe|4
Diagnosis and monitoring|important estimate of variable risk factors|help determine the risk factor variables|748fc0ae4f9540b99b2387c5ec4e9efe|4
variable risk factors|diagnosis, monitoring and treatment|are in|c6cdcb69a6b34d12a32c3734ee4839f8|4
INTERHEART|major inter-national clinical study|is a|c6cdcb69a6b34d12a32c3734ee4839f8|4
52 countries|included in the study|participated in|c6cdcb69a6b34d12a32c3734ee4839f8|4
results of INTERHEART|published in 2004|were published in|c6cdcb69a6b34d12a32c3734ee4839f8|4
European Society of Cardiology (ESC) Guidelines|recommendations are based on|according to|c6cdcb69a6b34d12a32c3734ee4839f8|4
Cardiology (ESC) Guidelines|recommendations|are given for managing variable CVD risk fac-tors in the way presented below|77909c09c6bb4f1895dfd4edfd5ebec6|4
4.1. Smoking|Smoking cigarettes|is a dominant risk factor for cardio-vascular and non-cardiovascular mortality and morbidity|77909c09c6bb4f1895dfd4edfd5ebec6|4
smoking cigarettes|estimated 1.6 billion smokers in the world|by the year 2025, there will be|77909c09c6bb4f1895dfd4edfd5ebec6|4
estimated 1.6 billion smokers in the world|10 million people a year will die for smoking|it is estimated that|77909c09c6bb4f1895dfd4edfd5ebec6|4
smoking cigarettes|rise in smokers among women and adolescents in Europe|Unfortunately, there is still a rise in smokers among women and adolescents in Europe|77909c09c6bb4f1895dfd4edfd5ebec6|4
Cardiology (ESC) Guidelines|managing variable CVD risk factors|recommendations are given for managing variable CVD risk fac-tors in the way presented below|77909c09c6bb4f1895dfd4edfd5ebec6|4
women and adolescents|Europe|Location|e551275ff8e54e718b528361af682d5d|4
ten-year risk|fatal cardiovascular events|Relation|e551275ff8e54e718b528361af682d5d|4
smokers|risk of fatal cardiovascular events|Effect|e551275ff8e54e718b528361af682d5d|4
ten-year risk|smokers|Effect|e551275ff8e54e718b528361af682d5d|4
passive smoking|CVD|Increases Risk|e551275ff8e54e718b528361af682d5d|4
risk of CVD|smokers|Effect|e551275ff8e54e718b528361af682d5d|4
Smoking|preventable risk factor|is a|3f1c3ab98cbc4966a0dd1da4c98ee17d|4
Smoking|greatest contribution in the development of CVD|has|3f1c3ab98cbc4966a0dd1da4c98ee17d|4
physician|reduce|tend to|3f1c3ab98cbc4966a0dd1da4c98ee17d|4
measures|help the patient|are used to|3f1c3ab98cbc4966a0dd1da4c98ee17d|4
recommendations|range from individual approaches through group therapies to medication approaches|can include|3f1c3ab98cbc4966a0dd1da4c98ee17d|4
self-help technique|recommendation|is a|3f1c3ab98cbc4966a0dd1da4c98ee17d|4
individual advisory|recommendation|is a|3f1c3ab98cbc4966a0dd1da4c98ee17d|4
group|therapies|are part of|3f1c3ab98cbc4966a0dd1da4c98ee17d|4
medication approaches|recommendation|is a|3f1c3ab98cbc4966a0dd1da4c98ee17d|4
Individual advisory|Group therapy|promoting non-smoking includes social programs|c8a4be9bc9bc43c5b224f042485edcb3|4
Substitution therapy with nicotine|Antidepressants|smoking cessation and nicotine up-set can provoke depression|c8a4be9bc9bc43c5b224f042485edcb3|4
smoking ban|public health measures and legislation|part of the public health measures and legislation|6d046c4c31304c5bb5f2ccce5a4d5e73|4
tobacco tax|public health measures and legislation|part of the public health measures and legislation|6d046c4c31304c5bb5f2ccce5a4d5e73|4
media campaigns|public health measures and legislation|part of the public health measures and legislation|6d046c4c31304c5bb5f2ccce5a4d5e73|4
youth smoking|High taxes on all tobacco products|effective measure to reduce youth smoking|6d046c4c31304c5bb5f2ccce5a4d5e73|4
children in schools|healthy life-style habits|where children should be taught with healthy life-style habits|6d046c4c31304c5bb5f2ccce5a4d5e73|4
noxiousness smoking lectures|healthy life-style habits|included in the teaching of healthy life-style habits|6d046c4c31304c5bb5f2ccce5a4d5e73|4
smoking|young people|recommended to not start or stop|34cabee536be4e7fb1793657efaa74ae|4
CVD development|physical inactivity|risk factor for|34cabee536be4e7fb1793657efaa74ae|4
chronic diseases|physical inactivity|development of a number of other|34cabee536be4e7fb1793657efaa74ae|4
CVD risk|sedentary lifestyle|increased by 1.5 times in people living|34cabee536be4e7fb1793657efaa74ae|4
deaths per year|physical inactivity|causes 2 million|34cabee536be4e7fb1793657efaa74ae|4
deaths per year|ischemic heart dis-ease|cause and effect|9d436967b6a94a7498f1fa223bc6f1fd|4
physical inactivity of young people|higher increase in CVD|cause and effect|9d436967b6a94a7498f1fa223bc6f1fd|4
regular physical activity|reduction of already existing vascular lesions|effect|9d436967b6a94a7498f1fa223bc6f1fd|4
regular physical activity|other risk factors|affects|9d436967b6a94a7498f1fa223bc6f1fd|4
regular physical activity|coronary dis-ease|decreases the incidence of|9d436967b6a94a7498f1fa223bc6f1fd|4
dis-ease|atherosclerosis|reduces the progression|408a0393df7640d2a20cb02a17f4eaff|4
dis-ease|oxidative stress|protects the patient from|408a0393df7640d2a20cb02a17f4eaff|4
dis-ease|insulin sensitivity|increases|408a0393df7640d2a20cb02a17f4eaff|4
dis-ease|malignant arrhythmias|decreases the incidence of|408a0393df7640d2a20cb02a17f4eaff|4
dis-ease|vegetative system|balances|408a0393df7640d2a20cb02a17f4eaff|4
physical activity|childhood|should start in|408a0393df7640d2a20cb02a17f4eaff|4
physical activity|age groups|is important in all|408a0393df7640d2a20cb02a17f4eaff|4
physical activity|preventative CVD measures|part of|408a0393df7640d2a20cb02a17f4eaff|4
cardiovascular patients|acute coronary syndrome|especially after|408a0393df7640d2a20cb02a17f4eaff|4
acute coronary syndrome|coronary arteries or heart surgery|intervention on the coronary arteries or heart surgery after acute coronary syndrome|bd2295ca19f14ae783c6aaaa7650a800|4
CVD rehabilitation program|patient|should undergo a CVD rehabilitation program during which they will be monitored|bd2295ca19f14ae783c6aaaa7650a800|4
ECG|treadmill bicycle exercise|tested using treadmill bicycle exercise with Electrocardiography (ECG)|bd2295ca19f14ae783c6aaaa7650a800|4
blood pressure monitoring|ECG and blood pressure monitoring|monitoring, and tested using treadmill bicycle exercise with Electrocardiography (ECG) and blood pressure monitoring|bd2295ca19f14ae783c6aaaa7650a800|4
pulse monitor|patient frequency|patient should monitor his fre-quency on the pulse monitor while exercising at home|bd2295ca19f14ae783c6aaaa7650a800|4
coronary patients with low clinical risk|moderately or intensively exercise|coronary patients with low clinical risk should moderately or intensively exercise 30 minutes 3 to 5 times a week|bd2295ca19f14ae783c6aaaa7650a800|4
Coronary|exercise|coronary patients with low clinical risk should exercise 30 minutes 3 to 5 times a week|bd2295ca19f14ae783c6aaaa7650a800|4
exercise|30 minutes|duration for exercise|e323eee6acec48268aff5c073d979acb|4
exercise|3 to 5 times a week|frequency of exercise|e323eee6acec48268aff5c073d979acb|4
coronary patients|moderate to high clinical risk|condition or state they are in|e323eee6acec48268aff5c073d979acb|4
heaviest patients|benefit from low intensity exercise|can perform low intensity exercise|e323eee6acec48268aff5c073d979acb|4
low intensity exercise|under the supervision of experts|requirement for supervision|e323eee6acec48268aff5c073d979acb|4
exercising|encourages self-reliance and reduces depression|benefits of exercising|e323eee6acec48268aff5c073d979acb|4
regular exercise|important in primary and secondary CVD prevention|significance of regular exercise|e323eee6acec48268aff5c073d979acb|4
determining the intensity of exercise|before starting the exercise|need to determine exercise intensity beforehand|e323eee6acec48268aff5c073d979acb|4
intensity of the exercise|CV risk|important to stratify|7b45e09f516042148f85e6d301ef4dd5|4
ESC Guidelines|recommendations|According to|7b45e09f516042148f85e6d301ef4dd5|4
healthy adults all ages|ages of 2.5 to 5h a week|of moder-ate physical activity|7b45e09f516042148f85e6d301ef4dd5|4
healthy adults all ages|1 to 2.5h per week|of intense physical activity|7b45e09f516042148f85e6d301ef4dd5|4
healthy adults sedentary lifestyle|light exercise intensity|should be encouraged to start with|7b45e09f516042148f85e6d301ef4dd5|4
patients coronary heart disease myocardial|coronary heart disease|Patients with|7b45e09f516042148f85e6d301ef4dd5|4
coronary heart disease|myocardial infarction|Patients with coronary heart disease (myocardial in-farction, after aortic coronary bypass or coronary intervention with stable angina pectoris, with stable heart failure) need 3 or more times a week moderate to intense aerobic exercise for 30 minutes.|d6288066949249a5a7acc95398390be5|4
coronary heart disease|aortic coronary bypass|Patients with coronary heart disease (myocardial in-farction, after aortic coronary bypass or coronary intervention with stable angina pectoris, with stable heart failure) need 3 or more times a week moderate to intense aerobic exercise for 30 minutes.|d6288066949249a5a7acc95398390be5|4
coronary heart disease|coronary intervention|Patients with coronary heart disease (myocardial in-farction, after aortic coronary bypass or coronary intervention with stable angina pectoris, with stable heart failure) need 3 or more times a week moderate to intense aerobic exercise for 30 minutes.|d6288066949249a5a7acc95398390be5|4
coronary heart disease|stable angina pectoris|Patients with coronary heart disease (myocardial in-farction, after aortic coronary bypass or coronary intervention with stable angina pectoris, with stable heart failure) need 3 or more times a week moderate to intense aerobic exercise for 30 minutes.|d6288066949249a5a7acc95398390be5|4
coronary heart disease|stable heart failure|Patients with coronary heart disease (myocardial in-farction, after aortic coronary bypass or coronary intervention with stable angina pectoris, with stable heart failure) need 3 or more times a week moderate to intense aerobic exercise for 30 minutes.|d6288066949249a5a7acc95398390be5|4
coronary heart disease|light exercise|Patients with coronary heart disease conducting a sedentary lifestyle should begin with light exercise af-ter CVD risk assessing.|d6288066949249a5a7acc95398390be5|4
coronary heart disease|CVD risk assessing|Patients with coronary heart disease conducting a sedentary lifestyle should begin with light exercise af-ter CVD risk assessing.|d6288066949249a5a7acc95398390be5|4
blood pressure|persistent blood pressure 140/90 mmHg|Blood pressure (BP) is commonly defined as persistent blood pressure 140/90 mmHg and above,|d6288066949249a5a7acc95398390be5|4
blood pressure|coronary heart disease|Patients with coronary heart disease should begin with light exercise af-ter CVD risk assessing.|d6288066949249a5a7acc95398390be5|4
persistent blood pressure 140/90 mmHg and above|one quarter of the adult population|affects|9473f0ea1cce4feebd7be6e5be7c0f98|4
arterial hypertension (AH)|most important preventable factors of premature mortality in the world|is one of|9473f0ea1cce4feebd7be6e5be7c0f98|4
arterial hypertension (AH)|most important independent risk factor of CVD|is|9473f0ea1cce4feebd7be6e5be7c0f98|4
more than 30% of adults|suffer from AH in most developed countries|in|9473f0ea1cce4feebd7be6e5be7c0f98|4
arterial hypertension (AH)|risk factor of CVD, but also mortality from coronary illness or|is a|9473f0ea1cce4feebd7be6e5be7c0f98|4
CVD|coronary illness|affects|ba0c0cc3b734482b9625bc00af73501c|4
CVD|stroke|affects|ba0c0cc3b734482b9625bc00af73501c|4
CVD risk|increase in BP|doubled with every increase|ba0c0cc3b734482b9625bc00af73501c|4
diastolic for 10 mmHg|systolic for 20 mmHg|for each increase|ba0c0cc3b734482b9625bc00af73501c|4
ESC guidelines|Classification of BP and AH|according to|ba0c0cc3b734482b9625bc00af73501c|4
Optimal BP|1st degree AH|range for|ba0c0cc3b734482b9625bc00af73501c|4
Normal BP|Highly Normal BP|range for|ba0c0cc3b734482b9625bc00af73501c|4
1st degree AH|2nd degree AH|range for|ba0c0cc3b734482b9625bc00af73501c|4
CVD Measurable Risk Factors|Current Cardiology Reviews|is a publication in|c20c2bbc85ba423ebb0a4c64cf758931|4
2018, Vol. 14, No. 3|CVD Measurable Risk Factors Current Cardiology Reviews|is a part of|c20c2bbc85ba423ebb0a4c64cf758931|4
2017 American Heart Association (AHA) Guidelines|for high blood pressure in adults|are based on|c20c2bbc85ba423ebb0a4c64cf758931|4
AH|and BP|are both considered as|c20c2bbc85ba423ebb0a4c64cf758931|4
Systolic BP (mmHg)|Diastolic BP (mmHg)|are the classifications for blood pressure|c20c2bbc85ba423ebb0a4c64cf758931|4
Normal BP|<120 and <80|is defined by|c20c2bbc85ba423ebb0a4c64cf758931|4
Elevated BP|120-129 and <80|is defined by|c20c2bbc85ba423ebb0a4c64cf758931|4
Stage 1|130-139 or 80-89 AH|is defined by|c20c2bbc85ba423ebb0a4c64cf758931|4
Stage 2|≥140 and ≥90|is defined by|c20c2bbc85ba423ebb0a4c64cf758931|4
AH|to prevent|it is important to|c20c2bbc85ba423ebb0a4c64cf758931|4
AH|measures in childhood|to prevent|4f427010f962479bab5cfc67cb710c85|4
BP|life habits and pharmacotherapy|can be reduced by changing|4f427010f962479bab5cfc67cb710c85|4
reduced intake of salt in food|life habits in BP reduction|include|4f427010f962479bab5cfc67cb710c85|4
decrease in intake of alcoholic beverages|life habits in BP reduction|include|4f427010f962479bab5cfc67cb710c85|4
Mediterranean diet type|life habits in BP reduction|include|4f427010f962479bab5cfc67cb710c85|4
increased physical activity|life habits in BP reduction|include|4f427010f962479bab5cfc67cb710c85|4
smoking cessation|life habits in BP reduction|include|4f427010f962479bab5cfc67cb710c85|4
body weight regulation|life habits in BP reduction|include|4f427010f962479bab5cfc67cb710c85|4
Healthy Lifestyle|Smoking Cessation|recommended by AHA guidelines|5d8c7e7b49e944bdbd7b8159c0cf41fd|4
Healthy Lifestyle|Body Weight Regulation|part of a healthy lifestyle|5d8c7e7b49e944bdbd7b8159c0cf41fd|4
ESC Guidelines|Lower BP to 140/90 mmHg|goal for patients without diabetes|5d8c7e7b49e944bdbd7b8159c0cf41fd|4
ESC Guidelines|Lower than 140/85 mmHg|goal for diabetics|5d8c7e7b49e944bdbd7b8159c0cf41fd|4
Pharmacotherapy|Estimated total CVD risk|depends on|5d8c7e7b49e944bdbd7b8159c0cf41fd|4
Pharmacotherapy|Degree of AH|depends on|5d8c7e7b49e944bdbd7b8159c0cf41fd|4
Anti-hypertensive|Choice|depends on the already present disease|5d8c7e7b49e944bdbd7b8159c0cf41fd|4
Already Present Disease|Pharmacotherapy|starts immediately|5d8c7e7b49e944bdbd7b8159c0cf41fd|4
AHA guidelines|healthy lifestyle recommendation|recommend|da3f1d1c45964db38032b9ae3e250f23|4
AH stage 1|one BP lowering medication|for patients with|da3f1d1c45964db38032b9ae3e250f23|4
AH stage 1|10-year risk for heart disease and stroke assessment|>10% or they have CVD, diabetes mellitus or chronic kidney disease|da3f1d1c45964db38032b9ae3e250f23|4
AH stage 2|two medications of different class|recommended immediately for patients with|da3f1d1c45964db38032b9ae3e250f23|4
eating habits|CVD risk|well-known association between|da3f1d1c45964db38032b9ae3e250f23|4
CVD risk|Seven Countries Study|Proves connection between poor eating habits and onset of ischemic heart disease|b001f9bc99e24c23bf531788cebb3ba2|4
Poor eating habits|Food rich in saturated fats|Causes correlation with onset of ischemic heart disease|b001f9bc99e24c23bf531788cebb3ba2|4
Healthy nutrition|CV prevention|Basis for preventing cardiovascular diseases|b001f9bc99e24c23bf531788cebb3ba2|4
Food habits|Level of fat and blood sugar, BP, body weight|Affecting these factors|b001f9bc99e24c23bf531788cebb3ba2|4
Healthy nutrition|Reduces risk of other chronic diseases|Preventive aspect for other health conditions|b001f9bc99e24c23bf531788cebb3ba2|4
Mediterranean type of nutrition|healthy nutritional recommendations|satisfies|1e8470b1e5ae4b27a7494431c0a22162|4
Healthy food|Saturated fatty acids|must contain < 10% of total daily energy intake|1e8470b1e5ae4b27a7494431c0a22162|4
Healthy food|Polyunsaturated fatty acids|replace them|1e8470b1e5ae4b27a7494431c0a22162|4
Healthy food|Transfat acids|should be avoided (< 1% of total energy input)|1e8470b1e5ae4b27a7494431c0a22162|4
Healthy food|Salt|should be < 5g per day|1e8470b1e5ae4b27a7494431c0a22162|4
Healthy food|Fiber|30 to 45 grams per day (whole grains, fruits, vegetables)|1e8470b1e5ae4b27a7494431c0a22162|4
Healthy food|Fruit|200g a day (2 to 3 meals per)|1e8470b1e5ae4b27a7494431c0a22162|4
5. 200g of fruit a day|6. 200g vegetables a day|recommended daily consumption|7aa76ccb88984bdba85a917985440d65|4
Alcoholic beverages: 2 glasses a day (men)|Alcoholic beverages: 1 glass per day (women)|different limits for men and women|7aa76ccb88984bdba85a917985440d65|4
SBP 130-139|Other risk Factors, Asymp-tomatic Organ Damage or Disease|category in stratification of CVD risk|7aa76ccb88984bdba85a917985440d65|4
SBP 140-159|Other risk Factors, Asymp-tomatic Organ Damage or Disease|category in stratification of CVD risk|7aa76ccb88984bdba85a917985440d65|4
SBP 160-179|Other risk Factors, Asymp-tomatic Organ Damage or Disease|category in stratification of CVD risk|7aa76ccb88984bdba85a917985440d65|4
SBP ≥|Other risk Factors, Asymp-tomatic Organ Damage or Disease|category in stratification of CVD risk|7aa76ccb88984bdba85a917985440d65|4
SBP|DBP|≥180 or ≥110|a5173f3b292d47bd837d167216beb78c|4
Low risk|Moderate risk|No other RF|a5173f3b292d47bd837d167216beb78c|4
Low risk|High risk|Grade 3 HT SBP ≥ 180 or DBP ≥ 110|a5173f3b292d47bd837d167216beb78c|4
Moderate risk|High risk|1-2 RF, OD, CKD stage 3 or diabetes, Moderate to high risk, High risk, ≥3 RF|a5173f3b292d47bd837d167216beb78c|4
Moderate risk|Moderate to high risk|Low risk, Low to moderate risk|a5173f3b292d47bd837d167216beb78c|4
Moderate to high risk|High risk|OD, CKD stage 3 or diabetes, Moderate to high risk, High risk, High to very high risk|a5173f3b292d47bd837d167216beb78c|4
High risk|Very high risk|Symptomatic CVD, CKD stage ≥4 or diabetes with OD/RFs|a5173f3b292d47bd837d167216beb78c|4
risk BP|Blood Pressure|is defined as|f9c7157a529740a3aae705cdf0b17fc3|4
risk BP|Chronic Kidney Disease|is a risk factor for|f9c7157a529740a3aae705cdf0b17fc3|4
CKD|Cardiovascular|is associated with|f9c7157a529740a3aae705cdf0b17fc3|4
CV|Cardiovascular Disease|refers to the same as|f9c7157a529740a3aae705cdf0b17fc3|4
DBP|Diastolic Blood Pressure|is a term for|f9c7157a529740a3aae705cdf0b17fc3|4
HT|Hypertension|is another name for|f9c7157a529740a3aae705cdf0b17fc3|4
OD|Organ Damage|is a term for|f9c7157a529740a3aae705cdf0b17fc3|4
RF|Risk Factor|is a term for|f9c7157a529740a3aae705cdf0b17fc3|4
SBP|Systolic Blood Pressure|is a term for|f9c7157a529740a3aae705cdf0b17fc3|4
population approach|dietary measures, physical activity, smoking|relationship between the two concepts in one sentence|94f4e21f2d444dcba350c0056af33e40|4
new ESC Guidelines on CVD prevention|population approach|relationship between the two concepts in one sentence|94f4e21f2d444dcba350c0056af33e40|4
Structural measures|limiting marketing, taxing unhealthy food, reducing price of healthy food, making them better labelled, consumer-friendly|relationship between the two concepts in one sentence|94f4e21f2d444dcba350c0056af33e40|4
Healthy lifestyles|consumer-friendly|relationship between the two concepts in one sentence|94f4e21f2d444dcba350c0056af33e40|4
Healthy lifestyles|community, schools and workplaces|should be stimulated in|dc4ca6c342c04fde8cb06fc46b70ea08|4
A healthy diet|according to ESC recommendations|are according to|dc4ca6c342c04fde8cb06fc46b70ea08|4
1. A varied well-balanced diet|general recommendations of a healthy diet|is one of the general recommendations|dc4ca6c342c04fde8cb06fc46b70ea08|4
Proper energy intake with regular physical activity|good body weight control|contributes to|dc4ca6c342c04fde8cb06fc46b70ea08|4
Regularly consume fish|a healthy diet|is part of a healthy diet|dc4ca6c342c04fde8cb06fc46b70ea08|4
Eat fruits, vegetables, cereals and whole grain products|healthy diet|is included in|dc4ca6c342c04fde8cb06fc46b70ea08|4
Consume non-fat milk products|healthy diet|is part of|dc4ca6c342c04fde8cb06fc46b70ea08|4
Eat unleavened meat, avoid fried|unleavened meat, avoid fried|are recommendations for|dc4ca6c342c04fde8cb06fc46b70ea08|4
Use vegetable|healthy diet|is a part of|dc4ca6c342c04fde8cb06fc46b70ea08|4
unleavened meat|fried|avoid fried. 7.|ea51ba47c5de47ccba8998a708807f50|4
vegetable oils|mono and polyunsaturated fats|Use vegetable oils rich in mono and polyunsatu-rated fats. 7.|ea51ba47c5de47ccba8998a708807f50|4
food products|trans fat acid|Avoid salty and factory processed foods. Legislative regulations (except, of course, existing) are needed to limit trans fat acid and salt in food products.|ea51ba47c5de47ccba8998a708807f50|4
food industry|salt reduction|The food industry can significantly contribute to salt reduction in processed food [8].|ea51ba47c5de47ccba8998a708807f50|4
obesity|world prevalence|The prevalence of obesity in the world is rising, espe-cially in industrialized countries.|ea51ba47c5de47ccba8998a708807f50|4
obesity|CVD increase|It contributes to a signifi-cant increase in CVD|ea51ba47c5de47ccba8998a708807f50|4
CVD morbidity|Sedentary lifestyle, Bad nutrition habits|contributing cause|73389fe7dc8446da9c9bbf90b4b107df|4
Obesity|CVD morbidity|associated with|73389fe7dc8446da9c9bbf90b4b107df|4
Obesity|Sedentary lifestyle, Bad nutrition habits|cause of|73389fe7dc8446da9c9bbf90b4b107df|4
CVD mortality|Obesity|associated with|73389fe7dc8446da9c9bbf90b4b107df|4
BMI, Obesity, Abdominal thickness|Total mortality|linearly associated with|73389fe7dc8446da9c9bbf90b4b107df|4
Mortality rate|BMI ranges 20 to 25 kg/m2|lowest in|73389fe7dc8446da9c9bbf90b4b107df|4
Effects of obesity|Increased insulin resistance, Increased systemic inflammation and prothrombotic|causes|73389fe7dc8446da9c9bbf90b4b107df|4
Increased systemic inflammation|prothrombotic effect|3. Dyslipidemia. 4. Albuminuria.|3d0c8537d6e24a54a941320d70aae4e0|4
Dyslipidemia|Albuminuria|5. Disorder of the cardiovascular system|3d0c8537d6e24a54a941320d70aae4e0|4
kindergarten|healthy environment|should provide|51d7da0ab722484dae29a24323422e50|4
school|healthy meals|should provide|51d7da0ab722484dae29a24323422e50|4
school|physical activity|should be promoted in childhood|51d7da0ab722484dae29a24323422e50|4
school|30 minutes to 60 minutes physical activity per day|should provide|51d7da0ab722484dae29a24323422e50|4
person|physical activity|should be moderately active for at least 150 minutes a week or more intense for 75 minutes a week|51d7da0ab722484dae29a24323422e50|4
lifestyle changes|unsuccessful in long-term treatment|are often|d003fcb45fd3417b87138a5a57580936|4
BMI >40 kg/m2|pharmacotherapy (orlistat) or bariatric surgery|recommended in cases of|d003fcb45fd3417b87138a5a57580936|4
BMI >35 kg/m2 with comorbidities|high risk group|leading the patients into|d003fcb45fd3417b87138a5a57580936|4
pharmacotherapy (orlistat)|bad lifestyle habits changes|along with are recommended,|d003fcb45fd3417b87138a5a57580936|4
blood plasma lipids|lipoproteins associated with proteins (apolipo-proteins)|circulate as|d003fcb45fd3417b87138a5a57580936|4
cholesterol and triglycerides|blood plasma lipids|are part of|d003fcb45fd3417b87138a5a57580936|4
apolipo-proteins|LDL cholesterol|associated with|d2a40f62bb6849f08e1dac7dd9dc1525|4
Hypercholesterolemia|Increased risk|indicator of|d2a40f62bb6849f08e1dac7dd9dc1525|4
Total LDL cholesterol|CVD|positive association between|d2a40f62bb6849f08e1dac7dd9dc1525|4
Triglyceride-rich lipoprotein|Chylomicrons and VLDL|are related to|d2a40f62bb6849f08e1dac7dd9dc1525|4
Triglyceride-rich lipoprotein|Pancreatitis|can lead to at high concentrations|d2a40f62bb6849f08e1dac7dd9dc1525|4
pancreatitis|high concentrations|causal relationship|eb5aad42a1344cd883bd687c151859ed|4
disturbed lipid metabolism|dyslipidemia|causal relationship|eb5aad42a1344cd883bd687c151859ed|4
dyslipidemia|CVD risk factors|interaction|eb5aad42a1344cd883bd687c151859ed|4
dyslipidemia|atherosclerosis|causal relationship|eb5aad42a1344cd883bd687c151859ed|4
dyslipidemia|CVD|causal relationship|eb5aad42a1344cd883bd687c151859ed|4
genetic predisposition|hereditary dyslipidemia|relationship|eb5aad42a1344cd883bd687c151859ed|4
dyslipidemia|other diseases|part of|eb5aad42a1344cd883bd687c151859ed|4
external factors|saturated fats and carbohydrates|relationship|eb5aad42a1344cd883bd687c151859ed|4
external factors|reduced body activity|relationship|eb5aad42a1344cd883bd687c151859ed|4
external factors|smoking|relationship|eb5aad42a1344cd883bd687c151859ed|4
external factors|stress|relationship|eb5aad42a1344cd883bd687c151859ed|4
body activity|smoking|influenced by|f26a7825206b41f09ff04e78e8d0d51a|4
cholesterol reduction|coronary events|leads to a reduction in|f26a7825206b41f09ff04e78e8d0d51a|4
studies [43]|Scandinavian Simvastatin Survival Study (4S)|are studies|f26a7825206b41f09ff04e78e8d0d51a|4
studies [44]|Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID)|are studies|f26a7825206b41f09ff04e78e8d0d51a|4
studies [45]|Cholesterol and Recurrent Events (CARE)|are studies|f26a7825206b41f09ff04e78e8d0d51a|4
West of Scotland Coronary Prevention Study|Heart AIR Force Texas Coronary Atherosclerosis Protection Study|both are studies that evaluated cardiac patients with hypercholesterolemia|298d84df88a443de9097e4f306b0da21|4
Hypercholesterolemia|Cardiovascular Disease Risk|hypercholesterolemia is a condition that can contribute to cardiovascular disease risk|298d84df88a443de9097e4f306b0da21|4
Cardiovascular Disease Risk|CVD Risk Protocols|protocols are used to estimate total cardiovascular disease risk in individuals|298d84df88a443de9097e4f306b0da21|4
Lipid Analysis|CVD Risk Protocols|lipid analysis is a part of CVD risk protocols|298d84df88a443de9097e4f306b0da21|4
CVD risk protocols|lipid analysis|recommended|03f4fc21f5474c4791a2c8fabaf0bb4b|4
Total Cholesterol (TC)|lipid analysis|part of|03f4fc21f5474c4791a2c8fabaf0bb4b|4
Low Density Lipoprotein (LDL)-Cholesterol (LDL-C)|lipid analysis|part of|03f4fc21f5474c4791a2c8fabaf0bb4b|4
Triglycerides (TG)|lipid analysis|part of|03f4fc21f5474c4791a2c8fabaf0bb4b|4
HDL Cholesterol (HDL-C)|lipid analysis|part of|03f4fc21f5474c4791a2c8fabaf0bb4b|4
CVD Measurable Risk Factors|Current Cardiology Reviews, 2018, Vol. 14, No. 3|is a publication of|ac1d109f1f6341eba87a941f6fb313c7|4
Non HDL cholesterol|Alternative risk factors (mixed dyslipidemia, diabetes, metabolic syndrome, chronic kidney disease).|is a type of|ac1d109f1f6341eba87a941f6fb313c7|4
Lipoprotein (A)|high CVD risk and positive family history of early CVD.|is associated with|ac1d109f1f6341eba87a941f6fb313c7|4
APO B|alternative marker (mixed dyslipidemia, diabetes, metabolic syndrome, chronic kidney disease).|is an alternative to|ac1d109f1f6341eba87a941f6fb313c7|4
The ratio APO B/APO A|alternative to the probing.|is an alternative to|ac1d109f1f6341eba87a941f6fb313c7|4
The ratio of non HDL C / HDL C|alternative in|is an alternative to|ac1d109f1f6341eba87a941f6fb313c7|4
non HDL C / HDL C|LDL C and TC|both are closely related to CVD risk|6007a08811fc4e268d85b7599d6e86d0|4
LDL C|therapy response|it is an indicator to therapy response and its values are monitored during treatment|6007a08811fc4e268d85b7599d6e86d0|4
appropriate LDL C target values|patient category|are recommended for each patient category|6007a08811fc4e268d85b7599d6e86d0|4
moderate to severe chronic kidney dis-ease|SCORE >10%|has|cc754f985ecf4c0c9855cd554a619d8c|4
target LDL C <1.8mmol/l and/or >50% LDL C|moderate to severe chronic kidney dis-ease, SCORE >10%|used for treatment|cc754f985ecf4c0c9855cd554a619d8c|4
high CVD risk|diabetes mellitus type 2 without other risk factors or target organ damage|includes|cc754f985ecf4c0c9855cd554a619d8c|4
significantly high individual risk factors|high CVD risk|part of|cc754f985ecf4c0c9855cd554a619d8c|4
SCORE >5% and less than 10%|high CVD risk|corresponds to|cc754f985ecf4c0c9855cd554a619d8c|4
target LDL K <2.5mmol/l|high CVD risk|used for treatment|cc754f985ecf4c0c9855cd554a619d8c|4
Moderate CVD risk|SCORE >1% and less than 5%|corresponds to|cc754f985ecf4c0c9855cd554a619d8c|4
target LDL C <3.0mmol/l|Moderate CVD risk|used for treatment|cc754f985ecf4c0c9855cd554a619d8c|4
Hypertriglyceridemia|risk factor for|related to|cc754f985ecf4c0c9855cd554a619d8c|4
hypertriglyceridemia|CVD risk factor|hypertiglyceridemia is a risk factor for CVD|ed3cfe313ea244bc8af25a2b4a4dbeb4|4
hypertriglyceridemia|hypercholesterolemia|hypertriglyceridemia is less associated with CVD than hypercholesterolemia|ed3cfe313ea244bc8af25a2b4a4dbeb4|4
hypertriglyceridemia|obesity|obesity is a possible cause of hypertriglyceridemia|ed3cfe313ea244bc8af25a2b4a4dbeb4|4
hypertriglyceridemia|non-insulin-dependent diabetes mellitus (NIDDM)|non-insulin-dependent diabetes mellitus is a possible cause of hypertriglyceridemia|ed3cfe313ea244bc8af25a2b4a4dbeb4|4
hypertriglyceridemia|alcohol consumption|alcohol consumption is a possible cause of hypertriglyceridemia|ed3cfe313ea244bc8af25a2b4a4dbeb4|4
hypertriglyceridemia|simple carbohydrate-rich diets|simple carbohydrate-rich diets are a possible cause of hypertriglyceridemia|ed3cfe313ea244bc8af25a2b4a4dbeb4|4
hypertriglyceridemia|chronic kidney disease|chronic kidney disease is a possible cause of hypertriglyceridemia|ed3cfe313ea244bc8af25a2b4a4dbeb4|4
hypertriglyceridemia|hypothyroidism|hypothyroidism is a possible cause of hypertriglyceridemia|ed3cfe313ea244bc8af25a2b4a4dbeb4|4
hypertriglyceridemia|pregnancy|pregnancy is a possible cause of hypertriglyceridemia|ed3cfe313ea244bc8af25a2b4a4dbeb4|4
hypertriglyceridemia|autoimmune diseases|autoimmune diseases are a possible cause of hypertriglyceridemia|ed3cfe313ea244bc8af25a2b4a4dbeb4|4
hypertriglyceridemia|drugs (corticosteroids, estrogens, tamoxifen, beta blockers, thiazides)|drugs are a possible cause of hypertriglyceridemia|ed3cfe313ea244bc8af25a2b4a4dbeb4|4
estrogens|tamoxifen|mentioned in the same sentence|8657b622efd045b090448634e77f2d83|4
beta blockers|thiazides|mentioned in the same sentence|8657b622efd045b090448634e77f2d83|4
isotretinoin|cyclosporine|mentioned in the same sentence|8657b622efd045b090448634e77f2d83|4
antiretroviral drugs|psychotropic drugs|mentioned in the same sentence|8657b622efd045b090448634e77f2d83|4
goal|statin|Select a statin that can achieve this reduction.|c9673cee378c44f781f15d1d05943593|4
dose titration|target values of LDL C|The dose titration of the drug is required to reach the target values of LDL C|c9673cee378c44f781f15d1d05943593|4
treatment response|statins|the response to the treatment of statins is different.|c9673cee378c44f781f15d1d05943593|4
combination of drugs|LDL target value|Consider introducing a combination of drugs if the statins do not reach the LDL target value.|c9673cee378c44f781f15d1d05943593|4
patient's condition|pharmacological treatment|Take into account the clinical condition of the pa-tient|c9673cee378c44f781f15d1d05943593|4
drug interactions|patient|possible drug interactions that the patient is taking|c9673cee378c44f781f15d1d05943593|4
statin intolerance|pharmacological treatment|statin intolerance.|c9673cee378c44f781f15d1d05943593|4
recommendations for pharmacological treatment|hypercholesterolemia|treatment of|fab1a3c2c27e441bad76001cc5699b23|4
statin|patient tolerates|to achieve the target values of LDL C|fab1a3c2c27e441bad76001cc5699b23|4
ionic exchangers|non toleration|administer in case|fab1a3c2c27e441bad76001cc5699b23|4
nicotinic acid|non toleration|administer in case|fab1a3c2c27e441bad76001cc5699b23|4
cholesterol absorption inhibitors|if target values of LDL C not reached|consider in combination with ion exchangers or nicotinic acid|fab1a3c2c27e441bad76001cc5699b23|4
statin|combination|consider if target values of LDL C not reached|fab1a3c2c27e441bad76001cc5699b23|4
cholesterol|statin|in combination with|ebb76dac985843768e4e14242a6e7bbe|4
reduction of LDL cholesterol|CV mortality and nonfatal myocardial infarction|leads to|ebb76dac985843768e4e14242a6e7bbe|4
Hypertriglyceridemia|high total CV risk|in the case of patients with|ebb76dac985843768e4e14242a6e7bbe|4
TG >2.3 mmol/l|cannot be reduced by changing lifestyle|which cannot be|ebb76dac985843768e4e14242a6e7bbe|4
fibrate, nia-cin, niacin + laropiprant, omega 3 fatty acid, statin + nicotinic acid|should be given|the following medications should be|ebb76dac985843768e4e14242a6e7bbe|4
omega 3 fatty acid|statin|combination|329a827e19924d3c9b34c639a890adc9|4
statin|nico-tinic acid|combination|329a827e19924d3c9b34c639a890adc9|4
omega 3 fatty acids|fibrate|combination|329a827e19924d3c9b34c639a890adc9|4
low HDL cholesterol|CVD risk|association|329a827e19924d3c9b34c639a890adc9|4
physical activities|healthy habits|increase HDL cholesterol|329a827e19924d3c9b34c639a890adc9|4
mixed dyslipidemia|therapy combination|important to combine therapy|329a827e19924d3c9b34c639a890adc9|4
familial hypercholesterolemia|high doses of statin|should receive|329a827e19924d3c9b34c639a890adc9|4
Statin|Ezetimibe|are often used in combination|110bc4fe8f0442ae8dd3696a0f27d34c|4
Elderly people|Proven CVD|should receive high doses of statin|110bc4fe8f0442ae8dd3696a0f27d34c|4
Diabetics|CVD risk factors or target organ damage|LDL C should have < 2.6 mmol/l|110bc4fe8f0442ae8dd3696a0f27d34c|4
Patients with acute coronary syndrome|Percutaneous coronary intervention|are preparing for percutaneous coronary intervention|110bc4fe8f0442ae8dd3696a0f27d34c|4
coronary intervention|severe renal disease|are mentioned together in the context|d7c1e1b3b9b2404b8ff64bb6535bc0a8|4
coronary intervention|peripheral arterial disease|are mentioned together in the context|d7c1e1b3b9b2404b8ff64bb6535bc0a8|4
severe renal disease|peripheral arterial disease|are mentioned together in the context|d7c1e1b3b9b2404b8ff64bb6535bc0a8|4
diabetes mellitus|type 2 diabetes mellitus (T2DM)|synonymous terms|d7c1e1b3b9b2404b8ff64bb6535bc0a8|4
diabetes mellitus|CVD|are related through the context|d7c1e1b3b9b2404b8ff64bb6535bc0a8|4
World Health Organization|American Diabetes Society|both organizations classify diabetes mellitus types|08fae885ef264a208f65359c4bf8c687|4
Frančula-Zaninović and Nola|Current Cardiology Reviews|authors of the article published in Current Cardiology Reviews|08fae885ef264a208f65359c4bf8c687|4
ESC guidelines|World Health Organization|WHO set diagnostic criteria for ESC guidelines|08fae885ef264a208f65359c4bf8c687|4
American Diabetes Association|diagnostic criteria|designated by the ADA in diagnosing diabetes mellitus types|08fae885ef264a208f65359c4bf8c687|4
HbA1c|Diabetes mellitus|is a diagnostic criteria|bee368f5ceb448a58ac0ded4cfeea051|4
WHO|ADA|used as reference|bee368f5ceb448a58ac0ded4cfeea051|4
Glucose intolerance|GI|is a diagnostic criteria|bee368f5ceb448a58ac0ded4cfeea051|4
GUK starving|glucose after 2h of a meal|used as diagnostic criteria for GI and Glucose maturation disorder|bee368f5ceb448a58ac0ded4cfeea051|4
5.6 -6.9mmol/l|glucose after 2h of the meal <7.8mmol/l|standards for blood glucose levels in Diabetes Management|050784499b934a39bfd1a2718266fba3|4
ADA|criterion|reference used to define the criterion|050784499b934a39bfd1a2718266fba3|4
GI cases|modify lifestyle habits|prevention measures in GI cases|050784499b934a39bfd1a2718266fba3|4
DM|high risk|situation of people with DM|050784499b934a39bfd1a2718266fba3|4
SCORE table|People with DM do not evaluate their risk|people's lack of evaluation of their risk|050784499b934a39bfd1a2718266fba3|4
European Guidelines for Diabetes (ESC/EASD)|establish|providing recommendations|050784499b934a39bfd1a2718266fba3|4
Patient centres|Healthy living habits|support|dd3fd872a6c1463883b4f0f5e6822ef1|4
Patient centres|Dis-ease management and treatment|support|dd3fd872a6c1463883b4f0f5e6822ef1|4
Multidisciplinary approach|Patient centres|supported by|dd3fd872a6c1463883b4f0f5e6822ef1|4
ESC/EASD|Guidelines on diabetes in order to prevent CVD|give recommendations based on|dd3fd872a6c1463883b4f0f5e6822ef1|4
HbA1c target|Recommendations|part of|dd3fd872a6c1463883b4f0f5e6822ef1|4
Statins therapy|Recommendations|part of|dd3fd872a6c1463883b4f0f5e6822ef1|4
Avoid hypoglycemia|Recommendations|part of|dd3fd872a6c1463883b4f0f5e6822ef1|4
Avoid hypoglycemia|Increase body weight|Reason to avoid hypoglycemia and increase body weight|c4fdd27fab41424c87dc17f590319cb5|4
Metformin|First line of DM treatment|First-line therapy for diabetic patients|c4fdd27fab41424c87dc17f590319cb5|4
<6.5% HbA1c|Reduce microvascular events|Target to reduce the risk of microvascular events in DM patients|c4fdd27fab41424c87dc17f590319cb5|4
<140/85mmHg|Target BP|Blood pressure target for diabetic patients|c4fdd27fab41424c87dc17f590319cb5|4
<2.5mmol/l|LDL target|Cholesterol target in high-risk LDL patients|c4fdd27fab41424c87dc17f590319cb5|4
Intensive treatment of hypertriglyceridemia|Reduce CVD risk|Treatment for reducing cardiovascular disease risk in DM patients|c4fdd27fab41424c87dc17f590319cb5|4
AH treatment|Reduce CVD risk|Aggressive lipid-lowering therapy reduces the risk of cardiovascular diseases|c4fdd27fab41424c87dc17f590319cb5|4
Intensive AH treatment|CVD risk|reduces|8fb20871452e4b609ac907d5aa37eda1|4
more antihypertensive drugs|achieve the target BP|in therapy|8fb20871452e4b609ac907d5aa37eda1|4
each risky CVD factor in diabetes|target BP|should be treated according to|8fb20871452e4b609ac907d5aa37eda1|4
low socioeconomic status|risk of high risk for the disease|increase|8fb20871452e4b609ac907d5aa37eda1|4
lack of social support|high risk for the disease|increase|8fb20871452e4b609ac907d5aa37eda1|4
stress|risk of high risk for the disease|increase|8fb20871452e4b609ac907d5aa37eda1|4
depression|risk of high risk for the disease|increase|8fb20871452e4b609ac907d5aa37eda1|4
anxiety|risk of high risk for the disease|increase|8fb20871452e4b609ac907d5aa37eda1|4
type D personality|risk of high risk for the disease|increase|8fb20871452e4b609ac907d5aa37eda1|4
psychosocial factors|difficult treatment|make|8fb20871452e4b609ac907d5aa37eda1|4
Low socioeconomic status|Low level of education|includes|bccad3066d084ce2b0a98fb5c9617b8e|4
Low socioeconomic status|low financial income|includes|bccad3066d084ce2b0a98fb5c9617b8e|4
Low socioeconomic status|low level of business status|includes|bccad3066d084ce2b0a98fb5c9617b8e|4
Low socioeconomic status|poor living environment|leads to|bccad3066d084ce2b0a98fb5c9617b8e|4
Social isolation and low social support|people who live isolated from society|affects|bccad3066d084ce2b0a98fb5c9617b8e|4
Social isolation and low social support|increased risk of premature deaths|results in|bccad3066d084ce2b0a98fb5c9617b8e|4
Social isolation and low social support|low social support|affects|bccad3066d084ce2b0a98fb5c9617b8e|4
increased risk of premature deaths|a weaker prognosis of CVD|cause and effect relationship|1abbde54648d4564a51a62d5baea576d|4
work or family stress|increases the risk of CVD|cause and effect relationship|1abbde54648d4564a51a62d5baea576d|4
depression|increases the incidence of CVD and exacerbates the prognosis of the disease|cause and effect relationship|1abbde54648d4564a51a62d5baea576d|4
anxiety|increases the risk of CVD|cause and effect relationship|1abbde54648d4564a51a62d5baea576d|4
D type of distress|those with negative affectivity, social inhibition - has a poorer prognosis of CVD|cause and effect relationship|1abbde54648d4564a51a62d5baea576d|4
poor psychosocial factors|higher incidence of smoking|are often associated with|576c1616199a41c59ce7f984e21d4fc5|4
poor psychosocial factors|poor eating habits|are often associated with|576c1616199a41c59ce7f984e21d4fc5|4
poor psychosocial factors|decreased physical activity|are often associated with|576c1616199a41c59ce7f984e21d4fc5|4
poor psychosocial factors|greater risk of CVD|are associated with|576c1616199a41c59ce7f984e21d4fc5|4
such patients|more difficult to accept medical advice and treatment|they are more difficult to define the relationship.|576c1616199a41c59ce7f984e21d4fc5|4
psychosocial risk factors|interviews or questionnaires|should assess|576c1616199a41c59ce7f984e21d4fc5|4
psychosocial risk factors|interview|A doctor should do the interview to assess psychosocial risk factors|2e740c01b5664ccf981b0e0f519a4623|4
psychosocial risk factors|healthy living habits|Psychosocial interventions are needed to remove stress, depression, anxiety and adopt healthy living habits|2e740c01b5664ccf981b0e0f519a4623|4
ESC guidelines|management of psychosocial factors|The ESC guidelines provide recommendations for the management of psychosocial factors|2e740c01b5664ccf981b0e0f519a4623|4
multimodal behavioural interventions|health education|- Multimodal behavioural interventions, health educa-tion are recommended in the ESC guidelines|2e740c01b5664ccf981b0e0f519a4623|4
physical activity|psychological therapy|- Physical activity is recommended alongside psychological therapy when needed in the ESC guidelines|2e740c01b5664ccf981b0e0f519a4623|4
clinical symptoms of depression|anxiety|In the case of clinical symptoms of depression, anxiety|2e740c01b5664ccf981b0e0f519a4623|4
clinical symptoms of depression, anxiety|psychotherapy and pharmacotherapy|should be applied to|a47689271cde4f27991ef0a9fb9a037f|4
psychological interventions|stress|reduce|a47689271cde4f27991ef0a9fb9a037f|4
psychological interventions|healthy habits|promote|a47689271cde4f27991ef0a9fb9a037f|4
psychological interventions|CVD prevention and treatment|affect|a47689271cde4f27991ef0a9fb9a037f|4
CVD prevention|CVD treatment|Both are related to preventing and treating Cardiovascular Disease|c996328ed58141d1b3452c48bb68fecd|4
CVD prevention|mortality|High mortality is a concern in the context of CVD prevention|c996328ed58141d1b3452c48bb68fecd|4
CVD prevention|Cardiology practice|CVD prevention is a concern in cardiology practice|c996328ed58141d1b3452c48bb68fecd|4
Cardiovascular Disease (CVD) Prevention|Health Care Professionals|need information about patients and their lifestyle to improve|94a91678c8d247e3a875ab8a6aaaf69f|4
Public Health|All health care professionals|should be involved in CVD prevention|94a91678c8d247e3a875ab8a6aaaf69f|4
CVD Prevention|Family Physicians|should start, coordinate and permanently monitor|94a91678c8d247e3a875ab8a6aaaf69f|4
CVD prevention|patient's|start, coordinate and permanently monitor|f666ab149e394f49a8622da34e80c850|4
CVD|patients with high|many patients remain undiagnosed, many have not achieved the target values of their risk factors, first manifestation of CVD is sudden death|f666ab149e394f49a8622da34e80c850|4
CVD prevention|established CVD|among patients with already established CVD, many have not achieved the target values of their risk factors|f666ab149e394f49a8622da34e80c850|4
lack of recognition|patients with high and very high risk|no adequate preventive measures or therapies are implemented|ad245ce7d36647338ad96c233b8307b0|4
development of complications|illness|endangered by the development of complications of illness|ad245ce7d36647338ad96c233b8307b0|4
fatal CVD outcomes|patients with high and very high risk|are endangered by the development of complications of illness or fatal CVD outcomes|ad245ce7d36647338ad96c233b8307b0|4
Europe|from 1995 to 2014|In Europe, from 1995 to 2014|ad245ce7d36647338ad96c233b8307b0|4
4 clinical studies|EU-ROSPIRE I-IV (including the Republic of Croatia)|conducted in Europe from 1995 to 2014|ad245ce7d36647338ad96c233b8307b0|4
ESC guidelines for CVD prevention|target not achieved|They have shown that at the level of Europe they do not achieve the target|ad245ce7d36647338ad96c233b8307b0|4
CVD prevention guidelines|GPs in Europe|compliance|18ab561b17df470f90ea43b34194183c|4
EU-ROSPIRE III study|Compliance of GPs|According to the study, only 36-57% of GPs in Europe comply with the CVD prevention guidelines|18ab561b17df470f90ea43b34194183c|4
Assess overall risk of patients|GPs in Europe|less than 50% of them assess|18ab561b17df470f90ea43b34194183c|4
SCORE table to estimate CVD risk|62% do not use it, rely on a subjective assessment|do not use it, but rely on a subjective assessment|18ab561b17df470f90ea43b34194183c|4
Subjective assessment|SCORE table to estimate CVD risk|instead of using the SCORE table, they rely on a subjective assessment|18ab561b17df470f90ea43b34194183c|4
Government policies|Reasons for not using the SCORE table in daily practice|There are several reasons: government policies|18ab561b17df470f90ea43b34194183c|4
government policies|local community polices|are both mentioned as reasons for the issue|a3405e177a96487eb2d71627539054fa|4
lack of time in work with a patient|over-burdening physicians, insufficient number of cardiologists|are the main causes that result in this problem|a3405e177a96487eb2d71627539054fa|4
SCORE table not implemented|through information technology|due to its absence from the IT system|a3405e177a96487eb2d71627539054fa|4
CVD risk assessment|prevention measures need to be more intense|are closely related as a part of CVD prevention process|a3405e177a96487eb2d71627539054fa|4
clinicians|quick CVD assessment|are important for this process|a3405e177a96487eb2d71627539054fa|4
CVD risk assessment|especially important in the quick CVD assessment|for its crucial role in this part of the procedure|a3405e177a96487eb2d71627539054fa|4
unrecognized CVD|CVD prevention|Identification of patients with unrecognized CVD is important for CVD prevention|42ead2f93d1f4894aaa8b479ddc3503f|4
estimated risk of CVD|risk assessment of CVD|Risk assessment should be repeated every 5 years for persons without proven CVD.|42ead2f93d1f4894aaa8b479ddc3503f|4
cardiologists in outpatient practice|family medicine practitioners and general internists|Cardiologists have an important role in CVD prevention as consultants of family medicine practitioners and general internists.|42ead2f93d1f4894aaa8b479ddc3503f|4
cardiovas-cular|medical evaluation|Cardiologists should do medical evaluation of cardiovas-cular|42ead2f93d1f4894aaa8b479ddc3503f|4
cardiovas-cular patients|medical evaluation|should do|b12add2060cd4dc481753c7f3279e4ac|4
cardiologist|evaluate the risk of CVD|will evaluate|b12add2060cd4dc481753c7f3279e4ac|4
CVD capacity (non-invasive, invasive)|cardiologist|estimate|b12add2060cd4dc481753c7f3279e4ac|4
echocardiographic and Doppler artery estimation|cardiologist|provides a detailed evaluation|b12add2060cd4dc481753c7f3279e4ac|4
CVD risk factors|GPs and general internists|should identify|b12add2060cd4dc481753c7f3279e4ac|4
healthy lifestyle habits|counseling|about|b12add2060cd4dc481753c7f3279e4ac|4
GPs and general internists|domain of|should be in the domain|b12add2060cd4dc481753c7f3279e4ac|4
cardiologist|GPs and general internists|is a counselor for|4256e862d6dd44c99fef14f83530e125|4
cardiologist|cases where doubts remain about the need for introducing therapy with preventative measures or there are various contraindications and/or complications.|is involved in|4256e862d6dd44c99fef14f83530e125|4
cardiologist|secondary and tertiary CVD prevention|always involved in|4256e862d6dd44c99fef14f83530e125|4
successful management of measurable variable risk factors for cardiovascular disease development|recognizing individual risk factors, monitoring them, and assisting in changes|will include|4256e862d6dd44c99fef14f83530e125|4
risk factors|patient's health|affect|4c20221a11fd400786ccd36bc5a9df20|4
monitoring and assistance|life-style habits|change|4c20221a11fd400786ccd36bc5a9df20|4
correction|risk factors|if|4c20221a11fd400786ccd36bc5a9df20|4
preventing cardiovascular disease development|success|expected to be the most|4c20221a11fd400786ccd36bc5a9df20|4
psychosocial support|adequate psychosocial support|in-dispensable|5423dfa2143a4089a99d88eb17b200e9|4
future stress|misunderstanding|greatly reduce the results of preventive actions|5423dfa2143a4089a99d88eb17b200e9|4
patient inadequacy|patient inadequacy|greatly reduce the results of preventive actions|5423dfa2143a4089a99d88eb17b200e9|4
multidisciplinary team of experts|entire community|contribute to improving the lifestyle of individuals and the entire community|5423dfa2143a4089a99d88eb17b200e9|4
governmental organizations|non-governmental organizations|support of governmental and non-governmental organizations|5423dfa2143a4089a99d88eb17b200e9|4
health care professionals|CVD prevention|need the simplest and most practicable guidelines|5ce8649b3abc4a87a1caa76c96cb2f72|4
health care professionals|national, cultural and socioeconomic aspects|in accordance with the national, cultural and so-cioeconomic aspects of their country of work|5ce8649b3abc4a87a1caa76c96cb2f72|4
CVD prevention|national, cultural and socioeconomic aspects|in accordance with the national, cultural and so-cioeconomic aspects of their country of work|5ce8649b3abc4a87a1caa76c96cb2f72|4
CDC|Million Hearts|Organization and initiative working together for a common goal|23b49d7bb70d4ca29d3c2897b70d113e|4
Prevalence|Cardiovascular Disease Risk Factors|Terms related to the main topic of discussion in this context|23b49d7bb70d4ca29d3c2897b70d113e|4
United States|CDC|Location and organization are connected through their work on US health issues|23b49d7bb70d4ca29d3c2897b70d113e|4
Morbidity and Mortality Weekly Report MMWR September 13, 2011, Vol. 60|Million Hearts|Both are mentioned in the same sentence, so they're related.|23b49d7bb70d4ca29d3c2897b70d113e|4
Kralj V|Brkić Biloš I|Authors of a study on morbidity and mortality from cardiovascular diseases|23b49d7bb70d4ca29d3c2897b70d113e|4
Heart Disease|Textbook of cardiovascular medicine|is a topic within|8d82832bf60f40008895bb9e0c52e240|4
Cardiovascular medicine|W.B. Saunders Company|published by|8d82832bf60f40008895bb9e0c52e240|4
Heart Disease|Philadelphia|is located in|8d82832bf60f40008895bb9e0c52e240|4
J 1991; 121: 293-8.|[6]|cite|0f31834a54a144e5866059ff680ef7ad|4
ESC Pocket Guidelines|2013 ESC Guidelines on diabetes, pre-diabetes and cardiovascular dis-eases|same sentence|0f31834a54a144e5866059ff680ef7ad|4
Adapted from the ESC Guidelines on diabetes, pre-diabets and cardiovascular dis-eases.|Eur Heart J 2013; 34(39): 3035-87.|adapted from|0f31834a54a144e5866059ff680ef7ad|4
Ryden L, Grant PJ, Anker SD, et al.|ESC Pocket Guidelines|authors of|0f31834a54a144e5866059ff680ef7ad|4
Nascimento BR, Brant LCC, Moraes DN, Ribeiro ALP.|Almanah 2014: Globalno zdravlje i kardiovaskularne bolesti.|authors of|0f31834a54a144e5866059ff680ef7ad|4
Cardiol Croat|10: 113-23.|cited in|0f31834a54a144e5866059ff680ef7ad|4
Perk J, De Backer G,|[8]|cite|0f31834a54a144e5866059ff680ef7ad|4
Perk J|De Backer G|co-authors|ab366119c7ff41f68708250eaaafe4b6|4
Gohlke H|EACPR|affiliation|ab366119c7ff41f68708250eaaafe4b6|4
ESC Committee for Practice Guidelines (CPG)|European Association for Cardiovascular Prevention & Rehabilitation (EACPR)|collaboration|ab366119c7ff41f68708250eaaafe4b6|4
Fifth Joint Task Force|European Society Cardiology|constituted by representatives of nine societies and invited experts|f2768417cfc149febc729fadfa2b3144|4
Fifth Joint Task Force|Other Societies on Cardiovascular Disease Prevention|constituted by representatives of nine societies and invited experts|f2768417cfc149febc729fadfa2b3144|4
Fifth Joint Task Force|Risk factor Detection and Modification|Task force focused on risk factor detection and modification in prevention of cardiovascular disease|f2768417cfc149febc729fadfa2b3144|4
Fifth Joint Task Force|Cardiology Reviews, 2018|Published a review article related to their work|f2768417cfc149febc729fadfa2b3144|4
Fifth Joint Task Force|Eur Heart J 2012|Referenced in Eur Heart J 2012|f2768417cfc149febc729fadfa2b3144|4
Camm AJ|Luscher TF|co-authors|7f45efdab2da478583eaac25b4831375|4
Camm AJ, Luscher TF, Serruys PW|The ESC Textbook of Cardiovascu-lar Medicine|edited by|7f45efdab2da478583eaac25b4831375|4
Luscher TF|Serruys PW|co-editors|7f45efdab2da478583eaac25b4831375|4
Camm AJ, Luscher TF, Serruys PW|Oxford: Blackwell, 2006|published by|7f45efdab2da478583eaac25b4831375|4
Pearson TA|Public policy approaches to the prevention of heart disease and stroke|author|7f45efdab2da478583eaac25b4831375|4
Circ.ahajournals.or/ content/124/23/2560|Online Referencing, http://circ.ahajournals.or/content/124/23/2560 (accessed 12 September 2016).|refers to|7f45efdab2da478583eaac25b4831375|4
Kotseva K|Global preventive policies. Strategies at European and worldwide level.|author|7f45efdab2da478583eaac25b4831375|4
Online Refrencing, http://www.revespcardiol.|http://www.revespcardiol.|refers to|7f45efdab2da478583eaac25b4831375|4
Online Refrencing|http://www.revespcardiol. org/eu/global-preventive-policies-strategies-at/articulo/13125894 (accessed 12 September 2016). [12]|citation|4d2eff17c0464b13b6a58d792f3b63fd|4
Online Refrencing|Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). [13]|citation|4d2eff17c0464b13b6a58d792f3b63fd|4
Online Refrencing|Online|context term reference|4d2eff17c0464b13b6a58d792f3b63fd|4
Online Referencing|European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)|mentioned in the same sentence|f052ed06b4e74308980492f1e60b6633|4
The Task Force for the Management of Dyslipidaemias|European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)|mentioned in the same sentence|f052ed06b4e74308980492f1e60b6633|4
Developed with the special contribution|European Association for Cardiovascular|mentioned in the same sentence|f052ed06b4e74308980492f1e60b6633|4
EACPR|European Assoccia-tion for Cardiovascular Prevention&Rehabilitation|is|3483a6f0d7fd4641860b13decfae103c|4
Online referencing|http://eurheartj.oxfordjournals.org/September 16,2016|provides a reference to|3483a6f0d7fd4641860b13decfae103c|4
Accessed date|16 September 2016|was accessed on|3483a6f0d7fd4641860b13decfae103c|4
EURIKA study|Achivement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe|is a study about|3483a6f0d7fd4641860b13decfae103c|4
Eur Heart J 2011|32: 2143-52|contains the EURIKA study|3483a6f0d7fd4641860b13decfae103c|4
Blood Pressure Lowering Treatment Trialists' Collaboration|Sund-strom J, Arima H|is a collaboration with|3483a6f0d7fd4641860b13decfae103c|4
Blood pressure-lowering treatment|Cardiovascular risk|is based on|ab99b56015cf454e9f4ac71bea523725|4
Meta-analysis of individual patient data|Blood pressure-lowering treatment|used to analyze|ab99b56015cf454e9f4ac71bea523725|4
Effects of blood pressure lowering on outcome incidence in hypertension|Cardiovascular risk|related to patients at different levels of|ab99b56015cf454e9f4ac71bea523725|4
3. Effects in patients at different levels of cardiovascular risk|Blood pressure lowering treatment|effects on|ab99b56015cf454e9f4ac71bea523725|4
Effects of blood pressure lowering|Outcome incidence in hypertension|relationship between the two concepts, node_1 and node_2 in one sentence|f27d55d6be3943fc9e2a09045a166840|4
Blood pressure lowering|Baseline blood pressure levels|relationship between the two concepts, node_1 and node_2 in one sentence|f27d55d6be3943fc9e2a09045a166840|4
Outcome incidence in hypertension|Achived blood pressure levels|relationship between the two concepts, node_1 and node_2 in one sentence|f27d55d6be3943fc9e2a09045a166840|4
Different baseline blood pressure levels|Achieved blood pressure levels|relationship between the two concepts, node_1 and node_2 in one sentence|f27d55d6be3943fc9e2a09045a166840|4
SCORE project|risk of fatal cardiovascular disease in Europe|The SCORE project is a study on risk of fatal cardiovascular disease in Europe.|35c9610aa44a45678418ea8b2a743c25|4
Eur Heart J 2003|SCORE project|The article from Eur Heart J 2003 provides information on the SCORE project.|35c9610aa44a45678418ea8b2a743c25|4
24: 97-1003|Eur Heart J 2003|The article is found in volume 24, pages 97-1003 of Eur Heart J.|35c9610aa44a45678418ea8b2a743c25|4
J Am Coll Cardiol 2009|Value and limitations of existing scores for the assessment of cardiovascular risk|The article from J Am Coll Cardiol 2009 discusses value and limitations of existing scores for cardiovascular risk.|35c9610aa44a45678418ea8b2a743c25|4
54(14): 1209-27|J Am Coll Cardiol 2009|The article is found in volume 54, issue 14, pages 1209-1227 of J Am Coll Cardiol.|35c9610aa44a45678418ea8b2a743c25|4
Multiple Risk Factor Intervention Trial (MRFIT)|Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease|The MRFIT is a study on serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease.|35c9610aa44a45678418ea8b2a743c25|4
Neaton JD, Wenthworth D|Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease|The authors of the study are Neaton JD and Wenthworth D.|35c9610aa44a45678418ea8b2a743c25|4
316 099 white men|Multiple Risk Factor Intervention Trial (MRFIT)|The MRFIT study includes data from 316,099 white men.|35c9610aa44a45678418ea8b2a743c25|4
Multiple Risk Factor Intervention Trial (MRFIT)|Research Gorup|is part of|dcab2942921f4ae18ae1b0ce92221969|4
Asia Pacific Cohort Study Collaboration (APCSC)|Circulation 2005; 112: 3384-90|is referenced in|dcab2942921f4ae18ae1b0ce92221969|4
Hunter DJ, Reddy KS|Noncommunicable diseases|authored|dcab2942921f4ae18ae1b0ce92221969|4
Volpe M, Calivieri C, Alonzo A|Modern cardiovascular risk management in clinical practice|authored|dcab2942921f4ae18ae1b0ce92221969|4
man-agement in clinical practice|Hypertension|Hypertension is a concept related to man-agement in clinical practice.|ef9fda4367b54029aee953b88f56d75b|4
man-agement in clinical practice|Hipertensión 2009; 26: 275-9|Hipertensión 2009; 26: 275-9 is a source related to man-agement in clinical practice.|ef9fda4367b54029aee953b88f56d75b|4
Yusuf S, Hawken S, Ounpun S, et al.|Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937-52|Yusuf S, Hawken S, Ounpun S, et al. is a source related to the study on potentially modifiable risk factors.|ef9fda4367b54029aee953b88f56d75b|4
Kotseva K.|Global preventive polices. Strategies at European and worldwide level. Online Referencing, http://www.revespcardiol. org/eu/global-preventive-policies-strategies-at/articulo/13125894.|Kotseva K. is a source related to global preventive polices.|ef9fda4367b54029aee953b88f56d75b|4
Online Referencing|http://www.revespcardiol.org/eu/global-preventive-policies-strategies-at/articulo/13125894.|The Online Referencing is a source related to the website link for global preventive policies.|ef9fda4367b54029aee953b88f56d75b|4
Law MR|Morris JK|co-authors|4d04823bfccb475081870961b49bba24|4
Law MR|Wald NJ|co-authors|4d04823bfccb475081870961b49bba24|4
Niebauer J|Hambrecht R|co-authors|4d04823bfccb475081870961b49bba24|4
Niebauer J|Velich T|co-authors|4d04823bfccb475081870961b49bba24|4
Niebauer J|et al.|co-authors|4d04823bfccb475081870961b49bba24|4
Online Referencing|http://www.escardio.org/|website|409ea3a06a994d7782d470473eb9b415|4
Country of the month|denmark-country-of-the-month-full-report.pdf|document related to country|409ea3a06a994d7782d470473eb9b415|4
Jelaković B, Zeljković-Vrkić T, Pećin I|Arterial hypertension in Croatia. Results of EH-UH study|research article on arterial hypertension|409ea3a06a994d7782d470473eb9b415|4
EH-UH study|Jelaković B, Zeljković-Vrkić T, Pećin I|study by authors|409ea3a06a994d7782d470473eb9b415|4
Acta Med Croatica 2007; 61(3)|287-92|publication details of research article|409ea3a06a994d7782d470473eb9b415|4
Task Force for the management of arterial hypertension|European Society of Hypertension (ESH)|is part of|7bd3091896ba4c00b298358e49a79618|4
European Society of Cardiology (ESC)|Task Force for the management of arterial hypertension|is part of|7bd3091896ba4c00b298358e49a79618|4
Eur Heart J 2013; 34: 2159-219|Task Force for the management of arterial hypertension|is related to|7bd3091896ba4c00b298358e49a79618|4
American College of Cardiology/American Heart Association Task Force on Clinical Practice|2017 ACC/AHA/ AAPA/ABC/ACPM/AGS/AphA/ASH/ASPC/NMA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults|is developed by|7bd3091896ba4c00b298358e49a79618|4
Heart Association Task Force on Clinical Practice Guidelines|J Am Coll Cardiol 2017|Published|6a5da3ee3a4d4c6c922d323de8000c95|4
Menott A, Puddu PE|How to seven countries study contibuted to the definition and development of the Mediterranean diet concept: A 50-year journey|Authors|6a5da3ee3a4d4c6c922d323de8000c95|4
Nutr Metab Cardiovasc Dis 2015|25: 245-52|Cited in|6a5da3ee3a4d4c6c922d323de8000c95|4
Astrup A, Dyerberg J, Elwood P, et al.|The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: Where does the evidence stand in 2010|Authors|6a5da3ee3a4d4c6c922d323de8000c95|4
Am J Clin|Published|Published|6a5da3ee3a4d4c6c922d323de8000c95|4
evidence|2010|Where does the evidence stand in 2010|9d1c5505c2ae4d35aa0b07e4b0943dcf|4
Am J Clin Nutr|2011; 93: 684-8|Am J Clin Nutr 2011; 93: 684-8|9d1c5505c2ae4d35aa0b07e4b0943dcf|4
Mensink RP, Katan MB|Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials.|Meta-analysis of 27 trials|9d1c5505c2ae4d35aa0b07e4b0943dcf|4
Arterioscler Thromb|1992; 12: 911-9|Arterioscler Thromb 1992; 12: 911-9|9d1c5505c2ae4d35aa0b07e4b0943dcf|4
Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC|Trans fatty-acids and cardiovascular disease. N Engl J Med 2006; 354: 1601-13.|Trans fatty-acids and cardiovascular disease|9d1c5505c2ae4d35aa0b07e4b0943dcf|4
Wen YT, Dai JH, Gao Q|Effects of omega-3 fatty acid on major cardiovascular events and mortality in patients with|Effects of omega-3 fatty acid on major cardiovascular events and mortality|9d1c5505c2ae4d35aa0b07e4b0943dcf|4
meta-analysis|randomized controlled trials|A meta-analysis of randomized controlled trials|a15d8ad8e536456a82f74e617f7cf831|4
coronary heart disease|mortality in patients|patients with coronary heart disease and their mortality|a15d8ad8e536456a82f74e617f7cf831|4
omega-3 fatty acid supplementation|risk of major cardiovascular disease events|omega-3 fatty acid supplementation and risk of major cardiovascular disease events|a15d8ad8e536456a82f74e617f7cf831|4
omega-3 fatty acids|JAMA 2012 publication|Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events found in a systematic review and meta-analysis published in JAMA 2012|a15d8ad8e536456a82f74e617f7cf831|4
systematic review|meta-analysis|A systematic review leads to a meta-analysis|a15d8ad8e536456a82f74e617f7cf831|4
Multiple Risk Factor Intervention Trial|MultipIe Risk Factor Intervention Trial Research Group|Research Group|d04c0fe0c2194f50a98ba2fcf6cc5588|4
Cholesterol Treatment Trialists' Collaboration|Mihaylova B, Em-berson J, Blackwll L, et al.|Researchers|d04c0fe0c2194f50a98ba2fcf6cc5588|4
Lancet|380: 581-90.|Publisher|d04c0fe0c2194f50a98ba2fcf6cc5588|4
Arch Intern Med|152: 1490-500.|Publisher|d04c0fe0c2194f50a98ba2fcf6cc5588|4
Scandinavian Simvastatin Survival Study (4S)|Reducing the risk of coronary events|study|eaf99e3494cb46d5a651b14f284f8589|4
4S|Kjekshus J, Pedersen TR|authors|eaf99e3494cb46d5a651b14f284f8589|4
Nutr|2005; 81: 1322-9|is a reference to|8a236d6921584e9e8a98c798565d1079|4
Pfeffer MA|Sacks FM, Moyé LA, et al|are authors of the paper|8a236d6921584e9e8a98c798565d1079|4
Influence of baseline lipids on effectiveness of pravastatin in the CARE trial cholesterol and recurrent events|J Am Coll Cardiol 1999; 33: 125-30|is a paper referred to|8a236d6921584e9e8a98c798565d1079|4
Heart Protection Study Collaborative Group|MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536|is a group that conducted the study|8a236d6921584e9e8a98c798565d1079|4
cholesterol and recurrent events|Influence of baseline lipids on effectiveness of pravastatin in the CARE trial|are part of a trial|8a236d6921584e9e8a98c798565d1079|4
CVD Measurable Risk Factors|Current Cardiology Reviews, 2018, Vol. 14, No. 3|refers to|88c8f99ebb8d465b9377321bb2b85c86|4
high-risk individuals|a randomised placebocontrolled trial|involved in|88c8f99ebb8d465b9377321bb2b85c86|4
Lancet 2002; 360: 7-22.|[48] Streja L, Packard CJ, Shepherd J, Cobbe S, Ford I. Factors affecting low-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 2002; 90: 731-6.|cites|88c8f99ebb8d465b9377321bb2b85c86|4
360: 7-22|Streja L, Packard CJ, Shepherd J, Cobbe S, Ford I. Factors affecting low-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 2002; 90: 731-6.|page and issue|88c8f99ebb8d465b9377321bb2b85c86|4
West of Scotland Coronary Prevention Study (WOSCOPS)|Streja L, Packard CJ, Shepherd J, Cobbe S, Ford I. Factors affecting low-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 2002; 90: 731-6.|study|88c8f99ebb8d465b9377321bb2b85c86|4
[49] Gotto AM Jr, Bocuzzi SJ, Cook JR.|Effect of lovastatin on cardio-vascular resource utilization and|cites|88c8f99ebb8d465b9377321bb2b85c86|4
cardio-vascular resource utilization and|Gotto AM Jr, Bocuzzi SJ, Cook JR. Effect of lovastatin on cardiovascular resource utilization and|article title|88c8f99ebb8d465b9377321bb2b85c86|4
cardio-vascular resource utilization|Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)|study of cardio-vascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study|fd1989090df64ff293a21911840e02b6|4
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)|AFCAPS/TexCAPS Research Group|research group responsible for the study|fd1989090df64ff293a21911840e02b6|4
AFCAPS/TexCAPS|Am J Cardiol 2000|published in Am J Cardiol 2000|fd1989090df64ff293a21911840e02b6|4
coronary heart disease|triglycerides|triglycerides and the risk of coronary heart disease|fd1989090df64ff293a21911840e02b6|4
triglycerides-rich lipoproteins|triglyceride-rich lipoproteins|mentioned together in context|fd1989090df64ff293a21911840e02b6|4
Triglyceride-rich lipoproteins|high-density lipoprotein cholesterol|in patients at high risk of cardiovascular disease|c4e46ee41b5d4799ad2c155025e151f8|4
evidence and guidance for management|P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Eur Heart J 2011; 32: 1345-61.|from the context|c4e46ee41b5d4799ad2c155025e151f8|4
traditional and novel risk factors|impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events|Albert MA, Glynn RJ, Burin J, Ridker PM. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events. Circulation 2006; 114: 1619-2626.|c4e46ee41b5d4799ad2c155025e151f8|4
socioeconomic status|functional recovery|Alter DA, Franklin B, Ko DT, et al. Socioeconomic status, functional recovery|c4e46ee41b5d4799ad2c155025e151f8|4
Socioeconomic status|Functional recovery|among patients surviving acute myocardial infarction.|bbca9d2c56d54797b0e0e2d05c292c38|4
Functional recovery|Longterm mortality|among patients surviving acute myocardial infarction.|bbca9d2c56d54797b0e0e2d05c292c38|4
Patients|Surviving acute myocardial infarction|study context|bbca9d2c56d54797b0e0e2d05c292c38|4
Socioeconomic status|Longterm mortality|among patients surviving acute myocardial infarction.|bbca9d2c56d54797b0e0e2d05c292c38|4
average lifespan of humans|65 and older age group|percentage of people entering|3b663ff9ec2b4dfc8b24ea8eda5259a9|4
increasing average lifespan of humans|next 20 years|continuing to do so|3b663ff9ec2b4dfc8b24ea8eda5259a9|4
age group|cardiovascular disease|leading cause of death|d80e2310a0ba45d2afab64cd2b57daad|4
aging|cardiovascular disease|largest risk factor|d80e2310a0ba45d2afab64cd2b57daad|4
aging|molecular biology of aging|field|39d17a2c3d99460d967f97a12a2daa26|4
aging pathways|cardiovascular health|role in|39d17a2c3d99460d967f97a12a2daa26|4
gap|merging together|beginning to close|39d17a2c3d99460d967f97a12a2daa26|4
lifespan|health span|regulating|39d17a2c3d99460d967f97a12a2daa26|4
sirtuins|key genes|involved in regulating|39d17a2c3d99460d967f97a12a2daa26|4
AMP-activated protein kinase|key genes|involved in regulating|39d17a2c3d99460d967f97a12a2daa26|4
mammalian target of rapamycin|key genes|involved in regulating|39d17a2c3d99460d967f97a12a2daa26|4
insulin-like growth factor 1|key genes|involved in regulating|39d17a2c3d99460d967f97a12a2daa26|4
cardiovascular health|person's age|The most important determinant of cardiovascular health is a person’s age.|64a4c473483f494080fc758654829a6d|4
aging genes|cardiovascular disease|discussing studies linking genes of aging and cardiovascular health|64a4c473483f494080fc758654829a6d|4
population|aged 65 or older|approximately 20%|73d72c468e5c4e9cb13c9a742c871511|4
CVD|leading cause|will result in 40% of all deaths|73d72c468e5c4e9cb13c9a742c871511|4
age group|critical component|remains vital that we understand why age is such a critical component|73d72c468e5c4e9cb13c9a742c871511|4
rodent studies|atherosclerosis or cardiomyopathies|Most rodent studies of atherosclerosis or cardiomyopathies|1c505c50fb124ac19e4f8c085fc85943|4
rodent studies|young mice|were performed in young mice,|1c505c50fb124ac19e4f8c085fc85943|4
studies|genetic and pharmacological interventions|that extend lifespan rarely assessed whether CVD or heart function are improved.|1c505c50fb124ac19e4f8c085fc85943|4
introductory review|discuss genetic pathways|we discuss genetic pathways that have been identified to regulate the process of aging.|1c505c50fb124ac19e4f8c085fc85943|4
changes in cardiovascular system|age|occur with age|d20b445a79774cefa87a72ef036464df|4
overview of changes|cardiovascular system|provide an overview|d20b445a79774cefa87a72ef036464df|4
recent breakthroughs|aging and cardiovascular research fields|bridge the gap between the two|d20b445a79774cefa87a72ef036464df|4
American Heart Association, Inc.|2012|provide an overview of changes that occur in the cardiovascular system with age and|d20b445a79774cefa87a72ef036464df|4
Correspondence to|Brian J. North, PhD|Correspondence to|d20b445a79774cefa87a72ef036464df|4
Correspondence to|David A. Sinclair, PhD|Correspondence to|d20b445a79774cefa87a72ef036464df|4
Ave Louis Pasteur|Boston, MA 02115|located at|fc8ff86567d141e580e40dcae3fe1e67|4
brian_north@hms.harvard.edu|Ave Louis Pasteur, Boston|contact information|fc8ff86567d141e580e40dcae3fe1e67|4
david_sinclair@hms.harvard.edu|Ave Louis Pasteur, Boston|contact information|fc8ff86567d141e580e40dcae3fe1e67|4
D.A.S.|consultant and inventor|role in|fc8ff86567d141e580e40dcae3fe1e67|4
D.A.S.|patents licensed to GSK|has relation with|fc8ff86567d141e580e40dcae3fe1e67|4
sirtuin-related medicines|developed by GSK|are related to|fc8ff86567d141e580e40dcae3fe1e67|4
NIH Public Access|Author Manuscript|format of the document|fc8ff86567d141e580e40dcae3fe1e67|4
Circ Res|Author manuscript|published as|fc8ff86567d141e580e40dcae3fe1e67|4
110(8): 1097–1108|Circ Res.|appeared in|fc8ff86567d141e580e40dcae3fe1e67|4
NIH-PA|Author Manuscript|is related to|c7a7d8d9d1884926a6864c4972ebac93|4
NIH-PA Author Manuscript|Manuscript|is a type of|c7a7d8d9d1884926a6864c4972ebac93|4
Aging|Progressive decline in physiological processes|associated with|17433bfbc9c74f37a59baafcd206731e|4
Aging|Increased risk of health complications and disease|leading to|17433bfbc9c74f37a59baafcd206731e|4
Cardiovascular system|Delivering oxygenated blood|By delivering|17433bfbc9c74f37a59baafcd206731e|4
Cardiovascular system|Health of every tissue|to all tissues in the body|17433bfbc9c74f37a59baafcd206731e|4
Aging|Effect on heart|Aging has a remarkable effect on|17433bfbc9c74f37a59baafcd206731e|4
arterial system|CVD including atherosclerosis, hypertension, myocardial infarction, stroke|cause and effect|92a571718ede4d25a397194d3063280e|4
aging cardiovascular tissues|pathological alterations including hypertrophy, altered LV diastolic function, diminished LV systolic reverse capacity, increased arterial stiffness, impaired endothelial function3,4|result and effects|92a571718ede4d25a397194d3063280e|4
health of the arterial and cardiac|pathological alterations including hypertrophy, altered LV diastolic function, diminished LV systolic reverse capacity, increased arterial stiffness, impaired endothelial function3,4|affected by|92a571718ede4d25a397194d3063280e|4
health of the arterial and cardiac|arterial system|related to|92a571718ede4d25a397194d3063280e|4
arterial stiffness|compensatory mechanisms|leads to|4db17bec3b3a4f328b8c18dcb60e70c0|4
increase in arterial stiffness|LV hypertrophy and fibroblast proliferation|results in|4db17bec3b3a4f328b8c18dcb60e70c0|4
decreased cardiac output|increase in fibrotic tissue|caused by|4db17bec3b3a4f328b8c18dcb60e70c0|4
heart rate modulation|age|affected by|4db17bec3b3a4f328b8c18dcb60e70c0|4
decrease in heart rate variability|maximum heart rate|affected by|4db17bec3b3a4f328b8c18dcb60e70c0|4
heart rate|age and other factors|influenced by|4db17bec3b3a4f328b8c18dcb60e70c0|4
loss of cells in the sinoatrial node|controlling heart rate|responsible for controlling heart rate|c0731e724c8145d09ba3c0cb158db8a4|4
LV diastolic filling rate|begins to decline|declines|c0731e724c8145d09ba3c0cb158db8a4|4
increasing arterial contraction|to sustain stroke volume and workload|compensation mechanism for maintaining sufficient|c0731e724c8145d09ba3c0cb158db8a4|4
ejection fraction|age|decreases with age|0effba81dfbb46478c5b8e23e25cb823|4
LV contractility|age|decreases with age|0effba81dfbb46478c5b8e23e25cb823|4
sympathetic modulation of heart rate|age|decreases with age|0effba81dfbb46478c5b8e23e25cb823|4
response to β-adrenergic receptor activation|age|decreases with age|0effba81dfbb46478c5b8e23e25cb823|4
cardiac output|decline in function with age|reduction due to|0effba81dfbb46478c5b8e23e25cb823|4
myocardium|muscle mass|stimulates the myocardium to compensate by increasing|0effba81dfbb46478c5b8e23e25cb823|4
cardiac output|short-term enhancement|provides short-term|0effba81dfbb46478c5b8e23e25cb823|4
cardiac output|long-term effect|the long-term effect of|0effba81dfbb46478c5b8e23e25cb823|4
hypertrophy|diminishes cardiac function|relationship found in one sentence|85983fcf1dd24dbca64072f5ef6b16a4|4
ventricular hypertrophy|result of increase in size of individual cardiomyocytes|relationship found in one sentence|85983fcf1dd24dbca64072f5ef6b16a4|4
ventricular hypertrophy|physiological (reversible) or pathological (irreversible)|relationship found in one sentence|85983fcf1dd24dbca64072f5ef6b16a4|4
hypertrophy|measured with a variety of techniques|relationship found in one sentence|85983fcf1dd24dbca64072f5ef6b16a4|4
echocardiography|measure LV size|relationship found in one sentence|85983fcf1dd24dbca64072f5ef6b16a4|4
histological analysis of heart|technique for measuring hypertrophy|relationship found in one sentence|85983fcf1dd24dbca64072f5ef6b16a4|4
tissue|cardiomyocytes|isolation of cardiomyocytes for cell size measurements|fd3736d571324390b74fca8d8940d318|4
echocardiography|measure alterations in cardiac size and functional parameters|noninvasive nature of echocardiography allows for the unique opportunity to measure alterations in cardiac size and functional parameters|fd3736d571324390b74fca8d8940d318|4
aging study cohort|measure longitudinally|echocardiography allows for the unique opportunity to measure alterations in cardiac size and functional parameters longitudinally in an aging study cohort|fd3736d571324390b74fca8d8940d318|4
vasculature|aging results|aging of the vasculature results in increased arterial thickening and stiffness as well as dysfunctional endothelium|fd3736d571324390b74fca8d8940d318|4
arterial thickening and stiffness|clinical changes|these changes result in increased systolic pressure|fd3736d571324390b74fca8d8940d318|4
atherosclerosis|hypertension and stroke|are major risk factors for development of|39cb5956d0524891ae505ee360eb08b6|4
vasculature undergoes|age-related macular degeneration|as a result of excessive growth and remodeling|39cb5956d0524891ae505ee360eb08b6|4
structure and function alterations with age|luminal enlargement|well documented|5563f49c703d4447894aee39819be53e|4
endothelial cell function|affecting endothelium-dependent dilation|negatively|5563f49c703d4447894aee39819be53e|4
endothelial cells|proliferate and migrate|after tissue injury|5563f49c703d4447894aee39819be53e|4
endothelial nitric oxide synthetase (eNOS)|NO|reducing the abundance of NO|5ddec773000f4746a2130e1aeaa1a7d1|4
Circ Res|Author manuscript|is related to|821631a1b412461185c32406d928b561|4
Circ Res|PMC|is available in|821631a1b412461185c32406d928b561|4
Author manuscript|PMC|is available in|821631a1b412461185c32406d928b561|4
Loss of NO|endothelial cell senescence|promotes|e3fb6afb74094dff81a49ed729575633|4
hemodynamic shear stress|eNOS activity|one of the most potent inducers of|e3fb6afb74094dff81a49ed729575633|4
vessels age|reduced blood flow|caused by decline in heart function|e3fb6afb74094dff81a49ed729575633|4
protective NO|shear stress|responsive to|9ede1868b82640baa7e133beb214e9e7|4
measuring arterial thickness and stiffness|in aged models|can lead to further understanding|9ede1868b82640baa7e133beb214e9e7|4
role various longevity genes influence|vasculature aging|influence|9ede1868b82640baa7e133beb214e9e7|4
activity in vessels|endothelial senescence|are factors related to vascular aging|b362f8f026fd48e88022f93ae76e3159|4
vascular aging|marker|activity in vessels and endothelial senescence serve as|b362f8f026fd48e88022f93ae76e3159|4
cellular composition|decrease in absolute number of cardiomyocytes|due to increased apoptosis and necrosis during aging|b362f8f026fd48e88022f93ae76e3159|4
cardiomyocytes|increased apoptosis and necrosis|affect during the heart's aging process|b362f8f026fd48e88022f93ae76e3159|4
decrease in repopulation of cardiomyocytes|cardiac stem cell reserves|are affected by changes in the heart's aging process|b362f8f026fd48e88022f93ae76e3159|4
cellular composition|decrease in repopulation of cardiomyocytes|are marked by a decrease due to increased apoptosis and necrosis|b362f8f026fd48e88022f93ae76e3159|4
oxidative stress|increase in oxidative stress|causal relationship|c6236950f1904af38a37802e7aec67d3|4
increase in reactive oxygen species (ROS) production|increase in oxidative stress|causal relationship|c6236950f1904af38a37802e7aec67d3|4
increase in reactive oxygen species (ROS) production with age|increase in oxidative stress due to|causal relationship|c6236950f1904af38a37802e7aec67d3|4
overall enhancement in the rate of cardiomyocyte death with age|increase in oxidative stress|causal relationship|c6236950f1904af38a37802e7aec67d3|4
cardiomyocytes undergo necrosis|release of cellular components|causal relationship|c6236950f1904af38a37802e7aec67d3|4
neighboring cardiomyocytes|survival affected by released cellular components|affected relationship|c6236950f1904af38a37802e7aec67d3|4
proinflammatory and profibrotic environments|development in the aging|promoted by relationship|c6236950f1904af38a37802e7aec67d3|4
Cardiomyocyte senescence|Increased expression of senescence markers and decreased telomere length|cause|2eb6da7386f14b9e9bcb014f3109d9c4|4
Cardiomyocyte senescence|Age|increases with|2eb6da7386f14b9e9bcb014f3109d9c4|4
Removal of senescence cells alone|Improvement in cardiac defects observed in some aging models|may not be sufficient to|2eb6da7386f14b9e9bcb014f3109d9c4|4
animal models of aging|better understanding of the link between aging and CVD|will lead to|b80981c739e246e788047d416e025065|4
aging|CVD|link between|b80981c739e246e788047d416e025065|4
senescence|expression of factors like p53, p21, p16, senescence-associated β-galactosidase activity|coupled with|b80981c739e246e788047d416e025065|4
immunoblotting|measuring senescence-associated β-galactosidase activity|can be measured by|b80981c739e246e788047d416e025065|4
histological techniques|measuring senescence-associated β-galactosidase activity|can be measured by|b80981c739e246e788047d416e025065|4
quantifying levels of 8-oxoguanine|assessing damaged nuclear and mitochondrial DNA|levels can be assessed by|b80981c739e246e788047d416e025065|4
oxidative stress|marker for fundamental damaged DNA pathways|related in same sentence|2d97056c9fbd4f52ab3dca44b91bbe8f|4
DNA damage|phosphorylation status of γ-H2Ax|related in same sentence|2d97056c9fbd4f52ab3dca44b91bbe8f|4
fibrosis|histological methods|related in same sentence|2d97056c9fbd4f52ab3dca44b91bbe8f|4
biomarkers of aging|used|related in same sentence|2d97056c9fbd4f52ab3dca44b91bbe8f|4
cardiac tissue|longevity genes|influence|d813cfe114d443c0a6df8541b33ba605|4
rate and degree|cardiovascular aging|at the cellular level|d813cfe114d443c0a6df8541b33ba605|4
postmitotic|cardiomyocytes|undergo division and regeneration|d813cfe114d443c0a6df8541b33ba605|4
recent work|cardiac regeneration|discovered|d813cfe114d443c0a6df8541b33ba605|4
maintaining cardiovascular health|cardiac regeneration|vital mechanism|d813cfe114d443c0a6df8541b33ba605|4
rate of regeneration in the aged|adequate maintenance|maintain cardiomyocyte numbers|d813cfe114d443c0a6df8541b33ba605|4
cardiomyocyte loss|response to|rate of regeneration|d813cfe114d443c0a6df8541b33ba605|4
Regenerated cardiac tissue|cardiac stem cells|involve|5f596dfc87a24f1a846d7f7defcc0e03|4
Regenerated cardiac tissue|small incompletely differentiated cardiomyocytes|can reenter the cell cycle|5f596dfc87a24f1a846d7f7defcc0e03|4
Regenerative capacity|proliferative index|can be measured by assessing|5f596dfc87a24f1a846d7f7defcc0e03|4
proliferation markers|Ki67 or proliferating cell nuclear antigen|such as|5f596dfc87a24f1a846d7f7defcc0e03|4
long-lived or short-lived progeroid animal models|alterations in their|tested for|5f596dfc87a24f1a846d7f7defcc0e03|4
regenerative capacity|aging cardiovascular system|involved in the aging cardiovascular system|5ff9de6e4e31433d8630b374ad3d379c|4
author manuscript|PMC 2012 October 13|available in PMC 2012 October 13|5ff9de6e4e31433d8630b374ad3d379c|4
aging heart|decrease in the number and function of sinoatrial nodal pacemaker cells|cause|eb8a81d5548f46709fd44c9f2072104e|4
aging heart|increase in conduction abnormalities|effect|eb8a81d5548f46709fd44c9f2072104e|4
aging heart|decrease in heart rate variability and maximum heart rate|result|eb8a81d5548f46709fd44c9f2072104e|4
abnormalities leading to arrhythmias|altered conduction system|leading to|16364d7084e14f4e861f958430cab0d3|4
aging models|assessed for alterations in cardiac conduction|have been assessed for|16364d7084e14f4e861f958430cab0d3|4
electrophysiology (EP) studies|testing aging models for alterations in EP parameters|use of|16364d7084e14f4e861f958430cab0d3|4
cultured cardiomyocytes|in vivo|are used for analysis|fcc8f2cabc5a447abb26f493b54c5e67|4
surface ECG analysis|echocardiography|measure the same aspects of cardiovascular health|fcc8f2cabc5a447abb26f493b54c5e67|4
surface ECGs|longitudinal studies in aging cohorts|are used for monitoring changes over time|fcc8f2cabc5a447abb26f493b54c5e67|4
aging and cardiovascular fields|low calorie diet combined with exercise|can increase health span of mammals|fcc8f2cabc5a447abb26f493b54c5e67|4
sedentary lifestyle|CVD|results from opposite effect|8af3806865bb44e3aabfc0159a58022a|4
traditional view|CVD|accumulation of cholesterol and fatty acids in tissues, which compromise tissue function and stimulate the production of inflammatory cytokines as well as ROS|8af3806865bb44e3aabfc0159a58022a|4
aging field|diet high in calories without exercise|proposes another fundamental process at work|8af3806865bb44e3aabfc0159a58022a|4
expression of|harmful effects|suppresses due to diet high in calories without exercise|8af3806865bb44e3aabfc0159a58022a|4
longevity genes|cellular defenses against aging|promote|1bbf9f533fd5492cbc61592708a75cb6|4
new concept|seminal observation by McCay et al in 1935|has its roots in|1bbf9f533fd5492cbc61592708a75cb6|4
caloric intake reduction|rat's lifespan extension|dramatically extends|1bbf9f533fd5492cbc61592708a75cb6|4
lifespan-extending properties|calorie restriction (CR)|has been observed in|1bbf9f533fd5492cbc61592708a75cb6|4
conflicting results|various inbred and outbred strains of mice and wild mice|are observed|5f3edf9d1dfa4c79a66cb40f2527bd16|4
CR|incidence of most age-related diseases|it reduces in mammals|5f3edf9d1dfa4c79a66cb40f2527bd16|4
data from human studies|Okinawans eat a moderately restricted diet|indicate|5f3edf9d1dfa4c79a66cb40f2527bd16|4
CR diets|coronary heart disease|lower rates|52dfeb63b98144be8c0fa19362f595b6|4
CR diets|centenarians|relatively high frequency|52dfeb63b98144be8c0fa19362f595b6|4
individuals on CR diets|physiology consistent with protection from CVD|protection|52dfeb63b98144be8c0fa19362f595b6|4
CR diets|triglycerides|reduced triglycerides|52dfeb63b98144be8c0fa19362f595b6|4
CR diets|blood pressure|lower blood pressure|52dfeb63b98144be8c0fa19362f595b6|4
CR diets|inflammatory markers|reduced inflammatory markers|52dfeb63b98144be8c0fa19362f595b6|4
CR diets|oxidative stress|decreased oxidative stress|52dfeb63b98144be8c0fa19362f595b6|4
CR|mitochondrial function|increases|531179863c024e6f9ee913e00caf6193|4
CR|oxidative stress in the vasculature|reducing|531179863c024e6f9ee913e00caf6193|4
CR|Nfr2 stress response transcription factor|inducing expression of|531179863c024e6f9ee913e00caf6193|4
CR|NADPH:quinone oxidoreductase 1|inducing expression of|531179863c024e6f9ee913e00caf6193|4
CR|heme oxygenase I|inducing expression of|531179863c024e6f9ee913e00caf6193|4
CR|glutathione S transferase|inducing expression of|531179863c024e6f9ee913e00caf6193|4
CR|inflammation|suppressing the activity of|531179863c024e6f9ee913e00caf6193|4
CR|vascular adhesion molecules|suppressing the activity of|531179863c024e6f9ee913e00caf6193|4
CR|prostanoids|suppressing the activity of|531179863c024e6f9ee913e00caf6193|4
cytokines|rodents and humans|are present in|7fe86ed524f74083afebdc15659dc3de|4
Endothelial function|CR|is enhanced by|7fe86ed524f74083afebdc15659dc3de|4
atherosclerosis and arterial stiffness|CR in rodents|are reduced by|7fe86ed524f74083afebdc15659dc3de|4
cardiac function|CR|is related to|7fe86ed524f74083afebdc15659dc3de|4
diastolic filling|age-related decline|is delayed by|7fe86ed524f74083afebdc15659dc3de|4
inflammation|cardiomyopathy, cardiac fibrosis, myocardial degeneration|are reduced by|7fe86ed524f74083afebdc15659dc3de|4
mimic|effects|In finding ways to mimic these effects|1bfa6f22a732460f8a734f8dc17ffa5f|4
pharmacological agents|finding ways|works and in finding ways to mimic these effects with pharmacological agents|1bfa6f22a732460f8a734f8dc17ffa5f|4
regulatory” pathways|insulin/insulin-like growth factor 1 (IGF-1)|part of the same regulatory pathway|c7f83c67d6b04da4a8681d8974489319|4
regulatory” pathways|mammalian target of rapamycin (mTOR)|part of the same regulatory pathway|c7f83c67d6b04da4a8681d8974489319|4
regulatory” pathways|AMP-activated kinase (AMPK)|part of the same regulatory pathway|c7f83c67d6b04da4a8681d8974489319|4
regulatory” pathways|nicotinamide adenine dinucleotide (NAD)+-dependent deacetylases (sirtuins)|part of the same regulatory pathway|c7f83c67d6b04da4a8681d8974489319|4
regulatory” pathways|which include insulin/insulin-like growth factor 1 (IGF-1),|pathway including term|c7f83c67d6b04da4a8681d8974489319|4
regulatory” pathways|the mammalian target of rapamycin (mTOR),|pathway including term|c7f83c67d6b04da4a8681d8974489319|4
regulatory” pathways|AMP-activated kinase (AMPK),|pathway including term|c7f83c67d6b04da4a8681d8974489319|4
regulatory” pathways|and nicotinamide adenine dinucleotide (NAD)+-dependent deacetylases (sirtuins).|pathway including term|c7f83c67d6b04da4a8681d8974489319|4
positive feedback|health benefits|improve health|09bb7fb822414ad3adc8a5f739255cae|4
negative feedback|control|relationship between the two concepts in one sentence|09bb7fb822414ad3adc8a5f739255cae|4
aging field|research area|intense research focus|09bb7fb822414ad3adc8a5f739255cae|4
longevity pathways|CR|important for understanding how CR works|09bb7fb822414ad3adc8a5f739255cae|4
longevity pathways|health benefits|underlie the health benefits of weight loss and exercise|09bb7fb822414ad3adc8a5f739255cae|4
weight loss|health benefits|individual who reduces caloric intake and starts exercising|09bb7fb822414ad3adc8a5f739255cae|4
exercise|health benefits|individual who reduces caloric intake and starts exercising|09bb7fb822414ad3adc8a5f739255cae|4
health|defense response|evolving for survival during adversity|96d42208de5a42e193c2c9cf17a74c8c|4
adiposity|cardiovascular system|adding stress and negatively affecting|96d42208de5a42e193c2c9cf17a74c8c|4
sedentary lifestyle|natural defense pathways|inhibiting|96d42208de5a42e193c2c9cf17a74c8c|4
beneficial effects|mimic|logical extension of this idea is that it should be possible to|96d42208de5a42e193c2c9cf17a74c8c|4
dieting and exercise|small molecules|tweaking the right pathways|1bbd60e99dee4e1ba9931c42e2b8dac9|4
CR mimetics|resveratrol and metformin|activate the SIRT1-AMPK system|1bbd60e99dee4e1ba9931c42e2b8dac9|4
CR mimetics|rapamycin|inhibits mTOR|1bbd60e99dee4e1ba9931c42e2b8dac9|4
obese and sedentary rodent|physiology of a lean animal|maintaining|1bbd60e99dee4e1ba9931c42e2b8dac9|4
recent work|secreting hormone|identified a termed irisin|1bbd60e99dee4e1ba9931c42e2b8dac9|4
expenditure in the absence of exercise|obesity and glucose homeostasis|positively influencing|94131a2412374c15bb8395b329f9538e|4
overall effect of irisin|cardiovascular disease|largely unexplored|94131a2412374c15bb8395b329f9538e|4
longevity genes|model organisms|identified in|94131a2412374c15bb8395b329f9538e|4
yeast Saccharomyces cerevisiae|nemotode Caenorhabditis elegans and fly Drosophila malanogaster|along with|94131a2412374c15bb8395b329f9538e|4
Sirtuins|mammals|Sirtuins are in mammals|d218fe8c1fe7442eb73e20c52686c175|4
sirtuin members|7|There are 7 sirtuin members|d218fe8c1fe7442eb73e20c52686c175|4
sirtuins|NAD+-dependent deacetylases and ribosyltransferases|Sirtuins function as NAD+-dependent deacetylases and ribosyltransferases|d218fe8c1fe7442eb73e20c52686c175|4
sirtuins|cellular functions|Sirtuins regulate a variety of cellular functions|d218fe8c1fe7442eb73e20c52686c175|4
degeneration|yeast to mammals|modulate aging|69b770efc44b477099164867705c395b|4
sirtuins|regulating lifespan|role in|69b770efc44b477099164867705c395b|4
worms and flies|challenged|direct role for sirtuins|69b770efc44b477099164867705c395b|4
sirtuins|longevity network|component of|69b770efc44b477099164867705c395b|4
SIRT1|nucleus|localized primarily in|69b770efc44b477099164867705c395b|4
SIRT1|AMPK pathway|regulate through deacetylation of|69b770efc44b477099164867705c395b|4
SIRT1|Insulin/IGF-1 pathway|regulates through modulation of UCP2 expression and direct regulation of the IGF-1 signaling pathway|d27adbd0f9a74c1fb5920f7430e9c5ba|4
SIRT1|UCP2|expression|d27adbd0f9a74c1fb5920f7430e9c5ba|4
SIRT1|IGF-1 signaling pathway|direct regulation|d27adbd0f9a74c1fb5920f7430e9c5ba|4
SIRT1|TSC1/2|interacts, inhibits mTOR activity|d27adbd0f9a74c1fb5920f7430e9c5ba|4
SIRT1|mTOR|activity is inhibited|d27adbd0f9a74c1fb5920f7430e9c5ba|4
SIRT1|Cardiovascular development and disease|knockout mice have greater injury in response to ischemia reperfusion|d27adbd0f9a74c1fb5920f7430e9c5ba|4
NIH-PA Author Manuscript|Author Manuscript|is a type of|6604d733d0964b9f9875f90aa41d6e24|4
SIRT1 transgenic mice|Studies|SIRT1 is studied in the context of injury, cardiomyopathy, and SIRT1 overexpression|18ed54e3f048405b878b3adaa009a9fc|4
Cardiac-specific SIRT1-overexpressing mice|Delayed age-dependent cardiomyopathies|SIRT1 overexpression leads to delayed age-dependent cardiomyopathies|18ed54e3f048405b878b3adaa009a9fc|4
Cardiac-specific SIRT1-overexpressing mice|Reduction of stress-induced apoptosis|SIRT1 overexpression results in reduced stress-induced apoptosis|18ed54e3f048405b878b3adaa009a9fc|4
Extensive SIRT1 overexpression|Oxidative stress, apoptosis, and cardiomyopathy|Excessive SIRT1 overexpression (≈ 20 fold) leads to oxidative stress, apoptosis, and cardiomyopathy|18ed54e3f048405b878b3adaa009a9fc|4
SIRT1|Pressure overload-induced cardiac hypertrophy|SIRT1 is involved in pressure overload-induced cardiac hypertrophy|18ed54e3f048405b878b3adaa009a9fc|4
SIRT1|Angiotensin II cardiac hypertrophy|SIRT1 is also involved in Angiotensin II-induced cardiac hypertrophy|18ed54e3f048405b878b3adaa009a9fc|4
hypertrophy of vascular smooth muscle|SIRT1|regulates|9508450fd46943c092632c7e026877c4|4
zebrafish and in mice|SIRT1|observed to regulate blood vessel growth in|9508450fd46943c092632c7e026877c4|4
notch signaling|SIRT1|regulates|9508450fd46943c092632c7e026877c4|4
arterial stiffness|SIRT1|regulates through preventing hyperphosphatemia-induced arterial calcification|9508450fd46943c092632c7e026877c4|4
SIRT3|knockout mice|exhibit both age-dependent and exercise/pressure overload–induced cardiac hypertrophy|9508450fd46943c092632c7e026877c4|4
knockout mice|cardiac hypertrophy|develop|5ff789f971904191b9892c586ed1cfee|4
knockout mice|inflammatory cardiomyopathy|develop|5ff789f971904191b9892c586ed1cfee|4
knockout mice|increase in fibrosis|characterized by|5ff789f971904191b9892c586ed1cfee|4
SIRT7 knockout mice|decreased resistance to oxidative stress|have|5ff789f971904191b9892c586ed1cfee|4
SIRT7 knockout mice|increase in apoptosis|have|5ff789f971904191b9892c586ed1cfee|4
sirtuins|effects on cardiovascular health|described|5ff789f971904191b9892c586ed1cfee|4
sirtuins|molecular mechanisms|regulate the heart and vasculature|5ff789f971904191b9892c586ed1cfee|4
CR|resveratrol|involved in some of the beneficial effects|8affcb5692c34f32b48279d068ade9d8|4
CR and resveratrol|CVD|positive influence may be modulated|8affcb5692c34f32b48279d068ade9d8|4
sirtuin proteins|positive influence of CR and resveratrol in CVD|may be modulated in part through|8affcb5692c34f32b48279d068ade9d8|4
IGF-1/Growth Hormone|lifespan extension|loss of IGF-1 was shown to extend|8affcb5692c34f32b48279d068ade9d8|4
C elegans|IGF-1|was one of the initial genes identified as a longevity gene|8affcb5692c34f32b48279d068ade9d8|4
pathway|lifespan regulation|characters|448d4e489d8f4a6cae62ff7ee79f6f11|4
IGF-1 signaling|mTOR activity|modulates|448d4e489d8f4a6cae62ff7ee79f6f11|4
IGF-1|lifespan regulation|role in|448d4e489d8f4a6cae62ff7ee79f6f11|4
mice deficient in IGF-1|dying after birth|result of|448d4e489d8f4a6cae62ff7ee79f6f11|4
mice|deficiency in growth|cause|448d4e489d8f4a6cae62ff7ee79f6f11|4
IGF-1 receptor–deficient mice|die postnatally|result of|448d4e489d8f4a6cae62ff7ee79f6f11|4
respiratory failure|IGF-1|Overexpression of IGF-1 in the heart prevented myocardial cell death after infarction|df719f1441934aafaaa9d02c0627c8fc|4
ventricular dilation, hypertrophy, and diabetic cardiomyopathy|IGF-1|Overexpression of IGF-1 in the heart prevented myocardial cell death after infarction|df719f1441934aafaaa9d02c0627c8fc|4
cardiac hypertrophy and failure|IGF-1|In a second overexpression study, IGF-1 led to cardiac hypertrophy and failure|df719f1441934aafaaa9d02c0627c8fc|4
diminished recovery of heart function after acute ischemic challenge|IGF-1|In a second overexpression study, IGF-1 led to cardiac hypertrophy and failure|df719f1441934aafaaa9d02c0627c8fc|4
oxidative stress|liver-specific IGF-1 knockout|Liver-specific IGF-1 knockout antagonized oxidative stress|df719f1441934aafaaa9d02c0627c8fc|4
stress and cell death|potent oxidant treatment|induced under|36d3be7bc6434b819c0cc86ce4ff8c6e|4
oxidant treatment|paraquat|treatment with|36d3be7bc6434b819c0cc86ce4ff8c6e|4
cardiomyocytes|IGF-1|induced under|36d3be7bc6434b819c0cc86ce4ff8c6e|4
autocrine and paracrine effects|IGF-1|of|36d3be7bc6434b819c0cc86ce4ff8c6e|4
Drosophila|primitve cardiovascular system|have a|36d3be7bc6434b819c0cc86ce4ff8c6e|4
deletion of InR|IGF-1 homologue|of|36d3be7bc6434b819c0cc86ce4ff8c6e|4
aging effects on the fly cardiovascular system|delayed by deletion of InR|due to|36d3be7bc6434b819c0cc86ce4ff8c6e|4
Forkhead Transcription Factors|FOXOs|are|567f6c0c9c1447d6b738376303371655|4
Forkhead transcription factors|cell growth, proliferation, differentiation, and longevity.|play a role in regulating expression of genes involved in|567f6c0c9c1447d6b738376303371655|4
FOXOs|IGF-1 signaling cascade|are downstream effectors of|567f6c0c9c1447d6b738376303371655|4
sirtuin-mediated deacetylation|FOXOs|are regulated by|567f6c0c9c1447d6b738376303371655|4
deficient vascular and cardiac growth|underdeveloped dorsal aorta|is a cause of|5b862d26c79348a1a234e4528d38ad14|4
deficient vascular and cardiac growth|impaired cardiac looping|is a cause of|5b862d26c79348a1a234e4528d38ad14|4
FOXO1 overexpression|embryonic lethality|leads to|5b862d26c79348a1a234e4528d38ad14|4
FOXO1 overexpression|impaired cardiomyocyte proliferation|leads to|5b862d26c79348a1a234e4528d38ad14|4
FOXO1 overexpression|reduced heart size|leads to|5b862d26c79348a1a234e4528d38ad14|4
FOXO1 overexpression|myocardium thickness|leads to|5b862d26c79348a1a234e4528d38ad14|4
FOXO1 overexpression|heart failure|leads to|5b862d26c79348a1a234e4528d38ad14|4
FOXO3a expression|reduction of|is a cause of|5b862d26c79348a1a234e4528d38ad14|4
cardiomyocyte size|FOXO factor|reduces hypertrophy|11193a8e1ed94fe59de0ce5d916460c3|4
FOXO3a deficiency|eNOS expression|increases|11193a8e1ed94fe59de0ce5d916460c3|4
FOXO3a deficiency|postnatalNorth and Sinclair Page 6|enhances|11193a8e1ed94fe59de0ce5d916460c3|4
vessel formation and maturation|FOXO family|expression disparity|744b47bf713d4e6f9de7a4603afb783e|4
cardiovascular development, function, disease|role of transcription factors|regulating|744b47bf713d4e6f9de7a4603afb783e|4
FOXO factors|longevity network in cardiovascular tissues|interaction|744b47bf713d4e6f9de7a4603afb783e|4
biosynthesis of ubiquinone (coenzyme Q)|electron transporter|is necessary for|800ca506ede4403f9da09830d9961e0b|4
clk-1 inactivation|lifespan extension|in C elegans and partial in mice|800ca506ede4403f9da09830d9961e0b|4
ischemia and reperfusion|vascular response to ischemic conditions|suggesting a potential role in modulation of|7b660fa0e2dd44a6b7eb0a46d03a31bf|4
AMPK|glucose and lipid metabolism|involved in|7b660fa0e2dd44a6b7eb0a46d03a31bf|4
AMPK|cell growth|involved in|7b660fa0e2dd44a6b7eb0a46d03a31bf|4
AMPK|autophagy|involved in|7b660fa0e2dd44a6b7eb0a46d03a31bf|4
AMPK|cellular polarity|involved in|7b660fa0e2dd44a6b7eb0a46d03a31bf|4
AMPK|gene expression|involved in|7b660fa0e2dd44a6b7eb0a46d03a31bf|4
AMPK|mitochondrial function|modulates by triggering the destruction of defective mitochondria through a process of mitochondrial-specific autophagy termed mitophagy and induction of new mitochondria|7b660fa0e2dd44a6b7eb0a46d03a31bf|4
mitochondrial biogenesis|metabolic sensor|through activation of|605c3cb48c0342a494a334b9ee38c4e9|4
AMPK|metabolic sensor|acts as|605c3cb48c0342a494a334b9ee38c4e9|4
AMP:ATP ratio|metabolic sensor|measuring the relative|605c3cb48c0342a494a334b9ee38c4e9|4
longevity network|AMPK|within|605c3cb48c0342a494a334b9ee38c4e9|4
mTOR|AMPK|regulates through direct phosphorylation of the TSC1/2 complex|605c3cb48c0342a494a334b9ee38c4e9|4
IGF-1 pathway|AMPK|modulates through the extracellular signal-regulated kinase (Erk) cascade|605c3cb48c0342a494a334b9ee38c4e9|4
sirtuin|AMPK|controls|605c3cb48c0342a494a334b9ee38c4e9|4
activity|NAD and nicotinamide phosphoribosyltransferase (Nampt)|regulating the abundance of|8c7a6058d09042b6baf56b27ce238a80|4
AMPK|cardioprotective during ischemia and reperfusion|during|8c7a6058d09042b6baf56b27ce238a80|4
mouse models using dominant-negative AMPK|exacerbated myocardial infarction|have|8c7a6058d09042b6baf56b27ce238a80|4
activation of AMPK by metformin|reduces pressure overload–induced cardiac hypertrophy|by reducing|8c7a6058d09042b6baf56b27ce238a80|4
mutations in the regulatory γ2 subunit of AMPK|inherited syndrome of|lead to|8c7a6058d09042b6baf56b27ce238a80|4
hypertrophic cardiomyopathy|ventricular preexcitation|are both involved in energy sensing|e5dc0610531743b7ab82689884a8ce7b|4
AMPK|CR and resveratrol|are mediators of the positive effects of CR and resveratrol on longevity and CVD|e5dc0610531743b7ab82689884a8ce7b|4
resveratrol|AMPK knockout mice|Many of the effects of resveratrol are lost in AMPK knockout mice.|e5dc0610531743b7ab82689884a8ce7b|4
dietary regimens, AMPK, and cardiovascular health|Further studies|are necessary to determine the interaction|e5dc0610531743b7ab82689884a8ce7b|4
p66shc|splice variant|is a|6f946bdf09734e65b33540851e8d4a88|4
p66shc|Shc locus|encoding proteins for|6f946bdf09734e65b33540851e8d4a88|4
p66shc|Src-homology 2 domain|carrying a|6f946bdf09734e65b33540851e8d4a88|4
p66shc|collagen-homology region|carrying a|6f946bdf09734e65b33540851e8d4a88|4
p66shc|phosphotyrosine-binding domain|carrying a|6f946bdf09734e65b33540851e8d4a88|4
p66shc|unique N-terminal region|which functions as a|6f946bdf09734e65b33540851e8d4a88|4
unique N-terminal region|redox enzyme modulating mitochondrial ROS|functions as a|6f946bdf09734e65b33540851e8d4a88|4
p66shc|ROS|is involved in|6f946bdf09734e65b33540851e8d4a88|4
loss of p66shc|decrease in ROS|leads to|6f946bdf09734e65b33540851e8d4a88|4
loss of p66shc|lifespan extension|leads to|6f946bdf09734e65b33540851e8d4a88|4
p66shc|cardiovascular system|functions in|6f946bdf09734e65b33540851e8d4a88|4
loss of p66shc|blocks the decline in|prevents|6f946bdf09734e65b33540851e8d4a88|4
cardiac progenitor cell senescence|decreases DNA damage, necrosis, and apoptosis|relationship in one sentence: decreases DNA damage, necrosis, and apoptosis when cardiac progenitor cells are senescent.|ce5729354d534ef4874f7413d525bb15|4
cardiac progenitor cell senescence|preserves LV volume and function|relationship in one sentence: preserves LV volume and function when cardiac progenitor cells are senescent.|ce5729354d534ef4874f7413d525bb15|4
cardiac progenitor cell senescence|reduces heart failure|relationship in one sentence: reduces heart failure when cardiac progenitor cells are senescent.|ce5729354d534ef4874f7413d525bb15|4
loss of p66shc|prevented Angiotensin II–induced hypertrophy and apoptotic cell death|relationship in one sentence: prevented Angiotensin II–induced hypertrophy and apoptotic cell death due to loss of p66shc.|ce5729354d534ef4874f7413d525bb15|4
loss of p66shc|protected mice from aortic lesions|relationship in one sentence: protected mice from aortic lesions due to loss of p66shc.|ce5729354d534ef4874f7413d525bb15|4
p66shc|plays a central role in the pathogenesis of atherosclerosis|relationship in one sentence: plays a central role in the pathogenesis of atherosclerosis.|ce5729354d534ef4874f7413d525bb15|4
Circ Res|Author manuscript|is related to|3fe39beb81d141a5a273952355c90f27|4
Circ Res|PMC 2012 October 13|available in|3fe39beb81d141a5a273952355c90f27|4
NIH-PA Author Manuscript|Circ Res|is an|3fe39beb81d141a5a273952355c90f27|4
NIH-PA Author Manuscript|Author manuscript|is referred to as|3fe39beb81d141a5a273952355c90f27|4
Catalase|hydrogen peroxide|converts one of the major ROS|532d251ac825438eac2a810114e3f039|4
Catalase|water and oxygen|into water and oxygen|532d251ac825438eac2a810114e3f039|4
peroxisomal catalase|mitochondria|Targeting to the mitochondria|532d251ac825438eac2a810114e3f039|4
lifespan extension|oxidative theory of aging|lending support to|532d251ac825438eac2a810114e3f039|4
mice|age-dependent LV hypertrophy and diastolic dysfunction|demonstrated reduction in|532d251ac825438eac2a810114e3f039|4
mice|Angiotensin II–induced cardiac hypertrophy|were also protected from|532d251ac825438eac2a810114e3f039|4
mice|pressure|also protected from pressure|532d251ac825438eac2a810114e3f039|4
overload–induced|heart failure|cause and effect|2e7f590aa1364ce094bde3c248741d58|4
G- α-q overexpression–induced|heart failure|cause and effect|2e7f590aa1364ce094bde3c248741d58|4
p66shc knockouts|mitochondrial-targeted catalase mice|similar to|2e7f590aa1364ce094bde3c248741d58|4
ROS in CVD|Pituitary Transcription Factor 1|emphasize the role of|2e7f590aa1364ce094bde3c248741d58|4
Pituitary Transcription Factor 1|transcriptional program|involved in|2e7f590aa1364ce094bde3c248741d58|4
pituitary transcription factor 1|normal development and function|of the pituitary gland|2e7f590aa1364ce094bde3c248741d58|4
patients with mutants in Pit-1|have|affected by|2e7f590aa1364ce094bde3c248741d58|4
growth hormone deficiencies|Prop-1|cause|addb231acefc494386472c99725baa96|4
secondary hypogonadism|growth hormone deficiencies|in addition to|addb231acefc494386472c99725baa96|4
deficiencies of growth hormone, prolactin, and thyroid-stimulating hormone|growth hormone deficiencies|seen in patients with Pit-1 mutations|addb231acefc494386472c99725baa96|4
Prophet of Pit-1|Prop-1|is also a pituitary transcription factor|addb231acefc494386472c99725baa96|4
Amest dwarf mice|Mutations in Prop-1|genetic basis for the phenotypes observed|addb231acefc494386472c99725baa96|4
gene alterations|cardiovascular function|related to each other|dfea01704b7b47979dc66dd11229f574|4
Cardiomyocyte size|Ames dwarf mice|reduced in young and old Ames dwarf mice compared with wild-type|dfea01704b7b47979dc66dd11229f574|4
Collagen content|young mice|reduced only in the young mice|dfea01704b7b47979dc66dd11229f574|4
Ames dwarf mice|longevity benefit|may receive some from reduced cardiomyocyte cell size and period of reduced collagen content in the heart during adulthood|dfea01704b7b47979dc66dd11229f574|4
Klotho|gene that is mutated|discovered in a mouse strain presenting multiple|dfea01704b7b47979dc66dd11229f574|4
premature aging phenotypes|a shortened lifespan|cause and effect relationship|416688185469449280d39a918ebafba6|4
overexpression of Klotho|increased lifespan|causal relationship|416688185469449280d39a918ebafba6|4
Klotho gene|single-pass transmembrane protein|encodes for|416688185469449280d39a918ebafba6|4
Klotho|renal tubular cells|expressed primarily in|416688185469449280d39a918ebafba6|4
Klotho|phosphate reabsorption and metabolism|functions in|416688185469449280d39a918ebafba6|4
Klotho|circulating hormone-like factor|observed as due to proteolytic cleavage by membrane-anchored proteases|416688185469449280d39a918ebafba6|4
sinoatrial node|pacemaker under stress|is required for the sinoatrial node to function as a|87228318984e4e8482f2399ec671e430|4
Target of Rapamycin/Rapamycin|serine-threonine protein kinase|is a serine-threonine protein kinase that is inhibited by the|87228318984e4e8482f2399ec671e430|4
Target of Rapamycin/Rapamycin|bacterial product rapamycin|is inhibited by the bacterial product rapamycin.|87228318984e4e8482f2399ec671e430|4
Target of Rapamycin/Rapamycin|insulin and growth factors|integrates signaling from insulin and growth factors as well as|87228318984e4e8482f2399ec671e430|4
Target of Rapamycin/Rapamycin|intracellular amino acid levels|sensing intracellular amino acid levels to regulate|87228318984e4e8482f2399ec671e430|4
cell size and growth|protein synthesis|both are related to each other|61369f34d2ab43a0b04fa236aa28b6d9|4
proliferation|mTOR|mTOR tends to play an effector role of upstream sirtuin/AMPK/IGF-1 activity|61369f34d2ab43a0b04fa236aa28b6d9|4
survival|TOR|Deletion of TOR or treatment with rapamycin has been observed to extend lifespan|61369f34d2ab43a0b04fa236aa28b6d9|4
suppressor of SNF1 protein 2/4|transcriptional induction|regulates|48f24a1e872b4437bfa58030c3b100a7|4
NAD synthesis enzyme Pnc1 (yeast homolog of Nampt)|activating sirtuin proteins|triggered by|48f24a1e872b4437bfa58030c3b100a7|4
pathway in higher organisms|conservation|to be described|48f24a1e872b4437bfa58030c3b100a7|4
mTOR signaling|inhibition in the heart|represses|48f24a1e872b4437bfa58030c3b100a7|4
cardiac hypertrophy mediated by pressure overload|inhibition of mTOR signaling|potentially through|48f24a1e872b4437bfa58030c3b100a7|4
mTOR control of protein translation and cell size|blocking|by mTOR signaling|48f24a1e872b4437bfa58030c3b100a7|4
PI3K/AKT signaling pathway|hypoxia-induced angiogenesis in tumors|regulates|401a12b56be641dcbd5ad1b741eb3e47|4
PI3K/AKT signaling pathway|hypoxia-inducible factor-1 α stabilization|mediates|401a12b56be641dcbd5ad1b741eb3e47|4
PI3K/AKT signaling pathway|vascular endothelial growth factor (VEGF) expression|regulates|401a12b56be641dcbd5ad1b741eb3e47|4
PI3K/AKT signaling pathway|PI3K/AKT inhibitors LY294002 and wortmannin|inhibition of|401a12b56be641dcbd5ad1b741eb3e47|4
North and Sinclair Page 8|Circ Res|from|401a12b56be641dcbd5ad1b741eb3e47|4
NIH-PA Author Manuscript|Manuscript|is a type of|b25a1f3e44be436e874f4c27dbf5bc2e|4
mTOR inhibitor|rapamycin|is|f82594ec5b3241a1b55137f4f973d4d2|4
decreases in VEGF secretion|rapamycin treatment|causes|f82594ec5b3241a1b55137f4f973d4d2|4
mTOR|autophagy|negatively regulates|f82594ec5b3241a1b55137f4f973d4d2|4
nutrient-poor conditions|rapamycin treatment|inhibits mTOR|f82594ec5b3241a1b55137f4f973d4d2|4
autophagy|destruction of defective molecules and organelles|allows for|f82594ec5b3241a1b55137f4f973d4d2|4
health of cardiovascular tissues|autophagy|promotes|f82594ec5b3241a1b55137f4f973d4d2|4
PI3K/AKT/mTOR pathway|numerous signaling pathways|lies at the intersections of|f82594ec5b3241a1b55137f4f973d4d2|4
positioning this pathway|vital mediator of aging and the cardiovascular system|relationship within the same sentence|192782e06ff647b5b29b48f134379761|4
BubR1|serine/threonine protein kinase|relationship within the same sentence|192782e06ff647b5b29b48f134379761|4
BubR1|inhibitor of the anaphase-promoting complex|relationship within the same sentence|192782e06ff647b5b29b48f134379761|4
BubR1|regulating the mitotic spindle assembly checkpoint|relationship within the same sentence|192782e06ff647b5b29b48f134379761|4
heterozygous mice|develop normally|relationship within the same sentence|192782e06ff647b5b29b48f134379761|4
homozygous BubR1 hypomorphic mice|develop premature aging phenotypes|relationship within the same sentence|192782e06ff647b5b29b48f134379761|4
BubR1 hypomorphic mice|arrhythmias|exhibit|3ec1ba6913f04aeb9c5258934fd49c36|4
arrhythmias|death|primary mechanism leading to their death|3ec1ba6913f04aeb9c5258934fd49c36|4
loss-of-BubR1 mice|arterial wall thickness|reduced|3ec1ba6913f04aeb9c5258934fd49c36|4
loss-of-BubR1 mice|inner diameter|reduced|3ec1ba6913f04aeb9c5258934fd49c36|4
loss-of-BubR1 mice|fibrosis|increased|3ec1ba6913f04aeb9c5258934fd49c36|4
loss-of-BubR1 mice|elastic properties|reduced|3ec1ba6913f04aeb9c5258934fd49c36|4
Cardiovascular Aging Review Series|role|plays in the heart|3ec1ba6913f04aeb9c5258934fd49c36|4
Cardiovascular Aging Review Series|mechanisms by which aging and obesity reduce cardiovascular function|discussed in the context|fc1d99748df347f4bc05e3e8f39e5432|4
understanding mechanisms|combat cardiovascular disease|aim of the work discussed|fc1d99748df347f4bc05e3e8f39e5432|4
first part|series|division of discussion in series|fc1d99748df347f4bc05e3e8f39e5432|4
Leeuwenburgh, Marzetti, and colleagues|mitochondrial dysfunction and deregulated autophagy|examined involvement of concepts in cardiovascular aging|fc1d99748df347f4bc05e3e8f39e5432|4
extensive evidence|supporting the concepts|used to support the concepts|fc1d99748df347f4bc05e3e8f39e5432|4
mitochondrial function|age|declines with age|32744b988f694e309e06c8412dcea04a|4
triggering cause|molecular mechanism|of age-associated mitochondrial decline is unclear|32744b988f694e309e06c8412dcea04a|4
functional consequences|cellular and tissue levels|have been well documented|32744b988f694e309e06c8412dcea04a|4
mitochondria|energy generation|generate energy through oxidative phosphorylation|32744b988f694e309e06c8412dcea04a|4
free radical– imposed damage|ROS production|is a byproduct|32744b988f694e309e06c8412dcea04a|4
macromolecules|cellular components|Control of mitochondria quality can occur at 3 basic stages|9e0038fbb08c411ab9a3b80578a0c362|4
mitochondria|quality control|Control of mitochondria quality can occur at 3 basic stages|9e0038fbb08c411ab9a3b80578a0c362|4
repair|damaged mitochondria|repair of damaged mitochondria|9e0038fbb08c411ab9a3b80578a0c362|4
removal|dysfunctional mitochondria|removal of dysfunctional mitochondria through autophagy|9e0038fbb08c411ab9a3b80578a0c362|4
autophagy|dysfunctional mitochondria|generation of new mitochondria through biogenesis|9e0038fbb08c411ab9a3b80578a0c362|4
biogenesis|new mitochondria|role that autophagy plays|9e0038fbb08c411ab9a3b80578a0c362|4
controlling mitochondria quality|cardiac hypertrophy|discussed in the context of|c6ed7859d22d409e88a48e42fb87232b|4
controlling mitochondria quality|ischemia|discussed in the context of|c6ed7859d22d409e88a48e42fb87232b|4
controlling mitochondria quality|heart failure|discussed in the context of|c6ed7859d22d409e88a48e42fb87232b|4
controlling mitochondria quality|diabetic cardiomyopathy|discussed in the context of|c6ed7859d22d409e88a48e42fb87232b|4
growth factors|cardiovascular aging|role in|c6ed7859d22d409e88a48e42fb87232b|4
molecular genetics|lifespan extension|pertaining to|c6ed7859d22d409e88a48e42fb87232b|4
loss of insulin-like growth factor 1 (IGF-1) signaling|lifespan extension in C elegans|led to|b4be58274e6d4a10814f68b706027b5b|4
IGF-1 pathways|MAPK and mTOR pathways|regulate downstream|b4be58274e6d4a10814f68b706027b5b|4
IGF-1 pathways|cell growth, proliferation, and survival|leading to effects on|b4be58274e6d4a10814f68b706027b5b|4
IGF-1 pathways|lipid and glucose metabolism|in addition to|b4be58274e6d4a10814f68b706027b5b|4
role of IGF-1 in cardiac function and aging|unknown|is largely|b4be58274e6d4a10814f68b706027b5b|4
recent data|complex picture|present|b4be58274e6d4a10814f68b706027b5b|4
growth factors|cardiovascular health|influences|3ae9ddd796e84a57bf9b7406cbe66078|4
clinical studies|associations|relies heavily on|3ae9ddd796e84a57bf9b7406cbe66078|4
limited direct mouse studies|conflicting results|gave|3ae9ddd796e84a57bf9b7406cbe66078|4
pathways regulated by growth factors in cardiomyocytes|cardiac aging|discussed|3ae9ddd796e84a57bf9b7406cbe66078|4
effects of IGF-1 on cardiac stem cell|myocardial regeneration|related to|3ae9ddd796e84a57bf9b7406cbe66078|4
adiposity of cardiac tissue|role|touched on|3ae9ddd796e84a57bf9b7406cbe66078|4
on.North|Sinclair|are mentioned in the same sentence|2b21d93217d64987933c125143844bde|4
Circ Res|Author manuscript|are mentioned in the same sentence|2b21d93217d64987933c125143844bde|4
Available in PMC|October 13|are mentioned in the same sentence|2b21d93217d64987933c125143844bde|4
NIH-PA Author Manuscript|Author Manuscript|are mentioned in the same sentence|2b21d93217d64987933c125143844bde|4
mitochondria|cardiovascular aging|are related to each other|1b0129eb202843e2bf6053ee8724c195|4
cellular sources for energy generation|mitochondria|are critically important for|1b0129eb202843e2bf6053ee8724c195|4
high energy–demanding tissues|heart|such as the|1b0129eb202843e2bf6053ee8724c195|4
production of ROS|mitochondria|are central to the rate of aging of these tissues|1b0129eb202843e2bf6053ee8724c195|4
murine models|reduced mitochondria ROS|reduce|4762c052cd62408082b7a48e1f10012a|4
age-associated changes|heart|in|4762c052cd62408082b7a48e1f10012a|4
review|role and molecular mechanisms regulating oxidative stress|discusses the|4762c052cd62408082b7a48e1f10012a|4
oxidative stress|aging cardiovascular system|in|4762c052cd62408082b7a48e1f10012a|4
role of retrograde mitochondrial signaling|communication from the mitochondria to the nucleus|discusses the role of|4762c052cd62408082b7a48e1f10012a|4
mitochondrial biogenesis|cardiovascular health|in|4762c052cd62408082b7a48e1f10012a|4
cellular aging|telomere attrition|cause and effect|33a111c97d4545fa90309718214fd150|4
telomere attrition|mitochondria in the aging heart|related concepts|33a111c97d4545fa90309718214fd150|4
cellular senescence|Loss of telomeric DNA|cause and effect|33a111c97d4545fa90309718214fd150|4
attrition|degeneration of stem and progenitor cell compartments|cause|871fb1a75d5c4b509ca53614e4ca29aa|4
loss of telomeres|highly dividing tissues|affects|871fb1a75d5c4b509ca53614e4ca29aa|4
studies|telomeric DNA loss effects in quiescent tissues|discussed|871fb1a75d5c4b509ca53614e4ca29aa|4
role of telomere attrition|augmenting age-related cardiac decline|discusses|871fb1a75d5c4b509ca53614e4ca29aa|4
p53/mitochondrial signaling pathway|characterize signaling pathways activated in response to loss of telomeric DNA|involved in|871fb1a75d5c4b509ca53614e4ca29aa|4
mitochondrial signaling pathway|FOXOs/sirtuins|role of FOXOs/sirtuins in vascular aging|edff3bed6a1a466e865dc716f7326e28|4
FOXOs|IGF-1 signaling|downstream effectors|edff3bed6a1a466e865dc716f7326e28|4
sirtuins|lifespan and age-related diseases|association|edff3bed6a1a466e865dc716f7326e28|4
vascular development|aging|both FOXO factors and sirtuins have been associated with|edff3bed6a1a466e865dc716f7326e28|4
FOXO/sirtuin factors|downstream effector pathway|are discussed, with particular emphasis|80e25705f0354e10a618ac01b767b48b|4
vascular flow|hypoxic responses|leading to modulators of these factors.|80e25705f0354e10a618ac01b767b48b|4
angiogenesis impairment|endothelial dysfunction|in cardiovascular aging|80e25705f0354e10a618ac01b767b48b|4
age-related impairment of angiogenesis|end-organ damage seen in the elderly|contributes to increased|80e25705f0354e10a618ac01b767b48b|4
angiogenesis impairment|endothelial dysfunction|directly|80e25705f0354e10a618ac01b767b48b|4
cardiovascular health|systemic tissue homeostasis|links|606ba196dc314c12964f89c38c23872f|4
angiogenesis|elderly|critical in|606ba196dc314c12964f89c38c23872f|4
angiogenesis|ischemic stroke|mechanism for repairing tissues after damage caused by|606ba196dc314c12964f89c38c23872f|4
angiogenesis|myocardial infarction|mechanism for repairing tissues after damage caused by|606ba196dc314c12964f89c38c23872f|4
angiogenesis|ischemia|mechanism for repairing tissues after damage caused by|606ba196dc314c12964f89c38c23872f|4
angiogenesis|lower-limb ischemia|mechanism for repairing tissues after damage caused by|606ba196dc314c12964f89c38c23872f|4
processes and pathways|impairment of angiogenesis|contributing to|606ba196dc314c12964f89c38c23872f|4
cellular senescence|impairment of angiogenesis|including|606ba196dc314c12964f89c38c23872f|4
telomere attrition|impairment of angiogenesis|including|606ba196dc314c12964f89c38c23872f|4
oxidative damage|impairment of angiogenesis|including|606ba196dc314c12964f89c38c23872f|4
NO|impairment of angiogenesis|including|606ba196dc314c12964f89c38c23872f|4
hypoxia|impairment of angiogenesis|including|606ba196dc314c12964f89c38c23872f|4
vascular growth factors|impairment of angiogenesis|including|606ba196dc314c12964f89c38c23872f|4
angiogenesis|therapeutic approaches|to improve angiogenesis|6853e08fe6914ed3a8c0d4917daa80e5|4
cardiovascular aging|nonmammalian models|discussed in the final part of the series|6853e08fe6914ed3a8c0d4917daa80e5|4
zebrafish|rudimentary heart and circulatory systems|observed in zebrafish|6853e08fe6914ed3a8c0d4917daa80e5|4
Drosophila|rudimentary heart and circulatory systems|observed in Drosophila|6853e08fe6914ed3a8c0d4917daa80e5|4
genetics|powerful use|in these systems has, and will continue|6853e08fe6914ed3a8c0d4917daa80e5|4
novel pathways|cardiovascular biology|for discovering|ad87ad78c4a241a79930a6af5dd1e552|4
zebrafish|aging research|not used for|ad87ad78c4a241a79930a6af5dd1e552|4
Drosophila|discovery and confirmation of various aging pathways|used in discovery and confirmation|ad87ad78c4a241a79930a6af5dd1e552|4
nonmammalian models|longevity|in terms of|ad87ad78c4a241a79930a6af5dd1e552|4
nonmammalian models|cardiovascular aging|both in terms of|ad87ad78c4a241a79930a6af5dd1e552|4
history and discoveries|various nonmammalian models|made in|ad87ad78c4a241a79930a6af5dd1e552|4
NIH-PA Author Manuscript|Author|is a document written by|afaeb0bcacb349b791d08908d918f0b0|4
Aging|Cardiovascular risk factor|Unavoidable|6912c06ec6a54e0abb510195c7c50e60|4
Aging|Other risk factors|Collectively|6912c06ec6a54e0abb510195c7c50e60|4
Aging|Cardiovascular disease (CVD)|May overcome|6912c06ec6a54e0abb510195c7c50e60|4
Understanding|Fundamental mechanisms of aging|Dictate the pace|6912c06ec6a54e0abb510195c7c50e60|4
Understanding|Aging and cardiovascular research|Interconnected roles|6912c06ec6a54e0abb510195c7c50e60|4
areas to investigate|research areas|integrating|8de620cd3d114970980645943effa477|4
investigators|work|could not be cited|8de620cd3d114970980645943effa477|4
space limitations|cited work|due to|8de620cd3d114970980645943effa477|4
investigator's work|acknowledgments|We would like to apologize|8de620cd3d114970980645943effa477|4
Akt|protein kinase B|also known as|406fa71635e2454ca079da6a9931b385|4
AMPK|AMP-activated protein kinase|equivalent meaning in the text|406fa71635e2454ca079da6a9931b385|4
BubR1|budding uninhibited by benzimidazoles related 1|same term with different abbreviation in text|406fa71635e2454ca079da6a9931b385|4
CLK-1|clock 1|equivalent meaning in the text|406fa71635e2454ca079da6a9931b385|4
CR|calorie restriction|abbreviation in text|406fa71635e2454ca079da6a9931b385|4
CVD|cardiovascular disease|abbreviation in text|406fa71635e2454ca079da6a9931b385|4
eNOS|endothelial nitric oxide synthetase|equivalent meaning in the text|406fa71635e2454ca079da6a9931b385|4
EP|electrophysiology|abbreviation in text|406fa71635e2454ca079da6a9931b385|4
Erk|extracellular signal-regulated kinase|equivalent meaning in the text|406fa71635e2454ca079da6a9931b385|4
FOXO|forkhead transcription factors|abbreviation in text|406fa71635e2454ca079da6a9931b385|4
IGF-1|insulin-like growth factor-1|abbreviation in text|406fa71635e2454ca079da6a9931b385|4
LV|left ventricle|abbreviation in text|406fa71635e2454ca079da6a9931b385|4
MCLK1|mammalian clock 1|equivalent meaning in the text|406fa71635e2454ca079da6a9931b385|4
LV|left ventricle|same abbreviation|afea973a3a234bef9aa6b6fc0cdb0cb8|4
MCLK1|mammalian clock 1|same concept|afea973a3a234bef9aa6b6fc0cdb0cb8|4
mTOR|mammalian target of rapamycin|same concept|afea973a3a234bef9aa6b6fc0cdb0cb8|4
NAD|nicotinamide adenine dinucleotide|same concept|afea973a3a234bef9aa6b6fc0cdb0cb8|4
NADPH|reduced nicotinamide adenine dinucleotide phosphate|same concept|afea973a3a234bef9aa6b6fc0cdb0cb8|4
Nampt|nicotinamide phosphoribosyltransferase|same concept|afea973a3a234bef9aa6b6fc0cdb0cb8|4
PI3K|phosphatidylinositol-3-kinase|same concept|afea973a3a234bef9aa6b6fc0cdb0cb8|4
Pit-1|pituitary transcription factor 1|same concept|afea973a3a234bef9aa6b6fc0cdb0cb8|4
PNC1|pyrazinamidase and nicotinamidase 1|same concept|afea973a3a234bef9aa6b6fc0cdb0cb8|4
Prop-1|prophet of Pit-1|same concept|afea973a3a234bef9aa6b6fc0cdb0cb8|4
ROS|reactive oxygen species|same concept|afea973a3a234bef9aa6b6fc0cdb0cb8|4
SIR2|silent information regulator 2|same concept|afea973a3a234bef9aa6b6fc0cdb0cb8|4
SIRT|sirtuin|same abbreviation|afea973a3a234bef9aa6b6fc0cdb0cb8|4
SIRT|sirtuinNorth|are related terms mentioned in the same sentence|896cb354fa834ba4a356bb676ec421c5|4
Circ Res|Author manuscript|are related terms mentioned in the same sentence|896cb354fa834ba4a356bb676ec421c5|4
TOR|target of rapamycin|is|13b19a9cc83642bbaba7e727bd35a439|4
TSC1/2|tuberous sclerosis complex 1/2|are|13b19a9cc83642bbaba7e727bd35a439|4
UCP2|uncoupling protein 2|is|13b19a9cc83642bbaba7e727bd35a439|4
VEGF|vascular endothelial growth factor|is|13b19a9cc83642bbaba7e727bd35a439|4
